<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01626079</url>
  </required_header>
  <id_info>
    <org_study_id>11-512</org_study_id>
    <nct_id>NCT01626079</nct_id>
  </id_info>
  <brief_title>Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients With Functional Mitral Regurgitation (The COAPT Trial)</brief_title>
  <acronym>COAPT</acronym>
  <official_title>A Clinical Evaluation of the Safety and Effectiveness of the MitraClip® System for the Treatment of Functional Mitral Regurgitation in Symptomatic Heart Failure Subjects (COAPT Recruitment Closed). COAPT CAS (Recruitment Closed)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abbott Medical Devices</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abbott Medical Devices</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy
      for Heart Failure Patients with Functional Mitral Regurgitation (COAPT) Trial is to confirm
      the safety and effectiveness of the MitraClip System for the treatment of moderate-to-severe
      or severe functional mitral regurgitation (FMR) in Symptomatic Heart Failure Subjects who are
      treated per standard of care and who have been determined by the site's local heart team as
      not appropriate for mitral valve surgery. This randomized controlled trial will provide the
      opportunity to strengthen or add labeling claims regarding safety and clinical benefits of
      the MitraClip System for symptomatic heart failure patients with moderate-to-severe or severe
      functional mitral regurgitation.

      Approximately 610 subjects will be randomized at up to 100 investigational sites with
      approximately 305 subjects targeted to receive the study device. COAPT study completed
      recruiting subjects in June 2017.

      As part of the COAPT trial, a subset of patients will be registered in the cardiopulmonary
      exercise (CPX) sub-study. The objective of this sub-study is to evaluate the exercise
      responses in a sub-cohort of COAPT subjects who receive MitraClip device (Device group)
      compared to the Control group who do not receive MitraClip device. (Note: the CPX Sub-study
      subjects will contribute to the analyses of the COAPT primary and secondary endpoints)

      As an extension of the COAPT RCT trial, COAPT CAS study will be conducted after COAPT
      enrollment is complete under the same investigational device exemption (IDE(G120024)). The
      objective of this study is to evaluate the MitraClip® NT System for the treatment of
      clinically significant functional mitral regurgitation (FMR) in symptomatic heart failure
      subjects who are treated per standard of care and who have been determined by the site's
      local heart team as not appropriate for mitral valve surgery. The anticipated Study
      Completion Date is July 2024. COAPT CAS completed recruiting subjects in March 2019.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Prospective, randomized, parallel-controlled, multicenter clinical evaluation of the
      MitraClip device for the treatment of clinically significant functional mitral regurgitation
      in symptomatic heart failure subjects who are treated per standard of care and who have been
      determined by the site's local heart team as not appropriate for mitral valve surgery.
      Eligible subjects will be randomized in a 1:1 ratio to the MitraClip device (Device group) or
      to no MitraClip device (Control group).

      As part of the COAPT trial, a subset of patients (at least 50 up to 100 in total) will be
      registered in the CPX Sub-study, which is designed as a prospective, randomized (1:1 ratio to
      the MitraClip or no MitraClip device), parallel-controlled, multicenter study registering
      approximately 50-100 subjects in up to 50 qualified US sites from the COAPT trial. Subjects
      registered and randomized in the CPX Sub-study will contribute to the total enrollment
      approximately of 610 subjects in the COAPT trial. Roll-in subjects will not participate in
      the CPX Sub-study.

      The COAPT CAS study is designed as a prospective, multicenter, single arm, continued access
      registry study. A maximum of 800 subjects (anticipated) will be registered from up to 75
      sites in the United States. The enrollment will end once pre-market approval (PMA) of the
      proposed expanded indication of MitraClip System is obtained. Active follow-up of patients
      will be performed through 12 months with scheduled visits at 30 days and 12 months. The
      national Trans catheter Valve Therapy Registry (TVT Registry) will be used for data
      collection through 12 months. Annual follow-up data from 2 years through year 5 post-implant
      will be obtained by linkage to the Centers for Medicare and Medicaid Services (CMS) Claims
      database.

      COAPT CAS data may be used to support the PMA application of the labeling claims for the
      treatment of moderate to severe or severe FMR in symptomatic heart failure subjects. This
      single arm registry will provide valuable new information regarding use of the MitraClip® NT
      System under more &quot;real world&quot; conditions.

      COAPT study completed recruiting subjects in June 2017. COAPT CAS completed recruiting
      subjects in March 2019.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">August 2012</start_date>
  <completion_date type="Anticipated">July 2024</completion_date>
  <primary_completion_date type="Actual">March 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary Safety Endpoint - Percentage of Participants With Freedom From Device Related Complications at 12 Months</measure>
    <time_frame>12 months</time_frame>
    <description>Percentage of Participants with Freedom from Device related Complications at 12 Months.
Composite of Single Leaflet Device Attachment (SLDA), device embolizations, endocarditis requiring surgery, Echocardiography Core Laboratory confirmed mitral stenosis requiring surgery, LVAD implant, heart transplant, and any device related complications requiring non-elective cardiovascular surgery.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Primary Effectiveness Endpoint</measure>
    <time_frame>24 months</time_frame>
    <description>Recurrent HF hospitalizations (HFH) through 24 months, analyzed when the last subject completes 12-month follow-up</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Recurrent Heart Failure (HF) Hospitalization (COAPT CAS Study Analysis)</measure>
    <time_frame>12 months</time_frame>
    <description>Number of recurrent Heart Failure hospitalization events at 12 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>New York Heart Association (NYHA) Functional Class (COAPT CAS Study Analysis)</measure>
    <time_frame>12 months</time_frame>
    <description>The New York Heart Association (NYHA) Classification provides a simple way of classifying the extent of heart failure. It classifies patients in one of four categories based on their limitations during physical activity:
Class I - No symptoms and no limitation in ordinary physical activity Class II - Mild symptoms (mild shortness of breath and/or angina) and slight limitation during ordinary activity. Class III - Marked limitation in activity due to symptoms Class IV - Severe limitations.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>New York Heart Association (NYHA) Functional Class (COAPT CAS Study Analysis)</measure>
    <time_frame>30 days</time_frame>
    <description>The New York Heart Association (NYHA) Classification provides a simple way of classifying the extent of heart failure. It classifies patients in one of four categories based on their limitations during physical activity:
Class I - No symptoms and no limitation in ordinary physical activity Class II - Mild symptoms (mild shortness of breath and/or angina) and slight limitation during ordinary activity. Class III - Marked limitation in activity due to symptoms Class IV - Severe limitations.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life (QOL) (COAPT CAS Study Analysis) Quality of Life (QoL) as Measured by the Kansas City Cardiomyopathy Questionnaire (KCCQ)</measure>
    <time_frame>12 months</time_frame>
    <description>COAPT Study is still on-going. Only the Primary and Major secondary endpoints were entered in the results section for the COAPT study after the FDA approval of the new indication. Subjects are still being followed in both the COAPT and COAPT CAS cohorts. COAPT CAS study is a single arm registry that will provide valuable new information regarding use of the MitraClip NT system under more &quot;real world&quot; conditions. COAPT study completed recruiting subjects in June 2017. COAPT CAS completed recruiting subjects in March 2019.
Remainder of the COAPT and COAPT CAS results will be entered when the study is closed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life (QOL) (COAPT CAS Study Analysis) Quality of Life (QoL) as Measured by the Kansas City Cardiomyopathy Questionnaire (KCCQ)</measure>
    <time_frame>30 days</time_frame>
    <description>The Kansas City Cardiomyopathy Questionnaire is a 23-item, self administered instrument that quantifies physical function, symptoms, social function, self-efficacy and knowledge, and quality of life. with a range of possible subscale scores from 0 to 100, with 100 representing the least burden of symptoms. The KCCQ tool quantifies the following six (6) distinct domains and two (2) summary scores: KCCQ Symptom Domain, KCCQ Physical Function Domain, KCCQ Quality of Life Domain, KCCQ Social Limitation Domain, KCCQ Self-efficacy Domain, KCCQ Symptom Stability Domain, Clinical Summary Score and Overall Summary Score. Clinical Summary Score includes total symptom and physical function scores to correspond with NYHA Classification. Overall Summary Score includes the total symptom, physical function, social limitations and quality of life scores.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Six Minute Walk Test (6MWT Distance or 6MWD) (COAPT CAS Study Analysis)</measure>
    <time_frame>12 months</time_frame>
    <description>COAPT Study is still on-going. Only the Primary and Major secondary endpoints were entered in the results section for the COAPT study after the FDA approval of the new indication. Subjects are still being followed in both the COAPT and COAPT CAS cohorts. COAPT CAS study is a single arm registry that will provide valuable new information regarding use of the MitraClip NT system under more &quot;real world&quot; conditions. COAPT study completed recruiting subjects in June 2017. COAPT CAS completed recruiting subjects in March 2019.
Remainder of the COAPT and COAPT CAS results will be entered when the study is closed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Six Minute Walk Test (6MWT Distance or 6MWD) (COAPT CAS Study Analysis)</measure>
    <time_frame>30 days</time_frame>
    <description>The Six Minute Walk Test (6MWT) is a practical simple test that requires a 100-ft hallway but no exercise equipment or advanced training for technicians. This test measures the distance that a patient can quickly walk on a flat, hard surface in a period of 6 minutes (the 6MWD). It evaluates the global and integrated responses of all the systems involved during exercise, including the pulmonary and cardiovascular systems, systemic circulation, peripheral circulation, blood, neuromuscular units, and muscle metabolism. It does not provide specific information on the function of each of the different organs and systems involved in exercise or the mechanism of exercise limitation, as is possible with maximal cardiopulmonary exercise testing. The self-paced 6MWT assesses the submaximal level of functional capacity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mitral Regurgitation (MR) Severity (COAPT CAS Study Analysis)</measure>
    <time_frame>12 months</time_frame>
    <description>COAPT Study is still on-going. Only the Primary and Major secondary endpoints were entered in the results section for the COAPT study after the FDA approval of the new indication. Subjects are still being followed in both the COAPT and COAPT CAS cohorts. COAPT CAS study is a single arm registry that will provide valuable new information regarding use of the MitraClip NT system under more &quot;real world&quot; conditions. COAPT study completed recruiting subjects in June 2017. COAPT CAS completed recruiting subjects in March 2019.
Remainder of the COAPT and COAPT CAS results will be entered when the study is closed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mitral Regurgitation (MR) Severity (COAPT CAS Study Analysis)</measure>
    <time_frame>30 days</time_frame>
    <description>MR Severity Grading was done by Quantitative Doppler Echocardiography and subjects were graded as below
MR 1+ - Regurgitant Volume &lt; 30 ml, Right ventricular EF &lt;30%, Effective regurgitant orifice area &lt; 20 mm^2 MR 2+ - Regurgitant Volume 30-44 ml, Right ventricular EF 30-39%, Effective regurgitant orifice area 20-29 mm^2 MR 3+ - Regurgitant Volume 45-59 ml, Right ventricular EF 40-49 %, Effective regurgitant orifice area 30-39 mm^2 MR 4+ - Regurgitant Volume &gt;= 60 ml, Right ventricular EF &gt;=50%, Effective regurgitant orifice area &gt;=40 mm^2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major and/or Life Threatening Bleeding (COAPT CAS Study Analysis)</measure>
    <time_frame>12 months</time_frame>
    <description>COAPT Study is still on-going. Only the Primary and Major secondary endpoints were entered in the results section for the COAPT study after the FDA approval of the new indication. Subjects are still being followed in both the COAPT and COAPT CAS cohorts. COAPT CAS study is a single arm registry that will provide valuable new information regarding use of the MitraClip NT system under more &quot;real world&quot; conditions. COAPT study completed recruiting subjects in June 2017. COAPT CAS completed recruiting subjects in March 2019.
Remainder of the COAPT and COAPT CAS results will be entered when the study is closed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major and/or Life Threatening Bleeding (COAPT CAS Study Analysis)</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major Vascular Complications (COAPT CAS Study Analysis)</measure>
    <time_frame>12 months</time_frame>
    <description>COAPT Study is still on-going. Only the Primary and Major secondary endpoints were entered in the results section for the COAPT study after the FDA approval of the new indication. Subjects are still being followed in both the COAPT and COAPT CAS cohorts. COAPT CAS study is a single arm registry that will provide valuable new information regarding use of the MitraClip NT system under more &quot;real world&quot; conditions. COAPT study completed recruiting subjects in June 2017. COAPT CAS completed recruiting subjects in March 2019.
Remainder of the COAPT and COAPT CAS results will be entered when the study is closed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major Vascular Complications (COAPT CAS Study Analysis)</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal Complication With Requirement for Dialysis (COAPT CAS Study Analysis)</measure>
    <time_frame>12 months</time_frame>
    <description>COAPT Study is still on-going. Only the Primary and Major secondary endpoints were entered in the results section for the COAPT study after the FDA approval of the new indication. Subjects are still being followed in both the COAPT and COAPT CAS cohorts. COAPT CAS study is a single arm registry that will provide valuable new information regarding use of the MitraClip NT system under more &quot;real world&quot; conditions. COAPT study completed recruiting subjects in June 2017. COAPT CAS completed recruiting subjects in March 2019.
Remainder of the COAPT and COAPT CAS results will be entered when the study is closed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal Complication With Requirement for Dialysis (COAPT CAS Study Analysis)</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transient Ischemic Attack (TIA) (COAPT CAS Study Analysis)</measure>
    <time_frame>12 months</time_frame>
    <description>COAPT Study is still on-going. Only the Primary and Major secondary endpoints were entered in the results section for the COAPT study after the FDA approval of the new indication. Subjects are still being followed in both the COAPT and COAPT CAS cohorts. COAPT CAS study is a single arm registry that will provide valuable new information regarding use of the MitraClip NT system under more &quot;real world&quot; conditions. COAPT study completed recruiting subjects in June 2017. COAPT CAS completed recruiting subjects in March 2019.
Remainder of the COAPT and COAPT CAS results will be entered when the study is closed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transient Ischemic Attack (TIA) (COAPT CAS Study Analysis)</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stroke (COAPT CAS Study Analysis)</measure>
    <time_frame>12 months</time_frame>
    <description>COAPT Study is still on-going. Only the Primary and Major secondary endpoints were entered in the results section for the COAPT study after the FDA approval of the new indication. Subjects are still being followed in both the COAPT and COAPT CAS cohorts. COAPT CAS study is a single arm registry that will provide valuable new information regarding use of the MitraClip NT system under more &quot;real world&quot; conditions. COAPT study completed recruiting subjects in June 2017. COAPT CAS completed recruiting subjects in March 2019.
Remainder of the COAPT and COAPT CAS results will be entered when the study is closed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stroke (COAPT CAS Study Analysis)</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial Infarction (MI) (COAPT CAS Study Analysis)</measure>
    <time_frame>12 months</time_frame>
    <description>COAPT Study is still on-going. Only the Primary and Major secondary endpoints were entered in the results section for the COAPT study after the FDA approval of the new indication. Subjects are still being followed in both the COAPT and COAPT CAS cohorts. COAPT CAS study is a single arm registry that will provide valuable new information regarding use of the MitraClip NT system under more &quot;real world&quot; conditions. COAPT study completed recruiting subjects in June 2017. COAPT CAS completed recruiting subjects in March 2019.
Remainder of the COAPT and COAPT CAS results will be entered when the study is closed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial Infarction (MI) (COAPT CAS Study Analysis)</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death and Primary Cause of Death (COAPT CAS Study Analysis)</measure>
    <time_frame>12 months</time_frame>
    <description>COAPT Study is still on-going. Only the Primary and Major secondary endpoints were entered in the results section for the COAPT study after the FDA approval of the new indication. Subjects are still being followed in both the COAPT and COAPT CAS cohorts. COAPT CAS study is a single arm registry that will provide valuable new information regarding use of the MitraClip NT system under more &quot;real world&quot; conditions. COAPT study completed recruiting subjects in June 2017. COAPT CAS completed recruiting subjects in March 2019.
Remainder of the COAPT and COAPT CAS results will be entered when the study is closed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death and Primary Cause of Death (COAPT CAS Study Analysis)</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients Free From the Composite of All-cause Death, Stroke, MI, or Non-elective Cardiovascular Surgery for Device Related Complications in the Device Group</measure>
    <time_frame>30 days post-procedure in the Device group</time_frame>
    <description>The percentage of patients free from the composite endpoint as described above.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Deaths at 12 Months (All Cause Mortality)</measure>
    <time_frame>12 months</time_frame>
    <description>Death from any cause mortality at 12months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Mitral Regurgitation Severity Grade of 2+ or Lower at 12 Months</measure>
    <time_frame>12 months</time_frame>
    <description>MR severity grade of 2+ or lower at 12 months MR Severity Grading was done by Quantitative Doppler Echocardiography and subjects were graded as below
MR 1+ - Regurgitant Volume &lt; 30 ml, Right ventricular EF &lt;30%, Effective regurgitant orifice area &lt; 20 mm^2 MR 2+ - Regurgitant Volume 30-44 ml, Right ventricular EF 30-39%, Effective regurgitant orifice area 20-29 mm^2 MR 3+ - Regurgitant Volume 45-59 ml, Right ventricular EF 40-49 %, Effective regurgitant orifice area 30-39 mm^2 MR 4+ - Regurgitant Volume &gt;= 60 ml, Right ventricular EF &gt;=50%, Effective regurgitant orifice area &gt;=40 mm^2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Distance Walked on the 6 Minute Walk Test (6MWT Distance or 6MWD)</measure>
    <time_frame>12 months over baseline</time_frame>
    <description>The 6MWT is a practical simple test that requires a 100-ft hallway but no exercise equipment or advanced training for technicians. This test measures the distance that a patient can quickly walk on a flat, hard surface in a period of 6 minutes (the 6MWD). It evaluates the global and integrated responses of all the systems involved during exercise, including the pulmonary and cardiovascular systems, systemic circulation, peripheral circulation, blood, neuromuscular units, and muscle metabolism. It does not provide specific information on the function of each of the different organs and systems involved in exercise or the mechanism of exercise limitation, as is possible with maximal cardiopulmonary exercise testing. The self-paced 6MWT assesses the submaximal level of functional capacity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Quality of Life (QoL) as Measured by the Kansas City Cardiomyopathy Questionnaire (KCCQ)</measure>
    <time_frame>12 months over baseline</time_frame>
    <description>Paired data looking at difference between the baseline Kansas City Cardiomyopathy Questionnaire (KCCQ) and 12 month KCCQ score.
The Kansas City Cardiomyopathy Questionnaire is a 23-item, self-administered instrument that quantifies physical function, symptoms, social function, self-efficacy and knowledge, and quality of life. with a range of possible subscale scores from 0 to 100, with 100 representing the least burden of symptoms. The KCCQ tool quantifies the following six (6) distinct domains and two (2) summary scores: KCCQ Symptom Domain, KCCQ Physical Function Domain, KCCQ Quality of Life Domain, KCCQ Social Limitation Domain, KCCQ Self-efficacy Domain, KCCQ Symptom Stability Domain, Clinical Summary Score and Overall Summary Score.
Clinical Summary Score includes total symptom and physical function scores to correspond with NYHA Classification.
Overall Summary Score includes the total symptom, physical function, social limitations and quality of life scores.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Left Ventricular End Diastolic Volume (LVEDV)</measure>
    <time_frame>12 months over baseline</time_frame>
    <description>Paired data comparing the Change in LVEDV at baseline vs 12 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With New York Heart Association (NYHA) Functional Class I/II</measure>
    <time_frame>12 months</time_frame>
    <description>NEW YORK HEART ASSOCIATION CLASSIFICATION (NYHA CLASS)
Class I: Patients with cardiac disease but without resulting limitations of physical activity.
Class II: Patients with cardiac disease resulting in slight limitation of physical activity. Patients are comfortable at rest. Ordinary physical activity results in fatigue, palpitation, dyspnea, or anginal pain.
Class III: Patients with cardiac disease resulting in marked limitation of physical activity. Patients are comfortable at rest. Less than ordinary physical activity causes fatigue, palpitation dyspnea, or anginal pain.
Class IV: Patients with cardiac disease resulting in inability to carry on any physical activity without discomfort. Symptoms of cardiac insufficiency or of the anginal syndrome may be present even at rest. If any physical activity is undertaken, discomfort is increased.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recurrent Hospitalizations - All Cause</measure>
    <time_frame>24 Months</time_frame>
    <description>Number of Recurrent Hospitalizations for any cause within 24 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death or HF Hospitalization Within 24 Months (Finkelstein-Schoenfeld Analysis of All-Cause Death or Recurrent HF Hospitalization Through 24 Months)</measure>
    <time_frame>24 months</time_frame>
    <description>The win ratio is a useful method for providing an estimate of the treatment effect when composite endpoints are analyzed as the analysis accounts for clinical significance of the outcomes of interest. For example, in the composite of death and recurrent HF hospitalizations through 24 months, subjects in the Device and Control groups were formed into matched pairs, where each pair of subjects was classified into 1 of 5 outcomes scenarios:
A. Death in Device group first B. Death in Control group first C. More HF hospitalizations in the Device group (or in the case of a tie, the first HF hospitalization in the Device group occurs first) D. More HF hospitalization in the Control group (or in the case of tie, the first HF hospitalization in the Control group occurs first) E. None of the above In this way, the number of &quot;Winners&quot; in the Device group was NW = NB + ND while the number of &quot;Losers&quot; in the Device group was NL = NA + NC. The &quot;Win Ratio&quot; was then calculated as NW/NL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death and Primary Cause of Death (COAPT CAS Study Analysis)</measure>
    <time_frame>2 years</time_frame>
    <description>The COAPT study is still on-going. Only the Primary and major secondary endpoints have been entered. Rest of the results will be entered when the study ends in July 2024.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death and Primary Cause of Death (COAPT CAS Study Analysis)</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death and Primary Cause of Death (COAPT CAS Study Analysis)</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death and Primary Cause of Death (COAPT CAS Study Analysis)</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial Infarction (MI) (COAPT CAS Study Analysis)</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial Infarction (MI) (COAPT CAS Study Analysis)</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial Infarction (MI) (COAPT CAS Study Analysis)</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial Infarction (MI) (COAPT CAS Study Analysis)</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stroke (COAPT CAS Study Analysis)</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stroke (COAPT CAS Study Analysis)</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stroke (COAPT CAS Study Analysis)</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stroke (COAPT CAS Study Analysis)</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recurrent Heart Failure (HF) Hospitalization (COAPT CAS Study Analysis)</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recurrent Heart Failure (HF) Hospitalization (COAPT CAS Study Analysis)</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recurrent Heart Failure (HF) Hospitalization (COAPT CAS Study Analysis)</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recurrent Heart Failure (HF) Hospitalization (COAPT CAS Study Analysis)</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Kaplan-Meier Freedom From All-cause Mortality</measure>
    <time_frame>24 months</time_frame>
    <description>Death from any cause within 24 months - no of events</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Device or Procedure-Related Adverse Events</measure>
    <time_frame>Within and after 30 days of the procedure</time_frame>
    <description>Device or procedure-related adverse events are defined as adverse events that are adjudicated by the Clinical Events Committee as possibly, probably or definitely device and/or procedure-related, regardless of the temporal relationship to the MitraClip procedure. Device or procedure-related adverse events will be broken down into those that occur within 30 days of the procedure and those that occur after 30 days of the procedure. Examples of device-related adverse events are: myocardial perforation, Single Leaflet Device Attachment, embolization of the MitraClip device or MitraClip System components, iatrogenic atrial septal defect, mitral valve stenosis, need for mitral valve replacement instead of repair due at least in part to the MitraClip procedure or the presence of the MitraClip device.</description>
  </other_outcome>
  <other_outcome>
    <measure>Implant Rate</measure>
    <time_frame>Day 0</time_frame>
    <description>Defined as the rate of successful delivery and deployment of the MitraClip device(s) with echocardiographic evidence of leaflet approximation and retrieval of the delivery catheter</description>
  </other_outcome>
  <other_outcome>
    <measure>Device Procedure Time</measure>
    <time_frame>Day 0</time_frame>
    <description>Defined as the time elapsed from the start of the transseptal procedure to the time the Steerable Guide Catheter is removed</description>
  </other_outcome>
  <other_outcome>
    <measure>Total Procedure Time</measure>
    <time_frame>Day 0</time_frame>
    <description>Defined as the time elapsed from the first of any of the following: intravascular catheter placement, anesthesia or sedation, or transesophageal echocardiogram (TEE), to the removal of the last catheter and TEE</description>
  </other_outcome>
  <other_outcome>
    <measure>Device Time</measure>
    <time_frame>Day 0</time_frame>
    <description>Defined as the time the Steerable Guide Catheter is placed in the intra-atrial septum until the time the MitraClip Delivery System (CDS) is retracted into the Steerable Guide Catheter</description>
  </other_outcome>
  <other_outcome>
    <measure>Fluoroscopy Duration</measure>
    <time_frame>Day 0</time_frame>
    <description>Defined as the duration of exposure to fluoroscopy during the MitraClip procedure</description>
  </other_outcome>
  <other_outcome>
    <measure>MR Severity Grade</measure>
    <time_frame>Baseline</time_frame>
    <description>MR Severity Grading was done by Quantitative Doppler Echocardiography and subjects were graded as below
MR 1+ - Regurgitant Volume &lt; 30 ml, Right ventricular EF &lt;30%, Effective regurgitant orifice area &lt; 20 mm^2 MR 2+ - Regurgitant Volume 30-44 ml, Right ventricular EF 30-39%, Effective regurgitant orifice area 20-29 mm^2 MR 3+ - Regurgitant Volume 45-59 ml, Right ventricular EF 40-49 %, Effective regurgitant orifice area 30-39 mm^2 MR 4+ - Regurgitant Volume &gt;= 60 ml, Right ventricular EF &gt;=50%, Effective regurgitant orifice area &gt;=40 mm^2</description>
  </other_outcome>
  <other_outcome>
    <measure>MR Severity Grade</measure>
    <time_frame>At discharge (or 30 days if discharge echocardiogram is not available)</time_frame>
    <description>MR Severity Grading was done by Quantitative Doppler Echocardiography and subjects were graded as below
MR 1+ - Regurgitant Volume &lt; 30 ml, Right ventricular EF &lt;30%, Effective regurgitant orifice area &lt; 20 mm^2 MR 2+ - Regurgitant Volume 30-44 ml, Right ventricular EF 30-39%, Effective regurgitant orifice area 20-29 mm^2 MR 3+ - Regurgitant Volume 45-59 ml, Right ventricular EF 40-49 %, Effective regurgitant orifice area 30-39 mm^2 MR 4+ - Regurgitant Volume &gt;= 60 ml, Right ventricular EF &gt;=50%, Effective regurgitant orifice area &gt;=40 mm^2</description>
  </other_outcome>
  <other_outcome>
    <measure>MR Severity Grade</measure>
    <time_frame>6 months</time_frame>
    <description>MR Severity Grading was done by Quantitative Doppler Echocardiography and subjects were graded as below
MR 1+ - Regurgitant Volume &lt; 30 ml, Right ventricular EF &lt;30%, Effective regurgitant orifice area &lt; 20 mm^2 MR 2+ - Regurgitant Volume 30-44 ml, Right ventricular EF 30-39%, Effective regurgitant orifice area 20-29 mm^2 MR 3+ - Regurgitant Volume 45-59 ml, Right ventricular EF 40-49 %, Effective regurgitant orifice area 30-39 mm^2 MR 4+ - Regurgitant Volume &gt;= 60 ml, Right ventricular EF &gt;=50%, Effective regurgitant orifice area &gt;=40 mm^2</description>
  </other_outcome>
  <other_outcome>
    <measure>MR Severity Grade</measure>
    <time_frame>12 months</time_frame>
    <description>MR Severity Grading was done by Quantitative Doppler Echocardiography and subjects were graded as below
MR 1+ - Regurgitant Volume &lt; 30 ml, Right ventricular EF &lt;30%, Effective regurgitant orifice area &lt; 20 mm^2 MR 2+ - Regurgitant Volume 30-44 ml, Right ventricular EF 30-39%, Effective regurgitant orifice area 20-29 mm^2 MR 3+ - Regurgitant Volume 45-59 ml, Right ventricular EF 40-49 %, Effective regurgitant orifice area 30-39 mm^2 MR 4+ - Regurgitant Volume &gt;= 60 ml, Right ventricular EF &gt;=50%, Effective regurgitant orifice area &gt;=40 mm^2</description>
  </other_outcome>
  <other_outcome>
    <measure>MR Severity Grade</measure>
    <time_frame>24 months</time_frame>
    <description>MR Severity Grading was done by Quantitative Doppler Echocardiography and subjects were graded as below
MR 1+ - Regurgitant Volume &lt; 30 ml, Right ventricular EF &lt;30%, Effective regurgitant orifice area &lt; 20 mm^2 MR 2+ - Regurgitant Volume 30-44 ml, Right ventricular EF 30-39%, Effective regurgitant orifice area 20-29 mm^2 MR 3+ - Regurgitant Volume 45-59 ml, Right ventricular EF 40-49 %, Effective regurgitant orifice area 30-39 mm^2 MR 4+ - Regurgitant Volume &gt;= 60 ml, Right ventricular EF &gt;=50%, Effective regurgitant orifice area &gt;=40 mm^2</description>
  </other_outcome>
  <other_outcome>
    <measure>MR Severity Grade</measure>
    <time_frame>3 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>MR Severity Grade</measure>
    <time_frame>4 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>MR Severity Grade</measure>
    <time_frame>5 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Effective Regurgitant Orifice Area</measure>
    <time_frame>Baseline</time_frame>
    <description>Effective Regurgitant Orifice area is defined as = Regurgitant flow / Regurgitant velocity</description>
  </other_outcome>
  <other_outcome>
    <measure>Effective Regurgitant Orifice Area</measure>
    <time_frame>At discharge (or 30 days if discharge echocardiogram is not available)</time_frame>
    <description>Effective Regurgitant Orifice area is defined as = Regurgitant flow / Regurgitant velocity</description>
  </other_outcome>
  <other_outcome>
    <measure>Effective Regurgitant Orifice Area</measure>
    <time_frame>6 months</time_frame>
    <description>Effective Regurgitant Orifice area is defined as = Regurgitant flow / Regurgitant velocity</description>
  </other_outcome>
  <other_outcome>
    <measure>Effective Regurgitant Orifice Area</measure>
    <time_frame>12 months</time_frame>
    <description>Effective Regurgitant Orifice area is defined as = Regurgitant flow / Regurgitant velocity</description>
  </other_outcome>
  <other_outcome>
    <measure>Effective Regurgitant Orifice Area</measure>
    <time_frame>24 months</time_frame>
    <description>Effective Regurgitant Orifice area is defined as = Regurgitant flow / Regurgitant velocity</description>
  </other_outcome>
  <other_outcome>
    <measure>Effective Regurgitant Orifice Area</measure>
    <time_frame>3 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Effective Regurgitant Orifice Area</measure>
    <time_frame>4 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Effective Regurgitant Orifice Area</measure>
    <time_frame>5 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Regurgitant Volume</measure>
    <time_frame>Baseline</time_frame>
    <description>Regurgitant Volume is calculated by subtracting the inflow volume across the mitral valve during diastole from the Left Ventricular Outflow Tract (LVOT) stroke volume during systole.</description>
  </other_outcome>
  <other_outcome>
    <measure>Regurgitant Volume</measure>
    <time_frame>At discharge (or 30 days if discharge echocardiogram is not available)</time_frame>
    <description>Regurgitant Volume is calculated by subtracting the inflow volume across the mitral valve during diastole from the Left Ventricular Outflow Tract (LVOT) stroke volume during systole.</description>
  </other_outcome>
  <other_outcome>
    <measure>Regurgitant Volume</measure>
    <time_frame>6 months</time_frame>
    <description>Regurgitant Volume is calculated by subtracting the inflow volume across the mitral valve during diastole from the Left Ventricular Outflow Tract (LVOT) stroke volume during systole.</description>
  </other_outcome>
  <other_outcome>
    <measure>Regurgitant Volume</measure>
    <time_frame>12 months</time_frame>
    <description>Regurgitant Volume is calculated by subtracting the inflow volume across the mitral valve during diastole from the Left Ventricular Outflow Tract (LVOT) stroke volume during systole.</description>
  </other_outcome>
  <other_outcome>
    <measure>Regurgitant Volume</measure>
    <time_frame>24 months</time_frame>
    <description>Regurgitant Volume is calculated by subtracting the inflow volume across the mitral valve during diastole from the Left Ventricular Outflow Tract (LVOT) stroke volume during systole.</description>
  </other_outcome>
  <other_outcome>
    <measure>Regurgitant Volume</measure>
    <time_frame>3 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Regurgitant Volume</measure>
    <time_frame>4 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Regurgitant Volume</measure>
    <time_frame>5 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Regurgitant Fraction</measure>
    <time_frame>Baseline</time_frame>
    <description>Regurgitant fraction is the percentage of blood that regurgitates back through the aortic valve to the left ventricle due to aortic insufficiency, or through the mitral valve to the atrium due to mitral insufficiency.</description>
  </other_outcome>
  <other_outcome>
    <measure>Regurgitant Fraction</measure>
    <time_frame>At discharge (or 30 days if discharge echocardiogram is not available)</time_frame>
    <description>Regurgitant fraction is the percentage of blood that regurgitates back through the aortic valve to the left ventricle due to aortic insufficiency, or through the mitral valve to the atrium due to mitral insufficiency.</description>
  </other_outcome>
  <other_outcome>
    <measure>Regurgitant Fraction</measure>
    <time_frame>6 months</time_frame>
    <description>Regurgitant fraction is the percentage of blood that regurgitates back through the aortic valve to the left ventricle due to aortic insufficiency, or through the mitral valve to the atrium due to mitral insufficiency.</description>
  </other_outcome>
  <other_outcome>
    <measure>Regurgitant Fraction</measure>
    <time_frame>12 months</time_frame>
    <description>Regurgitant fraction is the percentage of blood that regurgitates back through the aortic valve to the left ventricle due to aortic insufficiency, or through the mitral valve to the atrium due to mitral insufficiency.</description>
  </other_outcome>
  <other_outcome>
    <measure>Regurgitant Fraction</measure>
    <time_frame>24 months</time_frame>
    <description>Regurgitant fraction is the percentage of blood that regurgitates back through the aortic valve to the left ventricle due to aortic insufficiency, or through the mitral valve to the atrium due to mitral insufficiency.</description>
  </other_outcome>
  <other_outcome>
    <measure>Regurgitant Fraction</measure>
    <time_frame>3 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Regurgitant Fraction</measure>
    <time_frame>4 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Regurgitant Fraction</measure>
    <time_frame>5 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Left Ventricle End Diastolic Volume (LVEDV)</measure>
    <time_frame>Baseline</time_frame>
    <description>Left Ventricle End-diastolic volume is the amount of blood that is in the left ventricle before the heart contracts.</description>
  </other_outcome>
  <other_outcome>
    <measure>Left Ventricle End Diastolic Volume (LVEDV)</measure>
    <time_frame>At discharge (or 30 days if discharge echocardiogram is not available)</time_frame>
    <description>Left Ventricle End-diastolic volume is the amount of blood that is in the left ventricle before the heart contracts.</description>
  </other_outcome>
  <other_outcome>
    <measure>Left Ventricle End Diastolic Volume (LVEDV)</measure>
    <time_frame>6 months</time_frame>
    <description>Left Ventricle End-diastolic volume is the amount of blood that is in the left ventricle before the heart contracts.</description>
  </other_outcome>
  <other_outcome>
    <measure>Left Ventricle End Diastolic Volume (LVEDV)</measure>
    <time_frame>12 months</time_frame>
    <description>Left Ventricle End-diastolic volume is the amount of blood that is in the left ventricle before the heart contracts.</description>
  </other_outcome>
  <other_outcome>
    <measure>Left Ventricle End Diastolic Volume (LVEDV)</measure>
    <time_frame>24 months</time_frame>
    <description>Left Ventricle End-diastolic volume is the amount of blood that is in the left ventricle before the heart contracts.</description>
  </other_outcome>
  <other_outcome>
    <measure>Left Ventricle End Diastolic Volume (LVEDV)</measure>
    <time_frame>3 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Left Ventricle End Diastolic Volume (LVEDV)</measure>
    <time_frame>4 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Left Ventricle End Diastolic Volume (LVEDV)</measure>
    <time_frame>5 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Left Ventricular End Systolic Volume (LVESV)</measure>
    <time_frame>Baseline</time_frame>
    <description>Left Ventricular End-systolic volume (LVESV) is the volume of blood in the left ventricle at the end of contraction, or systole, and the beginning of filling, or diastole. LVESV is the lowest volume of blood in the left ventricle at any point in the cardiac cycle.</description>
  </other_outcome>
  <other_outcome>
    <measure>Left Ventricular End Systolic Volume (LVESV)</measure>
    <time_frame>At discharge (or 30 days if discharge echocardiogram is not available)</time_frame>
    <description>Left Ventricular End-systolic volume (LVESV) is the volume of blood in the left ventricle at the end of contraction, or systole, and the beginning of filling, or diastole. LVESV is the lowest volume of blood in the left ventricle at any point in the cardiac cycle.</description>
  </other_outcome>
  <other_outcome>
    <measure>Left Ventricular End Systolic Volume (LVESV)</measure>
    <time_frame>6 months</time_frame>
    <description>Left Ventricular End-systolic volume (LVESV) is the volume of blood in the left ventricle at the end of contraction, or systole, and the beginning of filling, or diastole. LVESV is the lowest volume of blood in the left ventricle at any point in the cardiac cycle.</description>
  </other_outcome>
  <other_outcome>
    <measure>Left Ventricular End Systolic Volume (LVESV)</measure>
    <time_frame>12 months</time_frame>
    <description>Left Ventricular End-systolic volume (LVESV) is the volume of blood in the left ventricle at the end of contraction, or systole, and the beginning of filling, or diastole. LVESV is the lowest volume of blood in the left ventricle at any point in the cardiac cycle.</description>
  </other_outcome>
  <other_outcome>
    <measure>Left Ventricular End Systolic Volume (LVESV)</measure>
    <time_frame>24 months</time_frame>
    <description>Left Ventricular End-systolic volume (LVESV) is the volume of blood in the left ventricle at the end of contraction, or systole, and the beginning of filling, or diastole. LVESV is the lowest volume of blood in the left ventricle at any point in the cardiac cycle.</description>
  </other_outcome>
  <other_outcome>
    <measure>Left Ventricular End Systolic Volume (LVESV)</measure>
    <time_frame>3 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Left Ventricular End Systolic Volume (LVESV)</measure>
    <time_frame>4 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Left Ventricular End Systolic Volume (LVESV)</measure>
    <time_frame>5 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Left Ventricular End Diastolic Dimension (LVEDD)</measure>
    <time_frame>Baseline</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Left Ventricular End Diastolic Dimension (LVEDD)</measure>
    <time_frame>At discharge (or 30 days if discharge echocardiogram is not available)</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Left Ventricular End Diastolic Dimension (LVEDD)</measure>
    <time_frame>6 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Left Ventricular End Diastolic Dimension (LVEDD)</measure>
    <time_frame>12 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Left Ventricular End Diastolic Dimension (LVEDD)</measure>
    <time_frame>24 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Left Ventricular End Diastolic Dimension (LVEDD)</measure>
    <time_frame>3 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Left Ventricular End Diastolic Dimension (LVEDD)</measure>
    <time_frame>4 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Left Ventricular End Diastolic Dimension (LVEDD)</measure>
    <time_frame>5 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Left Ventricular End Systolic Dimension (LVESD)</measure>
    <time_frame>Baseline</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Left Ventricular End Systolic Dimension (LVESD)</measure>
    <time_frame>At discharge (or 30 days if discharge echocardiogram is not available)</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Left Ventricular End Systolic Dimension (LVESD)</measure>
    <time_frame>6 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Left Ventricular End Systolic Dimension (LVESD)</measure>
    <time_frame>12 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Left Ventricular End Systolic Dimension (LVESD)</measure>
    <time_frame>24 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Left Ventricular End Systolic Dimension (LVESD)</measure>
    <time_frame>3 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Left Ventricular End Systolic Dimension (LVESD)</measure>
    <time_frame>4 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Left Ventricular End Systolic Dimension (LVESD)</measure>
    <time_frame>5 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Left Ventricular Ejection Fraction (LVEF)</measure>
    <time_frame>Baseline</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Left Ventricular Ejection Fraction (LVEF)</measure>
    <time_frame>At discharge (or 30 days if discharge echocardiogram is not available)</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Left Ventricular Ejection Fraction (LVEF)</measure>
    <time_frame>6 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Left Ventricular Ejection Fraction (LVEF)</measure>
    <time_frame>12 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Left Ventricular Ejection Fraction (LVEF)</measure>
    <time_frame>24 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Left Ventricular Ejection Fraction (LVEF)</measure>
    <time_frame>3 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Left Ventricular Ejection Fraction (LVEF)</measure>
    <time_frame>4 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Left Ventricular Ejection Fraction (LVEF)</measure>
    <time_frame>5 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Right Ventricular Systolic Pressure (RVSP)</measure>
    <time_frame>Baseline</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Right Ventricular Systolic Pressure (RVSP)</measure>
    <time_frame>At discharge (or 30 days if discharge echocardiogram is not available)</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Right Ventricular Systolic Pressure (RVSP)</measure>
    <time_frame>6 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Right Ventricular Systolic Pressure (RVSP)</measure>
    <time_frame>12 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Right Ventricular Systolic Pressure (RVSP)</measure>
    <time_frame>24 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Right Ventricular Systolic Pressure (RVSP)</measure>
    <time_frame>3 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Right Ventricular Systolic Pressure (RVSP)</measure>
    <time_frame>4 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Right Ventricular Systolic Pressure (RVSP)</measure>
    <time_frame>5 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Mitral Valve Area</measure>
    <time_frame>Baseline</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Mitral Valve Area</measure>
    <time_frame>At discharge (or 30 days if discharge echocardiogram is not available)</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Mitral Valve Area</measure>
    <time_frame>6 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Mitral Valve Area</measure>
    <time_frame>12 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Mitral Valve Area</measure>
    <time_frame>24 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Mitral Valve Area</measure>
    <time_frame>3 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Mitral Valve Area</measure>
    <time_frame>4 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Mitral Valve Area</measure>
    <time_frame>5 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Mean Mitral Valve Gradient</measure>
    <time_frame>Baseline</time_frame>
    <description>The normal area of the mitral valve orifice is about 4-6 cm2 when the mitral valve area goes below 2 cm2, the valve causes an impediment to the flow of blood into the left ventricle, creating a pressure gradient (mitral valve gradient) across the mitral valve. This gradient may increase by the rise in heart rate or cardiac output.</description>
  </other_outcome>
  <other_outcome>
    <measure>Mean Mitral Valve Gradient</measure>
    <time_frame>At discharge (or 30 days if discharge echocardiogram is not available)</time_frame>
    <description>The normal area of the mitral valve orifice is about 4-6 cm2 when the mitral valve area goes below 2 cm2, the valve causes an impediment to the flow of blood into the left ventricle, creating a pressure gradient (mitral valve gradient) across the mitral valve. This gradient may increase by the rise in heart rate or cardiac output.</description>
  </other_outcome>
  <other_outcome>
    <measure>Mean Mitral Valve Gradient</measure>
    <time_frame>6 months</time_frame>
    <description>The normal area of the mitral valve orifice is about 4-6 cm2 when the mitral valve area goes below 2 cm2, the valve causes an impediment to the flow of blood into the left ventricle, creating a pressure gradient (mitral valve gradient) across the mitral valve. This gradient may increase by the rise in heart rate or cardiac output.</description>
  </other_outcome>
  <other_outcome>
    <measure>Mean Mitral Valve Gradient</measure>
    <time_frame>12 months</time_frame>
    <description>The normal area of the mitral valve orifice is about 4-6 cm2 when the mitral valve area goes below 2 cm2, the valve causes an impediment to the flow of blood into the left ventricle, creating a pressure gradient (mitral valve gradient) across the mitral valve. This gradient may increase by the rise in heart rate or cardiac output.</description>
  </other_outcome>
  <other_outcome>
    <measure>Mean Mitral Valve Gradient</measure>
    <time_frame>24 months</time_frame>
    <description>The normal area of the mitral valve orifice is about 4-6 cm2 when the mitral valve area goes below 2 cm2, the valve causes an impediment to the flow of blood into the left ventricle, creating a pressure gradient (mitral valve gradient) across the mitral valve. This gradient may increase by the rise in heart rate or cardiac output.</description>
  </other_outcome>
  <other_outcome>
    <measure>Mean Mitral Valve Gradient</measure>
    <time_frame>3 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Mean Mitral Valve Gradient</measure>
    <time_frame>4 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Mean Mitral Valve Gradient</measure>
    <time_frame>5 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Systolic Anterior Motion of the Mitral Valve (Present or Absent)</measure>
    <time_frame>Baseline</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Systolic Anterior Motion of the Mitral Valve (Present or Absent)</measure>
    <time_frame>At discharge (or 30 days if discharge echocardiogram is not available)</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Systolic Anterior Motion of the Mitral Valve (Present or Absent)</measure>
    <time_frame>6 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Systolic Anterior Motion of the Mitral Valve (Present or Absent)</measure>
    <time_frame>12 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Systolic Anterior Motion of the Mitral Valve (Present or Absent)</measure>
    <time_frame>24 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Systolic Anterior Motion of the Mitral Valve (Present or Absent)</measure>
    <time_frame>3 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Systolic Anterior Motion of the Mitral Valve (Present or Absent)</measure>
    <time_frame>4 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Systolic Anterior Motion of the Mitral Valve (Present or Absent)</measure>
    <time_frame>5 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Cardiac Output</measure>
    <time_frame>Baseline</time_frame>
    <description>The amount of blood the heart pumps through the circulatory system in a minute.</description>
  </other_outcome>
  <other_outcome>
    <measure>Cardiac Output</measure>
    <time_frame>At discharge (or 30 days if discharge echocardiogram is not available)</time_frame>
    <description>The amount of blood the heart pumps through the circulatory system in a minute.</description>
  </other_outcome>
  <other_outcome>
    <measure>Cardiac Output</measure>
    <time_frame>6 months</time_frame>
    <description>The amount of blood the heart pumps through the circulatory system in a minute.</description>
  </other_outcome>
  <other_outcome>
    <measure>Cardiac Output</measure>
    <time_frame>12 months</time_frame>
    <description>The amount of blood the heart pumps through the circulatory system in a minute.</description>
  </other_outcome>
  <other_outcome>
    <measure>Cardiac Output</measure>
    <time_frame>24 months</time_frame>
    <description>The amount of blood the heart pumps through the circulatory system in a minute.</description>
  </other_outcome>
  <other_outcome>
    <measure>Cardiac Output</measure>
    <time_frame>3 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Cardiac Output</measure>
    <time_frame>4 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Cardiac Output</measure>
    <time_frame>5 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Forward Stroke Volume</measure>
    <time_frame>Baseline</time_frame>
    <description>Stroke volume is the amount of blood ejected from the ventricle with each cardiac cycle. It can be readily calculated by subtracting the end-systolic volume from the end-diastolic volume.</description>
  </other_outcome>
  <other_outcome>
    <measure>Forward Stroke Volume</measure>
    <time_frame>At discharge (or 30 days if discharge echocardiogram is not available)</time_frame>
    <description>Stroke volume is the amount of blood ejected from the ventricle with each cardiac cycle. It can be readily calculated by subtracting the end-systolic volume from the end-diastolic volume.</description>
  </other_outcome>
  <other_outcome>
    <measure>Forward Stroke Volume</measure>
    <time_frame>6 months</time_frame>
    <description>Stroke volume is the amount of blood ejected from the ventricle with each cardiac cycle. It can be readily calculated by subtracting the end-systolic volume from the end-diastolic volume.</description>
  </other_outcome>
  <other_outcome>
    <measure>Forward Stroke Volume</measure>
    <time_frame>12 months</time_frame>
    <description>Stroke volume is the amount of blood ejected from the ventricle with each cardiac cycle. It can be readily calculated by subtracting the end-systolic volume from the end-diastolic volume.</description>
  </other_outcome>
  <other_outcome>
    <measure>Forward Stroke Volume</measure>
    <time_frame>24 months</time_frame>
    <description>Stroke volume is the amount of blood ejected from the ventricle with each cardiac cycle. It can be readily calculated by subtracting the end-systolic volume from the end-diastolic volume.</description>
  </other_outcome>
  <other_outcome>
    <measure>Forward Stroke Volume</measure>
    <time_frame>3 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Forward Stroke Volume</measure>
    <time_frame>4 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Forward Stroke Volume</measure>
    <time_frame>5 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Kaplan-Meier Freedom From the Components of the Primary Safety Composite</measure>
    <time_frame>12 months in Device group</time_frame>
    <description>Freedom from the components of the primary safety composite of device related complications including Single Leaflet Device Attachment (SLDA), device embolizations, endocarditis requiring surgery, Echocardiography Core Laboratory confirmed mitral stenosis requiring surgery, LVAD implant, heart transplant, or any device related complications requiring non-elective cardiovascular surgery at 12 months will be the primary measure of safety.</description>
  </other_outcome>
  <other_outcome>
    <measure>Kaplan-Meier Freedom From the Components of the Primary Safety Composite</measure>
    <time_frame>24 months in Device group</time_frame>
    <description>Freedom from the components of the primary safety composite of device related complications including Single Leaflet Device Attachment (SLDA), device embolizations, endocarditis requiring surgery, Echocardiography Core Laboratory confirmed mitral stenosis requiring surgery, LVAD implant, heart transplant, or any device related complications requiring non-elective cardiovascular surgery at 12 months will be the primary measure of safety.</description>
  </other_outcome>
  <other_outcome>
    <measure>Kaplan-Meier Freedom From the Components of the Primary Safety Composite</measure>
    <time_frame>3 years in Device group</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Kaplan-Meier Freedom From the Components of the Primary Safety Composite</measure>
    <time_frame>4 years in Device group</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Kaplan-Meier Freedom From the Components of the Primary Safety Composite</measure>
    <time_frame>5 years in Device group</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Kaplan-Meier Freedom From the Primary Safety Composite</measure>
    <time_frame>24 months in Device group</time_frame>
    <description>Freedom from the primary safety composite of device related complications including Single Leaflet Device Attachment (SLDA), device embolizations, endocarditis requiring surgery, Echocardiography Core Laboratory confirmed mitral stenosis requiring surgery, LVAD implant, heart transplant, or any device related complications requiring non-elective cardiovascular surgery at 12 months will be the primary measure of safety.</description>
  </other_outcome>
  <other_outcome>
    <measure>Kaplan-Meier Freedom From the Primary Safety Composite</measure>
    <time_frame>3 years in Device group</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Kaplan-Meier Freedom From the Primary Safety Composite</measure>
    <time_frame>4 years in Device group</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Kaplan-Meier Freedom From the Primary Safety Composite</measure>
    <time_frame>5 years in Device group</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Kaplan-Meier Freedom From All-cause Mortality</measure>
    <time_frame>24 months</time_frame>
    <description>Kaplan-Meier survival rate for all cause mortality at 24 months</description>
  </other_outcome>
  <other_outcome>
    <measure>Kaplan-Meier Freedom From All-cause Mortality</measure>
    <time_frame>3 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Kaplan-Meier Freedom From All-cause Mortality</measure>
    <time_frame>4 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Kaplan-Meier Freedom From All-cause Mortality</measure>
    <time_frame>5 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Kaplan-Meier Freedom From Cardiovascular Mortality</measure>
    <time_frame>12 months</time_frame>
    <description>Kaplan-Meier survival rate for Cardiovascular mortality.</description>
  </other_outcome>
  <other_outcome>
    <measure>Kaplan-Meier Freedom From Cardiovascular Mortality</measure>
    <time_frame>24 months</time_frame>
    <description>Kaplan-Meier survival rate for Cardiovascular mortality.</description>
  </other_outcome>
  <other_outcome>
    <measure>Kaplan-Meier Freedom From Cardiovascular Mortality</measure>
    <time_frame>3 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Kaplan-Meier Freedom From Cardiovascular Mortality</measure>
    <time_frame>4 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Kaplan-Meier Freedom From Cardiovascular Mortality</measure>
    <time_frame>5 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Kaplan-Meier Freedom From the First HF Related Hospitalization</measure>
    <time_frame>12 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Kaplan-Meier Freedom From the First HF Related Hospitalization</measure>
    <time_frame>24 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Kaplan-Meier Freedom From the First HF Related Hospitalization</measure>
    <time_frame>3 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Kaplan-Meier Freedom From the First HF Related Hospitalization</measure>
    <time_frame>4 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Kaplan-Meier Freedom From the First HF Related Hospitalization</measure>
    <time_frame>5 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Kaplan-Meier Freedom From the First Cardiovascular Hospitalization</measure>
    <time_frame>12 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Kaplan-Meier Freedom From the First Cardiovascular Hospitalization</measure>
    <time_frame>24 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Kaplan-Meier Freedom From the First Cardiovascular Hospitalization</measure>
    <time_frame>3 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Kaplan-Meier Freedom From the First Cardiovascular Hospitalization</measure>
    <time_frame>4 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Kaplan-Meier Freedom From the First Cardiovascular Hospitalization</measure>
    <time_frame>5 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Kaplan-Meier Freedom From the First HF Related Hospitalization or All-cause Mortality</measure>
    <time_frame>12 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Kaplan-Meier Freedom From the First HF Related Hospitalization or All-cause Mortality</measure>
    <time_frame>24 months</time_frame>
    <description>Survival rate from the first HF related hospitalization or all-cause mortality.</description>
  </other_outcome>
  <other_outcome>
    <measure>Kaplan-Meier Freedom From the First HF Related Hospitalization or All-cause Mortality</measure>
    <time_frame>3 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Kaplan-Meier Freedom From the First HF Related Hospitalization or All-cause Mortality</measure>
    <time_frame>4 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Kaplan-Meier Freedom From the First HF Related Hospitalization or All-cause Mortality</measure>
    <time_frame>5 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>NYHA Functional Class</measure>
    <time_frame>Baseline</time_frame>
    <description>Measure Description: The New York Heart Association (NYHA) Classification provides a simple way of classifying the extent of heart failure. It classifies patients in one of four categories based on their limitations during physical activity:
Class I: No symptoms and no limitation in ordinary physical activity Class II: Mild symptoms (mild shortness of breath and/or angina) and slight limitation during ordinary activity Class III: Marked limitation in activity due to symptoms Class IV: Severe limitations</description>
  </other_outcome>
  <other_outcome>
    <measure>NYHA Functional Class</measure>
    <time_frame>30 days</time_frame>
    <description>Measure Description: The New York Heart Association (NYHA) Classification provides a simple way of classifying the extent of heart failure. It classifies patients in one of four categories based on their limitations during physical activity:
Class I: No symptoms and no limitation in ordinary physical activity Class II: Mild symptoms (mild shortness of breath and/or angina) and slight limitation during ordinary activity Class III: Marked limitation in activity due to symptoms Class IV: Severe limitations</description>
  </other_outcome>
  <other_outcome>
    <measure>NYHA Functional Class</measure>
    <time_frame>6 months</time_frame>
    <description>Measure Description: The New York Heart Association (NYHA) Classification provides a simple way of classifying the extent of heart failure. It classifies patients in one of four categories based on their limitations during physical activity:
Class I: No symptoms and no limitation in ordinary physical activity Class II: Mild symptoms (mild shortness of breath and/or angina) and slight limitation during ordinary activity Class III: Marked limitation in activity due to symptoms Class IV: Severe limitations</description>
  </other_outcome>
  <other_outcome>
    <measure>NYHA Functional Class</measure>
    <time_frame>12 months</time_frame>
    <description>Measure Description: The New York Heart Association (NYHA) Classification provides a simple way of classifying the extent of heart failure. It classifies patients in one of four categories based on their limitations during physical activity:
Class I: No symptoms and no limitation in ordinary physical activity Class II: Mild symptoms (mild shortness of breath and/or angina) and slight limitation during ordinary activity Class III: Marked limitation in activity due to symptoms Class IV: Severe limitations</description>
  </other_outcome>
  <other_outcome>
    <measure>NYHA Functional Class</measure>
    <time_frame>24 months</time_frame>
    <description>Measure Description: The New York Heart Association (NYHA) Classification provides a simple way of classifying the extent of heart failure. It classifies patients in one of four categories based on their limitations during physical activity:
Class I: No symptoms and no limitation in ordinary physical activity Class II: Mild symptoms (mild shortness of breath and/or angina) and slight limitation during ordinary activity Class III: Marked limitation in activity due to symptoms Class IV: Severe limitations</description>
  </other_outcome>
  <other_outcome>
    <measure>NYHA Functional Class</measure>
    <time_frame>3 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>NYHA Functional Class</measure>
    <time_frame>4 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>NYHA Functional Class</measure>
    <time_frame>5 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Six-Minute Walk Test Distance (6MWD)</measure>
    <time_frame>Baseline</time_frame>
    <description>Six-Minute Walk Test is a submaximal exercise test that entails measurement of distance walked over a span of 6 minutes. The 6-minute walk test distance (6 MWD) provides a measure for integrated global response of multiple cardiopulmonary and musculoskeletal systems involved in exercise.</description>
  </other_outcome>
  <other_outcome>
    <measure>6MWD</measure>
    <time_frame>30 days</time_frame>
    <description>Six-Minute Walk Test is a submaximal exercise test that entails measurement of distance walked over a span of 6 minutes. The 6-minute walk test distance (6 MWD) provides a measure for integrated global response of multiple cardiopulmonary and musculoskeletal systems involved in exercise.</description>
  </other_outcome>
  <other_outcome>
    <measure>6MWD</measure>
    <time_frame>6 months</time_frame>
    <description>Six-Minute Walk Test is a submaximal exercise test that entails measurement of distance walked over a span of 6 minutes. The 6-minute walk test distance (6 MWD) provides a measure for integrated global response of multiple cardiopulmonary and musculoskeletal systems involved in exercise.</description>
  </other_outcome>
  <other_outcome>
    <measure>6MWD</measure>
    <time_frame>12 months</time_frame>
    <description>Six-Minute Walk Test is a submaximal exercise test that entails measurement of distance walked over a span of 6 minutes. The 6-minute walk test distance (6 MWD) provides a measure for integrated global response of multiple cardiopulmonary and musculoskeletal systems involved in exercise.</description>
  </other_outcome>
  <other_outcome>
    <measure>6MWD</measure>
    <time_frame>24 months</time_frame>
    <description>Six-Minute Walk Test is a submaximal exercise test that entails measurement of distance walked over a span of 6 minutes. The 6-minute walk test distance (6 MWD) provides a measure for integrated global response of multiple cardiopulmonary and musculoskeletal systems involved in exercise.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in 6MWD From Baseline</measure>
    <time_frame>Between baseline and 30 days</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in 6MWD From Baseline</measure>
    <time_frame>Between baseline and 6 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in 6MWD From Baseline</measure>
    <time_frame>Between baseline and 12 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in 6MWD From Baseline</measure>
    <time_frame>Between baseline and 24 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Kansas City Cardiomyopathy Questionnaire (KCCQ) QoL Scores</measure>
    <time_frame>Baseline</time_frame>
    <description>The Kansas City Cardiomyopathy Questionnaire is a 23-item, self-administered instrument that quantifies physical function, symptoms, social function, self-efficacy and knowledge, and quality of life. with a range of possible subscale scores from 0 to 100, with 100 representing the least burden of symptoms. The KCCQ tool quantifies the following six (6) distinct domains and two (2) summary scores: KCCQ Symptom Domain, KCCQ Physical Function Domain, KCCQ Quality of Life Domain, KCCQ Social Limitation Domain, KCCQ Self-efficacy Domain, KCCQ Symptom Stability Domain, Clinical Summary Score and Overall Summary Score.
Clinical Summary Score includes total symptom and physical function scores to correspond with NYHA Classification.
Overall Summary Score includes the total symptom, physical function, social limitations and quality of life scores.</description>
  </other_outcome>
  <other_outcome>
    <measure>KCCQ QoL Scores</measure>
    <time_frame>30 days</time_frame>
    <description>The Kansas City Cardiomyopathy Questionnaire is a 23-item, self-administered instrument that quantifies physical function, symptoms, social function, self-efficacy and knowledge, and quality of life. with a range of possible subscale scores from 0 to 100, with 100 representing the least burden of symptoms. The KCCQ tool quantifies the following six (6) distinct domains and two (2) summary scores: KCCQ Symptom Domain, KCCQ Physical Function Domain, KCCQ Quality of Life Domain, KCCQ Social Limitation Domain, KCCQ Self-efficacy Domain, KCCQ Symptom Stability Domain, Clinical Summary Score and Overall Summary Score.
Clinical Summary Score includes total symptom and physical function scores to correspond with NYHA Classification.
Overall Summary Score includes the total symptom, physical function, social limitations and quality of life scores.</description>
  </other_outcome>
  <other_outcome>
    <measure>KCCQ QoL Scores</measure>
    <time_frame>6 months</time_frame>
    <description>The Kansas City Cardiomyopathy Questionnaire is a 23-item, self-administered instrument that quantifies physical function, symptoms, social function, self-efficacy and knowledge, and quality of life. with a range of possible subscale scores from 0 to 100, with 100 representing the least burden of symptoms. The KCCQ tool quantifies the following six (6) distinct domains and two (2) summary scores: KCCQ Symptom Domain, KCCQ Physical Function Domain, KCCQ Quality of Life Domain, KCCQ Social Limitation Domain, KCCQ Self-efficacy Domain, KCCQ Symptom Stability Domain, Clinical Summary Score and Overall Summary Score.
Clinical Summary Score includes total symptom and physical function scores to correspond with NYHA Classification.
Overall Summary Score includes the total symptom, physical function, social limitations and quality of life scores.</description>
  </other_outcome>
  <other_outcome>
    <measure>KCCQ QoL Scores</measure>
    <time_frame>12 months</time_frame>
    <description>The Kansas City Cardiomyopathy Questionnaire is a 23-item, self-administered instrument that quantifies physical function, symptoms, social function, self-efficacy and knowledge, and quality of life. with a range of possible subscale scores from 0 to 100, with 100 representing the least burden of symptoms. The KCCQ tool quantifies the following six (6) distinct domains and two (2) summary scores: KCCQ Symptom Domain, KCCQ Physical Function Domain, KCCQ Quality of Life Domain, KCCQ Social Limitation Domain, KCCQ Self-efficacy Domain, KCCQ Symptom Stability Domain, Clinical Summary Score and Overall Summary Score.
Clinical Summary Score includes total symptom and physical function scores to correspond with NYHA Classification.
Overall Summary Score includes the total symptom, physical function, social limitations and quality of life scores.</description>
  </other_outcome>
  <other_outcome>
    <measure>KCCQ QoL Scores</measure>
    <time_frame>24 months</time_frame>
    <description>The Kansas City Cardiomyopathy Questionnaire is a 23-item, self-administered instrument that quantifies physical function, symptoms, social function, self-efficacy and knowledge, and quality of life. with a range of possible subscale scores from 0 to 100, with 100 representing the least burden of symptoms. The KCCQ tool quantifies the following six (6) distinct domains and two (2) summary scores: KCCQ Symptom Domain, KCCQ Physical Function Domain, KCCQ Quality of Life Domain, KCCQ Social Limitation Domain, KCCQ Self-efficacy Domain, KCCQ Symptom Stability Domain, Clinical Summary Score and Overall Summary Score.
Clinical Summary Score includes total symptom and physical function scores to correspond with NYHA Classification.
Overall Summary Score includes the total symptom, physical function, social limitations and quality of life scores.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in KCCQ QoL Scores From Baseline</measure>
    <time_frame>Between baseline and 30 days</time_frame>
    <description>Paired data looking at difference between the baseline Kansas City Cardiomyopathy Questionnaire (KCCQ) and 30 days KCCQ score.
The Kansas City Cardiomyopathy Questionnaire is a 23-item, self-administered instrument that quantifies physical function, symptoms, social function, self-efficacy and knowledge, and quality of life. with a range of possible subscale scores from 0 to 100, with 100 representing the least burden of symptoms. The KCCQ tool quantifies the following six (6) distinct domains and two (2) summary scores: KCCQ Symptom Domain, KCCQ Physical Function Domain, KCCQ Quality of Life Domain, KCCQ Social Limitation Domain, KCCQ Self-efficacy Domain, KCCQ Symptom Stability Domain, Clinical Summary Score and Overall Summary Score.
Clinical Summary Score includes total symptom and physical function scores to correspond with NYHA Classification.
Overall Summary Score includes the total symptom, physical function, social limitations and quality of life scores.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in KCCQ QoL Scores From Baseline</measure>
    <time_frame>Between baseline and 6 months</time_frame>
    <description>Paired data looking at difference between the baseline Kansas City Cardiomyopathy Questionnaire (KCCQ) and 6 months KCCQ score.
The Kansas City Cardiomyopathy Questionnaire is a 23-item, self-administered instrument that quantifies physical function, symptoms, social function, self-efficacy and knowledge, and quality of life. with a range of possible subscale scores from 0 to 100, with 100 representing the least burden of symptoms. The KCCQ tool quantifies the following six (6) distinct domains and two (2) summary scores: KCCQ Symptom Domain, KCCQ Physical Function Domain, KCCQ Quality of Life Domain, KCCQ Social Limitation Domain, KCCQ Self-efficacy Domain, KCCQ Symptom Stability Domain, Clinical Summary Score and Overall Summary Score.
Clinical Summary Score includes total symptom and physical function scores to correspond with NYHA Classification.
Overall Summary Score includes the total symptom, physical function, social limitations and quality of life scores.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in KCCQ QoL Scores From Baseline</measure>
    <time_frame>Between baseline and 12 months</time_frame>
    <description>Paired data looking at difference between the baseline Kansas City Cardiomyopathy Questionnaire (KCCQ) and 12 months KCCQ score.
The Kansas City Cardiomyopathy Questionnaire is a 23-item, self-administered instrument that quantifies physical function, symptoms, social function, self-efficacy and knowledge, and quality of life. with a range of possible subscale scores from 0 to 100, with 100 representing the least burden of symptoms. The KCCQ tool quantifies the following six (6) distinct domains and two (2) summary scores: KCCQ Symptom Domain, KCCQ Physical Function Domain, KCCQ Quality of Life Domain, KCCQ Social Limitation Domain, KCCQ Self-efficacy Domain, KCCQ Symptom Stability Domain, Clinical Summary Score and Overall Summary Score.
Clinical Summary Score includes total symptom and physical function scores to correspond with NYHA Classification.
Overall Summary Score includes the total symptom, physical function, social limitations and quality of life scores.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in KCCQ QoL Scores From Baseline</measure>
    <time_frame>Between baseline and 24 months</time_frame>
    <description>Paired data looking at difference between the baseline Kansas City Cardiomyopathy Questionnaire (KCCQ) and 24 months KCCQ score.
The Kansas City Cardiomyopathy Questionnaire is a 23-item, self-administered instrument that quantifies physical function, symptoms, social function, self-efficacy and knowledge, and quality of life. with a range of possible subscale scores from 0 to 100, with 100 representing the least burden of symptoms. The KCCQ tool quantifies the following six (6) distinct domains and two (2) summary scores: KCCQ Symptom Domain, KCCQ Physical Function Domain, KCCQ Quality of Life Domain, KCCQ Social Limitation Domain, KCCQ Self-efficacy Domain, KCCQ Symptom Stability Domain, Clinical Summary Score and Overall Summary Score.
Clinical Summary Score includes total symptom and physical function scores to correspond with NYHA Classification.
Overall Summary Score includes the total symptom, physical function, social limitations and quality of life scores.</description>
  </other_outcome>
  <other_outcome>
    <measure>SF-36 QoL Scores</measure>
    <time_frame>Baseline</time_frame>
    <description>The 36-Item Short Form Health Survey questionnaire (SF-36) is a very popular instrument for evaluating Health-Related Quality of Life. with a range of possible subscale scores from 0 to 100, with 100 representing the least burden of symptoms. There are two distinct concepts measured by the SF-36: a physical dimension, represented by the Physical Component Summary (PCS), and a mental dimension, represented by the Mental Component Summary (MCS).</description>
  </other_outcome>
  <other_outcome>
    <measure>SF-36 QoL Scores</measure>
    <time_frame>30 days</time_frame>
    <description>The 36-Item Short Form Health Survey questionnaire (SF-36) is a very popular instrument for evaluating Health-Related Quality of Life. with a range of possible subscale scores from 0 to 100, with 100 representing the least burden of symptoms. There are two distinct concepts measured by the SF-36: a physical dimension, represented by the Physical Component Summary (PCS), and a mental dimension, represented by the Mental Component Summary (MCS).</description>
  </other_outcome>
  <other_outcome>
    <measure>SF-36 QoL Scores</measure>
    <time_frame>6 months</time_frame>
    <description>The 36-Item Short Form Health Survey questionnaire (SF-36) is a very popular instrument for evaluating Health-Related Quality of Life. with a range of possible subscale scores from 0 to 100, with 100 representing the least burden of symptoms. There are two distinct concepts measured by the SF-36: a physical dimension, represented by the Physical Component Summary (PCS), and a mental dimension, represented by the Mental Component Summary (MCS).</description>
  </other_outcome>
  <other_outcome>
    <measure>SF-36 QoL Scores</measure>
    <time_frame>12 months</time_frame>
    <description>The 36-Item Short Form Health Survey questionnaire (SF-36) is a very popular instrument for evaluating Health-Related Quality of Life. with a range of possible subscale scores from 0 to 100, with 100 representing the least burden of symptoms. There are two distinct concepts measured by the SF-36: a physical dimension, represented by the Physical Component Summary (PCS), and a mental dimension, represented by the Mental Component Summary (MCS).</description>
  </other_outcome>
  <other_outcome>
    <measure>SF-36 QoL Scores</measure>
    <time_frame>24 months</time_frame>
    <description>The 36-Item Short Form Health Survey questionnaire (SF-36) is a very popular instrument for evaluating Health-Related Quality of Life. with a range of possible subscale scores from 0 to 100, with 100 representing the least burden of symptoms. There are two distinct concepts measured by the SF-36: a physical dimension, represented by the Physical Component Summary (PCS), and a mental dimension, represented by the Mental Component Summary (MCS).</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in SF-36 QoL Scores From Baseline</measure>
    <time_frame>Between baseline and 30 days</time_frame>
    <description>Paired data looking at difference between the baseline SF-36 and 30 days SF-36. The 36-Item Short Form Health Survey questionnaire (SF-36) is a very popular instrument for evaluating Health-Related Quality of Life. with a range of possible subscale scores from 0 to 100, with 100 representing the least burden of symptoms. There are two distinct concepts measured by the SF-36: a physical dimension, represented by the Physical Component Summary (PCS), and a mental dimension, represented by the Mental Component Summary (MCS).</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in SF-36 QoL Scores From Baseline</measure>
    <time_frame>Between baseline and 6 months</time_frame>
    <description>Paired data looking at difference between the baseline SF-36 and 6 months days SF-36.
The 36-Item Short Form Health Survey questionnaire (SF-36) is a very popular instrument for evaluating Health-Related Quality of Life. with a range of possible subscale scores from 0 to 100, with 100 representing the least burden of symptoms. There are two distinct concepts measured by the SF-36: a physical dimension, represented by the Physical Component Summary (PCS), and a mental dimension, represented by the Mental Component Summary (MCS).</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in SF-36 QoL Scores From Baseline</measure>
    <time_frame>Between baseline and 12 months</time_frame>
    <description>Paired data looking at difference between the baseline SF-36 and 12 month SF-36.
The 36-Item Short Form Health Survey questionnaire (SF-36) is a very popular instrument for evaluating Health-Related Quality of Life. with a range of possible subscale scores from 0 to 100, with 100 representing the least burden of symptoms. There are two distinct concepts measured by the SF-36: a physical dimension, represented by the Physical Component Summary (PCS), and a mental dimension, represented by the Mental Component Summary (MCS).</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in SF-36 QoL Scores From Baseline</measure>
    <time_frame>Between baseline and 24 months</time_frame>
    <description>Paired data looking at difference between the baseline SF-36 and 24 months SF-36.
The 36-Item Short Form Health Survey questionnaire (SF-36) is a very popular instrument for evaluating Health-Related Quality of Life. with a range of possible subscale scores from 0 to 100, with 100 representing the least burden of symptoms. There are two distinct concepts measured by the SF-36: a physical dimension, represented by the Physical Component Summary (PCS), and a mental dimension, represented by the Mental Component Summary (MCS).</description>
  </other_outcome>
  <other_outcome>
    <measure>Mitral Valve Surgery (Including Type of Surgery), New Use of CRT, New Use of Single or Dual Chamber Pacemaker, Permanent LVAD Implant, Heart Transplant, Additional MitraClip Device Intervention in Device Group</measure>
    <time_frame>Through 5 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>De Novo MitraClip Device Intervention in Control Group</measure>
    <time_frame>Through 5 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Responder Analysis for 6MWD</measure>
    <time_frame>12 months</time_frame>
    <description>Where responder is defined as alive and experiencing an improvement of 24 meters and 50 meters (difference in proportion of responders between Device and Control groups)</description>
  </other_outcome>
  <other_outcome>
    <measure>Responder Analysis for 6MWD</measure>
    <time_frame>24 months</time_frame>
    <description>Where responder is defined as alive and experiencing an improvement of 24 meters and 50 meters (difference in proportion of responders between Device and Control groups)</description>
  </other_outcome>
  <other_outcome>
    <measure>Responder Analysis for LVEDV Index</measure>
    <time_frame>12 months</time_frame>
    <description>Where responder is defined as alive and experiencing an improvement of 12 ml/m2 (difference in proportion of responders between Device and Control groups)</description>
  </other_outcome>
  <other_outcome>
    <measure>Responder Analysis for LVEDV Index</measure>
    <time_frame>24 months</time_frame>
    <description>Where responder is defined as alive and experiencing an improvement of 12 ml/m2 (difference in proportion of responders between Device and Control groups)</description>
  </other_outcome>
  <other_outcome>
    <measure>Responder Analysis for LVEDV Index</measure>
    <time_frame>3 years</time_frame>
    <description>Where responder is defined as alive and experiencing an improvement of 12 ml/m2 (difference in proportion of responders between Device and Control groups)</description>
  </other_outcome>
  <other_outcome>
    <measure>Responder Analysis for LVEDV Index</measure>
    <time_frame>4 years</time_frame>
    <description>Where responder is defined as alive and experiencing an improvement of 12 ml/m2 (difference in proportion of responders between Device and Control groups)</description>
  </other_outcome>
  <other_outcome>
    <measure>Responder Analysis for LVEDV Index</measure>
    <time_frame>5 years</time_frame>
    <description>Where responder is defined as alive and experiencing an improvement of 12 ml/m2 (difference in proportion of responders between Device and Control groups)</description>
  </other_outcome>
  <other_outcome>
    <measure>Responder Analysis for QoL (KCCQ)</measure>
    <time_frame>12 months</time_frame>
    <description>Where responder is defined as alive and experiencing an improvement of 5 points (difference in proportion of responders between Device and Control groups)</description>
  </other_outcome>
  <other_outcome>
    <measure>Responder Analysis for QoL (KCCQ)</measure>
    <time_frame>24 months</time_frame>
    <description>Where responder is defined as alive and experiencing an improvement of 5 points (difference in proportion of responders between Device and Control groups)</description>
  </other_outcome>
  <other_outcome>
    <measure>Each Subscale for QoL (KCCQ)</measure>
    <time_frame>12 months</time_frame>
    <description>difference in means between Device and Control groups for the Kansas City Cardiomyopathy Questionnaire (KCCQ) for the physical limitation and symptom stability scores.</description>
  </other_outcome>
  <other_outcome>
    <measure>Each Subscale for QoL (KCCQ)</measure>
    <time_frame>24 months</time_frame>
    <description>difference in means between Device and Control groups for the Kansas City Cardiomyopathy Questionnaire (KCCQ) for the physical limitation and symptom stability scores.</description>
  </other_outcome>
  <other_outcome>
    <measure>Length of Index Hospitalization for MitraClip Procedure (Device Group)</measure>
    <time_frame>Before MitraClip procedure on day 0</time_frame>
    <description>Length of stay in the hospital for the MitraClip Index procedure (device group)</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of Hospitalizations and Reason for Hospitalization (i.e. Heart Failure, Cardiovascular, Non-cardiovascular)</measure>
    <time_frame>12 months</time_frame>
    <description>in each of the Device and Control groups</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of Hospitalizations and Reason for Hospitalization (i.e. Heart Failure, Cardiovascular, Non-cardiovascular)</measure>
    <time_frame>24 months</time_frame>
    <description>in each of the Device and Control groups</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of Days Alive and Out of Hospital</measure>
    <time_frame>From the time of randomization to 12 months</time_frame>
    <description>difference in mean between Device and Control groups</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of Days Alive and Out of Hospital</measure>
    <time_frame>From the time of randomization to 24 months</time_frame>
    <description>difference in means between Device and Control groups</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of Days Alive and Out of Hospital</measure>
    <time_frame>From the time of randomization to 3 Years</time_frame>
    <description>difference in medians between Device and Control groups</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of Days Alive and Out of Hospital</measure>
    <time_frame>From the time of randomization to 4 Years</time_frame>
    <description>difference in medians between Device and Control groups</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of Days Alive and Out of Hospital</measure>
    <time_frame>From the time of randomization to 5 Years</time_frame>
    <description>difference in medians between Device and Control groups</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of Days Hospitalized From the &quot;Treatment&quot; Visit</measure>
    <time_frame>12 months</time_frame>
    <description>difference in means between Device and Control groups</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of Days Hospitalized From the &quot;Treatment&quot; Visit</measure>
    <time_frame>24 months</time_frame>
    <description>difference in means between Device and Control groups</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of Days Hospitalized From the &quot;Treatment&quot; Visit</measure>
    <time_frame>3 Years</time_frame>
    <description>difference in medians between Device and Control groups</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of Days Hospitalized From the &quot;Treatment&quot; Visit</measure>
    <time_frame>4 Years</time_frame>
    <description>difference in medians between Device and Control groups</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of Days Hospitalized From the &quot;Treatment&quot; Visit</measure>
    <time_frame>5 Years</time_frame>
    <description>difference in medians between Device and Control groups</description>
  </other_outcome>
  <other_outcome>
    <measure>Proportion of Alive Time in Hospital</measure>
    <time_frame>12 months</time_frame>
    <description>summarized and compared between Device and Control groups</description>
  </other_outcome>
  <other_outcome>
    <measure>Proportion of Alive Time in Hospital</measure>
    <time_frame>24 months</time_frame>
    <description>summarized and compared between Device and Control groups</description>
  </other_outcome>
  <other_outcome>
    <measure>Proportion of Alive Time in Hospital</measure>
    <time_frame>3 years</time_frame>
    <description>summarized and compared between Device and Control groups</description>
  </other_outcome>
  <other_outcome>
    <measure>Proportion of Alive Time in Hospital</measure>
    <time_frame>4 years</time_frame>
    <description>summarized and compared between Device and Control groups</description>
  </other_outcome>
  <other_outcome>
    <measure>Proportion of Alive Time in Hospital</measure>
    <time_frame>5 years</time_frame>
    <description>summarized and compared between Device and Control groups</description>
  </other_outcome>
  <other_outcome>
    <measure>Proportion of Subjects Living in the Baseline Location</measure>
    <time_frame>12 months</time_frame>
    <description>Subjects living in the baseline location include : home, retirement home, nursing facility and other location.</description>
  </other_outcome>
  <other_outcome>
    <measure>Proportion of Subjects Living in the Baseline Location</measure>
    <time_frame>24 months</time_frame>
    <description>Subjects living in the baseline location include : home, retirement home, nursing facility and other location.</description>
  </other_outcome>
  <other_outcome>
    <measure>Proportion of Subjects Living in the Baseline Location</measure>
    <time_frame>3 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Proportion of Subjects Living in the Baseline Location</measure>
    <time_frame>4 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Proportion of Subjects Living in the Baseline Location</measure>
    <time_frame>5 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Mitral Valve Replacement Rates</measure>
    <time_frame>12 months</time_frame>
    <description>Subjects with mitral valve replacements in the Device and Control groups</description>
  </other_outcome>
  <other_outcome>
    <measure>Mitral Valve Replacement Rates</measure>
    <time_frame>24 months</time_frame>
    <description>Subjects with mitral valve replacements in the Device and Control groups</description>
  </other_outcome>
  <other_outcome>
    <measure>Mitral Valve Replacement Rates</measure>
    <time_frame>3 years</time_frame>
    <description>summarized and compared between Device and Control groups</description>
  </other_outcome>
  <other_outcome>
    <measure>Mitral Valve Replacement Rates</measure>
    <time_frame>4 years</time_frame>
    <description>summarized and compared between Device and Control groups</description>
  </other_outcome>
  <other_outcome>
    <measure>Mitral Valve Replacement Rates</measure>
    <time_frame>5 years</time_frame>
    <description>summarized and compared between Device and Control groups</description>
  </other_outcome>
  <other_outcome>
    <measure>New Onset of Permanent Atrial Fibrillation</measure>
    <time_frame>12 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>New Onset of Permanent Atrial Fibrillation</measure>
    <time_frame>24 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>New Onset of Permanent Atrial Fibrillation</measure>
    <time_frame>3 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>New Onset of Permanent Atrial Fibrillation</measure>
    <time_frame>4 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>New Onset of Permanent Atrial Fibrillation</measure>
    <time_frame>5 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Mitral Stenosis</measure>
    <time_frame>12 months</time_frame>
    <description>Defined as a mitral valve orifice area of less than 1.5 cm2 as measured by the Echocardiography Core Laboratory</description>
  </other_outcome>
  <other_outcome>
    <measure>Mitral Stenosis</measure>
    <time_frame>24 months</time_frame>
    <description>Defined as a mitral valve orifice area of less than 1.5 cm2 as measured by the Echocardiography Core Laboratory</description>
  </other_outcome>
  <other_outcome>
    <measure>Mitral Stenosis</measure>
    <time_frame>3 years</time_frame>
    <description>Defined as a mitral valve orifice area of less than 1.5 cm2 as measured by the Echocardiography Core Laboratory</description>
  </other_outcome>
  <other_outcome>
    <measure>Mitral Stenosis</measure>
    <time_frame>4 years</time_frame>
    <description>Defined as a mitral valve orifice area of less than 1.5 cm2 as measured by the Echocardiography Core Laboratory</description>
  </other_outcome>
  <other_outcome>
    <measure>Mitral Stenosis</measure>
    <time_frame>5 years</time_frame>
    <description>Defined as a mitral valve orifice area of less than 1.5 cm2 as measured by the Echocardiography Core Laboratory</description>
  </other_outcome>
  <other_outcome>
    <measure>Clinically Significant Atrial Septal Defect (ASD) That Requires Intervention</measure>
    <time_frame>12 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Clinically Significant Atrial Septal Defect (ASD) That Requires Intervention</measure>
    <time_frame>24 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Clinically Significant Atrial Septal Defect (ASD) That Requires Intervention</measure>
    <time_frame>3 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Clinically Significant Atrial Septal Defect (ASD) That Requires Intervention</measure>
    <time_frame>4 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Clinically Significant Atrial Septal Defect (ASD) That Requires Intervention</measure>
    <time_frame>5 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Device-related Complications in Device Group Subjects and Control Group Subjects Who Undergo the MitraClip Procedure</measure>
    <time_frame>Through 5 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Brain Natriuretic Peptide (BNP) or N-terminal Prohormone of Brain Natriuretic Peptide (NT-proBNP Levels)</measure>
    <time_frame>Baseline</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>BNP or NT-proBNP Levels</measure>
    <time_frame>30 days</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>BNP or NT-proBNP Levels</measure>
    <time_frame>12 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Modified Rankin Scale Score</measure>
    <time_frame>Baseline</time_frame>
    <description>MODIFIED RANKIN SCALE SCORE DESCRIPTIONS:
0- No symptoms at all; 1- No significant disability despite symptoms; able to carry out all usual duties and activities; 2- Slight disability; unable to carry out all previous activities, but able to look after own affairs without assistance; 3- Moderate disability; requiring some help, but able to walk without assistance; 4- Moderately severe disability; unable to walk without assistance and unable to attend to own bodily needs without assistance; 5- Severe disability; bedridden, incontinent and requiring constant nursing care and attention; 6- Dead</description>
  </other_outcome>
  <other_outcome>
    <measure>Modified Rankin Scale Score</measure>
    <time_frame>30 days</time_frame>
    <description>MODIFIED RANKIN SCALE SCORE DESCRIPTIONS:
0- No symptoms at all; 1- No significant disability despite symptoms; able to carry out all usual duties and activities; 2- Slight disability; unable to carry out all previous activities, but able to look after own affairs without assistance; 3- Moderate disability; requiring some help, but able to walk without assistance; 4- Moderately severe disability; unable to walk without assistance and unable to attend to own bodily needs without assistance; 5- Severe disability; bedridden, incontinent and requiring constant nursing care and attention; 6- Dead</description>
  </other_outcome>
  <other_outcome>
    <measure>Modified Rankin Scale Score</measure>
    <time_frame>6 months</time_frame>
    <description>MODIFIED RANKIN SCALE SCORE DESCRIPTIONS:
0- No symptoms at all; 1- No significant disability despite symptoms; able to carry out all usual duties and activities; 2- Slight disability; unable to carry out all previous activities, but able to look after own affairs without assistance; 3- Moderate disability; requiring some help, but able to walk without assistance; 4- Moderately severe disability; unable to walk without assistance and unable to attend to own bodily needs without assistance; 5- Severe disability; bedridden, incontinent and requiring constant nursing care and attention; 6- Dead</description>
  </other_outcome>
  <other_outcome>
    <measure>Modified Rankin Scale Score</measure>
    <time_frame>12 months</time_frame>
    <description>MODIFIED RANKIN SCALE SCORE DESCRIPTIONS:
0- No symptoms at all; 1- No significant disability despite symptoms; able to carry out all usual duties and activities; 2- Slight disability; unable to carry out all previous activities, but able to look after own affairs without assistance; 3- Moderate disability; requiring some help, but able to walk without assistance; 4- Moderately severe disability; unable to walk without assistance and unable to attend to own bodily needs without assistance; 5- Severe disability; bedridden, incontinent and requiring constant nursing care and attention; 6- Dead</description>
  </other_outcome>
  <other_outcome>
    <measure>Major Bleeding</measure>
    <time_frame>30 days</time_frame>
    <description>Major bleeding is defined as bleeding ≥ Type 3 based on a modified Bleeding Academic Research Consortium (BARC) definition</description>
  </other_outcome>
  <other_outcome>
    <measure>Prolonged Ventilation</measure>
    <time_frame>30 days</time_frame>
    <description>Defined as pulmonary insufficiency requiring ventilatory support for greater than 48 hours post-catheterization</description>
  </other_outcome>
  <other_outcome>
    <measure>Average Dosages of Guideline Directed Medical Therapy (GDMT)</measure>
    <time_frame>Baseline</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Average Dosages of GDMT</measure>
    <time_frame>30 days</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Average Dosages of GDMT</measure>
    <time_frame>6 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Average Dosages of GDMT</measure>
    <time_frame>12 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Average Dosages of GDMT</measure>
    <time_frame>24 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Average Dosages of GDMT</measure>
    <time_frame>3 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Average Dosages of GDMT</measure>
    <time_frame>4 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Average Dosages of GDMT</measure>
    <time_frame>5 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>The Number of Subjects With Changes in GDMT Dosage From Baseline</measure>
    <time_frame>Between baseline and 30 days</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>The Number of Subjects With Changes in GDMT Dosage From Baseline to 6 Months</measure>
    <time_frame>Between baseline and 6 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>The Number of Subjects With Changes in GDMT Dosage From Baseline and 12 Months</measure>
    <time_frame>Between baseline and 12 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>The Number of Subjects With Changes in GDMT Dosage From Baseline and 24 Months</measure>
    <time_frame>Between baseline and 24 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>The Number and Reasons for Any Changes in GDMT and GDMT Dosage From Baseline</measure>
    <time_frame>Between baseline and 3 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>The Number and Reasons for Any Changes in GDMT and GDMT Dosage From Baseline</measure>
    <time_frame>Between baseline and 4 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>The Number and Reasons for Any Changes in GDMT and GDMT Dosage From Baseline</measure>
    <time_frame>Between baseline and 5 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>The Number of Subjects With Change in GDMT From Baseline That Result in a Greater Than 100% Increase or Greater Than 50% Decrease in Dose</measure>
    <time_frame>Between baseline and 30 days</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>The Number of Subjects With Any Changes in GDMT From Baseline That Result in a Greater Than 100% Increase or Greater Than 50% Decrease in Dose</measure>
    <time_frame>Between baseline and 6 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>The Number of Subjects With Any Changes in GDMT From Baseline That Result in a Greater Than 100% Increase or Greater Than 50% Decrease in Dose</measure>
    <time_frame>Between baseline and 12 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>The Number of Subjects With Any Changes in GDMT From Baseline That Result in a Greater Than 100% Increase or Greater Than 50% Decrease in Dose</measure>
    <time_frame>Between baseline and 24 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>The Number and Reasons for Any Changes in GDMT From Baseline That Result in a Greater Than 100% Increase or Greater Than 50% Decrease in Dose</measure>
    <time_frame>Between baseline and 3 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>The Number and Reasons for Any Changes in GDMT From Baseline That Result in a Greater Than 100% Increase or Greater Than 50% Decrease in Dose</measure>
    <time_frame>Between baseline and 4 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>The Number and Reasons for Any Changes in GDMT From Baseline That Result in a Greater Than 100% Increase or Greater Than 50% Decrease in Dose</measure>
    <time_frame>Between baseline and 5 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Cardiopulmonary Exercise (CPX) Testing</measure>
    <time_frame>Baseline</time_frame>
    <description>A substudy endpoint will utilize peak oxygen consumption oxygen uptake (VO2) as a parameter for cardiopulmonary exercise testing on a total of at least 50 and up to 100 subjects.
The CPX analysis variables are:
Peak VO2 (ml/kg/min) - CPX Sub-study endpoint, descriptive analysis only, not powered for statistical significance
Exercise duration (min)
Peak workload (watts)
Maximum heart rate during exercise (beats/min)
Peak VE (l/min)
Respiratory Exchange Ratio (RER, VCO2/VO2)
VE/VCO2 slope
Ventilatory Threshold (ml/kg/min)
Borg scale
Exercise termination reason
Type of exercise (treadmill vs cycling)</description>
  </other_outcome>
  <other_outcome>
    <measure>Cardiopulmonary Exercise (CPX) Testing</measure>
    <time_frame>12 months</time_frame>
    <description>A substudy endpoint will utilize peak oxygen consumption oxygen uptake (VO2) as a parameter for cardiopulmonary exercise testing on a total of at least 50 and up to 100 subjects.
The CPX analysis variables are:
Peak VO2 (ml/kg/min) - CPX Sub-study endpoint, descriptive analysis only, not powered for statistical significance
Exercise duration (min)
Peak workload (watts)
Maximum heart rate during exercise (beats/min)
Peak VE (l/min)
Respiratory Exchange Ratio (RER, VCO2/VO2)
VE/VCO2 slope
Ventilatory Threshold (ml/kg/min)
Borg scale
Exercise termination reason
Type of exercise (treadmill vs cycling)</description>
  </other_outcome>
  <other_outcome>
    <measure>Cardiopulmonary Exercise (CPX) Testing: Mean Changes in Peak VO2</measure>
    <time_frame>Between baseline and 12 months</time_frame>
    <description>Mean changes in peak VO2 (ml/kg/min) will be summarized at 12 months from baseline for the subset of patients who complete a CPX test at baseline and 12 months. A comparison of change from baseline between Device and Control groups will be presented.
The CPX analysis variables are:
Peak VO2 (ml/kg/min) - CPX Sub-study endpoint, descriptive analysis only, not powered for statistical significance
Exercise duration (min)
Peak workload (watts)
Maximum heart rate during exercise (beats/min)
Peak VE (l/min)
Respiratory Exchange Ratio (RER, VCO2/VO2)
VE/VCO2 slope
Ventilatory Threshold (ml/kg/min)
Borg scale
Exercise termination reason
Type of exercise (treadmill vs cycling)</description>
  </other_outcome>
  <other_outcome>
    <measure>Health Economic Data</measure>
    <time_frame>Through 5 years</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">614</enrollment>
  <condition>Mitral Regurgitation</condition>
  <condition>Mitral Valve Regurgitation</condition>
  <condition>Treatment of Functional Mitral Regurgitation in Symptomatic Heart Failure Subjects</condition>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>MitraClip System</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Percutaneous mitral valve repair using MitraClip System</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients with mitral regurgitation managed non-surgically based on standard hospital clinical practice.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>MitraClip System</intervention_name>
    <description>Percutaneous mitral valve repair using MitraClip System</description>
    <arm_group_label>MitraClip System</arm_group_label>
    <other_name>MitraClip device</other_name>
    <other_name>MitraClip</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Symptomatic functional MR (≥3+) due to cardiomyopathy of either ischemic or
             non-ischemic etiology determined by assessment of a qualifying transthoracic
             echocardiogram (TTE) obtained within 90 days and transesophageal echocardiogram (TEE)
             obtained within 180 days prior to subject registration, with MR severity based
             principally on the TTE study, confirmed by the Echocardiography Core Lab (ECL). The
             ECL may request a transesophageal echocardiogram (TEE) to confirm MR etiology.

             Note: Functional MR requires the presence of global or regional left ventricular wall
             motion abnormalities, which are believed to be the primary cause of the MR. If a flail
             leaflet or other evidence of degenerative MR is present, the subject is not eligible
             even if global or regional left ventricular systolic dysfunction is present.

             Note: Qualifying TTE must be obtained after the subject has been stabilized on optimal
             therapy including Guideline Directed Medical Therapy (GDMT) and at least 30 days
             after:

               1. a greater than 100% increase or greater than 50% decrease in dose of GDMT

               2. revascularization and/or implant of Cardiac Resynchronization Therapy device (CRT
                  or CRT-D) or reprogramming of an implanted CRT or CRT-D that results in increased
                  biventricular pacing (from &lt;92% to ≥92%)

          2. In the judgment of the HF specialist investigator at the site, the subject has been
             adequately treated per applicable standards, including for coronary artery disease,
             left ventricular dysfunction, mitral regurgitation and heart failure (e.g., with
             cardiac resynchronization therapy, revascularization, and/or GDMT). The Eligibility
             Committee must also concur that the subject has been adequately treated.

          3. New York Heart Association (NYHA) Functional Class II, III or ambulatory IV.

          4. The Local Site Heart Team (CT surgeon and HF specialist investigators) and the Central
             Eligibility Committee concur that surgery will not be offered as a treatment option
             and that medical therapy is the intended therapy for the subject, even if the subject
             is randomized to the Control group.

          5. The subject has had at least one hospitalization for heart failure in the 12 months
             prior to subject registration and/or a corrected brain natriuretic peptide (BNP) ≥300
             pg/ml or corrected n-Terminal pro- brain natriuretic peptide NT-proBNP ≥1500 pg/ml
             measured within 90 days prior to subject registration (&quot;corrected&quot; refers to a 4%
             reduction in the BNP or NT-proBNP cutoff for every increase of 1 kg/m2 in BMI above a
             reference BMI of 20 kg/m2).

             Note: BNP or NT-proBNP must be obtained after the subject has been stabilized on GDMT
             and at least 30 days after:

               1. a greater than 100% increase or greater than 50% decrease in dose of GDMT

               2. revascularization and/or implant of Cardiac Resynchronization Therapy device (CRT
                  or CRT-D) or reprogramming of an implanted CRT or CRT-D that results in increased
                  biventricular pacing (from &lt;92% to ≥92%).

          6. Left Ventricular Ejection Fraction (LVEF) is ≥20% and ≤50% within 90 days prior to
             subject registration, assessed by the site using any one of the following methods:
             echocardiography, contrast left ventriculography, gated blood pool scan or cardiac
             magnetic resonance imaging (MRI).

             Note: The method must provide a quantitative readout (not a visual assessment).

          7. The primary regurgitant jet is non-commissural, and in the opinion of the MitraClip
             implanting investigator can be successfully be treated by the MitraClip. If a
             secondary jet exists, it must be considered clinically insignificant.

          8. Creatine Kinase-MB (CK-MB) obtained within prior 14 days &lt; local laboratory Upper
             Limit of Normal (ULN).

          9. Transseptal catheterization and femoral vein access is determined to be feasible by
             the MitraClip implanting investigator.

         10. Age 18 years or older.

         11. The subject or the subject's legal representative understands and agrees that should
             he/she be assigned to the Control group, he/she will be treated with medical therapy
             and conservative management without surgery and without the MitraClip, either
             domestically or abroad. If the subject would actively contemplate surgery and/or
             MitraClip if randomized to Control, he/she should not be registered in this trial.

         12. The subject or the subject's legal representative has been informed of the nature of
             the trial and agrees to its provisions, including the possibility of randomization to
             the Control group and returning for all required post-procedure follow-up visits, and
             has provided written informed consent.

         13. Left Ventricular End Systolic Dimension (LVESD) is ≤ 70 mm assessed by site based on a
             transthoracic echocardiographic (TTE) obtained within 90 days prior to subject
             registration.

        For the CPX Sub-study: Subjects have to meet the COAPT study eligibility criteria to be
        registered in the CPX Sub-study.

        COAPT CAS study Inclusion Criteria:

        1. Subjects must meet all of the above COAPT RCT inclusion criteria, and must have national
        Medicare coverage by the Centers for Medicare and Medicaid Services (CMS).

        Exclusion Criteria:

          1. Chronic Obstructive Pulmonary Disease (COPD) requiring continuous home oxygen therapy
             or chronic outpatient oral steroid use.

          2. Untreated clinically significant coronary artery disease requiring revascularization.

          3. Coronary artery bypass grafting (CABG) within 30 days prior to subject registration.

          4. Percutaneous coronary intervention within 30 days prior to subject registration.

          5. Transcatheter aortic valve replacement (TAVR) within 30 days prior to subject
             registration.

          6. Tricuspid valve disease requiring surgery or transcatheter intervention.

          7. Aortic valve disease requiring surgery.

          8. Cerebrovascular accident within 30 days prior to subject registration.

          9. Severe symptomatic carotid stenosis (&gt; 70% by ultrasound).

         10. Carotid surgery or stenting within 30 days prior to subject registration.

         11. American College of Cardiology /American Heart Association (ACC/AHA) Stage D heart
             failure.

         12. Presence of any of the following:

               -  Estimated pulmonary artery systolic pressure (PASP) &gt; 70 mm Hg assessed by site
                  based on echocardiography or right heart catheterization, unless active
                  vasodilator therapy in the cath lab is able to reduce the pulmonary vascular
                  resistance (PVR) to &lt; 3 Wood Units or between 3 and 4.5 Wood Units with v wave
                  less than twice the mean of the pulmonary capillary wedge pressure

               -  Hypertrophic cardiomyopathy, restrictive cardiomyopathy, constrictive
                  pericarditis, or any other structural heart disease causing heart failure other
                  than dilated cardiomyopathy of either ischemic or non ischemic etiology

               -  Infiltrative cardiomyopathies (e.g., amyloidosis, hemochromatosis, sarcoidosis)

               -  Hemodynamic instability requiring inotropic support or mechanical heart
                  assistance.

         13. Physical evidence of right-sided congestive heart failure with echocardiographic
             evidence of moderate or severe right ventricular dysfunction as assessed by site.

         14. Implant of any Cardiac Resynchronization Therapy (CRT) or Cardiac Resynchronization
             Therapy with cardioverter-defibrillator (CRT-D) within the last 30days prior to
             subject registration.

         15. Mitral valve orifice area &lt; 4.0 cm2 assessed by site based on a transthoracic
             echocardiogram (TTE) within 90 days prior to subject registration.

         16. Leaflet anatomy which may preclude MitraClip implantation, proper MitraClip
             positioning on the leaflets or sufficient reduction in MR by the MitraClip. This
             evaluation is based on transesophageal echocardiogram (TEE) evaluation of the mitral
             valve within 180 days prior to subject registration and includes:

               -  Insufficient mobile leaflet available for grasping with the MitraClip device

               -  Evidence of calcification in the grasping area

               -  Presence of a significant cleft in the grasping area

               -  Lack of both primary and secondary chordal support in the grasping area

               -  Leaflet mobility length &lt; 1 cm

         17. Hemodynamic instability defined as systolic pressure &lt; 90 mmHg with or without
             afterload reduction, cardiogenic shock or the need for inotropic support or
             intra-aortic balloon pump or other hemodynamic support device.

         18. Need for emergent or urgent surgery for any reason or any planned cardiac surgery
             within the next 12 months.

         19. Life expectancy &lt; 12 months due to non-cardiac conditions.

         20. Modified Rankin Scale ≥ 4 disability.

         21. Status 1 heart transplant or prior orthotopic heart transplantation.

         22. Prior mitral valve leaflet surgery or any currently implanted prosthetic mitral valve,
             or any prior transcatheter mitral valve procedure.

         23. Echocardiographic evidence of intracardiac mass, thrombus or vegetation.

         24. Active endocarditis or active rheumatic heart disease or leaflets degenerated from
             rheumatic disease (i.e., noncompliant, perforated).

         25. Active infections requiring current antibiotic therapy.

         26. Subjects in whom transesophageal echocardiography (TEE) is contraindicated or high
             risk.

         27. Known hypersensitivity or contraindication to procedural medications which cannot be
             adequately managed medically.

         28. Pregnant or planning pregnancy within next 12 months.

             Note: Female patients of childbearing age should be instructed to use safe
             contraception (e.g. intrauterine devices, hormonal contraceptives: contraceptive
             pills, implants, transdermal patches hormonal vaginal devices, injections with
             prolonged release.

         29. Currently participating in an investigational drug or another device study that has
             not reached its primary endpoint. Note: Trials requiring extended follow-up for
             products that were investigational, but have since become commercially available, are
             not considered investigational trials.

         30. Subject belongs to a vulnerable population per investigator's judgment or subject has
             any kind of disorder that compromises his/her ability to give written informed consent
             and/or to comply with study procedures.

        For the CPX Sub-study: Subjects who have any contraindications to CPX and are not capable
        of performing CPX per investigator's assessment should not be registered in the CPX
        Sub-study.

        COAPT CAS study Exclusion Criteria:

        1. Subjects must not meet any of the above COAPT RCT exclusion criteria.

        .
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Mack, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Baylor Health Care System</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gregg Stone, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Columbia University Medical Center / New York-Presbyterian Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>William T Abraham, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Ohio State University Heart Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>JoAnn Lindenfeld, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vanderbilt University Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Banner Good Samaritan Medical Center</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85006</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Scottsdale Healthcare Hospitals</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85258</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Scripps Green Hospital</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cedars-Sinai Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>El Camino Hospital</name>
      <address>
        <city>Mountain View</city>
        <state>California</state>
        <zip>94040</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University California Davis Medical Center</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente - San Francisco Hospital</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford Hospital and Clinics</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Colorado Hospital</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hartford Hospital</name>
      <address>
        <city>Hartford</city>
        <state>Connecticut</state>
        <zip>06106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yale - New Haven Hospital</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medstar Washington Hospital Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Morton Plant Hospital</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <zip>33756</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Medical Center</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33140</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Hospital Orlando</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32803</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sarasota Memorial Hospital</name>
      <address>
        <city>Sarasota</city>
        <state>Florida</state>
        <zip>34239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tallahassee Memorial Hospital</name>
      <address>
        <city>Tallahassee</city>
        <state>Florida</state>
        <zip>32308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tampa General Hospital</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Piedmont Hospital Atlanta</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30309</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University Hospital</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Queen's Medical Center</name>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <zip>96813</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwestern Memorial Hospital</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rush University Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Evanston Hospital</name>
      <address>
        <city>Evanston</city>
        <state>Illinois</state>
        <zip>60201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Vincent Heart Center of Indiana</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46290</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Iowa Heart Center</name>
      <address>
        <city>Des Moines</city>
        <state>Iowa</state>
        <zip>50266</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Kansas Hosp Authority</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Via Christi</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>66866</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Joseph's Hospital - Lexington, KY</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40504</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jewish Hospital</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40245</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ochsner Clinic Foundation</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70121</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maine Medical Center</name>
      <address>
        <city>Portland</city>
        <state>Maine</state>
        <zip>04102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Maryland Baltimore</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tufts Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan Hospitals</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Henry Ford Hospital</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>William Beaumont Hospital</name>
      <address>
        <city>Royal Oak</city>
        <state>Michigan</state>
        <zip>48073-6796</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Abbott Northwestern Hospital</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55407</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Foundation for Med Edu And Research</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Luke's Hospital</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Barnes Jewish Hospital</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Patrick Hospital</name>
      <address>
        <city>Missoula</city>
        <state>Montana</state>
        <zip>59802</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nebraska Heart Institute Heart Hospital</name>
      <address>
        <city>Lincoln</city>
        <state>Nebraska</state>
        <zip>68526</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cooper University Hospital</name>
      <address>
        <city>Camden</city>
        <state>New Jersey</state>
        <zip>08103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Morristown Medical Center</name>
      <address>
        <city>Morristown</city>
        <state>New Jersey</state>
        <zip>07960</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Shore</name>
      <address>
        <city>Manhasset</city>
        <state>New York</state>
        <zip>11030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NYU Langone Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center / New York Presbyterian Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NYP Weill Cornell Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Francis Hospital</name>
      <address>
        <city>Roslyn</city>
        <state>New York</state>
        <zip>11576</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carolinas Medical Center</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vidant Medical Center</name>
      <address>
        <city>Greenville</city>
        <state>North Carolina</state>
        <zip>27834</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Christ Hospital</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ohio State University Medical Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Riverside Methodist Hospital</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43214-3907</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oklahoma Heart Hospital</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73120</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Providence St. Vincent Medical Center</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97225</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Health and Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital of University Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Temple University Hospital</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19140</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UPMC Presbyterian</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pinnacle Health at Harrisburg Hospital</name>
      <address>
        <city>Wormleysburg</city>
        <state>Pennsylvania</state>
        <zip>17043</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29403</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Thomas Hospital</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seton Medical Center Austin</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor Heart and Vascular Hospital</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UT Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75235</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Houston Methodist Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Hermann Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Intermountain Medical Center</name>
      <address>
        <city>Murray</city>
        <state>Utah</state>
        <zip>84107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Virginia</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Commonwealth University Medical Center</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23284</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carilion Roanoke Memorial Hospital</name>
      <address>
        <city>Roanoke</city>
        <state>Virginia</state>
        <zip>24014</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Swedish Medical Center Cherry Hill Campus</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Paul's - Providence Health Care</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6Z 1Y6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hamilton Health Sciences</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8L 2X2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Michael's Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5B 1W8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montreal Heart Institute</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H1T 1C8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Alberta</name>
      <address>
        <city>Edmonton</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>June 20, 2012</study_first_submitted>
  <study_first_submitted_qc>June 21, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 22, 2012</study_first_posted>
  <results_first_submitted>July 30, 2019</results_first_submitted>
  <results_first_submitted_qc>April 26, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">May 6, 2020</results_first_posted>
  <last_update_submitted>April 26, 2020</last_update_submitted>
  <last_update_submitted_qc>April 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Functional Mitral Regurgitation</keyword>
  <keyword>Mitral Valve Regurgitation</keyword>
  <keyword>Symptomatic Heart Failure</keyword>
  <keyword>Functional MR</keyword>
  <keyword>MitraClip</keyword>
  <keyword>Mitral Valve Insufficiency</keyword>
  <keyword>Cardiopulmonary exercise testing</keyword>
  <keyword>COAPT CAS</keyword>
  <keyword>COAPT Continued Access Study</keyword>
  <keyword>MitraClip NT</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Mitral Valve Insufficiency</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>October 12, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/79/NCT01626079/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>June 4, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/79/NCT01626079/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>In COAPT, 614 subjects were randomized. Enrollment concluded on June 23, 2017.
Of the 614 randomized subjects, 302 were in Device group and 312 in the Control group. Subject follow-up is on-going.</recruitment_details>
      <pre_assignment_details>This section includes the results for the primary safety, primary effectiveness, and the 10 secondary endpoints that are the most essential outcomes of the trial.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>MitraClip System</title>
          <description>Percutaneous mitral valve repair using MitraClip System
MitraClip System: Percutaneous mitral valve repair using MitraClip System</description>
        </group>
        <group group_id="P2">
          <title>Control Group</title>
          <description>Patients with mitral regurgitation managed non-surgically based on standard hospital clinical practice.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="302"/>
                <participants group_id="P2" count="312"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="135"/>
                <participants group_id="P2" count="96"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="167"/>
                <participants group_id="P2" count="216"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="78"/>
                <participants group_id="P2" count="115"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="29"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Visits Expected or Not Due</title>
              <participants_list>
                <participants group_id="P1" count="74"/>
                <participants group_id="P2" count="69"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Of the 614 subjects, 302 from MitraClip system group and 312 from Control group completed the baseline visit.</population>
      <group_list>
        <group group_id="B1">
          <title>MitraClip System</title>
          <description>Percutaneous mitral valve repair using MitraClip System
MitraClip System: Percutaneous mitral valve repair using MitraClip System</description>
        </group>
        <group group_id="B2">
          <title>Control Group</title>
          <description>Patients with mitral regurgitation managed non-surgically based on standard hospital clinical practice.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="302"/>
            <count group_id="B2" value="312"/>
            <count group_id="B3" value="614"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="302"/>
                    <count group_id="B2" value="312"/>
                    <count group_id="B3" value="614"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="71.7" spread="11.8"/>
                    <measurement group_id="B2" value="72.8" spread="10.5"/>
                    <measurement group_id="B3" value="72.2" spread="11.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="302"/>
                    <count group_id="B2" value="312"/>
                    <count group_id="B3" value="614"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="101"/>
                    <measurement group_id="B2" value="120"/>
                    <measurement group_id="B3" value="221"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="201"/>
                    <measurement group_id="B2" value="192"/>
                    <measurement group_id="B3" value="393"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Race/Ethnicity</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="302"/>
                    <count group_id="B2" value="312"/>
                    <count group_id="B3" value="614"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="44"/>
                    <measurement group_id="B2" value="44"/>
                    <measurement group_id="B3" value="88"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="40"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White or Caucasian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="225"/>
                    <measurement group_id="B2" value="232"/>
                    <measurement group_id="B3" value="457"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Other</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Canada</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="302"/>
                    <count group_id="B2" value="312"/>
                    <count group_id="B3" value="614"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="302"/>
                    <count group_id="B2" value="312"/>
                    <count group_id="B3" value="614"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="290"/>
                    <measurement group_id="B2" value="298"/>
                    <measurement group_id="B3" value="588"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height</title>
          <population>Data is missing for 1 subject in Device group and 6 subjects in control group</population>
          <units>Cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="301"/>
                    <count group_id="B2" value="306"/>
                    <count group_id="B3" value="607"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="170.84" spread="10.35"/>
                    <measurement group_id="B2" value="169.86" spread="10.75"/>
                    <measurement group_id="B3" value="170.34" spread="10.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <population>Data is missing for 1 subject in Device group and 5 subjects in Control group.</population>
          <units>Kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="301"/>
                    <count group_id="B2" value="307"/>
                    <count group_id="B3" value="608"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="78.79" spread="17.23"/>
                    <measurement group_id="B2" value="78.40" spread="20.06"/>
                    <measurement group_id="B3" value="78.59" spread="18.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index (kg/m^2)</title>
          <population>Data is missing for 2 subjects for Device and 7 subjects for Control group.</population>
          <units>Kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="301"/>
                    <count group_id="B2" value="305"/>
                    <count group_id="B3" value="606"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27.04" spread="5.81"/>
                    <measurement group_id="B2" value="27.05" spread="5.96"/>
                    <measurement group_id="B3" value="27.05" spread="5.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Serum Creatinine (mg/dL)</title>
          <population>Data is missing for 2 subjects in Device group and 6 subjects in Control group.</population>
          <units>(mg/dL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="300"/>
                    <count group_id="B2" value="306"/>
                    <count group_id="B3" value="606"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.77" spread="1.22"/>
                    <measurement group_id="B2" value="1.80" spread="1.42"/>
                    <measurement group_id="B3" value="1.79" spread="1.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Creatinine Clearance (mL/min)</title>
          <population>Data is missing for 3 subjects in Device group and 10 subjects in Control group.</population>
          <units>mL/min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="299"/>
                    <count group_id="B2" value="302"/>
                    <count group_id="B3" value="601"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50.87" spread="28.48"/>
                    <measurement group_id="B2" value="47.76" spread="24.97"/>
                    <measurement group_id="B3" value="49.31" spread="26.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Creatinine Clearance &lt;= 60mL/min</title>
          <population>Data is missing for 3 subjects in Device group and 10 subjects in Control group</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="299"/>
                    <count group_id="B2" value="302"/>
                    <count group_id="B3" value="601"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="214"/>
                    <measurement group_id="B2" value="227"/>
                    <measurement group_id="B3" value="441"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Brain Natriuretic Peptide (Pg/mL)</title>
          <population>Not all subjects had Brain Natriuretic Peptide (BNP) value collected. some subjects were on NT-proBNP.</population>
          <units>Pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="208"/>
                    <count group_id="B2" value="209"/>
                    <count group_id="B3" value="417"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1014.77" spread="1085.98"/>
                    <measurement group_id="B2" value="1017.13" spread="1212.77"/>
                    <measurement group_id="B3" value="1015.95" spread="1149.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>NT-proBNP (pg/mL)</title>
          <population>Majority of subjects had BNP available. Subjects who did not have BNP had NT-proBNP available.</population>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="74"/>
                    <count group_id="B2" value="85"/>
                    <count group_id="B3" value="159"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5174.33" spread="6566.61"/>
                    <measurement group_id="B2" value="5943.86" spread="8437.61"/>
                    <measurement group_id="B3" value="5585.71" spread="7610.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Elevated BNP or NT-BNP prior to Enrollment</title>
          <population>All available data reported</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="286"/>
                    <count group_id="B2" value="303"/>
                    <count group_id="B3" value="589"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="267"/>
                    <measurement group_id="B2" value="282"/>
                    <measurement group_id="B3" value="549"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Extremely High Risk for MV Surgery</title>
          <description>High surgical risk if investigational site assessed a predicted surgical mortality for mitral valve surgery of ≥ 12% based on either:
I) STS (Society of Thoracic Surgeons) mortality risk ≥ 12%, or
II) The presence of at least one of the following:
Porcelain aorta or mobile ascending aortic atheroma
Post-radiation mediastinum
Previous mediastinitis
Functional MR with EF &lt; 40%
Over 75 years old with EF &lt; 40%
Prior re-operation with patent grafts
Two or more prior chest surgeries
Hepatic cirrhosis
Three or more of the following STS high risk factors</description>
          <population>Not all subjects met the criteria for High Risk for MV Surgery</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="299"/>
                    <count group_id="B2" value="312"/>
                    <count group_id="B3" value="611"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="205"/>
                    <measurement group_id="B2" value="218"/>
                    <measurement group_id="B3" value="423"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Diabetes</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="302"/>
                    <count group_id="B2" value="312"/>
                    <count group_id="B3" value="614"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="106"/>
                    <measurement group_id="B2" value="123"/>
                    <measurement group_id="B3" value="229"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Hypertension</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="302"/>
                    <count group_id="B2" value="312"/>
                    <count group_id="B3" value="614"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="243"/>
                    <measurement group_id="B2" value="251"/>
                    <measurement group_id="B3" value="494"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Hypercholesterolemia</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="302"/>
                    <count group_id="B2" value="312"/>
                    <count group_id="B3" value="614"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="166"/>
                    <measurement group_id="B2" value="163"/>
                    <measurement group_id="B3" value="329"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Previous Myocardial Infarction</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="302"/>
                    <count group_id="B2" value="312"/>
                    <count group_id="B3" value="614"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="156"/>
                    <measurement group_id="B2" value="160"/>
                    <measurement group_id="B3" value="316"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Previous Percutaneous Coronary Intervention</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="302"/>
                    <count group_id="B2" value="312"/>
                    <count group_id="B3" value="614"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="130"/>
                    <measurement group_id="B2" value="153"/>
                    <measurement group_id="B3" value="283"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Previous Coronary Artery Bypass Grafting</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="302"/>
                    <count group_id="B2" value="312"/>
                    <count group_id="B3" value="614"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="121"/>
                    <measurement group_id="B2" value="126"/>
                    <measurement group_id="B3" value="247"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Previous Stroke or Transient Ischemic Attack</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="302"/>
                    <count group_id="B2" value="312"/>
                    <count group_id="B3" value="614"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56"/>
                    <measurement group_id="B2" value="49"/>
                    <measurement group_id="B3" value="105"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Peripheral Vascular Disease</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="302"/>
                    <count group_id="B2" value="312"/>
                    <count group_id="B3" value="614"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52"/>
                    <measurement group_id="B2" value="57"/>
                    <measurement group_id="B3" value="109"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Chronic Obstructive Pulmonary Disease</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="302"/>
                    <count group_id="B2" value="312"/>
                    <count group_id="B3" value="614"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="71"/>
                    <measurement group_id="B2" value="72"/>
                    <measurement group_id="B3" value="143"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>History of Atrial Fibrillation or Flutter</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="302"/>
                    <count group_id="B2" value="312"/>
                    <count group_id="B3" value="614"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="173"/>
                    <measurement group_id="B2" value="166"/>
                    <measurement group_id="B3" value="339"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Anemia</title>
          <population>All available data is reported</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="301"/>
                    <count group_id="B2" value="306"/>
                    <count group_id="B3" value="607"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="180"/>
                    <measurement group_id="B2" value="192"/>
                    <measurement group_id="B3" value="372"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>STS Risk Score</title>
          <description>The STS score is a validated risk-prediction model for open surgery based on data from the STS National Adult Cardiac Surgery Database. In general, an STS predicted risk of surgical mortality of 4%-8% is considered intermediate risk and 8% or greater is considered high risk.
As of November 15, 2018, The Society of Thoracic Surgeons released an updated short-term risk calculator to reflect the latest 2018 adult cardiac surgery risk models. The STS Calculator allows you to calculate a patient’s risk of mortality and morbidities for the most commonly performed cardiac surgeries.</description>
          <units>percentage of expected mortality</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="302"/>
                    <count group_id="B2" value="312"/>
                    <count group_id="B3" value="614"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7.83" spread="5.53"/>
                    <measurement group_id="B2" value="8.5" spread="6.15"/>
                    <measurement group_id="B3" value="8.17" spread="5.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>STS Risk Score &gt;= 8%</title>
          <description>The STS score is a validated risk-prediction model for open surgery based on data from the STS National Adult Cardiac Surgery Database. In general, an STS predicted risk of surgical mortality of 4%-8% is considered intermediate risk and 8% or greater is considered high risk.
As of November 15, 2018, The Society of Thoracic Surgeons released an updated short-term risk calculator to reflect the latest 2018 adult cardiac surgery risk models. The STS Calculator allows you to calculate a patient’s risk of mortality and morbidities for the most commonly performed cardiac surgeries.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="302"/>
                    <count group_id="B2" value="312"/>
                    <count group_id="B3" value="614"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="126"/>
                    <measurement group_id="B2" value="136"/>
                    <measurement group_id="B3" value="262"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Risk of Surgery-related complications or death</title>
          <description>Subjects were evaluated by the Local Site Heart Team based on their medical history to determine their risk of surgery related complications or death.</description>
          <population>All available data is reported</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>High</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="299"/>
                    <count group_id="B2" value="312"/>
                    <count group_id="B3" value="611"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="205"/>
                    <measurement group_id="B2" value="218"/>
                    <measurement group_id="B3" value="423"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not High</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="299"/>
                    <count group_id="B2" value="312"/>
                    <count group_id="B3" value="611"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="94"/>
                    <measurement group_id="B2" value="94"/>
                    <measurement group_id="B3" value="188"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Cardiomyopathy</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Ischemic</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="302"/>
                    <count group_id="B2" value="312"/>
                    <count group_id="B3" value="614"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="184"/>
                    <measurement group_id="B2" value="189"/>
                    <measurement group_id="B3" value="373"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-Ischemic</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="302"/>
                    <count group_id="B2" value="312"/>
                    <count group_id="B3" value="614"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="118"/>
                    <measurement group_id="B2" value="123"/>
                    <measurement group_id="B3" value="241"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>New York Heart Association (NYHA) Classification</title>
          <description>The New York Heart Association (NYHA) Classification provides a simple way of classifying the extent of heart failure. It classifies patients in one of four categories based on their limitations during physical activity:
Class I - No symptoms and no limitation in ordinary physical activity Class II - Mild symptoms (mild shortness of breath and/or angina) and slight limitation during ordinary activity.
Class III - Marked limitation in activity due to symptoms Class IV - Severe limitations.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>NYHA Class I</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="302"/>
                    <count group_id="B2" value="312"/>
                    <count group_id="B3" value="614"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NYHA Class II</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="302"/>
                    <count group_id="B2" value="312"/>
                    <count group_id="B3" value="614"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="129"/>
                    <measurement group_id="B2" value="110"/>
                    <measurement group_id="B3" value="239"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NYHA Class III</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="302"/>
                    <count group_id="B2" value="312"/>
                    <count group_id="B3" value="614"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="154"/>
                    <measurement group_id="B2" value="168"/>
                    <measurement group_id="B3" value="322"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NYHA Class IVa, ambulatory</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="302"/>
                    <count group_id="B2" value="312"/>
                    <count group_id="B3" value="614"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Hospitalization for Heart Failure within Previous 1 yr</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="302"/>
                    <count group_id="B2" value="312"/>
                    <count group_id="B3" value="614"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="176"/>
                    <measurement group_id="B2" value="175"/>
                    <measurement group_id="B3" value="351"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Previous Cardiac Resynchronization Therapy</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="302"/>
                    <count group_id="B2" value="312"/>
                    <count group_id="B3" value="614"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="115"/>
                    <measurement group_id="B2" value="109"/>
                    <measurement group_id="B3" value="224"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Previous Implantation of Defibrillator</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="302"/>
                    <count group_id="B2" value="312"/>
                    <count group_id="B3" value="614"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="91"/>
                    <measurement group_id="B2" value="101"/>
                    <measurement group_id="B3" value="192"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Severity of Mitral Regurgitation</title>
          <population>In the Control group, baseline echocardiography data was not readable. Hence 311 participants were analyzed.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Moderate-to-severe, grade 3+</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="302"/>
                    <count group_id="B2" value="311"/>
                    <count group_id="B3" value="613"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="148"/>
                    <measurement group_id="B2" value="172"/>
                    <measurement group_id="B3" value="320"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe, grade 4+</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="302"/>
                    <count group_id="B2" value="311"/>
                    <count group_id="B3" value="613"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="154"/>
                    <measurement group_id="B2" value="139"/>
                    <measurement group_id="B3" value="293"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Effective Regurgitat Orifice Area</title>
          <population>EROA was not measurable for all subjects</population>
          <units>Cm2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="289"/>
                    <count group_id="B2" value="302"/>
                    <count group_id="B3" value="591"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.41" spread="0.15"/>
                    <measurement group_id="B2" value="0.40" spread="0.15"/>
                    <measurement group_id="B3" value="0.41" spread="0.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Left Ventricular End Systolic Dimension (Diameter)</title>
          <description>left ventricle end-systolic diameter, is measured at end systole, on the frame preceding mitral valve opening. It corresponds to the smallest cardiac dimension.</description>
          <population>LVESD was not measurable for all subjects</population>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="301"/>
                    <count group_id="B2" value="306"/>
                    <count group_id="B3" value="607"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5.28" spread="0.86"/>
                    <measurement group_id="B2" value="5.30" spread="0.89"/>
                    <measurement group_id="B3" value="5.29" spread="0.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Left Ventricular End-Diastolic Dimension</title>
          <population>LVEDD was not measurable in all subjects</population>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="301"/>
                    <count group_id="B2" value="307"/>
                    <count group_id="B3" value="608"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6.17" spread="0.73"/>
                    <measurement group_id="B2" value="6.19" spread="0.75"/>
                    <measurement group_id="B3" value="6.18" spread="0.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Left Ventricular End-Systolic Volume</title>
          <population>LVESV was not measurable for all subjects</population>
          <units>mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="281"/>
                    <count group_id="B2" value="294"/>
                    <count group_id="B3" value="575"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="135.5" spread="56.1"/>
                    <measurement group_id="B2" value="134.3" spread="60.3"/>
                    <measurement group_id="B3" value="134.9" spread="58.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Left Ventricular End-Diastolic Volume</title>
          <population>LVEDV was not measurable in all subjects</population>
          <units>mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="281"/>
                    <count group_id="B2" value="294"/>
                    <count group_id="B3" value="575"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="194.4" spread="69.2"/>
                    <measurement group_id="B2" value="191.0" spread="72.9"/>
                    <measurement group_id="B3" value="192.7" spread="71.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Left Ventricular Ejection Fraction</title>
          <population>LVEF was not measured for all subjects</population>
          <units>%</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="281"/>
                    <count group_id="B2" value="294"/>
                    <count group_id="B3" value="575"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31.32" spread="9.07"/>
                    <measurement group_id="B2" value="31.30" spread="9.58"/>
                    <measurement group_id="B3" value="31.31" spread="9.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>LVEF &gt;= 40%</title>
          <population>All available data is reported</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="281"/>
                    <count group_id="B2" value="294"/>
                    <count group_id="B3" value="575"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="231"/>
                    <measurement group_id="B2" value="241"/>
                    <measurement group_id="B3" value="472"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Right Ventricular Systolic Pressure</title>
          <population>All available data is reported</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="253"/>
                    <count group_id="B2" value="275"/>
                    <count group_id="B3" value="528"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43.95" spread="13.44"/>
                    <measurement group_id="B2" value="44.56" spread="13.96"/>
                    <measurement group_id="B3" value="44.26" spread="13.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Primary Safety Endpoint - Percentage of Participants With Freedom From Device Related Complications at 12 Months</title>
        <description>Percentage of Participants with Freedom from Device related Complications at 12 Months.
Composite of Single Leaflet Device Attachment (SLDA), device embolizations, endocarditis requiring surgery, Echocardiography Core Laboratory confirmed mitral stenosis requiring surgery, LVAD implant, heart transplant, and any device related complications requiring non-elective cardiovascular surgery.</description>
        <time_frame>12 months</time_frame>
        <population>Subjects who were randomized with attempted procedure to the device group with available data. Performance goal was 88%.</population>
        <group_list>
          <group group_id="O1">
            <title>MitraClip System</title>
            <description>Percutaneous mitral valve repair using MitraClip System
MitraClip System: Percutaneous mitral valve repair using MitraClip System</description>
          </group>
        </group_list>
        <measure>
          <title>Primary Safety Endpoint - Percentage of Participants With Freedom From Device Related Complications at 12 Months</title>
          <description>Percentage of Participants with Freedom from Device related Complications at 12 Months.
Composite of Single Leaflet Device Attachment (SLDA), device embolizations, endocarditis requiring surgery, Echocardiography Core Laboratory confirmed mitral stenosis requiring surgery, LVAD implant, heart transplant, and any device related complications requiring non-elective cardiovascular surgery.</description>
          <population>Subjects who were randomized with attempted procedure to the device group with available data. Performance goal was 88%.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="293"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.966" lower_limit="0.948" upper_limit="NA">Upper limit is NA as this is a one sided 95% confidence interval.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Two thousand (2000) simulations were performed to calculate sample size and power for the primary safety endpoint. Assuming 22% mortality and 7.5% attrition at 12 months, a total of 305 subjects in the Device group will provide &gt; 95% power to reject the null hypothesis at the one-sided significance level of 5%.</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <method>Z test Using Kaplan Meier Survival</method>
            <method_desc>P-value calculated from Z test using Kaplan Meier survival estimate together with Greenwood method estimated variance</method_desc>
            <param_type>Kaplan Meier</param_type>
            <param_value>0.966</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.011</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>1-Sided</ci_n_sides>
            <ci_lower_limit>0.948</ci_lower_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Primary Effectiveness Endpoint</title>
        <description>Recurrent HF hospitalizations (HFH) through 24 months, analyzed when the last subject completes 12-month follow-up</description>
        <time_frame>24 months</time_frame>
        <population>302 subjects from device group and 312 subjects from the control group were analyzed for Recurrent HF hospitalizations through 24 months</population>
        <group_list>
          <group group_id="O1">
            <title>MitraClip System</title>
            <description>Percutaneous mitral valve repair using MitraClip System
MitraClip System: Percutaneous mitral valve repair using MitraClip System</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Patients with mitral regurgitation managed non-surgically based on standard hospital clinical practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Primary Effectiveness Endpoint</title>
          <description>Recurrent HF hospitalizations (HFH) through 24 months, analyzed when the last subject completes 12-month follow-up</description>
          <population>302 subjects from device group and 312 subjects from the control group were analyzed for Recurrent HF hospitalizations through 24 months</population>
          <units>events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="302"/>
                <count group_id="O2" value="312"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="160"/>
                    <measurement group_id="O2" value="283"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Primary Effectiveness Endpoint</title>
        <description>Recurrent HF hospitalizations (HFH) through 24 months, analyzed when the last subject completes 12-month follow-up</description>
        <time_frame>24 months</time_frame>
        <population>302 subjects from device group and 312 subjects from the control group were analyzed for Recurrent HF hospitalizations through 24 months</population>
        <group_list>
          <group group_id="O1">
            <title>MitraClip System</title>
            <description>Percutaneous mitral valve repair using MitraClip System
MitraClip System: Percutaneous mitral valve repair using MitraClip System</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Patients with mitral regurgitation managed non-surgically based on standard hospital clinical practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Primary Effectiveness Endpoint</title>
          <description>Recurrent HF hospitalizations (HFH) through 24 months, analyzed when the last subject completes 12-month follow-up</description>
          <population>302 subjects from device group and 312 subjects from the control group were analyzed for Recurrent HF hospitalizations through 24 months</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="302"/>
                <count group_id="O2" value="312"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92"/>
                    <measurement group_id="O2" value="151"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Recurrent Heart Failure (HF) Hospitalization (COAPT CAS Study Analysis)</title>
        <description>Number of recurrent Heart Failure hospitalization events at 12 months.</description>
        <time_frame>12 months</time_frame>
        <population>A total of 157 subjects were enrolled in the COAPT CAS study.</population>
        <group_list>
          <group group_id="O1">
            <title>MitraClip System</title>
            <description>Percutaneous mitral valve repair using MitraClip System
MitraClip System: Percutaneous mitral valve repair using MitraClip System</description>
          </group>
        </group_list>
        <measure>
          <title>Recurrent Heart Failure (HF) Hospitalization (COAPT CAS Study Analysis)</title>
          <description>Number of recurrent Heart Failure hospitalization events at 12 months.</description>
          <population>A total of 157 subjects were enrolled in the COAPT CAS study.</population>
          <units>Events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="157"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>New York Heart Association (NYHA) Functional Class (COAPT CAS Study Analysis)</title>
        <description>The New York Heart Association (NYHA) Classification provides a simple way of classifying the extent of heart failure. It classifies patients in one of four categories based on their limitations during physical activity:
Class I - No symptoms and no limitation in ordinary physical activity Class II - Mild symptoms (mild shortness of breath and/or angina) and slight limitation during ordinary activity. Class III - Marked limitation in activity due to symptoms Class IV - Severe limitations.</description>
        <time_frame>12 months</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>New York Heart Association (NYHA) Functional Class (COAPT CAS Study Analysis)</title>
        <description>The New York Heart Association (NYHA) Classification provides a simple way of classifying the extent of heart failure. It classifies patients in one of four categories based on their limitations during physical activity:
Class I - No symptoms and no limitation in ordinary physical activity Class II - Mild symptoms (mild shortness of breath and/or angina) and slight limitation during ordinary activity. Class III - Marked limitation in activity due to symptoms Class IV - Severe limitations.</description>
        <time_frame>30 days</time_frame>
        <population>A total of 157 subjects were enrolled in the COAPT CAS study. Of them NYHA data was available for a total of 114 subjects at 30 days.</population>
        <group_list>
          <group group_id="O1">
            <title>MitraClip System</title>
            <description>Percutaneous mitral valve repair using MitraClip System
MitraClip System: Percutaneous mitral valve repair using MitraClip System</description>
          </group>
        </group_list>
        <measure>
          <title>New York Heart Association (NYHA) Functional Class (COAPT CAS Study Analysis)</title>
          <description>The New York Heart Association (NYHA) Classification provides a simple way of classifying the extent of heart failure. It classifies patients in one of four categories based on their limitations during physical activity:
Class I - No symptoms and no limitation in ordinary physical activity Class II - Mild symptoms (mild shortness of breath and/or angina) and slight limitation during ordinary activity. Class III - Marked limitation in activity due to symptoms Class IV - Severe limitations.</description>
          <population>A total of 157 subjects were enrolled in the COAPT CAS study. Of them NYHA data was available for a total of 114 subjects at 30 days.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="114"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>NYHA Class I</title>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                  </measurement_list>
                </category>
                <category>
                  <title>NYHA Class II</title>
                  <measurement_list>
                    <measurement group_id="O1" value="53"/>
                  </measurement_list>
                </category>
                <category>
                  <title>NYHA Class III</title>
                  <measurement_list>
                    <measurement group_id="O1" value="33"/>
                  </measurement_list>
                </category>
                <category>
                  <title>NYHA Class IV</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quality of Life (QOL) (COAPT CAS Study Analysis) Quality of Life (QoL) as Measured by the Kansas City Cardiomyopathy Questionnaire (KCCQ)</title>
        <description>COAPT Study is still on-going. Only the Primary and Major secondary endpoints were entered in the results section for the COAPT study after the FDA approval of the new indication. Subjects are still being followed in both the COAPT and COAPT CAS cohorts. COAPT CAS study is a single arm registry that will provide valuable new information regarding use of the MitraClip NT system under more &quot;real world&quot; conditions. COAPT study completed recruiting subjects in June 2017. COAPT CAS completed recruiting subjects in March 2019.
Remainder of the COAPT and COAPT CAS results will be entered when the study is closed.</description>
        <time_frame>12 months</time_frame>
        <posting_date>07/2024</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quality of Life (QOL) (COAPT CAS Study Analysis) Quality of Life (QoL) as Measured by the Kansas City Cardiomyopathy Questionnaire (KCCQ)</title>
        <description>The Kansas City Cardiomyopathy Questionnaire is a 23-item, self administered instrument that quantifies physical function, symptoms, social function, self-efficacy and knowledge, and quality of life. with a range of possible subscale scores from 0 to 100, with 100 representing the least burden of symptoms. The KCCQ tool quantifies the following six (6) distinct domains and two (2) summary scores: KCCQ Symptom Domain, KCCQ Physical Function Domain, KCCQ Quality of Life Domain, KCCQ Social Limitation Domain, KCCQ Self-efficacy Domain, KCCQ Symptom Stability Domain, Clinical Summary Score and Overall Summary Score. Clinical Summary Score includes total symptom and physical function scores to correspond with NYHA Classification. Overall Summary Score includes the total symptom, physical function, social limitations and quality of life scores.</description>
        <time_frame>30 days</time_frame>
        <population>A total of 157 subjects were enrolled in the COAPT CAS study. Data was available for 117 subjects at 30 days.</population>
        <group_list>
          <group group_id="O1">
            <title>MitraClip System</title>
            <description>Percutaneous mitral valve repair using MitraClip System
MitraClip System: Percutaneous mitral valve repair using MitraClip System</description>
          </group>
        </group_list>
        <measure>
          <title>Quality of Life (QOL) (COAPT CAS Study Analysis) Quality of Life (QoL) as Measured by the Kansas City Cardiomyopathy Questionnaire (KCCQ)</title>
          <description>The Kansas City Cardiomyopathy Questionnaire is a 23-item, self administered instrument that quantifies physical function, symptoms, social function, self-efficacy and knowledge, and quality of life. with a range of possible subscale scores from 0 to 100, with 100 representing the least burden of symptoms. The KCCQ tool quantifies the following six (6) distinct domains and two (2) summary scores: KCCQ Symptom Domain, KCCQ Physical Function Domain, KCCQ Quality of Life Domain, KCCQ Social Limitation Domain, KCCQ Self-efficacy Domain, KCCQ Symptom Stability Domain, Clinical Summary Score and Overall Summary Score. Clinical Summary Score includes total symptom and physical function scores to correspond with NYHA Classification. Overall Summary Score includes the total symptom, physical function, social limitations and quality of life scores.</description>
          <population>A total of 157 subjects were enrolled in the COAPT CAS study. Data was available for 117 subjects at 30 days.</population>
          <units>KCCQ score on a points scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="117"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.38" spread="25.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Six Minute Walk Test (6MWT Distance or 6MWD) (COAPT CAS Study Analysis)</title>
        <description>COAPT Study is still on-going. Only the Primary and Major secondary endpoints were entered in the results section for the COAPT study after the FDA approval of the new indication. Subjects are still being followed in both the COAPT and COAPT CAS cohorts. COAPT CAS study is a single arm registry that will provide valuable new information regarding use of the MitraClip NT system under more &quot;real world&quot; conditions. COAPT study completed recruiting subjects in June 2017. COAPT CAS completed recruiting subjects in March 2019.
Remainder of the COAPT and COAPT CAS results will be entered when the study is closed.</description>
        <time_frame>12 months</time_frame>
        <posting_date>07/2024</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Six Minute Walk Test (6MWT Distance or 6MWD) (COAPT CAS Study Analysis)</title>
        <description>The Six Minute Walk Test (6MWT) is a practical simple test that requires a 100-ft hallway but no exercise equipment or advanced training for technicians. This test measures the distance that a patient can quickly walk on a flat, hard surface in a period of 6 minutes (the 6MWD). It evaluates the global and integrated responses of all the systems involved during exercise, including the pulmonary and cardiovascular systems, systemic circulation, peripheral circulation, blood, neuromuscular units, and muscle metabolism. It does not provide specific information on the function of each of the different organs and systems involved in exercise or the mechanism of exercise limitation, as is possible with maximal cardiopulmonary exercise testing. The self-paced 6MWT assesses the submaximal level of functional capacity.</description>
        <time_frame>30 days</time_frame>
        <population>A total of 157 subjects were enrolled in the COAPT CAS study. 6MWT data was available for 98 subjects at 30 days..</population>
        <group_list>
          <group group_id="O1">
            <title>MitraClip System</title>
            <description>Percutaneous mitral valve repair using MitraClip System
MitraClip System: Percutaneous mitral valve repair using MitraClip System</description>
          </group>
        </group_list>
        <measure>
          <title>Six Minute Walk Test (6MWT Distance or 6MWD) (COAPT CAS Study Analysis)</title>
          <description>The Six Minute Walk Test (6MWT) is a practical simple test that requires a 100-ft hallway but no exercise equipment or advanced training for technicians. This test measures the distance that a patient can quickly walk on a flat, hard surface in a period of 6 minutes (the 6MWD). It evaluates the global and integrated responses of all the systems involved during exercise, including the pulmonary and cardiovascular systems, systemic circulation, peripheral circulation, blood, neuromuscular units, and muscle metabolism. It does not provide specific information on the function of each of the different organs and systems involved in exercise or the mechanism of exercise limitation, as is possible with maximal cardiopulmonary exercise testing. The self-paced 6MWT assesses the submaximal level of functional capacity.</description>
          <population>A total of 157 subjects were enrolled in the COAPT CAS study. 6MWT data was available for 98 subjects at 30 days..</population>
          <units>meters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="98"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="232.59" spread="145.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mitral Regurgitation (MR) Severity (COAPT CAS Study Analysis)</title>
        <description>COAPT Study is still on-going. Only the Primary and Major secondary endpoints were entered in the results section for the COAPT study after the FDA approval of the new indication. Subjects are still being followed in both the COAPT and COAPT CAS cohorts. COAPT CAS study is a single arm registry that will provide valuable new information regarding use of the MitraClip NT system under more &quot;real world&quot; conditions. COAPT study completed recruiting subjects in June 2017. COAPT CAS completed recruiting subjects in March 2019.
Remainder of the COAPT and COAPT CAS results will be entered when the study is closed.</description>
        <time_frame>12 months</time_frame>
        <posting_date>07/2024</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mitral Regurgitation (MR) Severity (COAPT CAS Study Analysis)</title>
        <description>MR Severity Grading was done by Quantitative Doppler Echocardiography and subjects were graded as below
MR 1+ - Regurgitant Volume &lt; 30 ml, Right ventricular EF &lt;30%, Effective regurgitant orifice area &lt; 20 mm^2 MR 2+ - Regurgitant Volume 30-44 ml, Right ventricular EF 30-39%, Effective regurgitant orifice area 20-29 mm^2 MR 3+ - Regurgitant Volume 45-59 ml, Right ventricular EF 40-49 %, Effective regurgitant orifice area 30-39 mm^2 MR 4+ - Regurgitant Volume &gt;= 60 ml, Right ventricular EF &gt;=50%, Effective regurgitant orifice area &gt;=40 mm^2</description>
        <time_frame>30 days</time_frame>
        <population>Echocardiogram data was available for 120 subjects at 30 days.</population>
        <group_list>
          <group group_id="O1">
            <title>MitraClip System</title>
            <description>Percutaneous mitral valve repair using MitraClip System
MitraClip System: Percutaneous mitral valve repair using MitraClip System</description>
          </group>
        </group_list>
        <measure>
          <title>Mitral Regurgitation (MR) Severity (COAPT CAS Study Analysis)</title>
          <description>MR Severity Grading was done by Quantitative Doppler Echocardiography and subjects were graded as below
MR 1+ - Regurgitant Volume &lt; 30 ml, Right ventricular EF &lt;30%, Effective regurgitant orifice area &lt; 20 mm^2 MR 2+ - Regurgitant Volume 30-44 ml, Right ventricular EF 30-39%, Effective regurgitant orifice area 20-29 mm^2 MR 3+ - Regurgitant Volume 45-59 ml, Right ventricular EF 40-49 %, Effective regurgitant orifice area 30-39 mm^2 MR 4+ - Regurgitant Volume &gt;= 60 ml, Right ventricular EF &gt;=50%, Effective regurgitant orifice area &gt;=40 mm^2</description>
          <population>Echocardiogram data was available for 120 subjects at 30 days.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="120"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>None or Trace/Trivial</title>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Mild (1+)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="68"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Moderate (2+)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="35"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Moderate - Severe (3+)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Severe (4+)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Major and/or Life Threatening Bleeding (COAPT CAS Study Analysis)</title>
        <description>COAPT Study is still on-going. Only the Primary and Major secondary endpoints were entered in the results section for the COAPT study after the FDA approval of the new indication. Subjects are still being followed in both the COAPT and COAPT CAS cohorts. COAPT CAS study is a single arm registry that will provide valuable new information regarding use of the MitraClip NT system under more &quot;real world&quot; conditions. COAPT study completed recruiting subjects in June 2017. COAPT CAS completed recruiting subjects in March 2019.
Remainder of the COAPT and COAPT CAS results will be entered when the study is closed.</description>
        <time_frame>12 months</time_frame>
        <posting_date>07/2024</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Major and/or Life Threatening Bleeding (COAPT CAS Study Analysis)</title>
        <time_frame>30 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>MitraClip System</title>
            <description>Percutaneous mitral valve repair using MitraClip System
MitraClip System: Percutaneous mitral valve repair using MitraClip System</description>
          </group>
        </group_list>
        <measure>
          <title>Major and/or Life Threatening Bleeding (COAPT CAS Study Analysis)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="157"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Major Vascular Complications (COAPT CAS Study Analysis)</title>
        <description>COAPT Study is still on-going. Only the Primary and Major secondary endpoints were entered in the results section for the COAPT study after the FDA approval of the new indication. Subjects are still being followed in both the COAPT and COAPT CAS cohorts. COAPT CAS study is a single arm registry that will provide valuable new information regarding use of the MitraClip NT system under more &quot;real world&quot; conditions. COAPT study completed recruiting subjects in June 2017. COAPT CAS completed recruiting subjects in March 2019.
Remainder of the COAPT and COAPT CAS results will be entered when the study is closed.</description>
        <time_frame>12 months</time_frame>
        <posting_date>07/2024</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Major Vascular Complications (COAPT CAS Study Analysis)</title>
        <time_frame>30 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>MitraClip System</title>
            <description>Percutaneous mitral valve repair using MitraClip System
MitraClip System: Percutaneous mitral valve repair using MitraClip System</description>
          </group>
        </group_list>
        <measure>
          <title>Major Vascular Complications (COAPT CAS Study Analysis)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="157"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Renal Complication With Requirement for Dialysis (COAPT CAS Study Analysis)</title>
        <description>COAPT Study is still on-going. Only the Primary and Major secondary endpoints were entered in the results section for the COAPT study after the FDA approval of the new indication. Subjects are still being followed in both the COAPT and COAPT CAS cohorts. COAPT CAS study is a single arm registry that will provide valuable new information regarding use of the MitraClip NT system under more &quot;real world&quot; conditions. COAPT study completed recruiting subjects in June 2017. COAPT CAS completed recruiting subjects in March 2019.
Remainder of the COAPT and COAPT CAS results will be entered when the study is closed.</description>
        <time_frame>12 months</time_frame>
        <posting_date>07/2024</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Renal Complication With Requirement for Dialysis (COAPT CAS Study Analysis)</title>
        <time_frame>30 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>MitraClip System</title>
            <description>Percutaneous mitral valve repair using MitraClip System
MitraClip System: Percutaneous mitral valve repair using MitraClip System</description>
          </group>
        </group_list>
        <measure>
          <title>Renal Complication With Requirement for Dialysis (COAPT CAS Study Analysis)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="157"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Transient Ischemic Attack (TIA) (COAPT CAS Study Analysis)</title>
        <description>COAPT Study is still on-going. Only the Primary and Major secondary endpoints were entered in the results section for the COAPT study after the FDA approval of the new indication. Subjects are still being followed in both the COAPT and COAPT CAS cohorts. COAPT CAS study is a single arm registry that will provide valuable new information regarding use of the MitraClip NT system under more &quot;real world&quot; conditions. COAPT study completed recruiting subjects in June 2017. COAPT CAS completed recruiting subjects in March 2019.
Remainder of the COAPT and COAPT CAS results will be entered when the study is closed.</description>
        <time_frame>12 months</time_frame>
        <posting_date>07/2024</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Transient Ischemic Attack (TIA) (COAPT CAS Study Analysis)</title>
        <time_frame>30 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>MitraClip System</title>
            <description>Percutaneous mitral valve repair using MitraClip System
MitraClip System: Percutaneous mitral valve repair using MitraClip System</description>
          </group>
        </group_list>
        <measure>
          <title>Transient Ischemic Attack (TIA) (COAPT CAS Study Analysis)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="157"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Stroke (COAPT CAS Study Analysis)</title>
        <description>COAPT Study is still on-going. Only the Primary and Major secondary endpoints were entered in the results section for the COAPT study after the FDA approval of the new indication. Subjects are still being followed in both the COAPT and COAPT CAS cohorts. COAPT CAS study is a single arm registry that will provide valuable new information regarding use of the MitraClip NT system under more &quot;real world&quot; conditions. COAPT study completed recruiting subjects in June 2017. COAPT CAS completed recruiting subjects in March 2019.
Remainder of the COAPT and COAPT CAS results will be entered when the study is closed.</description>
        <time_frame>12 months</time_frame>
        <posting_date>07/2024</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Stroke (COAPT CAS Study Analysis)</title>
        <time_frame>30 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>MitraClip System</title>
            <description>Percutaneous mitral valve repair using MitraClip System
MitraClip System: Percutaneous mitral valve repair using MitraClip System</description>
          </group>
        </group_list>
        <measure>
          <title>Stroke (COAPT CAS Study Analysis)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="157"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Myocardial Infarction (MI) (COAPT CAS Study Analysis)</title>
        <description>COAPT Study is still on-going. Only the Primary and Major secondary endpoints were entered in the results section for the COAPT study after the FDA approval of the new indication. Subjects are still being followed in both the COAPT and COAPT CAS cohorts. COAPT CAS study is a single arm registry that will provide valuable new information regarding use of the MitraClip NT system under more &quot;real world&quot; conditions. COAPT study completed recruiting subjects in June 2017. COAPT CAS completed recruiting subjects in March 2019.
Remainder of the COAPT and COAPT CAS results will be entered when the study is closed.</description>
        <time_frame>12 months</time_frame>
        <posting_date>07/2024</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Myocardial Infarction (MI) (COAPT CAS Study Analysis)</title>
        <time_frame>30 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>MitraClip System</title>
            <description>Percutaneous mitral valve repair using MitraClip System
MitraClip System: Percutaneous mitral valve repair using MitraClip System</description>
          </group>
        </group_list>
        <measure>
          <title>Myocardial Infarction (MI) (COAPT CAS Study Analysis)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="157"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Death and Primary Cause of Death (COAPT CAS Study Analysis)</title>
        <description>COAPT Study is still on-going. Only the Primary and Major secondary endpoints were entered in the results section for the COAPT study after the FDA approval of the new indication. Subjects are still being followed in both the COAPT and COAPT CAS cohorts. COAPT CAS study is a single arm registry that will provide valuable new information regarding use of the MitraClip NT system under more &quot;real world&quot; conditions. COAPT study completed recruiting subjects in June 2017. COAPT CAS completed recruiting subjects in March 2019.
Remainder of the COAPT and COAPT CAS results will be entered when the study is closed.</description>
        <time_frame>12 months</time_frame>
        <posting_date>07/2024</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Death and Primary Cause of Death (COAPT CAS Study Analysis)</title>
        <time_frame>30 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>MitraClip System</title>
            <description>Percutaneous mitral valve repair using MitraClip System
MitraClip System: Percutaneous mitral valve repair using MitraClip System</description>
          </group>
        </group_list>
        <measure>
          <title>Death and Primary Cause of Death (COAPT CAS Study Analysis)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="157"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cardiac</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neurologic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Renal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vascular</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Infection</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Valvular</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients Free From the Composite of All-cause Death, Stroke, MI, or Non-elective Cardiovascular Surgery for Device Related Complications in the Device Group</title>
        <description>The percentage of patients free from the composite endpoint as described above.</description>
        <time_frame>30 days post-procedure in the Device group</time_frame>
        <population>All device subjects</population>
        <group_list>
          <group group_id="O1">
            <title>MitraClip System</title>
            <description>Percutaneous mitral valve repair using MitraClip System
MitraClip System: Percutaneous mitral valve repair using MitraClip System</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients Free From the Composite of All-cause Death, Stroke, MI, or Non-elective Cardiovascular Surgery for Device Related Complications in the Device Group</title>
          <description>The percentage of patients free from the composite endpoint as described above.</description>
          <population>All device subjects</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="302"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.9" lower_limit="94.7" upper_limit="96.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Deaths at 12 Months (All Cause Mortality)</title>
        <description>Death from any cause mortality at 12months.</description>
        <time_frame>12 months</time_frame>
        <population>All device and control group subjects were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>MitraClip System</title>
            <description>Percutaneous mitral valve repair using MitraClip System
MitraClip System: Percutaneous mitral valve repair using MitraClip System</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Patients with mitral regurgitation managed non-surgically based on standard hospital clinical practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Deaths at 12 Months (All Cause Mortality)</title>
          <description>Death from any cause mortality at 12months.</description>
          <population>All device and control group subjects were included in the analysis.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="302"/>
                <count group_id="O2" value="312"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57"/>
                    <measurement group_id="O2" value="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Mitral Regurgitation Severity Grade of 2+ or Lower at 12 Months</title>
        <description>MR severity grade of 2+ or lower at 12 months MR Severity Grading was done by Quantitative Doppler Echocardiography and subjects were graded as below
MR 1+ - Regurgitant Volume &lt; 30 ml, Right ventricular EF &lt;30%, Effective regurgitant orifice area &lt; 20 mm^2 MR 2+ - Regurgitant Volume 30-44 ml, Right ventricular EF 30-39%, Effective regurgitant orifice area 20-29 mm^2 MR 3+ - Regurgitant Volume 45-59 ml, Right ventricular EF 40-49 %, Effective regurgitant orifice area 30-39 mm^2 MR 4+ - Regurgitant Volume &gt;= 60 ml, Right ventricular EF &gt;=50%, Effective regurgitant orifice area &gt;=40 mm^2</description>
        <time_frame>12 months</time_frame>
        <population>Echocardiography data was available for 210 subjects in Device group and 175 subjects in Control group</population>
        <group_list>
          <group group_id="O1">
            <title>MitraClip System</title>
            <description>Percutaneous mitral valve repair using MitraClip System
MitraClip System: Percutaneous mitral valve repair using MitraClip System</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Patients with mitral regurgitation managed non-surgically based on standard hospital clinical practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Mitral Regurgitation Severity Grade of 2+ or Lower at 12 Months</title>
          <description>MR severity grade of 2+ or lower at 12 months MR Severity Grading was done by Quantitative Doppler Echocardiography and subjects were graded as below
MR 1+ - Regurgitant Volume &lt; 30 ml, Right ventricular EF &lt;30%, Effective regurgitant orifice area &lt; 20 mm^2 MR 2+ - Regurgitant Volume 30-44 ml, Right ventricular EF 30-39%, Effective regurgitant orifice area 20-29 mm^2 MR 3+ - Regurgitant Volume 45-59 ml, Right ventricular EF 40-49 %, Effective regurgitant orifice area 30-39 mm^2 MR 4+ - Regurgitant Volume &gt;= 60 ml, Right ventricular EF &gt;=50%, Effective regurgitant orifice area &gt;=40 mm^2</description>
          <population>Echocardiography data was available for 210 subjects in Device group and 175 subjects in Control group</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="210"/>
                <count group_id="O2" value="175"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="199"/>
                    <measurement group_id="O2" value="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Distance Walked on the 6 Minute Walk Test (6MWT Distance or 6MWD)</title>
        <description>The 6MWT is a practical simple test that requires a 100-ft hallway but no exercise equipment or advanced training for technicians. This test measures the distance that a patient can quickly walk on a flat, hard surface in a period of 6 minutes (the 6MWD). It evaluates the global and integrated responses of all the systems involved during exercise, including the pulmonary and cardiovascular systems, systemic circulation, peripheral circulation, blood, neuromuscular units, and muscle metabolism. It does not provide specific information on the function of each of the different organs and systems involved in exercise or the mechanism of exercise limitation, as is possible with maximal cardiopulmonary exercise testing. The self-paced 6MWT assesses the submaximal level of functional capacity.</description>
        <time_frame>12 months over baseline</time_frame>
        <population>Analysis population includes subjects still active and with paired available compared to baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>MitraClip System</title>
            <description>Percutaneous mitral valve repair using MitraClip System
MitraClip System: Percutaneous mitral valve repair using MitraClip System</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Patients with mitral regurgitation managed non-surgically based on standard hospital clinical practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Distance Walked on the 6 Minute Walk Test (6MWT Distance or 6MWD)</title>
          <description>The 6MWT is a practical simple test that requires a 100-ft hallway but no exercise equipment or advanced training for technicians. This test measures the distance that a patient can quickly walk on a flat, hard surface in a period of 6 minutes (the 6MWD). It evaluates the global and integrated responses of all the systems involved during exercise, including the pulmonary and cardiovascular systems, systemic circulation, peripheral circulation, blood, neuromuscular units, and muscle metabolism. It does not provide specific information on the function of each of the different organs and systems involved in exercise or the mechanism of exercise limitation, as is possible with maximal cardiopulmonary exercise testing. The self-paced 6MWT assesses the submaximal level of functional capacity.</description>
          <population>Analysis population includes subjects still active and with paired available compared to baseline.</population>
          <units>meters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="230"/>
                <count group_id="O2" value="237"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.17" spread="9.12"/>
                    <measurement group_id="O2" value="-60.2" spread="8.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Quality of Life (QoL) as Measured by the Kansas City Cardiomyopathy Questionnaire (KCCQ)</title>
        <description>Paired data looking at difference between the baseline Kansas City Cardiomyopathy Questionnaire (KCCQ) and 12 month KCCQ score.
The Kansas City Cardiomyopathy Questionnaire is a 23-item, self-administered instrument that quantifies physical function, symptoms, social function, self-efficacy and knowledge, and quality of life. with a range of possible subscale scores from 0 to 100, with 100 representing the least burden of symptoms. The KCCQ tool quantifies the following six (6) distinct domains and two (2) summary scores: KCCQ Symptom Domain, KCCQ Physical Function Domain, KCCQ Quality of Life Domain, KCCQ Social Limitation Domain, KCCQ Self-efficacy Domain, KCCQ Symptom Stability Domain, Clinical Summary Score and Overall Summary Score.
Clinical Summary Score includes total symptom and physical function scores to correspond with NYHA Classification.
Overall Summary Score includes the total symptom, physical function, social limitations and quality of life scores.</description>
        <time_frame>12 months over baseline</time_frame>
        <population>Analysis population includes subjects still active and with paired available compared to baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>MitraClip System</title>
            <description>Percutaneous mitral valve repair using MitraClip System
MitraClip System: Percutaneous mitral valve repair using MitraClip System</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Patients with mitral regurgitation managed non-surgically based on standard hospital clinical practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Quality of Life (QoL) as Measured by the Kansas City Cardiomyopathy Questionnaire (KCCQ)</title>
          <description>Paired data looking at difference between the baseline Kansas City Cardiomyopathy Questionnaire (KCCQ) and 12 month KCCQ score.
The Kansas City Cardiomyopathy Questionnaire is a 23-item, self-administered instrument that quantifies physical function, symptoms, social function, self-efficacy and knowledge, and quality of life. with a range of possible subscale scores from 0 to 100, with 100 representing the least burden of symptoms. The KCCQ tool quantifies the following six (6) distinct domains and two (2) summary scores: KCCQ Symptom Domain, KCCQ Physical Function Domain, KCCQ Quality of Life Domain, KCCQ Social Limitation Domain, KCCQ Self-efficacy Domain, KCCQ Symptom Stability Domain, Clinical Summary Score and Overall Summary Score.
Clinical Summary Score includes total symptom and physical function scores to correspond with NYHA Classification.
Overall Summary Score includes the total symptom, physical function, social limitations and quality of life scores.</description>
          <population>Analysis population includes subjects still active and with paired available compared to baseline.</population>
          <units>KCCQ Score on a points scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="237"/>
                <count group_id="O2" value="228"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.5" spread="1.8"/>
                    <measurement group_id="O2" value="-3.6" spread="1.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Left Ventricular End Diastolic Volume (LVEDV)</title>
        <description>Paired data comparing the Change in LVEDV at baseline vs 12 months</description>
        <time_frame>12 months over baseline</time_frame>
        <population>Analysis population includes subjects with echocardiography paired data available</population>
        <group_list>
          <group group_id="O1">
            <title>MitraClip System</title>
            <description>Percutaneous mitral valve repair using MitraClip System
MitraClip System: Percutaneous mitral valve repair using MitraClip System</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Patients with mitral regurgitation managed non-surgically based on standard hospital clinical practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Left Ventricular End Diastolic Volume (LVEDV)</title>
          <description>Paired data comparing the Change in LVEDV at baseline vs 12 months</description>
          <population>Analysis population includes subjects with echocardiography paired data available</population>
          <units>mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="175"/>
                <count group_id="O2" value="174"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.71" spread="5.08"/>
                    <measurement group_id="O2" value="17.06" spread="5.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With New York Heart Association (NYHA) Functional Class I/II</title>
        <description>NEW YORK HEART ASSOCIATION CLASSIFICATION (NYHA CLASS)
Class I: Patients with cardiac disease but without resulting limitations of physical activity.
Class II: Patients with cardiac disease resulting in slight limitation of physical activity. Patients are comfortable at rest. Ordinary physical activity results in fatigue, palpitation, dyspnea, or anginal pain.
Class III: Patients with cardiac disease resulting in marked limitation of physical activity. Patients are comfortable at rest. Less than ordinary physical activity causes fatigue, palpitation dyspnea, or anginal pain.
Class IV: Patients with cardiac disease resulting in inability to carry on any physical activity without discomfort. Symptoms of cardiac insufficiency or of the anginal syndrome may be present even at rest. If any physical activity is undertaken, discomfort is increased.</description>
        <time_frame>12 months</time_frame>
        <population>Analysis population includes subjects with available NYHA class data at 12 months</population>
        <group_list>
          <group group_id="O1">
            <title>MitraClip System</title>
            <description>Percutaneous mitral valve repair using MitraClip System
MitraClip System: Percutaneous mitral valve repair using MitraClip System</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Patients with mitral regurgitation managed non-surgically based on standard hospital clinical practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With New York Heart Association (NYHA) Functional Class I/II</title>
          <description>NEW YORK HEART ASSOCIATION CLASSIFICATION (NYHA CLASS)
Class I: Patients with cardiac disease but without resulting limitations of physical activity.
Class II: Patients with cardiac disease resulting in slight limitation of physical activity. Patients are comfortable at rest. Ordinary physical activity results in fatigue, palpitation, dyspnea, or anginal pain.
Class III: Patients with cardiac disease resulting in marked limitation of physical activity. Patients are comfortable at rest. Less than ordinary physical activity causes fatigue, palpitation dyspnea, or anginal pain.
Class IV: Patients with cardiac disease resulting in inability to carry on any physical activity without discomfort. Symptoms of cardiac insufficiency or of the anginal syndrome may be present even at rest. If any physical activity is undertaken, discomfort is increased.</description>
          <population>Analysis population includes subjects with available NYHA class data at 12 months</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="237"/>
                <count group_id="O2" value="232"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="171"/>
                    <measurement group_id="O2" value="115"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Recurrent Hospitalizations - All Cause</title>
        <description>Number of Recurrent Hospitalizations for any cause within 24 months.</description>
        <time_frame>24 Months</time_frame>
        <population>All randomized subjects in Device and Control Group</population>
        <group_list>
          <group group_id="O1">
            <title>MitraClip System</title>
            <description>Percutaneous mitral valve repair using MitraClip System
MitraClip System: Percutaneous mitral valve repair using MitraClip System</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Patients with mitral regurgitation managed non-surgically based on standard hospital clinical practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Recurrent Hospitalizations - All Cause</title>
          <description>Number of Recurrent Hospitalizations for any cause within 24 months.</description>
          <population>All randomized subjects in Device and Control Group</population>
          <units>Number of Events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="302"/>
                <count group_id="O2" value="312"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="474"/>
                    <measurement group_id="O2" value="610"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.02</p_value>
            <method>Joint Fraility Model</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.76</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.60</ci_lower_limit>
            <ci_upper_limit>0.96</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Death or HF Hospitalization Within 24 Months (Finkelstein-Schoenfeld Analysis of All-Cause Death or Recurrent HF Hospitalization Through 24 Months)</title>
        <description>The win ratio is a useful method for providing an estimate of the treatment effect when composite endpoints are analyzed as the analysis accounts for clinical significance of the outcomes of interest. For example, in the composite of death and recurrent HF hospitalizations through 24 months, subjects in the Device and Control groups were formed into matched pairs, where each pair of subjects was classified into 1 of 5 outcomes scenarios:
A. Death in Device group first B. Death in Control group first C. More HF hospitalizations in the Device group (or in the case of a tie, the first HF hospitalization in the Device group occurs first) D. More HF hospitalization in the Control group (or in the case of tie, the first HF hospitalization in the Control group occurs first) E. None of the above In this way, the number of &quot;Winners&quot; in the Device group was NW = NB + ND while the number of &quot;Losers&quot; in the Device group was NL = NA + NC. The &quot;Win Ratio&quot; was then calculated as NW/NL.</description>
        <time_frame>24 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Randomized Group</title>
            <description>Randomized group contains both Device and Control Group</description>
          </group>
        </group_list>
        <measure>
          <title>Death or HF Hospitalization Within 24 Months (Finkelstein-Schoenfeld Analysis of All-Cause Death or Recurrent HF Hospitalization Through 24 Months)</title>
          <description>The win ratio is a useful method for providing an estimate of the treatment effect when composite endpoints are analyzed as the analysis accounts for clinical significance of the outcomes of interest. For example, in the composite of death and recurrent HF hospitalizations through 24 months, subjects in the Device and Control groups were formed into matched pairs, where each pair of subjects was classified into 1 of 5 outcomes scenarios:
A. Death in Device group first B. Death in Control group first C. More HF hospitalizations in the Device group (or in the case of a tie, the first HF hospitalization in the Device group occurs first) D. More HF hospitalization in the Control group (or in the case of tie, the first HF hospitalization in the Control group occurs first) E. None of the above In this way, the number of &quot;Winners&quot; in the Device group was NW = NB + ND while the number of &quot;Losers&quot; in the Device group was NL = NA + NC. The &quot;Win Ratio&quot; was then calculated as NW/NL.</description>
          <units>Win Ratio</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="614"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.61" lower_limit="1.29" upper_limit="2.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Finkelstein-Schoenfeld Analysis</method>
            <param_type>Win Ratio</param_type>
            <param_value>1.61</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.29</ci_lower_limit>
            <ci_upper_limit>2.04</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Death and Primary Cause of Death (COAPT CAS Study Analysis)</title>
        <description>The COAPT study is still on-going. Only the Primary and major secondary endpoints have been entered. Rest of the results will be entered when the study ends in July 2024.</description>
        <time_frame>2 years</time_frame>
        <posting_date>07/2024</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Death and Primary Cause of Death (COAPT CAS Study Analysis)</title>
        <time_frame>3 years</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Death and Primary Cause of Death (COAPT CAS Study Analysis)</title>
        <time_frame>4 years</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Death and Primary Cause of Death (COAPT CAS Study Analysis)</title>
        <time_frame>5 years</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Myocardial Infarction (MI) (COAPT CAS Study Analysis)</title>
        <time_frame>2 years</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Myocardial Infarction (MI) (COAPT CAS Study Analysis)</title>
        <time_frame>3 years</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Myocardial Infarction (MI) (COAPT CAS Study Analysis)</title>
        <time_frame>4 years</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Myocardial Infarction (MI) (COAPT CAS Study Analysis)</title>
        <time_frame>5 years</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Stroke (COAPT CAS Study Analysis)</title>
        <time_frame>2 years</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Stroke (COAPT CAS Study Analysis)</title>
        <time_frame>3 years</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Stroke (COAPT CAS Study Analysis)</title>
        <time_frame>4 years</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Stroke (COAPT CAS Study Analysis)</title>
        <time_frame>5 years</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Recurrent Heart Failure (HF) Hospitalization (COAPT CAS Study Analysis)</title>
        <time_frame>2 years</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Recurrent Heart Failure (HF) Hospitalization (COAPT CAS Study Analysis)</title>
        <time_frame>3 years</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Recurrent Heart Failure (HF) Hospitalization (COAPT CAS Study Analysis)</title>
        <time_frame>4 years</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Recurrent Heart Failure (HF) Hospitalization (COAPT CAS Study Analysis)</title>
        <time_frame>5 years</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Kaplan-Meier Freedom From All-cause Mortality</title>
        <description>Death from any cause within 24 months - no of events</description>
        <time_frame>24 months</time_frame>
        <population>Total number of subjects randomized in the Device and Control group</population>
        <group_list>
          <group group_id="O1">
            <title>MitraClip System</title>
            <description>Percutaneous mitral valve repair using MitraClip System
MitraClip System: Percutaneous mitral valve repair using MitraClip System</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Patients with mitral regurgitation managed non-surgically based on standard hospital clinical practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Kaplan-Meier Freedom From All-cause Mortality</title>
          <description>Death from any cause within 24 months - no of events</description>
          <population>Total number of subjects randomized in the Device and Control group</population>
          <units>no of events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="302"/>
                <count group_id="O2" value="312"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83"/>
                    <measurement group_id="O2" value="125"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Device or Procedure-Related Adverse Events</title>
        <description>Device or procedure-related adverse events are defined as adverse events that are adjudicated by the Clinical Events Committee as possibly, probably or definitely device and/or procedure-related, regardless of the temporal relationship to the MitraClip procedure. Device or procedure-related adverse events will be broken down into those that occur within 30 days of the procedure and those that occur after 30 days of the procedure. Examples of device-related adverse events are: myocardial perforation, Single Leaflet Device Attachment, embolization of the MitraClip device or MitraClip System components, iatrogenic atrial septal defect, mitral valve stenosis, need for mitral valve replacement instead of repair due at least in part to the MitraClip procedure or the presence of the MitraClip device.</description>
        <time_frame>Within and after 30 days of the procedure</time_frame>
        <population>All available data has been reported.</population>
        <group_list>
          <group group_id="O1">
            <title>MitraClip System</title>
            <description>Percutaneous mitral valve repair using MitraClip System
MitraClip System: Percutaneous mitral valve repair using MitraClip System</description>
          </group>
        </group_list>
        <measure>
          <title>Device or Procedure-Related Adverse Events</title>
          <description>Device or procedure-related adverse events are defined as adverse events that are adjudicated by the Clinical Events Committee as possibly, probably or definitely device and/or procedure-related, regardless of the temporal relationship to the MitraClip procedure. Device or procedure-related adverse events will be broken down into those that occur within 30 days of the procedure and those that occur after 30 days of the procedure. Examples of device-related adverse events are: myocardial perforation, Single Leaflet Device Attachment, embolization of the MitraClip device or MitraClip System components, iatrogenic atrial septal defect, mitral valve stenosis, need for mitral valve replacement instead of repair due at least in part to the MitraClip procedure or the presence of the MitraClip device.</description>
          <population>All available data has been reported.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="302"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Occurred within 30 days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Occurred between 31 days and 365 days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Implant Rate</title>
        <description>Defined as the rate of successful delivery and deployment of the MitraClip device(s) with echocardiographic evidence of leaflet approximation and retrieval of the delivery catheter</description>
        <time_frame>Day 0</time_frame>
        <population>Subjects randomized to the device arm</population>
        <group_list>
          <group group_id="O1">
            <title>MitraClip System</title>
            <description>Percutaneous mitral valve repair using MitraClip System
MitraClip System: Percutaneous mitral valve repair using MitraClip System</description>
          </group>
        </group_list>
        <measure>
          <title>Implant Rate</title>
          <description>Defined as the rate of successful delivery and deployment of the MitraClip device(s) with echocardiographic evidence of leaflet approximation and retrieval of the delivery catheter</description>
          <population>Subjects randomized to the device arm</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="302"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="287"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Device Procedure Time</title>
        <description>Defined as the time elapsed from the start of the transseptal procedure to the time the Steerable Guide Catheter is removed</description>
        <time_frame>Day 0</time_frame>
        <population>Device procedure time was not available for all implanted subjects. Data was available for 282 subjects from 302 randomized subjects in device arm.</population>
        <group_list>
          <group group_id="O1">
            <title>MitraClip System</title>
            <description>Percutaneous mitral valve repair using MitraClip System
MitraClip System: Percutaneous mitral valve repair using MitraClip System</description>
          </group>
        </group_list>
        <measure>
          <title>Device Procedure Time</title>
          <description>Defined as the time elapsed from the start of the transseptal procedure to the time the Steerable Guide Catheter is removed</description>
          <population>Device procedure time was not available for all implanted subjects. Data was available for 282 subjects from 302 randomized subjects in device arm.</population>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="282"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="118.9" spread="63.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Total Procedure Time</title>
        <description>Defined as the time elapsed from the first of any of the following: intravascular catheter placement, anesthesia or sedation, or transesophageal echocardiogram (TEE), to the removal of the last catheter and TEE</description>
        <time_frame>Day 0</time_frame>
        <population>Total procedure time was available for 293 subjects from the 302 subjects randomized to device arm.</population>
        <group_list>
          <group group_id="O1">
            <title>MitraClip System</title>
            <description>Percutaneous mitral valve repair using MitraClip System
MitraClip System: Percutaneous mitral valve repair using MitraClip System</description>
          </group>
        </group_list>
        <measure>
          <title>Total Procedure Time</title>
          <description>Defined as the time elapsed from the first of any of the following: intravascular catheter placement, anesthesia or sedation, or transesophageal echocardiogram (TEE), to the removal of the last catheter and TEE</description>
          <population>Total procedure time was available for 293 subjects from the 302 subjects randomized to device arm.</population>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="293"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="162.9" spread="118.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Device Time</title>
        <description>Defined as the time the Steerable Guide Catheter is placed in the intra-atrial septum until the time the MitraClip Delivery System (CDS) is retracted into the Steerable Guide Catheter</description>
        <time_frame>Day 0</time_frame>
        <population>Device time available for all 287 subjects implanted with MitraClip.</population>
        <group_list>
          <group group_id="O1">
            <title>MitraClip System</title>
            <description>Percutaneous mitral valve repair using MitraClip System
MitraClip System: Percutaneous mitral valve repair using MitraClip System</description>
          </group>
        </group_list>
        <measure>
          <title>Device Time</title>
          <description>Defined as the time the Steerable Guide Catheter is placed in the intra-atrial septum until the time the MitraClip Delivery System (CDS) is retracted into the Steerable Guide Catheter</description>
          <population>Device time available for all 287 subjects implanted with MitraClip.</population>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="287"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.7" spread="80.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Fluoroscopy Duration</title>
        <description>Defined as the duration of exposure to fluoroscopy during the MitraClip procedure</description>
        <time_frame>Day 0</time_frame>
        <population>Fluoroscopy duration for all available subjects with MitraClip device</population>
        <group_list>
          <group group_id="O1">
            <title>MitraClip System</title>
            <description>Percutaneous mitral valve repair using MitraClip System
MitraClip System: Percutaneous mitral valve repair using MitraClip System</description>
          </group>
        </group_list>
        <measure>
          <title>Fluoroscopy Duration</title>
          <description>Defined as the duration of exposure to fluoroscopy during the MitraClip procedure</description>
          <population>Fluoroscopy duration for all available subjects with MitraClip device</population>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="284"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.9" spread="23.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>MR Severity Grade</title>
        <description>MR Severity Grading was done by Quantitative Doppler Echocardiography and subjects were graded as below
MR 1+ - Regurgitant Volume &lt; 30 ml, Right ventricular EF &lt;30%, Effective regurgitant orifice area &lt; 20 mm^2 MR 2+ - Regurgitant Volume 30-44 ml, Right ventricular EF 30-39%, Effective regurgitant orifice area 20-29 mm^2 MR 3+ - Regurgitant Volume 45-59 ml, Right ventricular EF 40-49 %, Effective regurgitant orifice area 30-39 mm^2 MR 4+ - Regurgitant Volume &gt;= 60 ml, Right ventricular EF &gt;=50%, Effective regurgitant orifice area &gt;=40 mm^2</description>
        <time_frame>Baseline</time_frame>
        <population>echocardiogram data was available for 302 subjects in the device arm and 311 subjects in the control arm.</population>
        <group_list>
          <group group_id="O1">
            <title>MitraClip System</title>
            <description>Percutaneous mitral valve repair using MitraClip System
MitraClip System: Percutaneous mitral valve repair using MitraClip System</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Patients with mitral regurgitation managed non-surgically based on standard hospital clinical practice.</description>
          </group>
        </group_list>
        <measure>
          <title>MR Severity Grade</title>
          <description>MR Severity Grading was done by Quantitative Doppler Echocardiography and subjects were graded as below
MR 1+ - Regurgitant Volume &lt; 30 ml, Right ventricular EF &lt;30%, Effective regurgitant orifice area &lt; 20 mm^2 MR 2+ - Regurgitant Volume 30-44 ml, Right ventricular EF 30-39%, Effective regurgitant orifice area 20-29 mm^2 MR 3+ - Regurgitant Volume 45-59 ml, Right ventricular EF 40-49 %, Effective regurgitant orifice area 30-39 mm^2 MR 4+ - Regurgitant Volume &gt;= 60 ml, Right ventricular EF &gt;=50%, Effective regurgitant orifice area &gt;=40 mm^2</description>
          <population>echocardiogram data was available for 302 subjects in the device arm and 311 subjects in the control arm.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="302"/>
                <count group_id="O2" value="311"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>MR 3+</title>
                  <measurement_list>
                    <measurement group_id="O1" value="148"/>
                    <measurement group_id="O2" value="172"/>
                  </measurement_list>
                </category>
                <category>
                  <title>MR 4+</title>
                  <measurement_list>
                    <measurement group_id="O1" value="154"/>
                    <measurement group_id="O2" value="139"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>MR Severity Grade</title>
        <description>MR Severity Grading was done by Quantitative Doppler Echocardiography and subjects were graded as below
MR 1+ - Regurgitant Volume &lt; 30 ml, Right ventricular EF &lt;30%, Effective regurgitant orifice area &lt; 20 mm^2 MR 2+ - Regurgitant Volume 30-44 ml, Right ventricular EF 30-39%, Effective regurgitant orifice area 20-29 mm^2 MR 3+ - Regurgitant Volume 45-59 ml, Right ventricular EF 40-49 %, Effective regurgitant orifice area 30-39 mm^2 MR 4+ - Regurgitant Volume &gt;= 60 ml, Right ventricular EF &gt;=50%, Effective regurgitant orifice area &gt;=40 mm^2</description>
        <time_frame>At discharge (or 30 days if discharge echocardiogram is not available)</time_frame>
        <population>Echocardiogram data was available for 286 subjects in the device arm and 257 subjects in the control arm.</population>
        <group_list>
          <group group_id="O1">
            <title>MitraClip System</title>
            <description>Percutaneous mitral valve repair using MitraClip System
MitraClip System: Percutaneous mitral valve repair using MitraClip System</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Patients with mitral regurgitation managed non-surgically based on standard hospital clinical practice.</description>
          </group>
        </group_list>
        <measure>
          <title>MR Severity Grade</title>
          <description>MR Severity Grading was done by Quantitative Doppler Echocardiography and subjects were graded as below
MR 1+ - Regurgitant Volume &lt; 30 ml, Right ventricular EF &lt;30%, Effective regurgitant orifice area &lt; 20 mm^2 MR 2+ - Regurgitant Volume 30-44 ml, Right ventricular EF 30-39%, Effective regurgitant orifice area 20-29 mm^2 MR 3+ - Regurgitant Volume 45-59 ml, Right ventricular EF 40-49 %, Effective regurgitant orifice area 30-39 mm^2 MR 4+ - Regurgitant Volume &gt;= 60 ml, Right ventricular EF &gt;=50%, Effective regurgitant orifice area &gt;=40 mm^2</description>
          <population>Echocardiogram data was available for 286 subjects in the device arm and 257 subjects in the control arm.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="286"/>
                <count group_id="O2" value="257"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>MR None or 1+</title>
                  <measurement_list>
                    <measurement group_id="O1" value="230"/>
                    <measurement group_id="O2" value="21"/>
                  </measurement_list>
                </category>
                <category>
                  <title>MR 2+</title>
                  <measurement_list>
                    <measurement group_id="O1" value="39"/>
                    <measurement group_id="O2" value="67"/>
                  </measurement_list>
                </category>
                <category>
                  <title>MR 3+</title>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="96"/>
                  </measurement_list>
                </category>
                <category>
                  <title>MR 4+</title>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>MR Severity Grade</title>
        <description>MR Severity Grading was done by Quantitative Doppler Echocardiography and subjects were graded as below
MR 1+ - Regurgitant Volume &lt; 30 ml, Right ventricular EF &lt;30%, Effective regurgitant orifice area &lt; 20 mm^2 MR 2+ - Regurgitant Volume 30-44 ml, Right ventricular EF 30-39%, Effective regurgitant orifice area 20-29 mm^2 MR 3+ - Regurgitant Volume 45-59 ml, Right ventricular EF 40-49 %, Effective regurgitant orifice area 30-39 mm^2 MR 4+ - Regurgitant Volume &gt;= 60 ml, Right ventricular EF &gt;=50%, Effective regurgitant orifice area &gt;=40 mm^2</description>
        <time_frame>6 months</time_frame>
        <population>Echocardiogram data was available for only 240 subjects in the device group and 218 subjects in the control group</population>
        <group_list>
          <group group_id="O1">
            <title>MitraClip System</title>
            <description>Percutaneous mitral valve repair using MitraClip System
MitraClip System: Percutaneous mitral valve repair using MitraClip System</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Patients with mitral regurgitation managed non-surgically based on standard hospital clinical practice.</description>
          </group>
        </group_list>
        <measure>
          <title>MR Severity Grade</title>
          <description>MR Severity Grading was done by Quantitative Doppler Echocardiography and subjects were graded as below
MR 1+ - Regurgitant Volume &lt; 30 ml, Right ventricular EF &lt;30%, Effective regurgitant orifice area &lt; 20 mm^2 MR 2+ - Regurgitant Volume 30-44 ml, Right ventricular EF 30-39%, Effective regurgitant orifice area 20-29 mm^2 MR 3+ - Regurgitant Volume 45-59 ml, Right ventricular EF 40-49 %, Effective regurgitant orifice area 30-39 mm^2 MR 4+ - Regurgitant Volume &gt;= 60 ml, Right ventricular EF &gt;=50%, Effective regurgitant orifice area &gt;=40 mm^2</description>
          <population>Echocardiogram data was available for only 240 subjects in the device group and 218 subjects in the control group</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="240"/>
                <count group_id="O2" value="218"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>MR none or 1+</title>
                  <measurement_list>
                    <measurement group_id="O1" value="160"/>
                    <measurement group_id="O2" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>MR 2+</title>
                  <measurement_list>
                    <measurement group_id="O1" value="65"/>
                    <measurement group_id="O2" value="63"/>
                  </measurement_list>
                </category>
                <category>
                  <title>MR 3+</title>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="92"/>
                  </measurement_list>
                </category>
                <category>
                  <title>MR 4+</title>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>MR Severity Grade</title>
        <description>MR Severity Grading was done by Quantitative Doppler Echocardiography and subjects were graded as below
MR 1+ - Regurgitant Volume &lt; 30 ml, Right ventricular EF &lt;30%, Effective regurgitant orifice area &lt; 20 mm^2 MR 2+ - Regurgitant Volume 30-44 ml, Right ventricular EF 30-39%, Effective regurgitant orifice area 20-29 mm^2 MR 3+ - Regurgitant Volume 45-59 ml, Right ventricular EF 40-49 %, Effective regurgitant orifice area 30-39 mm^2 MR 4+ - Regurgitant Volume &gt;= 60 ml, Right ventricular EF &gt;=50%, Effective regurgitant orifice area &gt;=40 mm^2</description>
        <time_frame>12 months</time_frame>
        <population>Echocardiogram data was available for 210 subjects in the device arm and 175 subjects in the control arm.</population>
        <group_list>
          <group group_id="O1">
            <title>MitraClip System</title>
            <description>Percutaneous mitral valve repair using MitraClip System
MitraClip System: Percutaneous mitral valve repair using MitraClip System</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Patients with mitral regurgitation managed non-surgically based on standard hospital clinical practice.</description>
          </group>
        </group_list>
        <measure>
          <title>MR Severity Grade</title>
          <description>MR Severity Grading was done by Quantitative Doppler Echocardiography and subjects were graded as below
MR 1+ - Regurgitant Volume &lt; 30 ml, Right ventricular EF &lt;30%, Effective regurgitant orifice area &lt; 20 mm^2 MR 2+ - Regurgitant Volume 30-44 ml, Right ventricular EF 30-39%, Effective regurgitant orifice area 20-29 mm^2 MR 3+ - Regurgitant Volume 45-59 ml, Right ventricular EF 40-49 %, Effective regurgitant orifice area 30-39 mm^2 MR 4+ - Regurgitant Volume &gt;= 60 ml, Right ventricular EF &gt;=50%, Effective regurgitant orifice area &gt;=40 mm^2</description>
          <population>Echocardiogram data was available for 210 subjects in the device arm and 175 subjects in the control arm.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="210"/>
                <count group_id="O2" value="175"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>MR None or 1+</title>
                  <measurement_list>
                    <measurement group_id="O1" value="145"/>
                    <measurement group_id="O2" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>MR 2+</title>
                  <measurement_list>
                    <measurement group_id="O1" value="54"/>
                    <measurement group_id="O2" value="62"/>
                  </measurement_list>
                </category>
                <category>
                  <title>MR 3+</title>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="60"/>
                  </measurement_list>
                </category>
                <category>
                  <title>MR 4+</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>MR Severity Grade</title>
        <description>MR Severity Grading was done by Quantitative Doppler Echocardiography and subjects were graded as below
MR 1+ - Regurgitant Volume &lt; 30 ml, Right ventricular EF &lt;30%, Effective regurgitant orifice area &lt; 20 mm^2 MR 2+ - Regurgitant Volume 30-44 ml, Right ventricular EF 30-39%, Effective regurgitant orifice area 20-29 mm^2 MR 3+ - Regurgitant Volume 45-59 ml, Right ventricular EF 40-49 %, Effective regurgitant orifice area 30-39 mm^2 MR 4+ - Regurgitant Volume &gt;= 60 ml, Right ventricular EF &gt;=50%, Effective regurgitant orifice area &gt;=40 mm^2</description>
        <time_frame>24 months</time_frame>
        <population>Echocardiogram data was available for 162 subjects in the device arm and 124 subjects in the control arm.</population>
        <group_list>
          <group group_id="O1">
            <title>MitraClip System</title>
            <description>Percutaneous mitral valve repair using MitraClip System
MitraClip System: Percutaneous mitral valve repair using MitraClip System</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Patients with mitral regurgitation managed non-surgically based on standard hospital clinical practice.</description>
          </group>
        </group_list>
        <measure>
          <title>MR Severity Grade</title>
          <description>MR Severity Grading was done by Quantitative Doppler Echocardiography and subjects were graded as below
MR 1+ - Regurgitant Volume &lt; 30 ml, Right ventricular EF &lt;30%, Effective regurgitant orifice area &lt; 20 mm^2 MR 2+ - Regurgitant Volume 30-44 ml, Right ventricular EF 30-39%, Effective regurgitant orifice area 20-29 mm^2 MR 3+ - Regurgitant Volume 45-59 ml, Right ventricular EF 40-49 %, Effective regurgitant orifice area 30-39 mm^2 MR 4+ - Regurgitant Volume &gt;= 60 ml, Right ventricular EF &gt;=50%, Effective regurgitant orifice area &gt;=40 mm^2</description>
          <population>Echocardiogram data was available for 162 subjects in the device arm and 124 subjects in the control arm.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="162"/>
                <count group_id="O2" value="124"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>MR None or 1+</title>
                  <measurement_list>
                    <measurement group_id="O1" value="127"/>
                    <measurement group_id="O2" value="23"/>
                  </measurement_list>
                </category>
                <category>
                  <title>MR 2+</title>
                  <measurement_list>
                    <measurement group_id="O1" value="34"/>
                    <measurement group_id="O2" value="34"/>
                  </measurement_list>
                </category>
                <category>
                  <title>MR 3+</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="43"/>
                  </measurement_list>
                </category>
                <category>
                  <title>MR 4+</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>MR Severity Grade</title>
        <time_frame>3 years</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>MR Severity Grade</title>
        <time_frame>4 years</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>MR Severity Grade</title>
        <time_frame>5 years</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Effective Regurgitant Orifice Area</title>
        <description>Effective Regurgitant Orifice area is defined as = Regurgitant flow / Regurgitant velocity</description>
        <time_frame>Baseline</time_frame>
        <population>Echocardiogram data was available for the 289 subjects in the device arm and 302 subjects in the control arm.</population>
        <group_list>
          <group group_id="O1">
            <title>MitraClip System</title>
            <description>Percutaneous mitral valve repair using MitraClip System
MitraClip System: Percutaneous mitral valve repair using MitraClip System</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Patients with mitral regurgitation managed non-surgically based on standard hospital clinical practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Effective Regurgitant Orifice Area</title>
          <description>Effective Regurgitant Orifice area is defined as = Regurgitant flow / Regurgitant velocity</description>
          <population>Echocardiogram data was available for the 289 subjects in the device arm and 302 subjects in the control arm.</population>
          <units>cm^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="289"/>
                <count group_id="O2" value="302"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.41" spread="0.15"/>
                    <measurement group_id="O2" value="0.40" spread="0.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Effective Regurgitant Orifice Area</title>
        <description>Effective Regurgitant Orifice area is defined as = Regurgitant flow / Regurgitant velocity</description>
        <time_frame>At discharge (or 30 days if discharge echocardiogram is not available)</time_frame>
        <population>Echocardiogram data was available for 75 subjects in the device arm and 73 subjects in the control arm.</population>
        <group_list>
          <group group_id="O1">
            <title>MitraClip System</title>
            <description>Percutaneous mitral valve repair using MitraClip System
MitraClip System: Percutaneous mitral valve repair using MitraClip System</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Patients with mitral regurgitation managed non-surgically based on standard hospital clinical practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Effective Regurgitant Orifice Area</title>
          <description>Effective Regurgitant Orifice area is defined as = Regurgitant flow / Regurgitant velocity</description>
          <population>Echocardiogram data was available for 75 subjects in the device arm and 73 subjects in the control arm.</population>
          <units>cm^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="75"/>
                <count group_id="O2" value="73"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.14" spread="0.08"/>
                    <measurement group_id="O2" value="0.23" spread="0.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Effective Regurgitant Orifice Area</title>
        <description>Effective Regurgitant Orifice area is defined as = Regurgitant flow / Regurgitant velocity</description>
        <time_frame>6 months</time_frame>
        <population>Echocardiogram data was available for 39 subjects in the device arm and 54 subjects in the control arm</population>
        <group_list>
          <group group_id="O1">
            <title>MitraClip System</title>
            <description>Percutaneous mitral valve repair using MitraClip System
MitraClip System: Percutaneous mitral valve repair using MitraClip System</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Patients with mitral regurgitation managed non-surgically based on standard hospital clinical practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Effective Regurgitant Orifice Area</title>
          <description>Effective Regurgitant Orifice area is defined as = Regurgitant flow / Regurgitant velocity</description>
          <population>Echocardiogram data was available for 39 subjects in the device arm and 54 subjects in the control arm</population>
          <units>cm^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.22" spread="0.19"/>
                    <measurement group_id="O2" value="0.25" spread="0.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Effective Regurgitant Orifice Area</title>
        <description>Effective Regurgitant Orifice area is defined as = Regurgitant flow / Regurgitant velocity</description>
        <time_frame>12 months</time_frame>
        <population>Echocardiogram data was available for 39 subjects in the device arm and 46 subjects in the control arm</population>
        <group_list>
          <group group_id="O1">
            <title>MitraClip System</title>
            <description>Percutaneous mitral valve repair using MitraClip System
MitraClip System: Percutaneous mitral valve repair using MitraClip System</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Patients with mitral regurgitation managed non-surgically based on standard hospital clinical practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Effective Regurgitant Orifice Area</title>
          <description>Effective Regurgitant Orifice area is defined as = Regurgitant flow / Regurgitant velocity</description>
          <population>Echocardiogram data was available for 39 subjects in the device arm and 46 subjects in the control arm</population>
          <units>cm^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.18" spread="0.12"/>
                    <measurement group_id="O2" value="0.26" spread="0.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Effective Regurgitant Orifice Area</title>
        <description>Effective Regurgitant Orifice area is defined as = Regurgitant flow / Regurgitant velocity</description>
        <time_frame>24 months</time_frame>
        <population>Echocardiogram data was available for 18 subjects in the device arm and 24 subjects in the control arm</population>
        <group_list>
          <group group_id="O1">
            <title>MitraClip System</title>
            <description>Percutaneous mitral valve repair using MitraClip System
MitraClip System: Percutaneous mitral valve repair using MitraClip System</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Patients with mitral regurgitation managed non-surgically based on standard hospital clinical practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Effective Regurgitant Orifice Area</title>
          <description>Effective Regurgitant Orifice area is defined as = Regurgitant flow / Regurgitant velocity</description>
          <population>Echocardiogram data was available for 18 subjects in the device arm and 24 subjects in the control arm</population>
          <units>cm^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.15" spread="0.09"/>
                    <measurement group_id="O2" value="0.26" spread="0.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Effective Regurgitant Orifice Area</title>
        <time_frame>3 years</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Effective Regurgitant Orifice Area</title>
        <time_frame>4 years</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Effective Regurgitant Orifice Area</title>
        <time_frame>5 years</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Regurgitant Volume</title>
        <description>Regurgitant Volume is calculated by subtracting the inflow volume across the mitral valve during diastole from the Left Ventricular Outflow Tract (LVOT) stroke volume during systole.</description>
        <time_frame>Baseline</time_frame>
        <population>Echocardiogram data was available for 124 subjects in the device arm and 136 subjects in the control arm.</population>
        <group_list>
          <group group_id="O1">
            <title>MitraClip System</title>
            <description>Percutaneous mitral valve repair using MitraClip System
MitraClip System: Percutaneous mitral valve repair using MitraClip System</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Patients with mitral regurgitation managed non-surgically based on standard hospital clinical practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Regurgitant Volume</title>
          <description>Regurgitant Volume is calculated by subtracting the inflow volume across the mitral valve during diastole from the Left Ventricular Outflow Tract (LVOT) stroke volume during systole.</description>
          <population>Echocardiogram data was available for 124 subjects in the device arm and 136 subjects in the control arm.</population>
          <units>ml/beat</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="124"/>
                <count group_id="O2" value="136"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.80" spread="16.99"/>
                    <measurement group_id="O2" value="25.01" spread="15.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Regurgitant Volume</title>
        <description>Regurgitant Volume is calculated by subtracting the inflow volume across the mitral valve during diastole from the Left Ventricular Outflow Tract (LVOT) stroke volume during systole.</description>
        <time_frame>At discharge (or 30 days if discharge echocardiogram is not available)</time_frame>
        <population>Echocardiogram data was available for 85 subjects in device arm and 70 subjects in control arm</population>
        <group_list>
          <group group_id="O1">
            <title>MitraClip System</title>
            <description>Percutaneous mitral valve repair using MitraClip System
MitraClip System: Percutaneous mitral valve repair using MitraClip System</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Patients with mitral regurgitation managed non-surgically based on standard hospital clinical practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Regurgitant Volume</title>
          <description>Regurgitant Volume is calculated by subtracting the inflow volume across the mitral valve during diastole from the Left Ventricular Outflow Tract (LVOT) stroke volume during systole.</description>
          <population>Echocardiogram data was available for 85 subjects in device arm and 70 subjects in control arm</population>
          <units>ml/beat</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="85"/>
                <count group_id="O2" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.04" spread="11.86"/>
                    <measurement group_id="O2" value="25.97" spread="15.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Regurgitant Volume</title>
        <description>Regurgitant Volume is calculated by subtracting the inflow volume across the mitral valve during diastole from the Left Ventricular Outflow Tract (LVOT) stroke volume during systole.</description>
        <time_frame>6 months</time_frame>
        <population>Echocardiogram data was available for 45 subjects in the device arm and 54 subjects in the control arm.</population>
        <group_list>
          <group group_id="O1">
            <title>MitraClip System</title>
            <description>Percutaneous mitral valve repair using MitraClip System
MitraClip System: Percutaneous mitral valve repair using MitraClip System</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Patients with mitral regurgitation managed non-surgically based on standard hospital clinical practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Regurgitant Volume</title>
          <description>Regurgitant Volume is calculated by subtracting the inflow volume across the mitral valve during diastole from the Left Ventricular Outflow Tract (LVOT) stroke volume during systole.</description>
          <population>Echocardiogram data was available for 45 subjects in the device arm and 54 subjects in the control arm.</population>
          <units>ml/beat</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.60" spread="16.00"/>
                    <measurement group_id="O2" value="32.59" spread="15.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Regurgitant Volume</title>
        <description>Regurgitant Volume is calculated by subtracting the inflow volume across the mitral valve during diastole from the Left Ventricular Outflow Tract (LVOT) stroke volume during systole.</description>
        <time_frame>12 months</time_frame>
        <population>Echocardiogram data was available for 33 subjects in the device arm and 45 subjects in the control arm.</population>
        <group_list>
          <group group_id="O1">
            <title>MitraClip System</title>
            <description>Percutaneous mitral valve repair using MitraClip System
MitraClip System: Percutaneous mitral valve repair using MitraClip System</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Patients with mitral regurgitation managed non-surgically based on standard hospital clinical practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Regurgitant Volume</title>
          <description>Regurgitant Volume is calculated by subtracting the inflow volume across the mitral valve during diastole from the Left Ventricular Outflow Tract (LVOT) stroke volume during systole.</description>
          <population>Echocardiogram data was available for 33 subjects in the device arm and 45 subjects in the control arm.</population>
          <units>ml/beat</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.61" spread="12.12"/>
                    <measurement group_id="O2" value="27.76" spread="14.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Regurgitant Volume</title>
        <description>Regurgitant Volume is calculated by subtracting the inflow volume across the mitral valve during diastole from the Left Ventricular Outflow Tract (LVOT) stroke volume during systole.</description>
        <time_frame>24 months</time_frame>
        <population>Echocardiogram data was available for 20 subjects in the device arm and 27 subjects in the control arm</population>
        <group_list>
          <group group_id="O1">
            <title>MitraClip System</title>
            <description>Percutaneous mitral valve repair using MitraClip System
MitraClip System: Percutaneous mitral valve repair using MitraClip System</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Patients with mitral regurgitation managed non-surgically based on standard hospital clinical practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Regurgitant Volume</title>
          <description>Regurgitant Volume is calculated by subtracting the inflow volume across the mitral valve during diastole from the Left Ventricular Outflow Tract (LVOT) stroke volume during systole.</description>
          <population>Echocardiogram data was available for 20 subjects in the device arm and 27 subjects in the control arm</population>
          <units>ml/beat</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.10" spread="11.50"/>
                    <measurement group_id="O2" value="33.37" spread="16.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Regurgitant Volume</title>
        <time_frame>3 years</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Regurgitant Volume</title>
        <time_frame>4 years</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Regurgitant Volume</title>
        <time_frame>5 years</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Regurgitant Fraction</title>
        <description>Regurgitant fraction is the percentage of blood that regurgitates back through the aortic valve to the left ventricle due to aortic insufficiency, or through the mitral valve to the atrium due to mitral insufficiency.</description>
        <time_frame>Baseline</time_frame>
        <population>Echocardiogram data was available for 123 subjects in the device group and 136 subjects in the control group.</population>
        <group_list>
          <group group_id="O1">
            <title>MitraClip System</title>
            <description>Percutaneous mitral valve repair using MitraClip System
MitraClip System: Percutaneous mitral valve repair using MitraClip System</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Patients with mitral regurgitation managed non-surgically based on standard hospital clinical practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Regurgitant Fraction</title>
          <description>Regurgitant fraction is the percentage of blood that regurgitates back through the aortic valve to the left ventricle due to aortic insufficiency, or through the mitral valve to the atrium due to mitral insufficiency.</description>
          <population>Echocardiogram data was available for 123 subjects in the device group and 136 subjects in the control group.</population>
          <units>percentage</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="123"/>
                <count group_id="O2" value="136"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.24" spread="13.81"/>
                    <measurement group_id="O2" value="34.81" spread="14.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Regurgitant Fraction</title>
        <description>Regurgitant fraction is the percentage of blood that regurgitates back through the aortic valve to the left ventricle due to aortic insufficiency, or through the mitral valve to the atrium due to mitral insufficiency.</description>
        <time_frame>At discharge (or 30 days if discharge echocardiogram is not available)</time_frame>
        <population>Echocardiogram data was available for 85 subjects in the device arm and 70 subjects in the control arm.</population>
        <group_list>
          <group group_id="O1">
            <title>MitraClip System</title>
            <description>Percutaneous mitral valve repair using MitraClip System
MitraClip System: Percutaneous mitral valve repair using MitraClip System</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Patients with mitral regurgitation managed non-surgically based on standard hospital clinical practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Regurgitant Fraction</title>
          <description>Regurgitant fraction is the percentage of blood that regurgitates back through the aortic valve to the left ventricle due to aortic insufficiency, or through the mitral valve to the atrium due to mitral insufficiency.</description>
          <population>Echocardiogram data was available for 85 subjects in the device arm and 70 subjects in the control arm.</population>
          <units>percentage</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="85"/>
                <count group_id="O2" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.00" spread="14.53"/>
                    <measurement group_id="O2" value="35.29" spread="15.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Regurgitant Fraction</title>
        <description>Regurgitant fraction is the percentage of blood that regurgitates back through the aortic valve to the left ventricle due to aortic insufficiency, or through the mitral valve to the atrium due to mitral insufficiency.</description>
        <time_frame>6 months</time_frame>
        <population>Echocardiogram data was available for 45 subjects in the device arm and 54 subjects in the control arm</population>
        <group_list>
          <group group_id="O1">
            <title>MitraClip System</title>
            <description>Percutaneous mitral valve repair using MitraClip System
MitraClip System: Percutaneous mitral valve repair using MitraClip System</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Patients with mitral regurgitation managed non-surgically based on standard hospital clinical practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Regurgitant Fraction</title>
          <description>Regurgitant fraction is the percentage of blood that regurgitates back through the aortic valve to the left ventricle due to aortic insufficiency, or through the mitral valve to the atrium due to mitral insufficiency.</description>
          <population>Echocardiogram data was available for 45 subjects in the device arm and 54 subjects in the control arm</population>
          <units>percentage</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.14" spread="15.89"/>
                    <measurement group_id="O2" value="42.20" spread="14.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Regurgitant Fraction</title>
        <description>Regurgitant fraction is the percentage of blood that regurgitates back through the aortic valve to the left ventricle due to aortic insufficiency, or through the mitral valve to the atrium due to mitral insufficiency.</description>
        <time_frame>12 months</time_frame>
        <population>Echocardiogram data was available for 33 subjects in the device arm and 45 subjects in the control arm.</population>
        <group_list>
          <group group_id="O1">
            <title>MitraClip System</title>
            <description>Percutaneous mitral valve repair using MitraClip System
MitraClip System: Percutaneous mitral valve repair using MitraClip System</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Patients with mitral regurgitation managed non-surgically based on standard hospital clinical practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Regurgitant Fraction</title>
          <description>Regurgitant fraction is the percentage of blood that regurgitates back through the aortic valve to the left ventricle due to aortic insufficiency, or through the mitral valve to the atrium due to mitral insufficiency.</description>
          <population>Echocardiogram data was available for 33 subjects in the device arm and 45 subjects in the control arm.</population>
          <units>percentage</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.15" spread="13.06"/>
                    <measurement group_id="O2" value="37.80" spread="15.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Regurgitant Fraction</title>
        <description>Regurgitant fraction is the percentage of blood that regurgitates back through the aortic valve to the left ventricle due to aortic insufficiency, or through the mitral valve to the atrium due to mitral insufficiency.</description>
        <time_frame>24 months</time_frame>
        <population>Echocardiogram data is available for 20 subjects in the device arm and 27 subjects in the control arm.</population>
        <group_list>
          <group group_id="O1">
            <title>MitraClip System</title>
            <description>Percutaneous mitral valve repair using MitraClip System
MitraClip System: Percutaneous mitral valve repair using MitraClip System</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Patients with mitral regurgitation managed non-surgically based on standard hospital clinical practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Regurgitant Fraction</title>
          <description>Regurgitant fraction is the percentage of blood that regurgitates back through the aortic valve to the left ventricle due to aortic insufficiency, or through the mitral valve to the atrium due to mitral insufficiency.</description>
          <population>Echocardiogram data is available for 20 subjects in the device arm and 27 subjects in the control arm.</population>
          <units>percentage</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.50" spread="14.43"/>
                    <measurement group_id="O2" value="42.23" spread="15.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Regurgitant Fraction</title>
        <time_frame>3 years</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Regurgitant Fraction</title>
        <time_frame>4 years</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Regurgitant Fraction</title>
        <time_frame>5 years</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Left Ventricle End Diastolic Volume (LVEDV)</title>
        <description>Left Ventricle End-diastolic volume is the amount of blood that is in the left ventricle before the heart contracts.</description>
        <time_frame>Baseline</time_frame>
        <population>All available echocardiogram data used for analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>MitraClip System</title>
            <description>Percutaneous mitral valve repair using MitraClip System
MitraClip System: Percutaneous mitral valve repair using MitraClip System</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Patients with mitral regurgitation managed non-surgically based on standard hospital clinical practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Left Ventricle End Diastolic Volume (LVEDV)</title>
          <description>Left Ventricle End-diastolic volume is the amount of blood that is in the left ventricle before the heart contracts.</description>
          <population>All available echocardiogram data used for analysis.</population>
          <units>mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="281"/>
                <count group_id="O2" value="294"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="194.4" spread="69.2"/>
                    <measurement group_id="O2" value="191.0" spread="72.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Left Ventricle End Diastolic Volume (LVEDV)</title>
        <description>Left Ventricle End-diastolic volume is the amount of blood that is in the left ventricle before the heart contracts.</description>
        <time_frame>At discharge (or 30 days if discharge echocardiogram is not available)</time_frame>
        <population>All available echocardiogram data has been presented.</population>
        <group_list>
          <group group_id="O1">
            <title>MitraClip System</title>
            <description>Percutaneous mitral valve repair using MitraClip System
MitraClip System: Percutaneous mitral valve repair using MitraClip System</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Patients with mitral regurgitation managed non-surgically based on standard hospital clinical practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Left Ventricle End Diastolic Volume (LVEDV)</title>
          <description>Left Ventricle End-diastolic volume is the amount of blood that is in the left ventricle before the heart contracts.</description>
          <population>All available echocardiogram data has been presented.</population>
          <units>mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="259"/>
                <count group_id="O2" value="223"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="176.0" spread="64.6"/>
                    <measurement group_id="O2" value="179.1" spread="68.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Left Ventricle End Diastolic Volume (LVEDV)</title>
        <description>Left Ventricle End-diastolic volume is the amount of blood that is in the left ventricle before the heart contracts.</description>
        <time_frame>6 months</time_frame>
        <population>All available echocardiogram data has been presented.</population>
        <group_list>
          <group group_id="O1">
            <title>MitraClip System</title>
            <description>Percutaneous mitral valve repair using MitraClip System
MitraClip System: Percutaneous mitral valve repair using MitraClip System</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Patients with mitral regurgitation managed non-surgically based on standard hospital clinical practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Left Ventricle End Diastolic Volume (LVEDV)</title>
          <description>Left Ventricle End-diastolic volume is the amount of blood that is in the left ventricle before the heart contracts.</description>
          <population>All available echocardiogram data has been presented.</population>
          <units>mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="200"/>
                <count group_id="O2" value="171"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="181.4" spread="65.1"/>
                    <measurement group_id="O2" value="182.6" spread="72.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Left Ventricle End Diastolic Volume (LVEDV)</title>
        <description>Left Ventricle End-diastolic volume is the amount of blood that is in the left ventricle before the heart contracts.</description>
        <time_frame>12 months</time_frame>
        <population>All available echocardiogram data has been presented.</population>
        <group_list>
          <group group_id="O1">
            <title>MitraClip System</title>
            <description>Percutaneous mitral valve repair using MitraClip System
MitraClip System: Percutaneous mitral valve repair using MitraClip System</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Patients with mitral regurgitation managed non-surgically based on standard hospital clinical practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Left Ventricle End Diastolic Volume (LVEDV)</title>
          <description>Left Ventricle End-diastolic volume is the amount of blood that is in the left ventricle before the heart contracts.</description>
          <population>All available echocardiogram data has been presented.</population>
          <units>mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="168"/>
                <count group_id="O2" value="146"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="179.4" spread="66.2"/>
                    <measurement group_id="O2" value="176.3" spread="65.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Left Ventricle End Diastolic Volume (LVEDV)</title>
        <description>Left Ventricle End-diastolic volume is the amount of blood that is in the left ventricle before the heart contracts.</description>
        <time_frame>24 months</time_frame>
        <population>All available echocardiogram data has been presented</population>
        <group_list>
          <group group_id="O1">
            <title>MitraClip System</title>
            <description>Percutaneous mitral valve repair using MitraClip System
MitraClip System: Percutaneous mitral valve repair using MitraClip System</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Patients with mitral regurgitation managed non-surgically based on standard hospital clinical practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Left Ventricle End Diastolic Volume (LVEDV)</title>
          <description>Left Ventricle End-diastolic volume is the amount of blood that is in the left ventricle before the heart contracts.</description>
          <population>All available echocardiogram data has been presented</population>
          <units>mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="116"/>
                <count group_id="O2" value="92"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="176.0" spread="60.8"/>
                    <measurement group_id="O2" value="185.7" spread="73.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Left Ventricle End Diastolic Volume (LVEDV)</title>
        <time_frame>3 years</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Left Ventricle End Diastolic Volume (LVEDV)</title>
        <time_frame>4 years</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Left Ventricle End Diastolic Volume (LVEDV)</title>
        <time_frame>5 years</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Left Ventricular End Systolic Volume (LVESV)</title>
        <description>Left Ventricular End-systolic volume (LVESV) is the volume of blood in the left ventricle at the end of contraction, or systole, and the beginning of filling, or diastole. LVESV is the lowest volume of blood in the left ventricle at any point in the cardiac cycle.</description>
        <time_frame>Baseline</time_frame>
        <population>All available echocardiogram data has been presented.</population>
        <group_list>
          <group group_id="O1">
            <title>MitraClip System</title>
            <description>Percutaneous mitral valve repair using MitraClip System
MitraClip System: Percutaneous mitral valve repair using MitraClip System</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Patients with mitral regurgitation managed non-surgically based on standard hospital clinical practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Left Ventricular End Systolic Volume (LVESV)</title>
          <description>Left Ventricular End-systolic volume (LVESV) is the volume of blood in the left ventricle at the end of contraction, or systole, and the beginning of filling, or diastole. LVESV is the lowest volume of blood in the left ventricle at any point in the cardiac cycle.</description>
          <population>All available echocardiogram data has been presented.</population>
          <units>mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="281"/>
                <count group_id="O2" value="294"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="135.5" spread="56.1"/>
                    <measurement group_id="O2" value="134.3" spread="60.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Left Ventricular End Systolic Volume (LVESV)</title>
        <description>Left Ventricular End-systolic volume (LVESV) is the volume of blood in the left ventricle at the end of contraction, or systole, and the beginning of filling, or diastole. LVESV is the lowest volume of blood in the left ventricle at any point in the cardiac cycle.</description>
        <time_frame>At discharge (or 30 days if discharge echocardiogram is not available)</time_frame>
        <population>All available echocardiogram data has been presented.</population>
        <group_list>
          <group group_id="O1">
            <title>MitraClip System</title>
            <description>Percutaneous mitral valve repair using MitraClip System
MitraClip System: Percutaneous mitral valve repair using MitraClip System</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Patients with mitral regurgitation managed non-surgically based on standard hospital clinical practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Left Ventricular End Systolic Volume (LVESV)</title>
          <description>Left Ventricular End-systolic volume (LVESV) is the volume of blood in the left ventricle at the end of contraction, or systole, and the beginning of filling, or diastole. LVESV is the lowest volume of blood in the left ventricle at any point in the cardiac cycle.</description>
          <population>All available echocardiogram data has been presented.</population>
          <units>mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="258"/>
                <count group_id="O2" value="223"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="129.3" spread="56.5"/>
                    <measurement group_id="O2" value="125.7" spread="57.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Left Ventricular End Systolic Volume (LVESV)</title>
        <description>Left Ventricular End-systolic volume (LVESV) is the volume of blood in the left ventricle at the end of contraction, or systole, and the beginning of filling, or diastole. LVESV is the lowest volume of blood in the left ventricle at any point in the cardiac cycle.</description>
        <time_frame>6 months</time_frame>
        <population>All available echocardiogram data has been presented.</population>
        <group_list>
          <group group_id="O1">
            <title>MitraClip System</title>
            <description>Percutaneous mitral valve repair using MitraClip System
MitraClip System: Percutaneous mitral valve repair using MitraClip System</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Patients with mitral regurgitation managed non-surgically based on standard hospital clinical practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Left Ventricular End Systolic Volume (LVESV)</title>
          <description>Left Ventricular End-systolic volume (LVESV) is the volume of blood in the left ventricle at the end of contraction, or systole, and the beginning of filling, or diastole. LVESV is the lowest volume of blood in the left ventricle at any point in the cardiac cycle.</description>
          <population>All available echocardiogram data has been presented.</population>
          <units>mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="200"/>
                <count group_id="O2" value="171"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="133.1" spread="59.2"/>
                    <measurement group_id="O2" value="129.1" spread="59.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Left Ventricular End Systolic Volume (LVESV)</title>
        <description>Left Ventricular End-systolic volume (LVESV) is the volume of blood in the left ventricle at the end of contraction, or systole, and the beginning of filling, or diastole. LVESV is the lowest volume of blood in the left ventricle at any point in the cardiac cycle.</description>
        <time_frame>12 months</time_frame>
        <population>All available echocardiogram data has been presented.</population>
        <group_list>
          <group group_id="O1">
            <title>MitraClip System</title>
            <description>Percutaneous mitral valve repair using MitraClip System
MitraClip System: Percutaneous mitral valve repair using MitraClip System</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Patients with mitral regurgitation managed non-surgically based on standard hospital clinical practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Left Ventricular End Systolic Volume (LVESV)</title>
          <description>Left Ventricular End-systolic volume (LVESV) is the volume of blood in the left ventricle at the end of contraction, or systole, and the beginning of filling, or diastole. LVESV is the lowest volume of blood in the left ventricle at any point in the cardiac cycle.</description>
          <population>All available echocardiogram data has been presented.</population>
          <units>mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="168"/>
                <count group_id="O2" value="146"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="133.0" spread="60.9"/>
                    <measurement group_id="O2" value="125.9" spread="54.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Left Ventricular End Systolic Volume (LVESV)</title>
        <description>Left Ventricular End-systolic volume (LVESV) is the volume of blood in the left ventricle at the end of contraction, or systole, and the beginning of filling, or diastole. LVESV is the lowest volume of blood in the left ventricle at any point in the cardiac cycle.</description>
        <time_frame>24 months</time_frame>
        <population>All available echocardiogram data has been presented.</population>
        <group_list>
          <group group_id="O1">
            <title>MitraClip System</title>
            <description>Percutaneous mitral valve repair using MitraClip System
MitraClip System: Percutaneous mitral valve repair using MitraClip System</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Patients with mitral regurgitation managed non-surgically based on standard hospital clinical practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Left Ventricular End Systolic Volume (LVESV)</title>
          <description>Left Ventricular End-systolic volume (LVESV) is the volume of blood in the left ventricle at the end of contraction, or systole, and the beginning of filling, or diastole. LVESV is the lowest volume of blood in the left ventricle at any point in the cardiac cycle.</description>
          <population>All available echocardiogram data has been presented.</population>
          <units>mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="116"/>
                <count group_id="O2" value="92"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="128.2" spread="52.9"/>
                    <measurement group_id="O2" value="133.2" spread="65.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Left Ventricular End Systolic Volume (LVESV)</title>
        <time_frame>3 years</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Left Ventricular End Systolic Volume (LVESV)</title>
        <time_frame>4 years</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Left Ventricular End Systolic Volume (LVESV)</title>
        <time_frame>5 years</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Left Ventricular End Diastolic Dimension (LVEDD)</title>
        <time_frame>Baseline</time_frame>
        <population>All available echocardiogram data has been presented.</population>
        <group_list>
          <group group_id="O1">
            <title>MitraClip System</title>
            <description>Percutaneous mitral valve repair using MitraClip System
MitraClip System: Percutaneous mitral valve repair using MitraClip System</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Patients with mitral regurgitation managed non-surgically based on standard hospital clinical practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Left Ventricular End Diastolic Dimension (LVEDD)</title>
          <population>All available echocardiogram data has been presented.</population>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="301"/>
                <count group_id="O2" value="307"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.17" spread="0.73"/>
                    <measurement group_id="O2" value="6.19" spread="0.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Left Ventricular End Diastolic Dimension (LVEDD)</title>
        <time_frame>At discharge (or 30 days if discharge echocardiogram is not available)</time_frame>
        <population>All available echocardiogram data has been presented.</population>
        <group_list>
          <group group_id="O1">
            <title>MitraClip System</title>
            <description>Percutaneous mitral valve repair using MitraClip System
MitraClip System: Percutaneous mitral valve repair using MitraClip System</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Patients with mitral regurgitation managed non-surgically based on standard hospital clinical practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Left Ventricular End Diastolic Dimension (LVEDD)</title>
          <population>All available echocardiogram data has been presented.</population>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="286"/>
                <count group_id="O2" value="249"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.10" spread="0.75"/>
                    <measurement group_id="O2" value="7.41" spread="19.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Left Ventricular End Diastolic Dimension (LVEDD)</title>
        <time_frame>6 months</time_frame>
        <population>All available echocardiogram data has been presented.</population>
        <group_list>
          <group group_id="O1">
            <title>MitraClip System</title>
            <description>Percutaneous mitral valve repair using MitraClip System
MitraClip System: Percutaneous mitral valve repair using MitraClip System</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Patients with mitral regurgitation managed non-surgically based on standard hospital clinical practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Left Ventricular End Diastolic Dimension (LVEDD)</title>
          <population>All available echocardiogram data has been presented.</population>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="231"/>
                <count group_id="O2" value="210"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.12" spread="0.77"/>
                    <measurement group_id="O2" value="6.15" spread="0.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Left Ventricular End Diastolic Dimension (LVEDD)</title>
        <time_frame>12 months</time_frame>
        <population>All available echocardiogram data has been presented.</population>
        <group_list>
          <group group_id="O1">
            <title>MitraClip System</title>
            <description>Percutaneous mitral valve repair using MitraClip System
MitraClip System: Percutaneous mitral valve repair using MitraClip System</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Patients with mitral regurgitation managed non-surgically based on standard hospital clinical practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Left Ventricular End Diastolic Dimension (LVEDD)</title>
          <population>All available echocardiogram data has been presented.</population>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="198"/>
                <count group_id="O2" value="174"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.08" spread="0.77"/>
                    <measurement group_id="O2" value="6.10" spread="0.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Left Ventricular End Diastolic Dimension (LVEDD)</title>
        <time_frame>24 months</time_frame>
        <population>All available echocardiogram data has been presented.</population>
        <group_list>
          <group group_id="O1">
            <title>MitraClip System</title>
            <description>Percutaneous mitral valve repair using MitraClip System
MitraClip System: Percutaneous mitral valve repair using MitraClip System</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Patients with mitral regurgitation managed non-surgically based on standard hospital clinical practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Left Ventricular End Diastolic Dimension (LVEDD)</title>
          <population>All available echocardiogram data has been presented.</population>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="152"/>
                <count group_id="O2" value="124"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.07" spread="0.92"/>
                    <measurement group_id="O2" value="6.19" spread="0.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Left Ventricular End Diastolic Dimension (LVEDD)</title>
        <time_frame>3 years</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Left Ventricular End Diastolic Dimension (LVEDD)</title>
        <time_frame>4 years</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Left Ventricular End Diastolic Dimension (LVEDD)</title>
        <time_frame>5 years</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Left Ventricular End Systolic Dimension (LVESD)</title>
        <time_frame>Baseline</time_frame>
        <population>All available echocardiogram data has been reported.</population>
        <group_list>
          <group group_id="O1">
            <title>MitraClip System</title>
            <description>Percutaneous mitral valve repair using MitraClip System
MitraClip System: Percutaneous mitral valve repair using MitraClip System</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Patients with mitral regurgitation managed non-surgically based on standard hospital clinical practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Left Ventricular End Systolic Dimension (LVESD)</title>
          <population>All available echocardiogram data has been reported.</population>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="301"/>
                <count group_id="O2" value="306"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.28" spread="0.86"/>
                    <measurement group_id="O2" value="5.30" spread="0.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Left Ventricular End Systolic Dimension (LVESD)</title>
        <time_frame>At discharge (or 30 days if discharge echocardiogram is not available)</time_frame>
        <population>All available echocardiogram data has been reported.</population>
        <group_list>
          <group group_id="O1">
            <title>MitraClip System</title>
            <description>Percutaneous mitral valve repair using MitraClip System
MitraClip System: Percutaneous mitral valve repair using MitraClip System</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Patients with mitral regurgitation managed non-surgically based on standard hospital clinical practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Left Ventricular End Systolic Dimension (LVESD)</title>
          <population>All available echocardiogram data has been reported.</population>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="286"/>
                <count group_id="O2" value="248"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.31" spread="0.89"/>
                    <measurement group_id="O2" value="6.12" spread="12.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Left Ventricular End Systolic Dimension (LVESD)</title>
        <time_frame>6 months</time_frame>
        <population>All available echocardiogram data has been reported.</population>
        <group_list>
          <group group_id="O1">
            <title>MitraClip System</title>
            <description>Percutaneous mitral valve repair using MitraClip System
MitraClip System: Percutaneous mitral valve repair using MitraClip System</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Patients with mitral regurgitation managed non-surgically based on standard hospital clinical practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Left Ventricular End Systolic Dimension (LVESD)</title>
          <population>All available echocardiogram data has been reported.</population>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="231"/>
                <count group_id="O2" value="208"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.34" spread="0.91"/>
                    <measurement group_id="O2" value="5.28" spread="0.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Left Ventricular End Systolic Dimension (LVESD)</title>
        <time_frame>12 months</time_frame>
        <population>All available echocardiogram data has been reported.</population>
        <group_list>
          <group group_id="O1">
            <title>MitraClip System</title>
            <description>Percutaneous mitral valve repair using MitraClip System
MitraClip System: Percutaneous mitral valve repair using MitraClip System</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Patients with mitral regurgitation managed non-surgically based on standard hospital clinical practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Left Ventricular End Systolic Dimension (LVESD)</title>
          <population>All available echocardiogram data has been reported.</population>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="197"/>
                <count group_id="O2" value="173"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.26" spread="0.95"/>
                    <measurement group_id="O2" value="5.25" spread="0.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Left Ventricular End Systolic Dimension (LVESD)</title>
        <time_frame>24 months</time_frame>
        <population>All available echocardiogram data has been reported.</population>
        <group_list>
          <group group_id="O1">
            <title>MitraClip System</title>
            <description>Percutaneous mitral valve repair using MitraClip System
MitraClip System: Percutaneous mitral valve repair using MitraClip System</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Patients with mitral regurgitation managed non-surgically based on standard hospital clinical practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Left Ventricular End Systolic Dimension (LVESD)</title>
          <population>All available echocardiogram data has been reported.</population>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="151"/>
                <count group_id="O2" value="121"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.24" spread="1.08"/>
                    <measurement group_id="O2" value="5.27" spread="1.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Left Ventricular End Systolic Dimension (LVESD)</title>
        <time_frame>3 years</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Left Ventricular End Systolic Dimension (LVESD)</title>
        <time_frame>4 years</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Left Ventricular End Systolic Dimension (LVESD)</title>
        <time_frame>5 years</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Left Ventricular Ejection Fraction (LVEF)</title>
        <time_frame>Baseline</time_frame>
        <population>All available echocardiogram data has been reported.</population>
        <group_list>
          <group group_id="O1">
            <title>MitraClip System</title>
            <description>Percutaneous mitral valve repair using MitraClip System
MitraClip System: Percutaneous mitral valve repair using MitraClip System</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Patients with mitral regurgitation managed non-surgically based on standard hospital clinical practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Left Ventricular Ejection Fraction (LVEF)</title>
          <population>All available echocardiogram data has been reported.</population>
          <units>percentage</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="281"/>
                <count group_id="O2" value="294"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.32" spread="9.07"/>
                    <measurement group_id="O2" value="31.30" spread="9.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Left Ventricular Ejection Fraction (LVEF)</title>
        <time_frame>At discharge (or 30 days if discharge echocardiogram is not available)</time_frame>
        <population>All available echocardiogram data has been reported.</population>
        <group_list>
          <group group_id="O1">
            <title>MitraClip System</title>
            <description>Percutaneous mitral valve repair using MitraClip System
MitraClip System: Percutaneous mitral valve repair using MitraClip System</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Patients with mitral regurgitation managed non-surgically based on standard hospital clinical practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Left Ventricular Ejection Fraction (LVEF)</title>
          <population>All available echocardiogram data has been reported.</population>
          <units>percentage</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="259"/>
                <count group_id="O2" value="223"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.88" spread="8.84"/>
                    <measurement group_id="O2" value="31.11" spread="10.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Left Ventricular Ejection Fraction (LVEF)</title>
        <time_frame>6 months</time_frame>
        <population>All available echocardiogram data has been reported.</population>
        <group_list>
          <group group_id="O1">
            <title>MitraClip System</title>
            <description>Percutaneous mitral valve repair using MitraClip System
MitraClip System: Percutaneous mitral valve repair using MitraClip System</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Patients with mitral regurgitation managed non-surgically based on standard hospital clinical practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Left Ventricular Ejection Fraction (LVEF)</title>
          <population>All available echocardiogram data has been reported.</population>
          <units>percentage</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="200"/>
                <count group_id="O2" value="171"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.38" spread="10.45"/>
                    <measurement group_id="O2" value="30.44" spread="10.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Left Ventricular Ejection Fraction (LVEF)</title>
        <time_frame>12 months</time_frame>
        <population>All available echocardiogram data has been reported.</population>
        <group_list>
          <group group_id="O1">
            <title>MitraClip System</title>
            <description>Percutaneous mitral valve repair using MitraClip System
MitraClip System: Percutaneous mitral valve repair using MitraClip System</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Patients with mitral regurgitation managed non-surgically based on standard hospital clinical practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Left Ventricular Ejection Fraction (LVEF)</title>
          <population>All available echocardiogram data has been reported.</population>
          <units>percentage</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="168"/>
                <count group_id="O2" value="146"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.74" spread="11.31"/>
                    <measurement group_id="O2" value="29.72" spread="10.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Left Ventricular Ejection Fraction (LVEF)</title>
        <time_frame>24 months</time_frame>
        <population>All available echocardiogram data has been reported.</population>
        <group_list>
          <group group_id="O1">
            <title>MitraClip System</title>
            <description>Percutaneous mitral valve repair using MitraClip System
MitraClip System: Percutaneous mitral valve repair using MitraClip System</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Patients with mitral regurgitation managed non-surgically based on standard hospital clinical practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Left Ventricular Ejection Fraction (LVEF)</title>
          <population>All available echocardiogram data has been reported.</population>
          <units>percentage</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="116"/>
                <count group_id="O2" value="92"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.2" spread="9.2"/>
                    <measurement group_id="O2" value="30.64" spread="12.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Left Ventricular Ejection Fraction (LVEF)</title>
        <time_frame>3 years</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Left Ventricular Ejection Fraction (LVEF)</title>
        <time_frame>4 years</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Left Ventricular Ejection Fraction (LVEF)</title>
        <time_frame>5 years</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Right Ventricular Systolic Pressure (RVSP)</title>
        <time_frame>Baseline</time_frame>
        <population>All available echocardiogram data has been reported.</population>
        <group_list>
          <group group_id="O1">
            <title>MitraClip System</title>
            <description>Percutaneous mitral valve repair using MitraClip System
MitraClip System: Percutaneous mitral valve repair using MitraClip System</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Patients with mitral regurgitation managed non-surgically based on standard hospital clinical practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Right Ventricular Systolic Pressure (RVSP)</title>
          <population>All available echocardiogram data has been reported.</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="253"/>
                <count group_id="O2" value="275"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.95" spread="13.44"/>
                    <measurement group_id="O2" value="44.56" spread="13.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Right Ventricular Systolic Pressure (RVSP)</title>
        <time_frame>At discharge (or 30 days if discharge echocardiogram is not available)</time_frame>
        <population>All available echocardiogram data has been reported.</population>
        <group_list>
          <group group_id="O1">
            <title>MitraClip System</title>
            <description>Percutaneous mitral valve repair using MitraClip System
MitraClip System: Percutaneous mitral valve repair using MitraClip System</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Patients with mitral regurgitation managed non-surgically based on standard hospital clinical practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Right Ventricular Systolic Pressure (RVSP)</title>
          <population>All available echocardiogram data has been reported.</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="257"/>
                <count group_id="O2" value="239"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.41" spread="11.63"/>
                    <measurement group_id="O2" value="43.81" spread="14.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Right Ventricular Systolic Pressure (RVSP)</title>
        <time_frame>6 months</time_frame>
        <population>All available echocardiogram data has been reported.</population>
        <group_list>
          <group group_id="O1">
            <title>MitraClip System</title>
            <description>Percutaneous mitral valve repair using MitraClip System
MitraClip System: Percutaneous mitral valve repair using MitraClip System</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Patients with mitral regurgitation managed non-surgically based on standard hospital clinical practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Right Ventricular Systolic Pressure (RVSP)</title>
          <population>All available echocardiogram data has been reported.</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="196"/>
                <count group_id="O2" value="188"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.96" spread="13.06"/>
                    <measurement group_id="O2" value="42.21" spread="14.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Right Ventricular Systolic Pressure (RVSP)</title>
        <time_frame>12 months</time_frame>
        <population>All available echocardiogram data has been reported.</population>
        <group_list>
          <group group_id="O1">
            <title>MitraClip System</title>
            <description>Percutaneous mitral valve repair using MitraClip System
MitraClip System: Percutaneous mitral valve repair using MitraClip System</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Patients with mitral regurgitation managed non-surgically based on standard hospital clinical practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Right Ventricular Systolic Pressure (RVSP)</title>
          <population>All available echocardiogram data has been reported.</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="170"/>
                <count group_id="O2" value="144"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.63" spread="13.00"/>
                    <measurement group_id="O2" value="39.31" spread="13.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Right Ventricular Systolic Pressure (RVSP)</title>
        <time_frame>24 months</time_frame>
        <population>All available echocardiogram data has been reported.</population>
        <group_list>
          <group group_id="O1">
            <title>MitraClip System</title>
            <description>Percutaneous mitral valve repair using MitraClip System
MitraClip System: Percutaneous mitral valve repair using MitraClip System</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Patients with mitral regurgitation managed non-surgically based on standard hospital clinical practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Right Ventricular Systolic Pressure (RVSP)</title>
          <population>All available echocardiogram data has been reported.</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="123"/>
                <count group_id="O2" value="98"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.67" spread="12.94"/>
                    <measurement group_id="O2" value="40.38" spread="14.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Right Ventricular Systolic Pressure (RVSP)</title>
        <time_frame>3 years</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Right Ventricular Systolic Pressure (RVSP)</title>
        <time_frame>4 years</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Right Ventricular Systolic Pressure (RVSP)</title>
        <time_frame>5 years</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Mitral Valve Area</title>
        <time_frame>Baseline</time_frame>
        <population>All available echocardiogram data has been reported.</population>
        <group_list>
          <group group_id="O1">
            <title>MitraClip System</title>
            <description>Percutaneous mitral valve repair using MitraClip System
MitraClip System: Percutaneous mitral valve repair using MitraClip System</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Patients with mitral regurgitation managed non-surgically based on standard hospital clinical practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Mitral Valve Area</title>
          <population>All available echocardiogram data has been reported.</population>
          <units>cm^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="284"/>
                <count group_id="O2" value="302"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.17" spread="1.26"/>
                    <measurement group_id="O2" value="5.16" spread="1.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Mitral Valve Area</title>
        <time_frame>At discharge (or 30 days if discharge echocardiogram is not available)</time_frame>
        <population>All available echocardiogram data has been reported.</population>
        <group_list>
          <group group_id="O1">
            <title>MitraClip System</title>
            <description>Percutaneous mitral valve repair using MitraClip System
MitraClip System: Percutaneous mitral valve repair using MitraClip System</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Patients with mitral regurgitation managed non-surgically based on standard hospital clinical practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Mitral Valve Area</title>
          <population>All available echocardiogram data has been reported.</population>
          <units>cm^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="174"/>
                <count group_id="O2" value="235"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.68" spread="0.92"/>
                    <measurement group_id="O2" value="4.81" spread="1.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Mitral Valve Area</title>
        <time_frame>6 months</time_frame>
        <population>All available echocardiogram data has been reported.</population>
        <group_list>
          <group group_id="O1">
            <title>MitraClip System</title>
            <description>Percutaneous mitral valve repair using MitraClip System
MitraClip System: Percutaneous mitral valve repair using MitraClip System</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Patients with mitral regurgitation managed non-surgically based on standard hospital clinical practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Mitral Valve Area</title>
          <population>All available echocardiogram data has been reported.</population>
          <units>cm^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="107"/>
                <count group_id="O2" value="189"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.84" spread="1.10"/>
                    <measurement group_id="O2" value="4.94" spread="1.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Mitral Valve Area</title>
        <time_frame>12 months</time_frame>
        <population>All available echocardiogram data has been reported.</population>
        <group_list>
          <group group_id="O1">
            <title>MitraClip System</title>
            <description>Percutaneous mitral valve repair using MitraClip System
MitraClip System: Percutaneous mitral valve repair using MitraClip System</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Patients with mitral regurgitation managed non-surgically based on standard hospital clinical practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Mitral Valve Area</title>
          <population>All available echocardiogram data has been reported.</population>
          <units>cm^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="106"/>
                <count group_id="O2" value="142"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.67" spread="0.86"/>
                    <measurement group_id="O2" value="4.88" spread="0.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Mitral Valve Area</title>
        <time_frame>24 months</time_frame>
        <population>All available echocardiogram data has been reported.</population>
        <group_list>
          <group group_id="O1">
            <title>MitraClip System</title>
            <description>Percutaneous mitral valve repair using MitraClip System
MitraClip System: Percutaneous mitral valve repair using MitraClip System</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Patients with mitral regurgitation managed non-surgically based on standard hospital clinical practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Mitral Valve Area</title>
          <population>All available echocardiogram data has been reported.</population>
          <units>cm^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="65"/>
                <count group_id="O2" value="92"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.85" spread="1.01"/>
                    <measurement group_id="O2" value="5.00" spread="1.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Mitral Valve Area</title>
        <time_frame>3 years</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Mitral Valve Area</title>
        <time_frame>4 years</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Mitral Valve Area</title>
        <time_frame>5 years</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Mean Mitral Valve Gradient</title>
        <description>The normal area of the mitral valve orifice is about 4-6 cm2 when the mitral valve area goes below 2 cm2, the valve causes an impediment to the flow of blood into the left ventricle, creating a pressure gradient (mitral valve gradient) across the mitral valve. This gradient may increase by the rise in heart rate or cardiac output.</description>
        <time_frame>Baseline</time_frame>
        <population>All available echocardiogram data has been reported.</population>
        <group_list>
          <group group_id="O1">
            <title>MitraClip System</title>
            <description>Percutaneous mitral valve repair using MitraClip System
MitraClip System: Percutaneous mitral valve repair using MitraClip System</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Patients with mitral regurgitation managed non-surgically based on standard hospital clinical practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Mitral Valve Gradient</title>
          <description>The normal area of the mitral valve orifice is about 4-6 cm2 when the mitral valve area goes below 2 cm2, the valve causes an impediment to the flow of blood into the left ventricle, creating a pressure gradient (mitral valve gradient) across the mitral valve. This gradient may increase by the rise in heart rate or cardiac output.</description>
          <population>All available echocardiogram data has been reported.</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="208"/>
                <count group_id="O2" value="234"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.46" spread="1.05"/>
                    <measurement group_id="O2" value="2.28" spread="0.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Mean Mitral Valve Gradient</title>
        <description>The normal area of the mitral valve orifice is about 4-6 cm2 when the mitral valve area goes below 2 cm2, the valve causes an impediment to the flow of blood into the left ventricle, creating a pressure gradient (mitral valve gradient) across the mitral valve. This gradient may increase by the rise in heart rate or cardiac output.</description>
        <time_frame>At discharge (or 30 days if discharge echocardiogram is not available)</time_frame>
        <population>All available echocardiogram data has been reported.</population>
        <group_list>
          <group group_id="O1">
            <title>MitraClip System</title>
            <description>Percutaneous mitral valve repair using MitraClip System
MitraClip System: Percutaneous mitral valve repair using MitraClip System</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Patients with mitral regurgitation managed non-surgically based on standard hospital clinical practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Mitral Valve Gradient</title>
          <description>The normal area of the mitral valve orifice is about 4-6 cm2 when the mitral valve area goes below 2 cm2, the valve causes an impediment to the flow of blood into the left ventricle, creating a pressure gradient (mitral valve gradient) across the mitral valve. This gradient may increase by the rise in heart rate or cardiac output.</description>
          <population>All available echocardiogram data has been reported.</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="282"/>
                <count group_id="O2" value="184"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.10" spread="2.18"/>
                    <measurement group_id="O2" value="2.28" spread="1.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Mean Mitral Valve Gradient</title>
        <description>The normal area of the mitral valve orifice is about 4-6 cm2 when the mitral valve area goes below 2 cm2, the valve causes an impediment to the flow of blood into the left ventricle, creating a pressure gradient (mitral valve gradient) across the mitral valve. This gradient may increase by the rise in heart rate or cardiac output.</description>
        <time_frame>6 months</time_frame>
        <population>All available echocardiogram data has been reported.</population>
        <group_list>
          <group group_id="O1">
            <title>MitraClip System</title>
            <description>Percutaneous mitral valve repair using MitraClip System
MitraClip System: Percutaneous mitral valve repair using MitraClip System</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Patients with mitral regurgitation managed non-surgically based on standard hospital clinical practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Mitral Valve Gradient</title>
          <description>The normal area of the mitral valve orifice is about 4-6 cm2 when the mitral valve area goes below 2 cm2, the valve causes an impediment to the flow of blood into the left ventricle, creating a pressure gradient (mitral valve gradient) across the mitral valve. This gradient may increase by the rise in heart rate or cardiac output.</description>
          <population>All available echocardiogram data has been reported.</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="222"/>
                <count group_id="O2" value="160"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.00" spread="1.98"/>
                    <measurement group_id="O2" value="2.28" spread="1.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Mean Mitral Valve Gradient</title>
        <description>The normal area of the mitral valve orifice is about 4-6 cm2 when the mitral valve area goes below 2 cm2, the valve causes an impediment to the flow of blood into the left ventricle, creating a pressure gradient (mitral valve gradient) across the mitral valve. This gradient may increase by the rise in heart rate or cardiac output.</description>
        <time_frame>12 months</time_frame>
        <population>All available echocardiogram data has been reported.</population>
        <group_list>
          <group group_id="O1">
            <title>MitraClip System</title>
            <description>Percutaneous mitral valve repair using MitraClip System
MitraClip System: Percutaneous mitral valve repair using MitraClip System</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Patients with mitral regurgitation managed non-surgically based on standard hospital clinical practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Mitral Valve Gradient</title>
          <description>The normal area of the mitral valve orifice is about 4-6 cm2 when the mitral valve area goes below 2 cm2, the valve causes an impediment to the flow of blood into the left ventricle, creating a pressure gradient (mitral valve gradient) across the mitral valve. This gradient may increase by the rise in heart rate or cardiac output.</description>
          <population>All available echocardiogram data has been reported.</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="197"/>
                <count group_id="O2" value="138"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.88" spread="2.17"/>
                    <measurement group_id="O2" value="2.15" spread="1.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Mean Mitral Valve Gradient</title>
        <description>The normal area of the mitral valve orifice is about 4-6 cm2 when the mitral valve area goes below 2 cm2, the valve causes an impediment to the flow of blood into the left ventricle, creating a pressure gradient (mitral valve gradient) across the mitral valve. This gradient may increase by the rise in heart rate or cardiac output.</description>
        <time_frame>24 months</time_frame>
        <population>All available echocardiogram data has been reported.</population>
        <group_list>
          <group group_id="O1">
            <title>MitraClip System</title>
            <description>Percutaneous mitral valve repair using MitraClip System
MitraClip System: Percutaneous mitral valve repair using MitraClip System</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Patients with mitral regurgitation managed non-surgically based on standard hospital clinical practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Mitral Valve Gradient</title>
          <description>The normal area of the mitral valve orifice is about 4-6 cm2 when the mitral valve area goes below 2 cm2, the valve causes an impediment to the flow of blood into the left ventricle, creating a pressure gradient (mitral valve gradient) across the mitral valve. This gradient may increase by the rise in heart rate or cardiac output.</description>
          <population>All available echocardiogram data has been reported.</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="147"/>
                <count group_id="O2" value="94"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.73" spread="1.77"/>
                    <measurement group_id="O2" value="2.27" spread="1.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Mean Mitral Valve Gradient</title>
        <time_frame>3 years</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Mean Mitral Valve Gradient</title>
        <time_frame>4 years</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Mean Mitral Valve Gradient</title>
        <time_frame>5 years</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Systolic Anterior Motion of the Mitral Valve (Present or Absent)</title>
        <time_frame>Baseline</time_frame>
        <population>All available echocardiogram data has been reported.</population>
        <group_list>
          <group group_id="O1">
            <title>MitraClip System</title>
            <description>Percutaneous mitral valve repair using MitraClip System
MitraClip System: Percutaneous mitral valve repair using MitraClip System</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Patients with mitral regurgitation managed non-surgically based on standard hospital clinical practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Systolic Anterior Motion of the Mitral Valve (Present or Absent)</title>
          <population>All available echocardiogram data has been reported.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="300"/>
                <count group_id="O2" value="310"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Present</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Absent</title>
                  <measurement_list>
                    <measurement group_id="O1" value="299"/>
                    <measurement group_id="O2" value="309"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Systolic Anterior Motion of the Mitral Valve (Present or Absent)</title>
        <time_frame>At discharge (or 30 days if discharge echocardiogram is not available)</time_frame>
        <population>All available echocardiogram data has been reported.</population>
        <group_list>
          <group group_id="O1">
            <title>MitraClip System</title>
            <description>Percutaneous mitral valve repair using MitraClip System
MitraClip System: Percutaneous mitral valve repair using MitraClip System</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Patients with mitral regurgitation managed non-surgically based on standard hospital clinical practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Systolic Anterior Motion of the Mitral Valve (Present or Absent)</title>
          <population>All available echocardiogram data has been reported.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="289"/>
                <count group_id="O2" value="258"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Present</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Absent</title>
                  <measurement_list>
                    <measurement group_id="O1" value="288"/>
                    <measurement group_id="O2" value="257"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Systolic Anterior Motion of the Mitral Valve (Present or Absent)</title>
        <time_frame>6 months</time_frame>
        <population>All available echocardiogram data has been reported.</population>
        <group_list>
          <group group_id="O1">
            <title>MitraClip System</title>
            <description>Percutaneous mitral valve repair using MitraClip System
MitraClip System: Percutaneous mitral valve repair using MitraClip System</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Patients with mitral regurgitation managed non-surgically based on standard hospital clinical practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Systolic Anterior Motion of the Mitral Valve (Present or Absent)</title>
          <population>All available echocardiogram data has been reported.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="239"/>
                <count group_id="O2" value="219"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Present</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Absent</title>
                  <measurement_list>
                    <measurement group_id="O1" value="239"/>
                    <measurement group_id="O2" value="218"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Systolic Anterior Motion of the Mitral Valve (Present or Absent)</title>
        <time_frame>12 months</time_frame>
        <population>All available echocardiogram has been reported.</population>
        <group_list>
          <group group_id="O1">
            <title>MitraClip System</title>
            <description>Percutaneous mitral valve repair using MitraClip System
MitraClip System: Percutaneous mitral valve repair using MitraClip System</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Patients with mitral regurgitation managed non-surgically based on standard hospital clinical practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Systolic Anterior Motion of the Mitral Valve (Present or Absent)</title>
          <population>All available echocardiogram has been reported.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="210"/>
                <count group_id="O2" value="177"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Present</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Absent</title>
                  <measurement_list>
                    <measurement group_id="O1" value="210"/>
                    <measurement group_id="O2" value="177"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Systolic Anterior Motion of the Mitral Valve (Present or Absent)</title>
        <time_frame>24 months</time_frame>
        <population>All available echocardiogram data has been reported.</population>
        <group_list>
          <group group_id="O1">
            <title>MitraClip System</title>
            <description>Percutaneous mitral valve repair using MitraClip System
MitraClip System: Percutaneous mitral valve repair using MitraClip System</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Patients with mitral regurgitation managed non-surgically based on standard hospital clinical practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Systolic Anterior Motion of the Mitral Valve (Present or Absent)</title>
          <population>All available echocardiogram data has been reported.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="159"/>
                <count group_id="O2" value="124"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Present</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Absent</title>
                  <measurement_list>
                    <measurement group_id="O1" value="159"/>
                    <measurement group_id="O2" value="124"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Systolic Anterior Motion of the Mitral Valve (Present or Absent)</title>
        <time_frame>3 years</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Systolic Anterior Motion of the Mitral Valve (Present or Absent)</title>
        <time_frame>4 years</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Systolic Anterior Motion of the Mitral Valve (Present or Absent)</title>
        <time_frame>5 years</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Cardiac Output</title>
        <description>The amount of blood the heart pumps through the circulatory system in a minute.</description>
        <time_frame>Baseline</time_frame>
        <population>All available echocardiogram data has been reported.</population>
        <group_list>
          <group group_id="O1">
            <title>MitraClip System</title>
            <description>Percutaneous mitral valve repair using MitraClip System
MitraClip System: Percutaneous mitral valve repair using MitraClip System</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Patients with mitral regurgitation managed non-surgically based on standard hospital clinical practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Cardiac Output</title>
          <description>The amount of blood the heart pumps through the circulatory system in a minute.</description>
          <population>All available echocardiogram data has been reported.</population>
          <units>Liters/minute</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="238"/>
                <count group_id="O2" value="251"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.61" spread="1.09"/>
                    <measurement group_id="O2" value="3.49" spread="1.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Cardiac Output</title>
        <description>The amount of blood the heart pumps through the circulatory system in a minute.</description>
        <time_frame>At discharge (or 30 days if discharge echocardiogram is not available)</time_frame>
        <population>All available echocardiogram data has been reported.</population>
        <group_list>
          <group group_id="O1">
            <title>MitraClip System</title>
            <description>Percutaneous mitral valve repair using MitraClip System
MitraClip System: Percutaneous mitral valve repair using MitraClip System</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Patients with mitral regurgitation managed non-surgically based on standard hospital clinical practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Cardiac Output</title>
          <description>The amount of blood the heart pumps through the circulatory system in a minute.</description>
          <population>All available echocardiogram data has been reported.</population>
          <units>Liters/minute</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="275"/>
                <count group_id="O2" value="236"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.79" spread="1.17"/>
                    <measurement group_id="O2" value="3.61" spread="1.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Cardiac Output</title>
        <description>The amount of blood the heart pumps through the circulatory system in a minute.</description>
        <time_frame>6 months</time_frame>
        <population>All available echocardiogram has been reported.</population>
        <group_list>
          <group group_id="O1">
            <title>MitraClip System</title>
            <description>Percutaneous mitral valve repair using MitraClip System
MitraClip System: Percutaneous mitral valve repair using MitraClip System</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Patients with mitral regurgitation managed non-surgically based on standard hospital clinical practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Cardiac Output</title>
          <description>The amount of blood the heart pumps through the circulatory system in a minute.</description>
          <population>All available echocardiogram has been reported.</population>
          <units>Liters/minute</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="217"/>
                <count group_id="O2" value="199"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.53" spread="1.06"/>
                    <measurement group_id="O2" value="3.53" spread="1.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Cardiac Output</title>
        <description>The amount of blood the heart pumps through the circulatory system in a minute.</description>
        <time_frame>12 months</time_frame>
        <population>All available echocardiogram data has been reported.</population>
        <group_list>
          <group group_id="O1">
            <title>MitraClip System</title>
            <description>Percutaneous mitral valve repair using MitraClip System
MitraClip System: Percutaneous mitral valve repair using MitraClip System</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Patients with mitral regurgitation managed non-surgically based on standard hospital clinical practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Cardiac Output</title>
          <description>The amount of blood the heart pumps through the circulatory system in a minute.</description>
          <population>All available echocardiogram data has been reported.</population>
          <units>Liters/minute</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="196"/>
                <count group_id="O2" value="157"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.59" spread="1.07"/>
                    <measurement group_id="O2" value="3.66" spread="1.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Cardiac Output</title>
        <description>The amount of blood the heart pumps through the circulatory system in a minute.</description>
        <time_frame>24 months</time_frame>
        <population>All available echocardiogram data has been reported.</population>
        <group_list>
          <group group_id="O1">
            <title>MitraClip System</title>
            <description>Percutaneous mitral valve repair using MitraClip System
MitraClip System: Percutaneous mitral valve repair using MitraClip System</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Patients with mitral regurgitation managed non-surgically based on standard hospital clinical practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Cardiac Output</title>
          <description>The amount of blood the heart pumps through the circulatory system in a minute.</description>
          <population>All available echocardiogram data has been reported.</population>
          <units>Liters/minute</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="139"/>
                <count group_id="O2" value="114"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.44" spread="0.95"/>
                    <measurement group_id="O2" value="3.39" spread="1.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Cardiac Output</title>
        <time_frame>3 years</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Cardiac Output</title>
        <time_frame>4 years</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Cardiac Output</title>
        <time_frame>5 years</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Forward Stroke Volume</title>
        <description>Stroke volume is the amount of blood ejected from the ventricle with each cardiac cycle. It can be readily calculated by subtracting the end-systolic volume from the end-diastolic volume.</description>
        <time_frame>Baseline</time_frame>
        <population>All available echocardiogram data has been reported.</population>
        <group_list>
          <group group_id="O1">
            <title>MitraClip System</title>
            <description>Percutaneous mitral valve repair using MitraClip System
MitraClip System: Percutaneous mitral valve repair using MitraClip System</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Patients with mitral regurgitation managed non-surgically based on standard hospital clinical practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Forward Stroke Volume</title>
          <description>Stroke volume is the amount of blood ejected from the ventricle with each cardiac cycle. It can be readily calculated by subtracting the end-systolic volume from the end-diastolic volume.</description>
          <population>All available echocardiogram data has been reported.</population>
          <units>mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="283"/>
                <count group_id="O2" value="292"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.47" spread="16.52"/>
                    <measurement group_id="O2" value="50.72" spread="16.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Forward Stroke Volume</title>
        <description>Stroke volume is the amount of blood ejected from the ventricle with each cardiac cycle. It can be readily calculated by subtracting the end-systolic volume from the end-diastolic volume.</description>
        <time_frame>At discharge (or 30 days if discharge echocardiogram is not available)</time_frame>
        <population>All available echocardiogram data has been reported.</population>
        <group_list>
          <group group_id="O1">
            <title>MitraClip System</title>
            <description>Percutaneous mitral valve repair using MitraClip System
MitraClip System: Percutaneous mitral valve repair using MitraClip System</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Patients with mitral regurgitation managed non-surgically based on standard hospital clinical practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Forward Stroke Volume</title>
          <description>Stroke volume is the amount of blood ejected from the ventricle with each cardiac cycle. It can be readily calculated by subtracting the end-systolic volume from the end-diastolic volume.</description>
          <population>All available echocardiogram data has been reported.</population>
          <units>mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="278"/>
                <count group_id="O2" value="243"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.41" spread="17.06"/>
                    <measurement group_id="O2" value="50.75" spread="17.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Forward Stroke Volume</title>
        <description>Stroke volume is the amount of blood ejected from the ventricle with each cardiac cycle. It can be readily calculated by subtracting the end-systolic volume from the end-diastolic volume.</description>
        <time_frame>6 months</time_frame>
        <population>All available echocardiogram data has been reported.</population>
        <group_list>
          <group group_id="O1">
            <title>MitraClip System</title>
            <description>Percutaneous mitral valve repair using MitraClip System
MitraClip System: Percutaneous mitral valve repair using MitraClip System</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Patients with mitral regurgitation managed non-surgically based on standard hospital clinical practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Forward Stroke Volume</title>
          <description>Stroke volume is the amount of blood ejected from the ventricle with each cardiac cycle. It can be readily calculated by subtracting the end-systolic volume from the end-diastolic volume.</description>
          <population>All available echocardiogram data has been reported.</population>
          <units>mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="222"/>
                <count group_id="O2" value="207"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.13" spread="16.60"/>
                    <measurement group_id="O2" value="49.89" spread="16.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Forward Stroke Volume</title>
        <description>Stroke volume is the amount of blood ejected from the ventricle with each cardiac cycle. It can be readily calculated by subtracting the end-systolic volume from the end-diastolic volume.</description>
        <time_frame>12 months</time_frame>
        <population>All available echocardiogram data has been reported.</population>
        <group_list>
          <group group_id="O1">
            <title>MitraClip System</title>
            <description>Percutaneous mitral valve repair using MitraClip System
MitraClip System: Percutaneous mitral valve repair using MitraClip System</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Patients with mitral regurgitation managed non-surgically based on standard hospital clinical practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Forward Stroke Volume</title>
          <description>Stroke volume is the amount of blood ejected from the ventricle with each cardiac cycle. It can be readily calculated by subtracting the end-systolic volume from the end-diastolic volume.</description>
          <population>All available echocardiogram data has been reported.</population>
          <units>mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="200"/>
                <count group_id="O2" value="165"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.33" spread="16.46"/>
                    <measurement group_id="O2" value="53.49" spread="17.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Forward Stroke Volume</title>
        <description>Stroke volume is the amount of blood ejected from the ventricle with each cardiac cycle. It can be readily calculated by subtracting the end-systolic volume from the end-diastolic volume.</description>
        <time_frame>24 months</time_frame>
        <population>All available echocardiogram data has been reported.</population>
        <group_list>
          <group group_id="O1">
            <title>MitraClip System</title>
            <description>Percutaneous mitral valve repair using MitraClip System
MitraClip System: Percutaneous mitral valve repair using MitraClip System</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Patients with mitral regurgitation managed non-surgically based on standard hospital clinical practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Forward Stroke Volume</title>
          <description>Stroke volume is the amount of blood ejected from the ventricle with each cardiac cycle. It can be readily calculated by subtracting the end-systolic volume from the end-diastolic volume.</description>
          <population>All available echocardiogram data has been reported.</population>
          <units>mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="142"/>
                <count group_id="O2" value="116"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.97" spread="15.73"/>
                    <measurement group_id="O2" value="49.37" spread="15.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Forward Stroke Volume</title>
        <time_frame>3 years</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Forward Stroke Volume</title>
        <time_frame>4 years</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Forward Stroke Volume</title>
        <time_frame>5 years</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Kaplan-Meier Freedom From the Components of the Primary Safety Composite</title>
        <description>Freedom from the components of the primary safety composite of device related complications including Single Leaflet Device Attachment (SLDA), device embolizations, endocarditis requiring surgery, Echocardiography Core Laboratory confirmed mitral stenosis requiring surgery, LVAD implant, heart transplant, or any device related complications requiring non-elective cardiovascular surgery at 12 months will be the primary measure of safety.</description>
        <time_frame>12 months in Device group</time_frame>
        <population>All eligible subjects with MitraClip until the 365 day window.</population>
        <group_list>
          <group group_id="O1">
            <title>MitraClip System</title>
            <description>Percutaneous mitral valve repair using MitraClip System
MitraClip System: Percutaneous mitral valve repair using MitraClip System</description>
          </group>
        </group_list>
        <measure>
          <title>Kaplan-Meier Freedom From the Components of the Primary Safety Composite</title>
          <description>Freedom from the components of the primary safety composite of device related complications including Single Leaflet Device Attachment (SLDA), device embolizations, endocarditis requiring surgery, Echocardiography Core Laboratory confirmed mitral stenosis requiring surgery, LVAD implant, heart transplant, or any device related complications requiring non-elective cardiovascular surgery at 12 months will be the primary measure of safety.</description>
          <population>All eligible subjects with MitraClip until the 365 day window.</population>
          <units>percentage</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="237"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Single Leaflet Device Attachment (SLDA)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="236"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Embolization</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="237"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Left Ventricular Assist Device (LVAD)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="235"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Heart Transplant</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="235"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-elective Cardiovascular surgery</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="237"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Kaplan-Meier Freedom From the Components of the Primary Safety Composite</title>
        <description>Freedom from the components of the primary safety composite of device related complications including Single Leaflet Device Attachment (SLDA), device embolizations, endocarditis requiring surgery, Echocardiography Core Laboratory confirmed mitral stenosis requiring surgery, LVAD implant, heart transplant, or any device related complications requiring non-elective cardiovascular surgery at 12 months will be the primary measure of safety.</description>
        <time_frame>24 months in Device group</time_frame>
        <population>All available subjects with data within the 2 year (731 days) window</population>
        <group_list>
          <group group_id="O1">
            <title>MitraClip System</title>
            <description>Percutaneous mitral valve repair using MitraClip System
MitraClip System: Percutaneous mitral valve repair using MitraClip System</description>
          </group>
        </group_list>
        <measure>
          <title>Kaplan-Meier Freedom From the Components of the Primary Safety Composite</title>
          <description>Freedom from the components of the primary safety composite of device related complications including Single Leaflet Device Attachment (SLDA), device embolizations, endocarditis requiring surgery, Echocardiography Core Laboratory confirmed mitral stenosis requiring surgery, LVAD implant, heart transplant, or any device related complications requiring non-elective cardiovascular surgery at 12 months will be the primary measure of safety.</description>
          <population>All available subjects with data within the 2 year (731 days) window</population>
          <units>percentage</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="175"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Single Leaflet Device Attachment (SLDA)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="174"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Embolization</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="175"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Left Ventricular Assist Device (LVAD)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="173"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Heart Transplant</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="172"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-elective cardiovascular surgery</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="175"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Kaplan-Meier Freedom From the Components of the Primary Safety Composite</title>
        <time_frame>3 years in Device group</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Kaplan-Meier Freedom From the Components of the Primary Safety Composite</title>
        <time_frame>4 years in Device group</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Kaplan-Meier Freedom From the Components of the Primary Safety Composite</title>
        <time_frame>5 years in Device group</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Kaplan-Meier Freedom From the Primary Safety Composite</title>
        <description>Freedom from the primary safety composite of device related complications including Single Leaflet Device Attachment (SLDA), device embolizations, endocarditis requiring surgery, Echocardiography Core Laboratory confirmed mitral stenosis requiring surgery, LVAD implant, heart transplant, or any device related complications requiring non-elective cardiovascular surgery at 12 months will be the primary measure of safety.</description>
        <time_frame>24 months in Device group</time_frame>
        <population>All available subjects with data within the 24 months (731 days) window.</population>
        <group_list>
          <group group_id="O1">
            <title>MitraClip System</title>
            <description>Percutaneous mitral valve repair using MitraClip System
MitraClip System: Percutaneous mitral valve repair using MitraClip System</description>
          </group>
        </group_list>
        <measure>
          <title>Kaplan-Meier Freedom From the Primary Safety Composite</title>
          <description>Freedom from the primary safety composite of device related complications including Single Leaflet Device Attachment (SLDA), device embolizations, endocarditis requiring surgery, Echocardiography Core Laboratory confirmed mitral stenosis requiring surgery, LVAD implant, heart transplant, or any device related complications requiring non-elective cardiovascular surgery at 12 months will be the primary measure of safety.</description>
          <population>All available subjects with data within the 24 months (731 days) window.</population>
          <units>percentage</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="169"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Kaplan-Meier Freedom From the Primary Safety Composite</title>
        <time_frame>3 years in Device group</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Kaplan-Meier Freedom From the Primary Safety Composite</title>
        <time_frame>4 years in Device group</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Kaplan-Meier Freedom From the Primary Safety Composite</title>
        <time_frame>5 years in Device group</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Kaplan-Meier Freedom From All-cause Mortality</title>
        <description>Kaplan-Meier survival rate for all cause mortality at 24 months</description>
        <time_frame>24 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>MitraClip System</title>
            <description>Percutaneous mitral valve repair using MitraClip System
MitraClip System: Percutaneous mitral valve repair using MitraClip System</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Patients with mitral regurgitation managed non-surgically based on standard hospital clinical practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Kaplan-Meier Freedom From All-cause Mortality</title>
          <description>Kaplan-Meier survival rate for all cause mortality at 24 months</description>
          <units>percentage</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="189"/>
                <count group_id="O2" value="145"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.8" lower_limit="66.3" upper_limit="76.6"/>
                    <measurement group_id="O2" value="57.0" lower_limit="51.1" upper_limit="62.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Kaplan-Meier Freedom From All-cause Mortality</title>
        <time_frame>3 years</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Kaplan-Meier Freedom From All-cause Mortality</title>
        <time_frame>4 years</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Kaplan-Meier Freedom From All-cause Mortality</title>
        <time_frame>5 years</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Kaplan-Meier Freedom From Cardiovascular Mortality</title>
        <description>Kaplan-Meier survival rate for Cardiovascular mortality.</description>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>MitraClip System</title>
            <description>Percutaneous mitral valve repair using MitraClip System
MitraClip System: Percutaneous mitral valve repair using MitraClip System</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Patients with mitral regurgitation managed non-surgically based on standard hospital clinical practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Kaplan-Meier Freedom From Cardiovascular Mortality</title>
          <description>Kaplan-Meier survival rate for Cardiovascular mortality.</description>
          <units>percentage</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="238"/>
                <count group_id="O2" value="223"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86.2" lower_limit="81.6" upper_limit="89.7"/>
                    <measurement group_id="O2" value="80.7" lower_limit="75.7" upper_limit="84.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Kaplan-Meier Freedom From Cardiovascular Mortality</title>
        <description>Kaplan-Meier survival rate for Cardiovascular mortality.</description>
        <time_frame>24 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>MitraClip System</title>
            <description>Percutaneous mitral valve repair using MitraClip System
MitraClip System: Percutaneous mitral valve repair using MitraClip System</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Patients with mitral regurgitation managed non-surgically based on standard hospital clinical practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Kaplan-Meier Freedom From Cardiovascular Mortality</title>
          <description>Kaplan-Meier survival rate for Cardiovascular mortality.</description>
          <units>percentage</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="189"/>
                <count group_id="O2" value="144"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.6" lower_limit="72.2" upper_limit="82.0"/>
                    <measurement group_id="O2" value="64.3" lower_limit="58.2" upper_limit="69.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Kaplan-Meier Freedom From Cardiovascular Mortality</title>
        <time_frame>3 years</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Kaplan-Meier Freedom From Cardiovascular Mortality</title>
        <time_frame>4 years</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Kaplan-Meier Freedom From Cardiovascular Mortality</title>
        <time_frame>5 years</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Kaplan-Meier Freedom From the First HF Related Hospitalization</title>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>MitraClip System</title>
            <description>Percutaneous mitral valve repair using MitraClip System
MitraClip System: Percutaneous mitral valve repair using MitraClip System</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Patients with mitral regurgitation managed non-surgically based on standard hospital clinical practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Kaplan-Meier Freedom From the First HF Related Hospitalization</title>
          <units>Percentage</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="196"/>
                <count group_id="O2" value="156"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.1" lower_limit="69.6" upper_limit="79.8"/>
                    <measurement group_id="O2" value="60.4" lower_limit="54.5" upper_limit="65.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Kaplan-Meier Freedom From the First HF Related Hospitalization</title>
        <time_frame>24 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>MitraClip System</title>
            <description>Percutaneous mitral valve repair using MitraClip System
MitraClip System: Percutaneous mitral valve repair using MitraClip System</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Patients with mitral regurgitation managed non-surgically based on standard hospital clinical practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Kaplan-Meier Freedom From the First HF Related Hospitalization</title>
          <units>Percentage</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="148"/>
                <count group_id="O2" value="87"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65.2" lower_limit="59.2" upper_limit="70.6"/>
                    <measurement group_id="O2" value="43.6" lower_limit="37.6" upper_limit="49.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Kaplan-Meier Freedom From the First HF Related Hospitalization</title>
        <time_frame>3 years</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Kaplan-Meier Freedom From the First HF Related Hospitalization</title>
        <time_frame>4 years</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Kaplan-Meier Freedom From the First HF Related Hospitalization</title>
        <time_frame>5 years</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Kaplan-Meier Freedom From the First Cardiovascular Hospitalization</title>
        <time_frame>12 months</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Kaplan-Meier Freedom From the First Cardiovascular Hospitalization</title>
        <time_frame>24 months</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Kaplan-Meier Freedom From the First Cardiovascular Hospitalization</title>
        <time_frame>3 years</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Kaplan-Meier Freedom From the First Cardiovascular Hospitalization</title>
        <time_frame>4 years</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Kaplan-Meier Freedom From the First Cardiovascular Hospitalization</title>
        <time_frame>5 years</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Kaplan-Meier Freedom From the First HF Related Hospitalization or All-cause Mortality</title>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>MitraClip System</title>
            <description>Percutaneous mitral valve repair using MitraClip System
MitraClip System: Percutaneous mitral valve repair using MitraClip System</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Patients with mitral regurgitation managed non-surgically based on standard hospital clinical practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Kaplan-Meier Freedom From the First HF Related Hospitalization or All-cause Mortality</title>
          <units>Percentage</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="196"/>
                <count group_id="O2" value="156"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.5" lower_limit="60.8" upper_limit="71.5"/>
                    <measurement group_id="O2" value="53.8" lower_limit="48.1" upper_limit="59.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Kaplan-Meier Freedom From the First HF Related Hospitalization or All-cause Mortality</title>
        <description>Survival rate from the first HF related hospitalization or all-cause mortality.</description>
        <time_frame>24 months</time_frame>
        <population>All available data has been reported.</population>
        <group_list>
          <group group_id="O1">
            <title>MitraClip System</title>
            <description>Percutaneous mitral valve repair using MitraClip System
MitraClip System: Percutaneous mitral valve repair using MitraClip System</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Patients with mitral regurgitation managed non-surgically based on standard hospital clinical practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Kaplan-Meier Freedom From the First HF Related Hospitalization or All-cause Mortality</title>
          <description>Survival rate from the first HF related hospitalization or all-cause mortality.</description>
          <population>All available data has been reported.</population>
          <units>percentage</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="148"/>
                <count group_id="O2" value="87"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.5" lower_limit="49.6" upper_limit="60.9"/>
                    <measurement group_id="O2" value="33.4" lower_limit="28.0" upper_limit="38.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Kaplan-Meier Freedom From the First HF Related Hospitalization or All-cause Mortality</title>
        <time_frame>3 years</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Kaplan-Meier Freedom From the First HF Related Hospitalization or All-cause Mortality</title>
        <time_frame>4 years</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Kaplan-Meier Freedom From the First HF Related Hospitalization or All-cause Mortality</title>
        <time_frame>5 years</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>NYHA Functional Class</title>
        <description>Measure Description: The New York Heart Association (NYHA) Classification provides a simple way of classifying the extent of heart failure. It classifies patients in one of four categories based on their limitations during physical activity:
Class I: No symptoms and no limitation in ordinary physical activity Class II: Mild symptoms (mild shortness of breath and/or angina) and slight limitation during ordinary activity Class III: Marked limitation in activity due to symptoms Class IV: Severe limitations</description>
        <time_frame>Baseline</time_frame>
        <population>NYHA Class data available for only 311 subjects</population>
        <group_list>
          <group group_id="O1">
            <title>MitraClip System</title>
            <description>Percutaneous mitral valve repair using MitraClip System
MitraClip System: Percutaneous mitral valve repair using MitraClip System</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Patients with mitral regurgitation managed non-surgically based on standard hospital clinical practice.</description>
          </group>
        </group_list>
        <measure>
          <title>NYHA Functional Class</title>
          <description>Measure Description: The New York Heart Association (NYHA) Classification provides a simple way of classifying the extent of heart failure. It classifies patients in one of four categories based on their limitations during physical activity:
Class I: No symptoms and no limitation in ordinary physical activity Class II: Mild symptoms (mild shortness of breath and/or angina) and slight limitation during ordinary activity Class III: Marked limitation in activity due to symptoms Class IV: Severe limitations</description>
          <population>NYHA Class data available for only 311 subjects</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="302"/>
                <count group_id="O2" value="312"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>NYHA Class I</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="302"/>
                    <count group_id="O2" value="311"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NYHA Class II</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="302"/>
                    <count group_id="O2" value="311"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="129"/>
                    <measurement group_id="O2" value="110"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NYHA Class III</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="302"/>
                    <count group_id="O2" value="311"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="154"/>
                    <measurement group_id="O2" value="168"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NYHA Class IV</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="302"/>
                    <count group_id="O2" value="311"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>NYHA Functional Class</title>
        <description>Measure Description: The New York Heart Association (NYHA) Classification provides a simple way of classifying the extent of heart failure. It classifies patients in one of four categories based on their limitations during physical activity:
Class I: No symptoms and no limitation in ordinary physical activity Class II: Mild symptoms (mild shortness of breath and/or angina) and slight limitation during ordinary activity Class III: Marked limitation in activity due to symptoms Class IV: Severe limitations</description>
        <time_frame>30 days</time_frame>
        <population>All available data at 30 day follow-up</population>
        <group_list>
          <group group_id="O1">
            <title>MitraClip System</title>
            <description>Percutaneous mitral valve repair using MitraClip System
MitraClip System: Percutaneous mitral valve repair using MitraClip System</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Patients with mitral regurgitation managed non-surgically based on standard hospital clinical practice.</description>
          </group>
        </group_list>
        <measure>
          <title>NYHA Functional Class</title>
          <description>Measure Description: The New York Heart Association (NYHA) Classification provides a simple way of classifying the extent of heart failure. It classifies patients in one of four categories based on their limitations during physical activity:
Class I: No symptoms and no limitation in ordinary physical activity Class II: Mild symptoms (mild shortness of breath and/or angina) and slight limitation during ordinary activity Class III: Marked limitation in activity due to symptoms Class IV: Severe limitations</description>
          <population>All available data at 30 day follow-up</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="281"/>
                <count group_id="O2" value="278"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>NYHA Class I</title>
                  <measurement_list>
                    <measurement group_id="O1" value="44"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>NYHA Class II</title>
                  <measurement_list>
                    <measurement group_id="O1" value="172"/>
                    <measurement group_id="O2" value="120"/>
                  </measurement_list>
                </category>
                <category>
                  <title>NYHA Class III</title>
                  <measurement_list>
                    <measurement group_id="O1" value="55"/>
                    <measurement group_id="O2" value="117"/>
                  </measurement_list>
                </category>
                <category>
                  <title>NYHA Class IV</title>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>NYHA Functional Class</title>
        <description>Measure Description: The New York Heart Association (NYHA) Classification provides a simple way of classifying the extent of heart failure. It classifies patients in one of four categories based on their limitations during physical activity:
Class I: No symptoms and no limitation in ordinary physical activity Class II: Mild symptoms (mild shortness of breath and/or angina) and slight limitation during ordinary activity Class III: Marked limitation in activity due to symptoms Class IV: Severe limitations</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>MitraClip System</title>
            <description>Percutaneous mitral valve repair using MitraClip System
MitraClip System: Percutaneous mitral valve repair using MitraClip System</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Patients with mitral regurgitation managed non-surgically based on standard hospital clinical practice.</description>
          </group>
        </group_list>
        <measure>
          <title>NYHA Functional Class</title>
          <description>Measure Description: The New York Heart Association (NYHA) Classification provides a simple way of classifying the extent of heart failure. It classifies patients in one of four categories based on their limitations during physical activity:
Class I: No symptoms and no limitation in ordinary physical activity Class II: Mild symptoms (mild shortness of breath and/or angina) and slight limitation during ordinary activity Class III: Marked limitation in activity due to symptoms Class IV: Severe limitations</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="253"/>
                <count group_id="O2" value="238"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>NYHA Class I</title>
                  <measurement_list>
                    <measurement group_id="O1" value="51"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>NYHA Class II</title>
                  <measurement_list>
                    <measurement group_id="O1" value="139"/>
                    <measurement group_id="O2" value="117"/>
                  </measurement_list>
                </category>
                <category>
                  <title>NYHA Class III</title>
                  <measurement_list>
                    <measurement group_id="O1" value="56"/>
                    <measurement group_id="O2" value="100"/>
                  </measurement_list>
                </category>
                <category>
                  <title>NYHA Class IV</title>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>NYHA Functional Class</title>
        <description>Measure Description: The New York Heart Association (NYHA) Classification provides a simple way of classifying the extent of heart failure. It classifies patients in one of four categories based on their limitations during physical activity:
Class I: No symptoms and no limitation in ordinary physical activity Class II: Mild symptoms (mild shortness of breath and/or angina) and slight limitation during ordinary activity Class III: Marked limitation in activity due to symptoms Class IV: Severe limitations</description>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>MitraClip System</title>
            <description>Percutaneous mitral valve repair using MitraClip System
MitraClip System: Percutaneous mitral valve repair using MitraClip System</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Patients with mitral regurgitation managed non-surgically based on standard hospital clinical practice.</description>
          </group>
        </group_list>
        <measure>
          <title>NYHA Functional Class</title>
          <description>Measure Description: The New York Heart Association (NYHA) Classification provides a simple way of classifying the extent of heart failure. It classifies patients in one of four categories based on their limitations during physical activity:
Class I: No symptoms and no limitation in ordinary physical activity Class II: Mild symptoms (mild shortness of breath and/or angina) and slight limitation during ordinary activity Class III: Marked limitation in activity due to symptoms Class IV: Severe limitations</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="219"/>
                <count group_id="O2" value="191"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>NYHA Class I</title>
                  <measurement_list>
                    <measurement group_id="O1" value="40"/>
                    <measurement group_id="O2" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>NYHA Class II</title>
                  <measurement_list>
                    <measurement group_id="O1" value="131"/>
                    <measurement group_id="O2" value="97"/>
                  </measurement_list>
                </category>
                <category>
                  <title>NYHA Class III</title>
                  <measurement_list>
                    <measurement group_id="O1" value="42"/>
                    <measurement group_id="O2" value="65"/>
                  </measurement_list>
                </category>
                <category>
                  <title>NYHA Class IV</title>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>NYHA Functional Class</title>
        <description>Measure Description: The New York Heart Association (NYHA) Classification provides a simple way of classifying the extent of heart failure. It classifies patients in one of four categories based on their limitations during physical activity:
Class I: No symptoms and no limitation in ordinary physical activity Class II: Mild symptoms (mild shortness of breath and/or angina) and slight limitation during ordinary activity Class III: Marked limitation in activity due to symptoms Class IV: Severe limitations</description>
        <time_frame>24 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>MitraClip System</title>
            <description>Percutaneous mitral valve repair using MitraClip System
MitraClip System: Percutaneous mitral valve repair using MitraClip System</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Patients with mitral regurgitation managed non-surgically based on standard hospital clinical practice.</description>
          </group>
        </group_list>
        <measure>
          <title>NYHA Functional Class</title>
          <description>Measure Description: The New York Heart Association (NYHA) Classification provides a simple way of classifying the extent of heart failure. It classifies patients in one of four categories based on their limitations during physical activity:
Class I: No symptoms and no limitation in ordinary physical activity Class II: Mild symptoms (mild shortness of breath and/or angina) and slight limitation during ordinary activity Class III: Marked limitation in activity due to symptoms Class IV: Severe limitations</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="176"/>
                <count group_id="O2" value="143"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>NYHA Class I</title>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>NYHA Class II</title>
                  <measurement_list>
                    <measurement group_id="O1" value="91"/>
                    <measurement group_id="O2" value="69"/>
                  </measurement_list>
                </category>
                <category>
                  <title>NYHA Class III</title>
                  <measurement_list>
                    <measurement group_id="O1" value="44"/>
                    <measurement group_id="O2" value="54"/>
                  </measurement_list>
                </category>
                <category>
                  <title>NYHA Class IV</title>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>NYHA Functional Class</title>
        <time_frame>3 years</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>NYHA Functional Class</title>
        <time_frame>4 years</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>NYHA Functional Class</title>
        <time_frame>5 years</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Six-Minute Walk Test Distance (6MWD)</title>
        <description>Six-Minute Walk Test is a submaximal exercise test that entails measurement of distance walked over a span of 6 minutes. The 6-minute walk test distance (6 MWD) provides a measure for integrated global response of multiple cardiopulmonary and musculoskeletal systems involved in exercise.</description>
        <time_frame>Baseline</time_frame>
        <population>All available 6MWD has been reported.</population>
        <group_list>
          <group group_id="O1">
            <title>MitraClip System</title>
            <description>Percutaneous mitral valve repair using MitraClip System
MitraClip System: Percutaneous mitral valve repair using MitraClip System</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Patients with mitral regurgitation managed non-surgically based on standard hospital clinical practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Six-Minute Walk Test Distance (6MWD)</title>
          <description>Six-Minute Walk Test is a submaximal exercise test that entails measurement of distance walked over a span of 6 minutes. The 6-minute walk test distance (6 MWD) provides a measure for integrated global response of multiple cardiopulmonary and musculoskeletal systems involved in exercise.</description>
          <population>All available 6MWD has been reported.</population>
          <units>meters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="296"/>
                <count group_id="O2" value="305"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="249.6" spread="123.8"/>
                    <measurement group_id="O2" value="234.5" spread="123.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>6MWD</title>
        <description>Six-Minute Walk Test is a submaximal exercise test that entails measurement of distance walked over a span of 6 minutes. The 6-minute walk test distance (6 MWD) provides a measure for integrated global response of multiple cardiopulmonary and musculoskeletal systems involved in exercise.</description>
        <time_frame>30 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>MitraClip System</title>
            <description>Percutaneous mitral valve repair using MitraClip System
MitraClip System: Percutaneous mitral valve repair using MitraClip System</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Patients with mitral regurgitation managed non-surgically based on standard hospital clinical practice.</description>
          </group>
        </group_list>
        <measure>
          <title>6MWD</title>
          <description>Six-Minute Walk Test is a submaximal exercise test that entails measurement of distance walked over a span of 6 minutes. The 6-minute walk test distance (6 MWD) provides a measure for integrated global response of multiple cardiopulmonary and musculoskeletal systems involved in exercise.</description>
          <units>meters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="265"/>
                <count group_id="O2" value="244"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="290.1" spread="122.8"/>
                    <measurement group_id="O2" value="243.0" spread="121.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>6MWD</title>
        <description>Six-Minute Walk Test is a submaximal exercise test that entails measurement of distance walked over a span of 6 minutes. The 6-minute walk test distance (6 MWD) provides a measure for integrated global response of multiple cardiopulmonary and musculoskeletal systems involved in exercise.</description>
        <time_frame>6 months</time_frame>
        <population>All available 6MWD has been reported</population>
        <group_list>
          <group group_id="O1">
            <title>MitraClip System</title>
            <description>Percutaneous mitral valve repair using MitraClip System
MitraClip System: Percutaneous mitral valve repair using MitraClip System</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Patients with mitral regurgitation managed non-surgically based on standard hospital clinical practice.</description>
          </group>
        </group_list>
        <measure>
          <title>6MWD</title>
          <description>Six-Minute Walk Test is a submaximal exercise test that entails measurement of distance walked over a span of 6 minutes. The 6-minute walk test distance (6 MWD) provides a measure for integrated global response of multiple cardiopulmonary and musculoskeletal systems involved in exercise.</description>
          <population>All available 6MWD has been reported</population>
          <units>meters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="237"/>
                <count group_id="O2" value="203"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="288.6" spread="128.0"/>
                    <measurement group_id="O2" value="253.9" spread="126.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>6MWD</title>
        <description>Six-Minute Walk Test is a submaximal exercise test that entails measurement of distance walked over a span of 6 minutes. The 6-minute walk test distance (6 MWD) provides a measure for integrated global response of multiple cardiopulmonary and musculoskeletal systems involved in exercise.</description>
        <time_frame>12 months</time_frame>
        <population>All available 6MWD has been reported</population>
        <group_list>
          <group group_id="O1">
            <title>MitraClip System</title>
            <description>Percutaneous mitral valve repair using MitraClip System
MitraClip System: Percutaneous mitral valve repair using MitraClip System</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Patients with mitral regurgitation managed non-surgically based on standard hospital clinical practice.</description>
          </group>
        </group_list>
        <measure>
          <title>6MWD</title>
          <description>Six-Minute Walk Test is a submaximal exercise test that entails measurement of distance walked over a span of 6 minutes. The 6-minute walk test distance (6 MWD) provides a measure for integrated global response of multiple cardiopulmonary and musculoskeletal systems involved in exercise.</description>
          <population>All available 6MWD has been reported</population>
          <units>meters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="193"/>
                <count group_id="O2" value="167"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="308.4" spread="116.7"/>
                    <measurement group_id="O2" value="269.7" spread="133.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>6MWD</title>
        <description>Six-Minute Walk Test is a submaximal exercise test that entails measurement of distance walked over a span of 6 minutes. The 6-minute walk test distance (6 MWD) provides a measure for integrated global response of multiple cardiopulmonary and musculoskeletal systems involved in exercise.</description>
        <time_frame>24 months</time_frame>
        <population>All available 6MWD has been reported.</population>
        <group_list>
          <group group_id="O1">
            <title>MitraClip System</title>
            <description>Percutaneous mitral valve repair using MitraClip System
MitraClip System: Percutaneous mitral valve repair using MitraClip System</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Patients with mitral regurgitation managed non-surgically based on standard hospital clinical practice.</description>
          </group>
        </group_list>
        <measure>
          <title>6MWD</title>
          <description>Six-Minute Walk Test is a submaximal exercise test that entails measurement of distance walked over a span of 6 minutes. The 6-minute walk test distance (6 MWD) provides a measure for integrated global response of multiple cardiopulmonary and musculoskeletal systems involved in exercise.</description>
          <population>All available 6MWD has been reported.</population>
          <units>meters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="143"/>
                <count group_id="O2" value="111"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="294.2" spread="131.2"/>
                    <measurement group_id="O2" value="273.8" spread="142.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change in 6MWD From Baseline</title>
        <time_frame>Between baseline and 30 days</time_frame>
        <population>All available data has been reported</population>
        <group_list>
          <group group_id="O1">
            <title>MitraClip System</title>
            <description>Percutaneous mitral valve repair using MitraClip System
MitraClip System: Percutaneous mitral valve repair using MitraClip System</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Patients with mitral regurgitation managed non-surgically based on standard hospital clinical practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in 6MWD From Baseline</title>
          <population>All available data has been reported</population>
          <units>meters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="260"/>
                <count group_id="O2" value="243"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.6" spread="106.4"/>
                    <measurement group_id="O2" value="-0.9" spread="83.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change in 6MWD From Baseline</title>
        <time_frame>Between baseline and 6 months</time_frame>
        <population>All available data has been reported.</population>
        <group_list>
          <group group_id="O1">
            <title>MitraClip System</title>
            <description>Percutaneous mitral valve repair using MitraClip System
MitraClip System: Percutaneous mitral valve repair using MitraClip System</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Patients with mitral regurgitation managed non-surgically based on standard hospital clinical practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in 6MWD From Baseline</title>
          <population>All available data has been reported.</population>
          <units>meters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="233"/>
                <count group_id="O2" value="201"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.9" spread="100.6"/>
                    <measurement group_id="O2" value="0.66" spread="99.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change in 6MWD From Baseline</title>
        <time_frame>Between baseline and 12 months</time_frame>
        <population>All available data has been reported.</population>
        <group_list>
          <group group_id="O1">
            <title>MitraClip System</title>
            <description>Percutaneous mitral valve repair using MitraClip System
MitraClip System: Percutaneous mitral valve repair using MitraClip System</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Patients with mitral regurgitation managed non-surgically based on standard hospital clinical practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in 6MWD From Baseline</title>
          <population>All available data has been reported.</population>
          <units>meters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="191"/>
                <count group_id="O2" value="166"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.9" spread="99.6"/>
                    <measurement group_id="O2" value="5.5" spread="115.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change in 6MWD From Baseline</title>
        <time_frame>Between baseline and 24 months</time_frame>
        <population>All available data has been reported.</population>
        <group_list>
          <group group_id="O1">
            <title>MitraClip System</title>
            <description>Percutaneous mitral valve repair using MitraClip System
MitraClip System: Percutaneous mitral valve repair using MitraClip System</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Patients with mitral regurgitation managed non-surgically based on standard hospital clinical practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in 6MWD From Baseline</title>
          <population>All available data has been reported.</population>
          <units>meters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="142"/>
                <count group_id="O2" value="110"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.5" spread="103.0"/>
                    <measurement group_id="O2" value="1.1" spread="133.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Kansas City Cardiomyopathy Questionnaire (KCCQ) QoL Scores</title>
        <description>The Kansas City Cardiomyopathy Questionnaire is a 23-item, self-administered instrument that quantifies physical function, symptoms, social function, self-efficacy and knowledge, and quality of life. with a range of possible subscale scores from 0 to 100, with 100 representing the least burden of symptoms. The KCCQ tool quantifies the following six (6) distinct domains and two (2) summary scores: KCCQ Symptom Domain, KCCQ Physical Function Domain, KCCQ Quality of Life Domain, KCCQ Social Limitation Domain, KCCQ Self-efficacy Domain, KCCQ Symptom Stability Domain, Clinical Summary Score and Overall Summary Score.
Clinical Summary Score includes total symptom and physical function scores to correspond with NYHA Classification.
Overall Summary Score includes the total symptom, physical function, social limitations and quality of life scores.</description>
        <time_frame>Baseline</time_frame>
        <population>All available data has been reported.</population>
        <group_list>
          <group group_id="O1">
            <title>MitraClip System</title>
            <description>Percutaneous mitral valve repair using MitraClip System
MitraClip System: Percutaneous mitral valve repair using MitraClip System</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Patients with mitral regurgitation managed non-surgically based on standard hospital clinical practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Kansas City Cardiomyopathy Questionnaire (KCCQ) QoL Scores</title>
          <description>The Kansas City Cardiomyopathy Questionnaire is a 23-item, self-administered instrument that quantifies physical function, symptoms, social function, self-efficacy and knowledge, and quality of life. with a range of possible subscale scores from 0 to 100, with 100 representing the least burden of symptoms. The KCCQ tool quantifies the following six (6) distinct domains and two (2) summary scores: KCCQ Symptom Domain, KCCQ Physical Function Domain, KCCQ Quality of Life Domain, KCCQ Social Limitation Domain, KCCQ Self-efficacy Domain, KCCQ Symptom Stability Domain, Clinical Summary Score and Overall Summary Score.
Clinical Summary Score includes total symptom and physical function scores to correspond with NYHA Classification.
Overall Summary Score includes the total symptom, physical function, social limitations and quality of life scores.</description>
          <population>All available data has been reported.</population>
          <units>KCCQ score on a points scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="302"/>
                <count group_id="O2" value="309"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.2" spread="22.8"/>
                    <measurement group_id="O2" value="51.6" spread="23.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>KCCQ QoL Scores</title>
        <description>The Kansas City Cardiomyopathy Questionnaire is a 23-item, self-administered instrument that quantifies physical function, symptoms, social function, self-efficacy and knowledge, and quality of life. with a range of possible subscale scores from 0 to 100, with 100 representing the least burden of symptoms. The KCCQ tool quantifies the following six (6) distinct domains and two (2) summary scores: KCCQ Symptom Domain, KCCQ Physical Function Domain, KCCQ Quality of Life Domain, KCCQ Social Limitation Domain, KCCQ Self-efficacy Domain, KCCQ Symptom Stability Domain, Clinical Summary Score and Overall Summary Score.
Clinical Summary Score includes total symptom and physical function scores to correspond with NYHA Classification.
Overall Summary Score includes the total symptom, physical function, social limitations and quality of life scores.</description>
        <time_frame>30 days</time_frame>
        <population>All available data has been reported.</population>
        <group_list>
          <group group_id="O1">
            <title>MitraClip System</title>
            <description>Percutaneous mitral valve repair using MitraClip System
MitraClip System: Percutaneous mitral valve repair using MitraClip System</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Patients with mitral regurgitation managed non-surgically based on standard hospital clinical practice.</description>
          </group>
        </group_list>
        <measure>
          <title>KCCQ QoL Scores</title>
          <description>The Kansas City Cardiomyopathy Questionnaire is a 23-item, self-administered instrument that quantifies physical function, symptoms, social function, self-efficacy and knowledge, and quality of life. with a range of possible subscale scores from 0 to 100, with 100 representing the least burden of symptoms. The KCCQ tool quantifies the following six (6) distinct domains and two (2) summary scores: KCCQ Symptom Domain, KCCQ Physical Function Domain, KCCQ Quality of Life Domain, KCCQ Social Limitation Domain, KCCQ Self-efficacy Domain, KCCQ Symptom Stability Domain, Clinical Summary Score and Overall Summary Score.
Clinical Summary Score includes total symptom and physical function scores to correspond with NYHA Classification.
Overall Summary Score includes the total symptom, physical function, social limitations and quality of life scores.</description>
          <population>All available data has been reported.</population>
          <units>KCCQ score on a points scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="279"/>
                <count group_id="O2" value="275"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.9" spread="21.1"/>
                    <measurement group_id="O2" value="54.6" spread="24.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>KCCQ QoL Scores</title>
        <description>The Kansas City Cardiomyopathy Questionnaire is a 23-item, self-administered instrument that quantifies physical function, symptoms, social function, self-efficacy and knowledge, and quality of life. with a range of possible subscale scores from 0 to 100, with 100 representing the least burden of symptoms. The KCCQ tool quantifies the following six (6) distinct domains and two (2) summary scores: KCCQ Symptom Domain, KCCQ Physical Function Domain, KCCQ Quality of Life Domain, KCCQ Social Limitation Domain, KCCQ Self-efficacy Domain, KCCQ Symptom Stability Domain, Clinical Summary Score and Overall Summary Score.
Clinical Summary Score includes total symptom and physical function scores to correspond with NYHA Classification.
Overall Summary Score includes the total symptom, physical function, social limitations and quality of life scores.</description>
        <time_frame>6 months</time_frame>
        <population>All available data has been reported.</population>
        <group_list>
          <group group_id="O1">
            <title>MitraClip System</title>
            <description>Percutaneous mitral valve repair using MitraClip System
MitraClip System: Percutaneous mitral valve repair using MitraClip System</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Patients with mitral regurgitation managed non-surgically based on standard hospital clinical practice.</description>
          </group>
        </group_list>
        <measure>
          <title>KCCQ QoL Scores</title>
          <description>The Kansas City Cardiomyopathy Questionnaire is a 23-item, self-administered instrument that quantifies physical function, symptoms, social function, self-efficacy and knowledge, and quality of life. with a range of possible subscale scores from 0 to 100, with 100 representing the least burden of symptoms. The KCCQ tool quantifies the following six (6) distinct domains and two (2) summary scores: KCCQ Symptom Domain, KCCQ Physical Function Domain, KCCQ Quality of Life Domain, KCCQ Social Limitation Domain, KCCQ Self-efficacy Domain, KCCQ Symptom Stability Domain, Clinical Summary Score and Overall Summary Score.
Clinical Summary Score includes total symptom and physical function scores to correspond with NYHA Classification.
Overall Summary Score includes the total symptom, physical function, social limitations and quality of life scores.</description>
          <population>All available data has been reported.</population>
          <units>KCCQ score on a points scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="252"/>
                <count group_id="O2" value="237"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.0" spread="21.3"/>
                    <measurement group_id="O2" value="59.0" spread="24.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>KCCQ QoL Scores</title>
        <description>The Kansas City Cardiomyopathy Questionnaire is a 23-item, self-administered instrument that quantifies physical function, symptoms, social function, self-efficacy and knowledge, and quality of life. with a range of possible subscale scores from 0 to 100, with 100 representing the least burden of symptoms. The KCCQ tool quantifies the following six (6) distinct domains and two (2) summary scores: KCCQ Symptom Domain, KCCQ Physical Function Domain, KCCQ Quality of Life Domain, KCCQ Social Limitation Domain, KCCQ Self-efficacy Domain, KCCQ Symptom Stability Domain, Clinical Summary Score and Overall Summary Score.
Clinical Summary Score includes total symptom and physical function scores to correspond with NYHA Classification.
Overall Summary Score includes the total symptom, physical function, social limitations and quality of life scores.</description>
        <time_frame>12 months</time_frame>
        <population>All available data has been reported.</population>
        <group_list>
          <group group_id="O1">
            <title>MitraClip System</title>
            <description>Percutaneous mitral valve repair using MitraClip System
MitraClip System: Percutaneous mitral valve repair using MitraClip System</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Patients with mitral regurgitation managed non-surgically based on standard hospital clinical practice.</description>
          </group>
        </group_list>
        <measure>
          <title>KCCQ QoL Scores</title>
          <description>The Kansas City Cardiomyopathy Questionnaire is a 23-item, self-administered instrument that quantifies physical function, symptoms, social function, self-efficacy and knowledge, and quality of life. with a range of possible subscale scores from 0 to 100, with 100 representing the least burden of symptoms. The KCCQ tool quantifies the following six (6) distinct domains and two (2) summary scores: KCCQ Symptom Domain, KCCQ Physical Function Domain, KCCQ Quality of Life Domain, KCCQ Social Limitation Domain, KCCQ Self-efficacy Domain, KCCQ Symptom Stability Domain, Clinical Summary Score and Overall Summary Score.
Clinical Summary Score includes total symptom and physical function scores to correspond with NYHA Classification.
Overall Summary Score includes the total symptom, physical function, social limitations and quality of life scores.</description>
          <population>All available data has been reported.</population>
          <units>KCCQ score on a points scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="219"/>
                <count group_id="O2" value="189"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.8" spread="22.2"/>
                    <measurement group_id="O2" value="60.2" spread="24.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>KCCQ QoL Scores</title>
        <description>The Kansas City Cardiomyopathy Questionnaire is a 23-item, self-administered instrument that quantifies physical function, symptoms, social function, self-efficacy and knowledge, and quality of life. with a range of possible subscale scores from 0 to 100, with 100 representing the least burden of symptoms. The KCCQ tool quantifies the following six (6) distinct domains and two (2) summary scores: KCCQ Symptom Domain, KCCQ Physical Function Domain, KCCQ Quality of Life Domain, KCCQ Social Limitation Domain, KCCQ Self-efficacy Domain, KCCQ Symptom Stability Domain, Clinical Summary Score and Overall Summary Score.
Clinical Summary Score includes total symptom and physical function scores to correspond with NYHA Classification.
Overall Summary Score includes the total symptom, physical function, social limitations and quality of life scores.</description>
        <time_frame>24 months</time_frame>
        <population>All available data has been reported.</population>
        <group_list>
          <group group_id="O1">
            <title>MitraClip System</title>
            <description>Percutaneous mitral valve repair using MitraClip System
MitraClip System: Percutaneous mitral valve repair using MitraClip System</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Patients with mitral regurgitation managed non-surgically based on standard hospital clinical practice.</description>
          </group>
        </group_list>
        <measure>
          <title>KCCQ QoL Scores</title>
          <description>The Kansas City Cardiomyopathy Questionnaire is a 23-item, self-administered instrument that quantifies physical function, symptoms, social function, self-efficacy and knowledge, and quality of life. with a range of possible subscale scores from 0 to 100, with 100 representing the least burden of symptoms. The KCCQ tool quantifies the following six (6) distinct domains and two (2) summary scores: KCCQ Symptom Domain, KCCQ Physical Function Domain, KCCQ Quality of Life Domain, KCCQ Social Limitation Domain, KCCQ Self-efficacy Domain, KCCQ Symptom Stability Domain, Clinical Summary Score and Overall Summary Score.
Clinical Summary Score includes total symptom and physical function scores to correspond with NYHA Classification.
Overall Summary Score includes the total symptom, physical function, social limitations and quality of life scores.</description>
          <population>All available data has been reported.</population>
          <units>KCCQ score on a points scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="175"/>
                <count group_id="O2" value="138"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.3" spread="23.3"/>
                    <measurement group_id="O2" value="58.9" spread="25.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change in KCCQ QoL Scores From Baseline</title>
        <description>Paired data looking at difference between the baseline Kansas City Cardiomyopathy Questionnaire (KCCQ) and 30 days KCCQ score.
The Kansas City Cardiomyopathy Questionnaire is a 23-item, self-administered instrument that quantifies physical function, symptoms, social function, self-efficacy and knowledge, and quality of life. with a range of possible subscale scores from 0 to 100, with 100 representing the least burden of symptoms. The KCCQ tool quantifies the following six (6) distinct domains and two (2) summary scores: KCCQ Symptom Domain, KCCQ Physical Function Domain, KCCQ Quality of Life Domain, KCCQ Social Limitation Domain, KCCQ Self-efficacy Domain, KCCQ Symptom Stability Domain, Clinical Summary Score and Overall Summary Score.
Clinical Summary Score includes total symptom and physical function scores to correspond with NYHA Classification.
Overall Summary Score includes the total symptom, physical function, social limitations and quality of life scores.</description>
        <time_frame>Between baseline and 30 days</time_frame>
        <population>All available paired data has been reported.</population>
        <group_list>
          <group group_id="O1">
            <title>MitraClip System</title>
            <description>Percutaneous mitral valve repair using MitraClip System
MitraClip System: Percutaneous mitral valve repair using MitraClip System</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Patients with mitral regurgitation managed non-surgically based on standard hospital clinical practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in KCCQ QoL Scores From Baseline</title>
          <description>Paired data looking at difference between the baseline Kansas City Cardiomyopathy Questionnaire (KCCQ) and 30 days KCCQ score.
The Kansas City Cardiomyopathy Questionnaire is a 23-item, self-administered instrument that quantifies physical function, symptoms, social function, self-efficacy and knowledge, and quality of life. with a range of possible subscale scores from 0 to 100, with 100 representing the least burden of symptoms. The KCCQ tool quantifies the following six (6) distinct domains and two (2) summary scores: KCCQ Symptom Domain, KCCQ Physical Function Domain, KCCQ Quality of Life Domain, KCCQ Social Limitation Domain, KCCQ Self-efficacy Domain, KCCQ Symptom Stability Domain, Clinical Summary Score and Overall Summary Score.
Clinical Summary Score includes total symptom and physical function scores to correspond with NYHA Classification.
Overall Summary Score includes the total symptom, physical function, social limitations and quality of life scores.</description>
          <population>All available paired data has been reported.</population>
          <units>KCCQ score on a points scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="279"/>
                <count group_id="O2" value="272"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.9" spread="22.8"/>
                    <measurement group_id="O2" value="2.1" spread="18.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change in KCCQ QoL Scores From Baseline</title>
        <description>Paired data looking at difference between the baseline Kansas City Cardiomyopathy Questionnaire (KCCQ) and 6 months KCCQ score.
The Kansas City Cardiomyopathy Questionnaire is a 23-item, self-administered instrument that quantifies physical function, symptoms, social function, self-efficacy and knowledge, and quality of life. with a range of possible subscale scores from 0 to 100, with 100 representing the least burden of symptoms. The KCCQ tool quantifies the following six (6) distinct domains and two (2) summary scores: KCCQ Symptom Domain, KCCQ Physical Function Domain, KCCQ Quality of Life Domain, KCCQ Social Limitation Domain, KCCQ Self-efficacy Domain, KCCQ Symptom Stability Domain, Clinical Summary Score and Overall Summary Score.
Clinical Summary Score includes total symptom and physical function scores to correspond with NYHA Classification.
Overall Summary Score includes the total symptom, physical function, social limitations and quality of life scores.</description>
        <time_frame>Between baseline and 6 months</time_frame>
        <population>All available paired data has been reported.</population>
        <group_list>
          <group group_id="O1">
            <title>MitraClip System</title>
            <description>Percutaneous mitral valve repair using MitraClip System
MitraClip System: Percutaneous mitral valve repair using MitraClip System</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Patients with mitral regurgitation managed non-surgically based on standard hospital clinical practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in KCCQ QoL Scores From Baseline</title>
          <description>Paired data looking at difference between the baseline Kansas City Cardiomyopathy Questionnaire (KCCQ) and 6 months KCCQ score.
The Kansas City Cardiomyopathy Questionnaire is a 23-item, self-administered instrument that quantifies physical function, symptoms, social function, self-efficacy and knowledge, and quality of life. with a range of possible subscale scores from 0 to 100, with 100 representing the least burden of symptoms. The KCCQ tool quantifies the following six (6) distinct domains and two (2) summary scores: KCCQ Symptom Domain, KCCQ Physical Function Domain, KCCQ Quality of Life Domain, KCCQ Social Limitation Domain, KCCQ Self-efficacy Domain, KCCQ Symptom Stability Domain, Clinical Summary Score and Overall Summary Score.
Clinical Summary Score includes total symptom and physical function scores to correspond with NYHA Classification.
Overall Summary Score includes the total symptom, physical function, social limitations and quality of life scores.</description>
          <population>All available paired data has been reported.</population>
          <units>KCCQ score on a points scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="252"/>
                <count group_id="O2" value="236"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.5" spread="24.9"/>
                    <measurement group_id="O2" value="5.3" spread="23.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change in KCCQ QoL Scores From Baseline</title>
        <description>Paired data looking at difference between the baseline Kansas City Cardiomyopathy Questionnaire (KCCQ) and 12 months KCCQ score.
The Kansas City Cardiomyopathy Questionnaire is a 23-item, self-administered instrument that quantifies physical function, symptoms, social function, self-efficacy and knowledge, and quality of life. with a range of possible subscale scores from 0 to 100, with 100 representing the least burden of symptoms. The KCCQ tool quantifies the following six (6) distinct domains and two (2) summary scores: KCCQ Symptom Domain, KCCQ Physical Function Domain, KCCQ Quality of Life Domain, KCCQ Social Limitation Domain, KCCQ Self-efficacy Domain, KCCQ Symptom Stability Domain, Clinical Summary Score and Overall Summary Score.
Clinical Summary Score includes total symptom and physical function scores to correspond with NYHA Classification.
Overall Summary Score includes the total symptom, physical function, social limitations and quality of life scores.</description>
        <time_frame>Between baseline and 12 months</time_frame>
        <population>All available paired data has been reported.</population>
        <group_list>
          <group group_id="O1">
            <title>MitraClip System</title>
            <description>Percutaneous mitral valve repair using MitraClip System
MitraClip System: Percutaneous mitral valve repair using MitraClip System</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Patients with mitral regurgitation managed non-surgically based on standard hospital clinical practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in KCCQ QoL Scores From Baseline</title>
          <description>Paired data looking at difference between the baseline Kansas City Cardiomyopathy Questionnaire (KCCQ) and 12 months KCCQ score.
The Kansas City Cardiomyopathy Questionnaire is a 23-item, self-administered instrument that quantifies physical function, symptoms, social function, self-efficacy and knowledge, and quality of life. with a range of possible subscale scores from 0 to 100, with 100 representing the least burden of symptoms. The KCCQ tool quantifies the following six (6) distinct domains and two (2) summary scores: KCCQ Symptom Domain, KCCQ Physical Function Domain, KCCQ Quality of Life Domain, KCCQ Social Limitation Domain, KCCQ Self-efficacy Domain, KCCQ Symptom Stability Domain, Clinical Summary Score and Overall Summary Score.
Clinical Summary Score includes total symptom and physical function scores to correspond with NYHA Classification.
Overall Summary Score includes the total symptom, physical function, social limitations and quality of life scores.</description>
          <population>All available paired data has been reported.</population>
          <units>KCCQ score on a points scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="219"/>
                <count group_id="O2" value="188"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.0" spread="25.4"/>
                    <measurement group_id="O2" value="5.1" spread="24.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change in KCCQ QoL Scores From Baseline</title>
        <description>Paired data looking at difference between the baseline Kansas City Cardiomyopathy Questionnaire (KCCQ) and 24 months KCCQ score.
The Kansas City Cardiomyopathy Questionnaire is a 23-item, self-administered instrument that quantifies physical function, symptoms, social function, self-efficacy and knowledge, and quality of life. with a range of possible subscale scores from 0 to 100, with 100 representing the least burden of symptoms. The KCCQ tool quantifies the following six (6) distinct domains and two (2) summary scores: KCCQ Symptom Domain, KCCQ Physical Function Domain, KCCQ Quality of Life Domain, KCCQ Social Limitation Domain, KCCQ Self-efficacy Domain, KCCQ Symptom Stability Domain, Clinical Summary Score and Overall Summary Score.
Clinical Summary Score includes total symptom and physical function scores to correspond with NYHA Classification.
Overall Summary Score includes the total symptom, physical function, social limitations and quality of life scores.</description>
        <time_frame>Between baseline and 24 months</time_frame>
        <population>All available paired data has been reported.</population>
        <group_list>
          <group group_id="O1">
            <title>MitraClip System</title>
            <description>Percutaneous mitral valve repair using MitraClip System
MitraClip System: Percutaneous mitral valve repair using MitraClip System</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Patients with mitral regurgitation managed non-surgically based on standard hospital clinical practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in KCCQ QoL Scores From Baseline</title>
          <description>Paired data looking at difference between the baseline Kansas City Cardiomyopathy Questionnaire (KCCQ) and 24 months KCCQ score.
The Kansas City Cardiomyopathy Questionnaire is a 23-item, self-administered instrument that quantifies physical function, symptoms, social function, self-efficacy and knowledge, and quality of life. with a range of possible subscale scores from 0 to 100, with 100 representing the least burden of symptoms. The KCCQ tool quantifies the following six (6) distinct domains and two (2) summary scores: KCCQ Symptom Domain, KCCQ Physical Function Domain, KCCQ Quality of Life Domain, KCCQ Social Limitation Domain, KCCQ Self-efficacy Domain, KCCQ Symptom Stability Domain, Clinical Summary Score and Overall Summary Score.
Clinical Summary Score includes total symptom and physical function scores to correspond with NYHA Classification.
Overall Summary Score includes the total symptom, physical function, social limitations and quality of life scores.</description>
          <population>All available paired data has been reported.</population>
          <units>KCCQ score on a points scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="175"/>
                <count group_id="O2" value="138"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.4" spread="25.8"/>
                    <measurement group_id="O2" value="3.4" spread="26.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>SF-36 QoL Scores</title>
        <description>The 36-Item Short Form Health Survey questionnaire (SF-36) is a very popular instrument for evaluating Health-Related Quality of Life. with a range of possible subscale scores from 0 to 100, with 100 representing the least burden of symptoms. There are two distinct concepts measured by the SF-36: a physical dimension, represented by the Physical Component Summary (PCS), and a mental dimension, represented by the Mental Component Summary (MCS).</description>
        <time_frame>Baseline</time_frame>
        <population>All available data has been reported.</population>
        <group_list>
          <group group_id="O1">
            <title>MitraClip System</title>
            <description>Percutaneous mitral valve repair using MitraClip System
MitraClip System: Percutaneous mitral valve repair using MitraClip System</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Patients with mitral regurgitation managed non-surgically based on standard hospital clinical practice.</description>
          </group>
        </group_list>
        <measure>
          <title>SF-36 QoL Scores</title>
          <description>The 36-Item Short Form Health Survey questionnaire (SF-36) is a very popular instrument for evaluating Health-Related Quality of Life. with a range of possible subscale scores from 0 to 100, with 100 representing the least burden of symptoms. There are two distinct concepts measured by the SF-36: a physical dimension, represented by the Physical Component Summary (PCS), and a mental dimension, represented by the Mental Component Summary (MCS).</description>
          <population>All available data has been reported.</population>
          <units>SF-36 score on a points scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="299"/>
                <count group_id="O2" value="308"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SF-36 PCS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.0" spread="9.1"/>
                    <measurement group_id="O2" value="32.6" spread="10.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SF-36 MCS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.7" spread="12.7"/>
                    <measurement group_id="O2" value="13.0" spread="12.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>SF-36 QoL Scores</title>
        <description>The 36-Item Short Form Health Survey questionnaire (SF-36) is a very popular instrument for evaluating Health-Related Quality of Life. with a range of possible subscale scores from 0 to 100, with 100 representing the least burden of symptoms. There are two distinct concepts measured by the SF-36: a physical dimension, represented by the Physical Component Summary (PCS), and a mental dimension, represented by the Mental Component Summary (MCS).</description>
        <time_frame>30 days</time_frame>
        <population>All available data has been reported.</population>
        <group_list>
          <group group_id="O1">
            <title>MitraClip System</title>
            <description>Percutaneous mitral valve repair using MitraClip System
MitraClip System: Percutaneous mitral valve repair using MitraClip System</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Patients with mitral regurgitation managed non-surgically based on standard hospital clinical practice.</description>
          </group>
        </group_list>
        <measure>
          <title>SF-36 QoL Scores</title>
          <description>The 36-Item Short Form Health Survey questionnaire (SF-36) is a very popular instrument for evaluating Health-Related Quality of Life. with a range of possible subscale scores from 0 to 100, with 100 representing the least burden of symptoms. There are two distinct concepts measured by the SF-36: a physical dimension, represented by the Physical Component Summary (PCS), and a mental dimension, represented by the Mental Component Summary (MCS).</description>
          <population>All available data has been reported.</population>
          <units>SF-36 score on a points scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="278"/>
                <count group_id="O2" value="272"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SF-36 PCS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.2" spread="9.2"/>
                    <measurement group_id="O2" value="33.6" spread="9.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SF-36 MCS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.4" spread="11.5"/>
                    <measurement group_id="O2" value="46.1" spread="13.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>SF-36 QoL Scores</title>
        <description>The 36-Item Short Form Health Survey questionnaire (SF-36) is a very popular instrument for evaluating Health-Related Quality of Life. with a range of possible subscale scores from 0 to 100, with 100 representing the least burden of symptoms. There are two distinct concepts measured by the SF-36: a physical dimension, represented by the Physical Component Summary (PCS), and a mental dimension, represented by the Mental Component Summary (MCS).</description>
        <time_frame>6 months</time_frame>
        <population>All available data has been reported.</population>
        <group_list>
          <group group_id="O1">
            <title>MitraClip System</title>
            <description>Percutaneous mitral valve repair using MitraClip System
MitraClip System: Percutaneous mitral valve repair using MitraClip System</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Patients with mitral regurgitation managed non-surgically based on standard hospital clinical practice.</description>
          </group>
        </group_list>
        <measure>
          <title>SF-36 QoL Scores</title>
          <description>The 36-Item Short Form Health Survey questionnaire (SF-36) is a very popular instrument for evaluating Health-Related Quality of Life. with a range of possible subscale scores from 0 to 100, with 100 representing the least burden of symptoms. There are two distinct concepts measured by the SF-36: a physical dimension, represented by the Physical Component Summary (PCS), and a mental dimension, represented by the Mental Component Summary (MCS).</description>
          <population>All available data has been reported.</population>
          <units>SF-36 scores on a points scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="251"/>
                <count group_id="O2" value="237"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SF-36 PCS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.0" spread="10.3"/>
                    <measurement group_id="O2" value="34.2" spread="9.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SF-36 MCS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.1" spread="10.3"/>
                    <measurement group_id="O2" value="47.0" spread="12.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>SF-36 QoL Scores</title>
        <description>The 36-Item Short Form Health Survey questionnaire (SF-36) is a very popular instrument for evaluating Health-Related Quality of Life. with a range of possible subscale scores from 0 to 100, with 100 representing the least burden of symptoms. There are two distinct concepts measured by the SF-36: a physical dimension, represented by the Physical Component Summary (PCS), and a mental dimension, represented by the Mental Component Summary (MCS).</description>
        <time_frame>12 months</time_frame>
        <population>All available data has been reported.</population>
        <group_list>
          <group group_id="O1">
            <title>MitraClip System</title>
            <description>Percutaneous mitral valve repair using MitraClip System
MitraClip System: Percutaneous mitral valve repair using MitraClip System</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Patients with mitral regurgitation managed non-surgically based on standard hospital clinical practice.</description>
          </group>
        </group_list>
        <measure>
          <title>SF-36 QoL Scores</title>
          <description>The 36-Item Short Form Health Survey questionnaire (SF-36) is a very popular instrument for evaluating Health-Related Quality of Life. with a range of possible subscale scores from 0 to 100, with 100 representing the least burden of symptoms. There are two distinct concepts measured by the SF-36: a physical dimension, represented by the Physical Component Summary (PCS), and a mental dimension, represented by the Mental Component Summary (MCS).</description>
          <population>All available data has been reported.</population>
          <units>SF-36 scores on a points scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="218"/>
                <count group_id="O2" value="190"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SF-36 PCS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.7" spread="10.2"/>
                    <measurement group_id="O2" value="34.6" spread="10.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SF-36 MCS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.3" spread="10.8"/>
                    <measurement group_id="O2" value="48.2" spread="13.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>SF-36 QoL Scores</title>
        <description>The 36-Item Short Form Health Survey questionnaire (SF-36) is a very popular instrument for evaluating Health-Related Quality of Life. with a range of possible subscale scores from 0 to 100, with 100 representing the least burden of symptoms. There are two distinct concepts measured by the SF-36: a physical dimension, represented by the Physical Component Summary (PCS), and a mental dimension, represented by the Mental Component Summary (MCS).</description>
        <time_frame>24 months</time_frame>
        <population>All available data has been reported.</population>
        <group_list>
          <group group_id="O1">
            <title>MitraClip System</title>
            <description>Percutaneous mitral valve repair using MitraClip System
MitraClip System: Percutaneous mitral valve repair using MitraClip System</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Patients with mitral regurgitation managed non-surgically based on standard hospital clinical practice.</description>
          </group>
        </group_list>
        <measure>
          <title>SF-36 QoL Scores</title>
          <description>The 36-Item Short Form Health Survey questionnaire (SF-36) is a very popular instrument for evaluating Health-Related Quality of Life. with a range of possible subscale scores from 0 to 100, with 100 representing the least burden of symptoms. There are two distinct concepts measured by the SF-36: a physical dimension, represented by the Physical Component Summary (PCS), and a mental dimension, represented by the Mental Component Summary (MCS).</description>
          <population>All available data has been reported.</population>
          <units>SF-36 scores on a points scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="174"/>
                <count group_id="O2" value="137"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SF-36 PCS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.7" spread="10.4"/>
                    <measurement group_id="O2" value="33.7" spread="9.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SF-36 MCS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.6" spread="12.1"/>
                    <measurement group_id="O2" value="47.2" spread="12.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change in SF-36 QoL Scores From Baseline</title>
        <description>Paired data looking at difference between the baseline SF-36 and 30 days SF-36. The 36-Item Short Form Health Survey questionnaire (SF-36) is a very popular instrument for evaluating Health-Related Quality of Life. with a range of possible subscale scores from 0 to 100, with 100 representing the least burden of symptoms. There are two distinct concepts measured by the SF-36: a physical dimension, represented by the Physical Component Summary (PCS), and a mental dimension, represented by the Mental Component Summary (MCS).</description>
        <time_frame>Between baseline and 30 days</time_frame>
        <population>All available data has been reported.</population>
        <group_list>
          <group group_id="O1">
            <title>MitraClip System</title>
            <description>Percutaneous mitral valve repair using MitraClip System
MitraClip System: Percutaneous mitral valve repair using MitraClip System</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Patients with mitral regurgitation managed non-surgically based on standard hospital clinical practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in SF-36 QoL Scores From Baseline</title>
          <description>Paired data looking at difference between the baseline SF-36 and 30 days SF-36. The 36-Item Short Form Health Survey questionnaire (SF-36) is a very popular instrument for evaluating Health-Related Quality of Life. with a range of possible subscale scores from 0 to 100, with 100 representing the least burden of symptoms. There are two distinct concepts measured by the SF-36: a physical dimension, represented by the Physical Component Summary (PCS), and a mental dimension, represented by the Mental Component Summary (MCS).</description>
          <population>All available data has been reported.</population>
          <units>SF-36 score on a points scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="276"/>
                <count group_id="O2" value="269"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SF-36 PCS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.0" spread="8.9"/>
                    <measurement group_id="O2" value="0.6" spread="8.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SF_36 MCS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.2" spread="12.2"/>
                    <measurement group_id="O2" value="0.4" spread="12.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change in SF-36 QoL Scores From Baseline</title>
        <description>Paired data looking at difference between the baseline SF-36 and 6 months days SF-36.
The 36-Item Short Form Health Survey questionnaire (SF-36) is a very popular instrument for evaluating Health-Related Quality of Life. with a range of possible subscale scores from 0 to 100, with 100 representing the least burden of symptoms. There are two distinct concepts measured by the SF-36: a physical dimension, represented by the Physical Component Summary (PCS), and a mental dimension, represented by the Mental Component Summary (MCS).</description>
        <time_frame>Between baseline and 6 months</time_frame>
        <population>All available data has been reported.</population>
        <group_list>
          <group group_id="O1">
            <title>MitraClip System</title>
            <description>Percutaneous mitral valve repair using MitraClip System
MitraClip System: Percutaneous mitral valve repair using MitraClip System</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Patients with mitral regurgitation managed non-surgically based on standard hospital clinical practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in SF-36 QoL Scores From Baseline</title>
          <description>Paired data looking at difference between the baseline SF-36 and 6 months days SF-36.
The 36-Item Short Form Health Survey questionnaire (SF-36) is a very popular instrument for evaluating Health-Related Quality of Life. with a range of possible subscale scores from 0 to 100, with 100 representing the least burden of symptoms. There are two distinct concepts measured by the SF-36: a physical dimension, represented by the Physical Component Summary (PCS), and a mental dimension, represented by the Mental Component Summary (MCS).</description>
          <population>All available data has been reported.</population>
          <units>SF-36 score on a points scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="248"/>
                <count group_id="O2" value="234"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SF-36 PCS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.5" spread="10.2"/>
                    <measurement group_id="O2" value="1.0" spread="8.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SF-36 MCS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.6" spread="12.2"/>
                    <measurement group_id="O2" value="1.1" spread="10.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change in SF-36 QoL Scores From Baseline</title>
        <description>Paired data looking at difference between the baseline SF-36 and 12 month SF-36.
The 36-Item Short Form Health Survey questionnaire (SF-36) is a very popular instrument for evaluating Health-Related Quality of Life. with a range of possible subscale scores from 0 to 100, with 100 representing the least burden of symptoms. There are two distinct concepts measured by the SF-36: a physical dimension, represented by the Physical Component Summary (PCS), and a mental dimension, represented by the Mental Component Summary (MCS).</description>
        <time_frame>Between baseline and 12 months</time_frame>
        <population>All available data has been reported.</population>
        <group_list>
          <group group_id="O1">
            <title>MitraClip System</title>
            <description>Percutaneous mitral valve repair using MitraClip System
MitraClip System: Percutaneous mitral valve repair using MitraClip System</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Patients with mitral regurgitation managed non-surgically based on standard hospital clinical practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in SF-36 QoL Scores From Baseline</title>
          <description>Paired data looking at difference between the baseline SF-36 and 12 month SF-36.
The 36-Item Short Form Health Survey questionnaire (SF-36) is a very popular instrument for evaluating Health-Related Quality of Life. with a range of possible subscale scores from 0 to 100, with 100 representing the least burden of symptoms. There are two distinct concepts measured by the SF-36: a physical dimension, represented by the Physical Component Summary (PCS), and a mental dimension, represented by the Mental Component Summary (MCS).</description>
          <population>All available data has been reported.</population>
          <units>SF-36 score on a points scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="215"/>
                <count group_id="O2" value="187"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SF-36 PCS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.0" spread="10.4"/>
                    <measurement group_id="O2" value="0.8" spread="9.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SF-36 MCS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.3" spread="13.2"/>
                    <measurement group_id="O2" value="1.9" spread="13.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change in SF-36 QoL Scores From Baseline</title>
        <description>Paired data looking at difference between the baseline SF-36 and 24 months SF-36.
The 36-Item Short Form Health Survey questionnaire (SF-36) is a very popular instrument for evaluating Health-Related Quality of Life. with a range of possible subscale scores from 0 to 100, with 100 representing the least burden of symptoms. There are two distinct concepts measured by the SF-36: a physical dimension, represented by the Physical Component Summary (PCS), and a mental dimension, represented by the Mental Component Summary (MCS).</description>
        <time_frame>Between baseline and 24 months</time_frame>
        <population>All available data has been reported.</population>
        <group_list>
          <group group_id="O1">
            <title>MitraClip System</title>
            <description>Percutaneous mitral valve repair using MitraClip System
MitraClip System: Percutaneous mitral valve repair using MitraClip System</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Patients with mitral regurgitation managed non-surgically based on standard hospital clinical practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in SF-36 QoL Scores From Baseline</title>
          <description>Paired data looking at difference between the baseline SF-36 and 24 months SF-36.
The 36-Item Short Form Health Survey questionnaire (SF-36) is a very popular instrument for evaluating Health-Related Quality of Life. with a range of possible subscale scores from 0 to 100, with 100 representing the least burden of symptoms. There are two distinct concepts measured by the SF-36: a physical dimension, represented by the Physical Component Summary (PCS), and a mental dimension, represented by the Mental Component Summary (MCS).</description>
          <population>All available data has been reported.</population>
          <units>SF-36 score on a points scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="171"/>
                <count group_id="O2" value="136"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SF-36 PCS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.0" spread="10.4"/>
                    <measurement group_id="O2" value="0.7" spread="10.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SF-36 MCS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.8" spread="14.2"/>
                    <measurement group_id="O2" value="-0.3" spread="12.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Mitral Valve Surgery (Including Type of Surgery), New Use of CRT, New Use of Single or Dual Chamber Pacemaker, Permanent LVAD Implant, Heart Transplant, Additional MitraClip Device Intervention in Device Group</title>
        <time_frame>Through 5 years</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>De Novo MitraClip Device Intervention in Control Group</title>
        <time_frame>Through 5 years</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Responder Analysis for 6MWD</title>
        <description>Where responder is defined as alive and experiencing an improvement of 24 meters and 50 meters (difference in proportion of responders between Device and Control groups)</description>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>MitraClip System</title>
            <description>Percutaneous mitral valve repair using MitraClip System
MitraClip System: Percutaneous mitral valve repair using MitraClip System</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Patients with mitral regurgitation managed non-surgically based on standard hospital clinical practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Responder Analysis for 6MWD</title>
          <description>Where responder is defined as alive and experiencing an improvement of 24 meters and 50 meters (difference in proportion of responders between Device and Control groups)</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="191"/>
                <count group_id="O2" value="166"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Experiencing Improvement &gt;= 24 meters</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                    <measurement group_id="O2" value="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Experiencing Improvement &gt;= 50 meters</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75"/>
                    <measurement group_id="O2" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Responder Analysis for 6MWD</title>
        <description>Where responder is defined as alive and experiencing an improvement of 24 meters and 50 meters (difference in proportion of responders between Device and Control groups)</description>
        <time_frame>24 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>MitraClip System</title>
            <description>Percutaneous mitral valve repair using MitraClip System
MitraClip System: Percutaneous mitral valve repair using MitraClip System</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Patients with mitral regurgitation managed non-surgically based on standard hospital clinical practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Responder Analysis for 6MWD</title>
          <description>Where responder is defined as alive and experiencing an improvement of 24 meters and 50 meters (difference in proportion of responders between Device and Control groups)</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="106"/>
                <count group_id="O2" value="72"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Experiencing Improvement &gt;= 24 meters</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44"/>
                    <measurement group_id="O2" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Experiencing Improvement &gt;= 50 meters</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34"/>
                    <measurement group_id="O2" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Responder Analysis for LVEDV Index</title>
        <description>Where responder is defined as alive and experiencing an improvement of 12 ml/m2 (difference in proportion of responders between Device and Control groups)</description>
        <time_frame>12 months</time_frame>
        <population>All available echocardiogram data has been reported.</population>
        <group_list>
          <group group_id="O1">
            <title>MitraClip System</title>
            <description>Percutaneous mitral valve repair using MitraClip System
MitraClip System: Percutaneous mitral valve repair using MitraClip System</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Patients with mitral regurgitation managed non-surgically based on standard hospital clinical practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Responder Analysis for LVEDV Index</title>
          <description>Where responder is defined as alive and experiencing an improvement of 12 ml/m2 (difference in proportion of responders between Device and Control groups)</description>
          <population>All available echocardiogram data has been reported.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="160"/>
                <count group_id="O2" value="130"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35"/>
                    <measurement group_id="O2" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Responder Analysis for LVEDV Index</title>
        <description>Where responder is defined as alive and experiencing an improvement of 12 ml/m2 (difference in proportion of responders between Device and Control groups)</description>
        <time_frame>24 months</time_frame>
        <population>All available echocardiogram data has been reported.</population>
        <group_list>
          <group group_id="O1">
            <title>MitraClip System</title>
            <description>Percutaneous mitral valve repair using MitraClip System
MitraClip System: Percutaneous mitral valve repair using MitraClip System</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Patients with mitral regurgitation managed non-surgically based on standard hospital clinical practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Responder Analysis for LVEDV Index</title>
          <description>Where responder is defined as alive and experiencing an improvement of 12 ml/m2 (difference in proportion of responders between Device and Control groups)</description>
          <population>All available echocardiogram data has been reported.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="74"/>
                <count group_id="O2" value="53"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Responder Analysis for LVEDV Index</title>
        <description>Where responder is defined as alive and experiencing an improvement of 12 ml/m2 (difference in proportion of responders between Device and Control groups)</description>
        <time_frame>3 years</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Responder Analysis for LVEDV Index</title>
        <description>Where responder is defined as alive and experiencing an improvement of 12 ml/m2 (difference in proportion of responders between Device and Control groups)</description>
        <time_frame>4 years</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Responder Analysis for LVEDV Index</title>
        <description>Where responder is defined as alive and experiencing an improvement of 12 ml/m2 (difference in proportion of responders between Device and Control groups)</description>
        <time_frame>5 years</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Responder Analysis for QoL (KCCQ)</title>
        <description>Where responder is defined as alive and experiencing an improvement of 5 points (difference in proportion of responders between Device and Control groups)</description>
        <time_frame>12 months</time_frame>
        <population>All available data has been reported.</population>
        <group_list>
          <group group_id="O1">
            <title>MitraClip System</title>
            <description>Percutaneous mitral valve repair using MitraClip System
MitraClip System: Percutaneous mitral valve repair using MitraClip System</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Patients with mitral regurgitation managed non-surgically based on standard hospital clinical practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Responder Analysis for QoL (KCCQ)</title>
          <description>Where responder is defined as alive and experiencing an improvement of 5 points (difference in proportion of responders between Device and Control groups)</description>
          <population>All available data has been reported.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="219"/>
                <count group_id="O2" value="188"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="151"/>
                    <measurement group_id="O2" value="103"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Responder Analysis for QoL (KCCQ)</title>
        <description>Where responder is defined as alive and experiencing an improvement of 5 points (difference in proportion of responders between Device and Control groups)</description>
        <time_frame>24 months</time_frame>
        <population>All available data has been reported.</population>
        <group_list>
          <group group_id="O1">
            <title>MitraClip System</title>
            <description>Percutaneous mitral valve repair using MitraClip System
MitraClip System: Percutaneous mitral valve repair using MitraClip System</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Patients with mitral regurgitation managed non-surgically based on standard hospital clinical practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Responder Analysis for QoL (KCCQ)</title>
          <description>Where responder is defined as alive and experiencing an improvement of 5 points (difference in proportion of responders between Device and Control groups)</description>
          <population>All available data has been reported.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="128"/>
                <count group_id="O2" value="90"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88"/>
                    <measurement group_id="O2" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Each Subscale for QoL (KCCQ)</title>
        <description>difference in means between Device and Control groups for the Kansas City Cardiomyopathy Questionnaire (KCCQ) for the physical limitation and symptom stability scores.</description>
        <time_frame>12 months</time_frame>
        <population>219 subjects from device group and 189 subjects from control group analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Randomized Group</title>
            <description>Randomized group contains both Device and Control Group</description>
          </group>
        </group_list>
        <measure>
          <title>Each Subscale for QoL (KCCQ)</title>
          <description>difference in means between Device and Control groups for the Kansas City Cardiomyopathy Questionnaire (KCCQ) for the physical limitation and symptom stability scores.</description>
          <population>219 subjects from device group and 189 subjects from control group analyzed.</population>
          <units>KCCQ score on a points scale</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="408"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.90" lower_limit="5.51" upper_limit="14.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Each Subscale for QoL (KCCQ)</title>
        <description>difference in means between Device and Control groups for the Kansas City Cardiomyopathy Questionnaire (KCCQ) for the physical limitation and symptom stability scores.</description>
        <time_frame>24 months</time_frame>
        <population>128 subjects in the device group and 90 subjects in the control group were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Randomized Group</title>
            <description>Randomized group contains both Device and Control Group</description>
          </group>
        </group_list>
        <measure>
          <title>Each Subscale for QoL (KCCQ)</title>
          <description>difference in means between Device and Control groups for the Kansas City Cardiomyopathy Questionnaire (KCCQ) for the physical limitation and symptom stability scores.</description>
          <population>128 subjects in the device group and 90 subjects in the control group were analyzed.</population>
          <units>KCCQ score on a points scale</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="218"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.01" lower_limit="1.68" upper_limit="14.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Length of Index Hospitalization for MitraClip Procedure (Device Group)</title>
        <description>Length of stay in the hospital for the MitraClip Index procedure (device group)</description>
        <time_frame>Before MitraClip procedure on day 0</time_frame>
        <population>Data was available for 293 subjects out of 302 subjects in the device group.</population>
        <group_list>
          <group group_id="O1">
            <title>MitraClip System</title>
            <description>Percutaneous mitral valve repair using MitraClip System
MitraClip System: Percutaneous mitral valve repair using MitraClip System</description>
          </group>
        </group_list>
        <measure>
          <title>Length of Index Hospitalization for MitraClip Procedure (Device Group)</title>
          <description>Length of stay in the hospital for the MitraClip Index procedure (device group)</description>
          <population>Data was available for 293 subjects out of 302 subjects in the device group.</population>
          <units>Days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="293"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.5" spread="2.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Hospitalizations and Reason for Hospitalization (i.e. Heart Failure, Cardiovascular, Non-cardiovascular)</title>
        <description>in each of the Device and Control groups</description>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>MitraClip System</title>
            <description>Percutaneous mitral valve repair using MitraClip System
MitraClip System: Percutaneous mitral valve repair using MitraClip System</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Patients with mitral regurgitation managed non-surgically based on standard hospital clinical practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Hospitalizations and Reason for Hospitalization (i.e. Heart Failure, Cardiovascular, Non-cardiovascular)</title>
          <description>in each of the Device and Control groups</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="302"/>
                <count group_id="O2" value="312"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Heart Failure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70"/>
                    <measurement group_id="O2" value="118"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cardiovascular</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52"/>
                    <measurement group_id="O2" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-Cardiovascular</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95"/>
                    <measurement group_id="O2" value="97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Hospitalizations and Reason for Hospitalization (i.e. Heart Failure, Cardiovascular, Non-cardiovascular)</title>
        <description>in each of the Device and Control groups</description>
        <time_frame>24 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>MitraClip System</title>
            <description>Percutaneous mitral valve repair using MitraClip System
MitraClip System: Percutaneous mitral valve repair using MitraClip System</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Patients with mitral regurgitation managed non-surgically based on standard hospital clinical practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Hospitalizations and Reason for Hospitalization (i.e. Heart Failure, Cardiovascular, Non-cardiovascular)</title>
          <description>in each of the Device and Control groups</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="302"/>
                <count group_id="O2" value="312"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Heart Failure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92"/>
                    <measurement group_id="O2" value="151"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cardiovascular</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72"/>
                    <measurement group_id="O2" value="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-Cardiovascular</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="124"/>
                    <measurement group_id="O2" value="128"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Days Alive and Out of Hospital</title>
        <description>difference in mean between Device and Control groups</description>
        <time_frame>From the time of randomization to 12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Randomized Group</title>
            <description>Randomized group contains both Device and Control Group</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Days Alive and Out of Hospital</title>
          <description>difference in mean between Device and Control groups</description>
          <units>Number of days</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="614"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.8" lower_limit="-3.5" upper_limit="27.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Days Alive and Out of Hospital</title>
        <description>difference in means between Device and Control groups</description>
        <time_frame>From the time of randomization to 24 months</time_frame>
        <population>226 subjects from the device group and 226 subjects from the control group.</population>
        <group_list>
          <group group_id="O1">
            <title>Randomized Group</title>
            <description>Randomized group contains both Device and Control Group</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Days Alive and Out of Hospital</title>
          <description>difference in means between Device and Control groups</description>
          <population>226 subjects from the device group and 226 subjects from the control group.</population>
          <units>Number of Days</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="452"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.5" lower_limit="21.9" upper_limit="111.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Days Alive and Out of Hospital</title>
        <description>difference in medians between Device and Control groups</description>
        <time_frame>From the time of randomization to 3 Years</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Days Alive and Out of Hospital</title>
        <description>difference in medians between Device and Control groups</description>
        <time_frame>From the time of randomization to 4 Years</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Days Alive and Out of Hospital</title>
        <description>difference in medians between Device and Control groups</description>
        <time_frame>From the time of randomization to 5 Years</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Days Hospitalized From the &quot;Treatment&quot; Visit</title>
        <description>difference in means between Device and Control groups</description>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Randomized Group</title>
            <description>Randomized group contains both Device and Control Group</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Days Hospitalized From the &quot;Treatment&quot; Visit</title>
          <description>difference in means between Device and Control groups</description>
          <units>Number of Days</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="614"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.4" lower_limit="-2.9" upper_limit="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Days Hospitalized From the &quot;Treatment&quot; Visit</title>
        <description>difference in means between Device and Control groups</description>
        <time_frame>24 months</time_frame>
        <population>226 subjects in the device group and 226 subjects in the control group.</population>
        <group_list>
          <group group_id="O1">
            <title>Randomized Group</title>
            <description>Randomized group contains both Device and Control Group</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Days Hospitalized From the &quot;Treatment&quot; Visit</title>
          <description>difference in means between Device and Control groups</description>
          <population>226 subjects in the device group and 226 subjects in the control group.</population>
          <units>Number of Days</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="452"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.5" lower_limit="-5.4" upper_limit="2.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Days Hospitalized From the &quot;Treatment&quot; Visit</title>
        <description>difference in medians between Device and Control groups</description>
        <time_frame>3 Years</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Days Hospitalized From the &quot;Treatment&quot; Visit</title>
        <description>difference in medians between Device and Control groups</description>
        <time_frame>4 Years</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Days Hospitalized From the &quot;Treatment&quot; Visit</title>
        <description>difference in medians between Device and Control groups</description>
        <time_frame>5 Years</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Proportion of Alive Time in Hospital</title>
        <description>summarized and compared between Device and Control groups</description>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>MitraClip System</title>
            <description>Percutaneous mitral valve repair using MitraClip System
MitraClip System: Percutaneous mitral valve repair using MitraClip System</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Patients with mitral regurgitation managed non-surgically based on standard hospital clinical practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Alive Time in Hospital</title>
          <description>summarized and compared between Device and Control groups</description>
          <units>Number of Days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="302"/>
                <count group_id="O2" value="312"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.05" spread="0.10"/>
                    <measurement group_id="O2" value="0.04" spread="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Proportion of Alive Time in Hospital</title>
        <description>summarized and compared between Device and Control groups</description>
        <time_frame>24 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>MitraClip System</title>
            <description>Percutaneous mitral valve repair using MitraClip System
MitraClip System: Percutaneous mitral valve repair using MitraClip System</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Patients with mitral regurgitation managed non-surgically based on standard hospital clinical practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Alive Time in Hospital</title>
          <description>summarized and compared between Device and Control groups</description>
          <units>Number of Days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="226"/>
                <count group_id="O2" value="226"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.05" spread="0.10"/>
                    <measurement group_id="O2" value="0.05" spread="0.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Proportion of Alive Time in Hospital</title>
        <description>summarized and compared between Device and Control groups</description>
        <time_frame>3 years</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Proportion of Alive Time in Hospital</title>
        <description>summarized and compared between Device and Control groups</description>
        <time_frame>4 years</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Proportion of Alive Time in Hospital</title>
        <description>summarized and compared between Device and Control groups</description>
        <time_frame>5 years</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Proportion of Subjects Living in the Baseline Location</title>
        <description>Subjects living in the baseline location include : home, retirement home, nursing facility and other location.</description>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>MitraClip System</title>
            <description>Percutaneous mitral valve repair using MitraClip System
MitraClip System: Percutaneous mitral valve repair using MitraClip System</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Patients with mitral regurgitation managed non-surgically based on standard hospital clinical practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Subjects Living in the Baseline Location</title>
          <description>Subjects living in the baseline location include : home, retirement home, nursing facility and other location.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="223"/>
                <count group_id="O2" value="206"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="217"/>
                    <measurement group_id="O2" value="198"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Proportion of Subjects Living in the Baseline Location</title>
        <description>Subjects living in the baseline location include : home, retirement home, nursing facility and other location.</description>
        <time_frame>24 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>MitraClip System</title>
            <description>Percutaneous mitral valve repair using MitraClip System
MitraClip System: Percutaneous mitral valve repair using MitraClip System</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Patients with mitral regurgitation managed non-surgically based on standard hospital clinical practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Subjects Living in the Baseline Location</title>
          <description>Subjects living in the baseline location include : home, retirement home, nursing facility and other location.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="132"/>
                <count group_id="O2" value="93"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="130"/>
                    <measurement group_id="O2" value="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Proportion of Subjects Living in the Baseline Location</title>
        <time_frame>3 years</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Proportion of Subjects Living in the Baseline Location</title>
        <time_frame>4 years</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Proportion of Subjects Living in the Baseline Location</title>
        <time_frame>5 years</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Mitral Valve Replacement Rates</title>
        <description>Subjects with mitral valve replacements in the Device and Control groups</description>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>MitraClip System</title>
            <description>Percutaneous mitral valve repair using MitraClip System
MitraClip System: Percutaneous mitral valve repair using MitraClip System</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Patients with mitral regurgitation managed non-surgically based on standard hospital clinical practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Mitral Valve Replacement Rates</title>
          <description>Subjects with mitral valve replacements in the Device and Control groups</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="302"/>
                <count group_id="O2" value="312"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Mitral Valve Replacement Rates</title>
        <description>Subjects with mitral valve replacements in the Device and Control groups</description>
        <time_frame>24 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>MitraClip System</title>
            <description>Percutaneous mitral valve repair using MitraClip System
MitraClip System: Percutaneous mitral valve repair using MitraClip System</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Patients with mitral regurgitation managed non-surgically based on standard hospital clinical practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Mitral Valve Replacement Rates</title>
          <description>Subjects with mitral valve replacements in the Device and Control groups</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="302"/>
                <count group_id="O2" value="312"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Mitral Valve Replacement Rates</title>
        <description>summarized and compared between Device and Control groups</description>
        <time_frame>3 years</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Mitral Valve Replacement Rates</title>
        <description>summarized and compared between Device and Control groups</description>
        <time_frame>4 years</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Mitral Valve Replacement Rates</title>
        <description>summarized and compared between Device and Control groups</description>
        <time_frame>5 years</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>New Onset of Permanent Atrial Fibrillation</title>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>MitraClip System</title>
            <description>Percutaneous mitral valve repair using MitraClip System
MitraClip System: Percutaneous mitral valve repair using MitraClip System</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Patients with mitral regurgitation managed non-surgically based on standard hospital clinical practice.</description>
          </group>
        </group_list>
        <measure>
          <title>New Onset of Permanent Atrial Fibrillation</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="302"/>
                <count group_id="O2" value="312"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>New Onset of Permanent Atrial Fibrillation</title>
        <time_frame>24 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>MitraClip System</title>
            <description>Percutaneous mitral valve repair using MitraClip System
MitraClip System: Percutaneous mitral valve repair using MitraClip System</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Patients with mitral regurgitation managed non-surgically based on standard hospital clinical practice.</description>
          </group>
        </group_list>
        <measure>
          <title>New Onset of Permanent Atrial Fibrillation</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="302"/>
                <count group_id="O2" value="312"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>New Onset of Permanent Atrial Fibrillation</title>
        <time_frame>3 years</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>New Onset of Permanent Atrial Fibrillation</title>
        <time_frame>4 years</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>New Onset of Permanent Atrial Fibrillation</title>
        <time_frame>5 years</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Mitral Stenosis</title>
        <description>Defined as a mitral valve orifice area of less than 1.5 cm2 as measured by the Echocardiography Core Laboratory</description>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>MitraClip System</title>
            <description>Percutaneous mitral valve repair using MitraClip System
MitraClip System: Percutaneous mitral valve repair using MitraClip System</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Patients with mitral regurgitation managed non-surgically based on standard hospital clinical practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Mitral Stenosis</title>
          <description>Defined as a mitral valve orifice area of less than 1.5 cm2 as measured by the Echocardiography Core Laboratory</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="302"/>
                <count group_id="O2" value="312"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Mitral Stenosis</title>
        <description>Defined as a mitral valve orifice area of less than 1.5 cm2 as measured by the Echocardiography Core Laboratory</description>
        <time_frame>24 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>MitraClip System</title>
            <description>Percutaneous mitral valve repair using MitraClip System
MitraClip System: Percutaneous mitral valve repair using MitraClip System</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Patients with mitral regurgitation managed non-surgically based on standard hospital clinical practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Mitral Stenosis</title>
          <description>Defined as a mitral valve orifice area of less than 1.5 cm2 as measured by the Echocardiography Core Laboratory</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="302"/>
                <count group_id="O2" value="312"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Mitral Stenosis</title>
        <description>Defined as a mitral valve orifice area of less than 1.5 cm2 as measured by the Echocardiography Core Laboratory</description>
        <time_frame>3 years</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Mitral Stenosis</title>
        <description>Defined as a mitral valve orifice area of less than 1.5 cm2 as measured by the Echocardiography Core Laboratory</description>
        <time_frame>4 years</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Mitral Stenosis</title>
        <description>Defined as a mitral valve orifice area of less than 1.5 cm2 as measured by the Echocardiography Core Laboratory</description>
        <time_frame>5 years</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Clinically Significant Atrial Septal Defect (ASD) That Requires Intervention</title>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>MitraClip System</title>
            <description>Percutaneous mitral valve repair using MitraClip System
MitraClip System: Percutaneous mitral valve repair using MitraClip System</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Patients with mitral regurgitation managed non-surgically based on standard hospital clinical practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Clinically Significant Atrial Septal Defect (ASD) That Requires Intervention</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="302"/>
                <count group_id="O2" value="312"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Clinically Significant Atrial Septal Defect (ASD) That Requires Intervention</title>
        <time_frame>24 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>MitraClip System</title>
            <description>Percutaneous mitral valve repair using MitraClip System
MitraClip System: Percutaneous mitral valve repair using MitraClip System</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Patients with mitral regurgitation managed non-surgically based on standard hospital clinical practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Clinically Significant Atrial Septal Defect (ASD) That Requires Intervention</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="302"/>
                <count group_id="O2" value="312"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Clinically Significant Atrial Septal Defect (ASD) That Requires Intervention</title>
        <time_frame>3 years</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Clinically Significant Atrial Septal Defect (ASD) That Requires Intervention</title>
        <time_frame>4 years</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Clinically Significant Atrial Septal Defect (ASD) That Requires Intervention</title>
        <time_frame>5 years</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Device-related Complications in Device Group Subjects and Control Group Subjects Who Undergo the MitraClip Procedure</title>
        <time_frame>Through 5 years</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Brain Natriuretic Peptide (BNP) or N-terminal Prohormone of Brain Natriuretic Peptide (NT-proBNP Levels)</title>
        <time_frame>Baseline</time_frame>
        <population>All available data has been reported.</population>
        <group_list>
          <group group_id="O1">
            <title>MitraClip System</title>
            <description>Percutaneous mitral valve repair using MitraClip System
MitraClip System: Percutaneous mitral valve repair using MitraClip System</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Patients with mitral regurgitation managed non-surgically based on standard hospital clinical practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Brain Natriuretic Peptide (BNP) or N-terminal Prohormone of Brain Natriuretic Peptide (NT-proBNP Levels)</title>
          <population>All available data has been reported.</population>
          <units>pg/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="302"/>
                <count group_id="O2" value="312"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>BNP</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="208"/>
                    <count group_id="O2" value="209"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1014.77" spread="1085.98"/>
                    <measurement group_id="O2" value="1017.13" spread="1212.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NT-proBNP</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="74"/>
                    <count group_id="O2" value="85"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5174.33" spread="6566.61"/>
                    <measurement group_id="O2" value="5943.86" spread="8437.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>BNP or NT-proBNP Levels</title>
        <time_frame>30 days</time_frame>
        <population>All available data has been reported.</population>
        <group_list>
          <group group_id="O1">
            <title>MitraClip System</title>
            <description>Percutaneous mitral valve repair using MitraClip System
MitraClip System: Percutaneous mitral valve repair using MitraClip System</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Patients with mitral regurgitation managed non-surgically based on standard hospital clinical practice.</description>
          </group>
        </group_list>
        <measure>
          <title>BNP or NT-proBNP Levels</title>
          <population>All available data has been reported.</population>
          <units>pg/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="302"/>
                <count group_id="O2" value="312"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>BNP</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="193"/>
                    <count group_id="O2" value="188"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="875.91" spread="931.18"/>
                    <measurement group_id="O2" value="1065.55" spread="1206.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NT-proBNP</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="74"/>
                    <count group_id="O2" value="77"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4907.58" spread="7483.72"/>
                    <measurement group_id="O2" value="5244.16" spread="7851.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>BNP or NT-proBNP Levels</title>
        <time_frame>12 months</time_frame>
        <population>All available data has been reported.</population>
        <group_list>
          <group group_id="O1">
            <title>MitraClip System</title>
            <description>Percutaneous mitral valve repair using MitraClip System
MitraClip System: Percutaneous mitral valve repair using MitraClip System</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Patients with mitral regurgitation managed non-surgically based on standard hospital clinical practice.</description>
          </group>
        </group_list>
        <measure>
          <title>BNP or NT-proBNP Levels</title>
          <population>All available data has been reported.</population>
          <units>pg/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="302"/>
                <count group_id="O2" value="312"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>BNP</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="146"/>
                    <count group_id="O2" value="122"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="621.45" spread="606.99"/>
                    <measurement group_id="O2" value="808.26" spread="1711.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NT-proBNP</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="63"/>
                    <count group_id="O2" value="61"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3362.49" spread="4332.12"/>
                    <measurement group_id="O2" value="3977.80" spread="5689.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Modified Rankin Scale Score</title>
        <description>MODIFIED RANKIN SCALE SCORE DESCRIPTIONS:
0- No symptoms at all; 1- No significant disability despite symptoms; able to carry out all usual duties and activities; 2- Slight disability; unable to carry out all previous activities, but able to look after own affairs without assistance; 3- Moderate disability; requiring some help, but able to walk without assistance; 4- Moderately severe disability; unable to walk without assistance and unable to attend to own bodily needs without assistance; 5- Severe disability; bedridden, incontinent and requiring constant nursing care and attention; 6- Dead</description>
        <time_frame>Baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>MitraClip System</title>
            <description>Percutaneous mitral valve repair using MitraClip System
MitraClip System: Percutaneous mitral valve repair using MitraClip System</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Patients with mitral regurgitation managed non-surgically based on standard hospital clinical practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Modified Rankin Scale Score</title>
          <description>MODIFIED RANKIN SCALE SCORE DESCRIPTIONS:
0- No symptoms at all; 1- No significant disability despite symptoms; able to carry out all usual duties and activities; 2- Slight disability; unable to carry out all previous activities, but able to look after own affairs without assistance; 3- Moderate disability; requiring some help, but able to walk without assistance; 4- Moderately severe disability; unable to walk without assistance and unable to attend to own bodily needs without assistance; 5- Severe disability; bedridden, incontinent and requiring constant nursing care and attention; 6- Dead</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="302"/>
                <count group_id="O2" value="308"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>0</title>
                  <measurement_list>
                    <measurement group_id="O1" value="170"/>
                    <measurement group_id="O2" value="158"/>
                  </measurement_list>
                </category>
                <category>
                  <title>1</title>
                  <measurement_list>
                    <measurement group_id="O1" value="52"/>
                    <measurement group_id="O2" value="55"/>
                  </measurement_list>
                </category>
                <category>
                  <title>2</title>
                  <measurement_list>
                    <measurement group_id="O1" value="55"/>
                    <measurement group_id="O2" value="58"/>
                  </measurement_list>
                </category>
                <category>
                  <title>3</title>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="35"/>
                  </measurement_list>
                </category>
                <category>
                  <title>4</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>5</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Modified Rankin Scale Score</title>
        <description>MODIFIED RANKIN SCALE SCORE DESCRIPTIONS:
0- No symptoms at all; 1- No significant disability despite symptoms; able to carry out all usual duties and activities; 2- Slight disability; unable to carry out all previous activities, but able to look after own affairs without assistance; 3- Moderate disability; requiring some help, but able to walk without assistance; 4- Moderately severe disability; unable to walk without assistance and unable to attend to own bodily needs without assistance; 5- Severe disability; bedridden, incontinent and requiring constant nursing care and attention; 6- Dead</description>
        <time_frame>30 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>MitraClip System</title>
            <description>Percutaneous mitral valve repair using MitraClip System
MitraClip System: Percutaneous mitral valve repair using MitraClip System</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Patients with mitral regurgitation managed non-surgically based on standard hospital clinical practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Modified Rankin Scale Score</title>
          <description>MODIFIED RANKIN SCALE SCORE DESCRIPTIONS:
0- No symptoms at all; 1- No significant disability despite symptoms; able to carry out all usual duties and activities; 2- Slight disability; unable to carry out all previous activities, but able to look after own affairs without assistance; 3- Moderate disability; requiring some help, but able to walk without assistance; 4- Moderately severe disability; unable to walk without assistance and unable to attend to own bodily needs without assistance; 5- Severe disability; bedridden, incontinent and requiring constant nursing care and attention; 6- Dead</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="278"/>
                <count group_id="O2" value="276"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>0</title>
                  <measurement_list>
                    <measurement group_id="O1" value="169"/>
                    <measurement group_id="O2" value="129"/>
                  </measurement_list>
                </category>
                <category>
                  <title>1</title>
                  <measurement_list>
                    <measurement group_id="O1" value="56"/>
                    <measurement group_id="O2" value="54"/>
                  </measurement_list>
                </category>
                <category>
                  <title>2</title>
                  <measurement_list>
                    <measurement group_id="O1" value="40"/>
                    <measurement group_id="O2" value="49"/>
                  </measurement_list>
                </category>
                <category>
                  <title>3</title>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="34"/>
                  </measurement_list>
                </category>
                <category>
                  <title>4</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>5</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Modified Rankin Scale Score</title>
        <description>MODIFIED RANKIN SCALE SCORE DESCRIPTIONS:
0- No symptoms at all; 1- No significant disability despite symptoms; able to carry out all usual duties and activities; 2- Slight disability; unable to carry out all previous activities, but able to look after own affairs without assistance; 3- Moderate disability; requiring some help, but able to walk without assistance; 4- Moderately severe disability; unable to walk without assistance and unable to attend to own bodily needs without assistance; 5- Severe disability; bedridden, incontinent and requiring constant nursing care and attention; 6- Dead</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>MitraClip System</title>
            <description>Percutaneous mitral valve repair using MitraClip System
MitraClip System: Percutaneous mitral valve repair using MitraClip System</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Patients with mitral regurgitation managed non-surgically based on standard hospital clinical practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Modified Rankin Scale Score</title>
          <description>MODIFIED RANKIN SCALE SCORE DESCRIPTIONS:
0- No symptoms at all; 1- No significant disability despite symptoms; able to carry out all usual duties and activities; 2- Slight disability; unable to carry out all previous activities, but able to look after own affairs without assistance; 3- Moderate disability; requiring some help, but able to walk without assistance; 4- Moderately severe disability; unable to walk without assistance and unable to attend to own bodily needs without assistance; 5- Severe disability; bedridden, incontinent and requiring constant nursing care and attention; 6- Dead</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="250"/>
                <count group_id="O2" value="234"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>0</title>
                  <measurement_list>
                    <measurement group_id="O1" value="145"/>
                    <measurement group_id="O2" value="120"/>
                  </measurement_list>
                </category>
                <category>
                  <title>1</title>
                  <measurement_list>
                    <measurement group_id="O1" value="60"/>
                    <measurement group_id="O2" value="48"/>
                  </measurement_list>
                </category>
                <category>
                  <title>2</title>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                    <measurement group_id="O2" value="38"/>
                  </measurement_list>
                </category>
                <category>
                  <title>3</title>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>4</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>5</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Modified Rankin Scale Score</title>
        <description>MODIFIED RANKIN SCALE SCORE DESCRIPTIONS:
0- No symptoms at all; 1- No significant disability despite symptoms; able to carry out all usual duties and activities; 2- Slight disability; unable to carry out all previous activities, but able to look after own affairs without assistance; 3- Moderate disability; requiring some help, but able to walk without assistance; 4- Moderately severe disability; unable to walk without assistance and unable to attend to own bodily needs without assistance; 5- Severe disability; bedridden, incontinent and requiring constant nursing care and attention; 6- Dead</description>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>MitraClip System</title>
            <description>Percutaneous mitral valve repair using MitraClip System
MitraClip System: Percutaneous mitral valve repair using MitraClip System</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Patients with mitral regurgitation managed non-surgically based on standard hospital clinical practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Modified Rankin Scale Score</title>
          <description>MODIFIED RANKIN SCALE SCORE DESCRIPTIONS:
0- No symptoms at all; 1- No significant disability despite symptoms; able to carry out all usual duties and activities; 2- Slight disability; unable to carry out all previous activities, but able to look after own affairs without assistance; 3- Moderate disability; requiring some help, but able to walk without assistance; 4- Moderately severe disability; unable to walk without assistance and unable to attend to own bodily needs without assistance; 5- Severe disability; bedridden, incontinent and requiring constant nursing care and attention; 6- Dead</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="219"/>
                <count group_id="O2" value="189"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>0</title>
                  <measurement_list>
                    <measurement group_id="O1" value="134"/>
                    <measurement group_id="O2" value="100"/>
                  </measurement_list>
                </category>
                <category>
                  <title>1</title>
                  <measurement_list>
                    <measurement group_id="O1" value="42"/>
                    <measurement group_id="O2" value="40"/>
                  </measurement_list>
                </category>
                <category>
                  <title>2</title>
                  <measurement_list>
                    <measurement group_id="O1" value="34"/>
                    <measurement group_id="O2" value="27"/>
                  </measurement_list>
                </category>
                <category>
                  <title>3</title>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>4</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>5</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Major Bleeding</title>
        <description>Major bleeding is defined as bleeding ≥ Type 3 based on a modified Bleeding Academic Research Consortium (BARC) definition</description>
        <time_frame>30 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>MitraClip System</title>
            <description>Percutaneous mitral valve repair using MitraClip System
MitraClip System: Percutaneous mitral valve repair using MitraClip System</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Patients with mitral regurgitation managed non-surgically based on standard hospital clinical practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Major Bleeding</title>
          <description>Major bleeding is defined as bleeding ≥ Type 3 based on a modified Bleeding Academic Research Consortium (BARC) definition</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="302"/>
                <count group_id="O2" value="312"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Prolonged Ventilation</title>
        <description>Defined as pulmonary insufficiency requiring ventilatory support for greater than 48 hours post-catheterization</description>
        <time_frame>30 days</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Average Dosages of Guideline Directed Medical Therapy (GDMT)</title>
        <time_frame>Baseline</time_frame>
        <population>All available data has been reported and includes subjects on the drugs mentioned below. Not all subjects were on all the drugs.</population>
        <group_list>
          <group group_id="O1">
            <title>MitraClip System</title>
            <description>Percutaneous mitral valve repair using MitraClip System
MitraClip System: Percutaneous mitral valve repair using MitraClip System</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Patients with mitral regurgitation managed non-surgically based on standard hospital clinical practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Average Dosages of Guideline Directed Medical Therapy (GDMT)</title>
          <population>All available data has been reported and includes subjects on the drugs mentioned below. Not all subjects were on all the drugs.</population>
          <units>mg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="302"/>
                <count group_id="O2" value="312"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ACE Inhibitors</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="138"/>
                    <count group_id="O2" value="115"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.18" spread="15.19"/>
                    <measurement group_id="O2" value="13.44" spread="13.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Angiotensin-Receptor Blockers (ARB)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="66"/>
                    <count group_id="O2" value="71"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.21" spread="9.37"/>
                    <measurement group_id="O2" value="12.35" spread="8.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Aldosterone Antagonists</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="153"/>
                    <count group_id="O2" value="154"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.51" spread="11.62"/>
                    <measurement group_id="O2" value="28.96" spread="34.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Beta Blockers</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="275"/>
                    <count group_id="O2" value="278"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.91" spread="24.90"/>
                    <measurement group_id="O2" value="29.92" spread="25.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vasodilators (Nitrate)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="25"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.61" spread="43.81"/>
                    <measurement group_id="O2" value="42.80" spread="26.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vasodilators (Hydralazine)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="50"/>
                    <count group_id="O2" value="55"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="139.85" spread="108.46"/>
                    <measurement group_id="O2" value="109.27" spread="86.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ARN Inhibitors</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.64" spread="9.31"/>
                    <measurement group_id="O2" value="9.65" spread="6.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Average Dosages of GDMT</title>
        <time_frame>30 days</time_frame>
        <population>All available data has been reported and includes subjects on the drugs mentioned below. Not all subjects were on all the drugs.</population>
        <group_list>
          <group group_id="O1">
            <title>MitraClip System</title>
            <description>Percutaneous mitral valve repair using MitraClip System
MitraClip System: Percutaneous mitral valve repair using MitraClip System</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Patients with mitral regurgitation managed non-surgically based on standard hospital clinical practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Average Dosages of GDMT</title>
          <population>All available data has been reported and includes subjects on the drugs mentioned below. Not all subjects were on all the drugs.</population>
          <units>mg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="302"/>
                <count group_id="O2" value="312"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ACE Inhibitors</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="138"/>
                    <count group_id="O2" value="115"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.61" spread="15.01"/>
                    <measurement group_id="O2" value="13.53" spread="13.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Angiotensin Receptor Blockers (ARBs)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="65"/>
                    <count group_id="O2" value="75"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.68" spread="9.34"/>
                    <measurement group_id="O2" value="11.89" spread="8.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Aldosterone Antagonists</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="154"/>
                    <count group_id="O2" value="154"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.21" spread="11.56"/>
                    <measurement group_id="O2" value="29.48" spread="34.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Beta Blockers</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="278"/>
                    <count group_id="O2" value="281"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.12" spread="24.81"/>
                    <measurement group_id="O2" value="29.25" spread="25.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vasodilators (Nitrate)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="29"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.38" spread="42.76"/>
                    <measurement group_id="O2" value="43.79" spread="27.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vasodilators (Hydralazine)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="51"/>
                    <count group_id="O2" value="57"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="133.41" spread="108.29"/>
                    <measurement group_id="O2" value="110.53" spread="87.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ARN Inhibitors</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.17" spread="11.15"/>
                    <measurement group_id="O2" value="8.85" spread="5.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Average Dosages of GDMT</title>
        <time_frame>6 months</time_frame>
        <population>All available data has been reported and includes subjects on the drugs mentioned below. Not all subjects were on all the drugs.</population>
        <group_list>
          <group group_id="O1">
            <title>MitraClip System</title>
            <description>Percutaneous mitral valve repair using MitraClip System
MitraClip System: Percutaneous mitral valve repair using MitraClip System</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Patients with mitral regurgitation managed non-surgically based on standard hospital clinical practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Average Dosages of GDMT</title>
          <population>All available data has been reported and includes subjects on the drugs mentioned below. Not all subjects were on all the drugs.</population>
          <units>mg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="302"/>
                <count group_id="O2" value="312"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ACE I</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="143"/>
                    <count group_id="O2" value="116"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.22" spread="14.59"/>
                    <measurement group_id="O2" value="12.90" spread="12.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ARB</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="68"/>
                    <count group_id="O2" value="79"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.73" spread="8.93"/>
                    <measurement group_id="O2" value="12.02" spread="8.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Aldosterone Antagonists</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="161"/>
                    <count group_id="O2" value="160"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.16" spread="11.19"/>
                    <measurement group_id="O2" value="29.42" spread="32.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Beta Blockers</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="285"/>
                    <count group_id="O2" value="284"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.01" spread="24.94"/>
                    <measurement group_id="O2" value="28.53" spread="25.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vasodilators (Nitrate)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="22"/>
                    <count group_id="O2" value="33"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.48" spread="41.64"/>
                    <measurement group_id="O2" value="48.59" spread="34.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vasodilators (Hydralazine)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="56"/>
                    <count group_id="O2" value="63"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="133.82" spread="104.93"/>
                    <measurement group_id="O2" value="109.01" spread="87.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ARNI</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="22"/>
                    <count group_id="O2" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.13" spread="8.15"/>
                    <measurement group_id="O2" value="7.68" spread="4.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Average Dosages of GDMT</title>
        <time_frame>12 months</time_frame>
        <population>All available data has been reported and includes subjects on the drugs mentioned below. Not all subjects were on all the drugs.</population>
        <group_list>
          <group group_id="O1">
            <title>MitraClip System</title>
            <description>Percutaneous mitral valve repair using MitraClip System
MitraClip System: Percutaneous mitral valve repair using MitraClip System</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Patients with mitral regurgitation managed non-surgically based on standard hospital clinical practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Average Dosages of GDMT</title>
          <population>All available data has been reported and includes subjects on the drugs mentioned below. Not all subjects were on all the drugs.</population>
          <units>mg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="302"/>
                <count group_id="O2" value="312"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ACE Inhibitors</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="143"/>
                    <count group_id="O2" value="122"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.73" spread="13.56"/>
                    <measurement group_id="O2" value="12.41" spread="12.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ARBs</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="73"/>
                    <count group_id="O2" value="81"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.76" spread="9.21"/>
                    <measurement group_id="O2" value="11.90" spread="8.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Aldosterone Antagonists</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="169"/>
                    <count group_id="O2" value="162"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.33" spread="12.17"/>
                    <measurement group_id="O2" value="29.45" spread="32.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Beta Blockers</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="287"/>
                    <count group_id="O2" value="287"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.10" spread="24.99"/>
                    <measurement group_id="O2" value="28.19" spread="24.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vasodilators (Nitrate)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="34"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.85" spread="41.50"/>
                    <measurement group_id="O2" value="48.56" spread="34.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vasodilators (Hydralazine)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="60"/>
                    <count group_id="O2" value="68"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="136.51" spread="99.05"/>
                    <measurement group_id="O2" value="108.74" spread="87.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ARN Inhibitors</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="31"/>
                    <count group_id="O2" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.36" spread="7.57"/>
                    <measurement group_id="O2" value="7.99" spread="4.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Average Dosages of GDMT</title>
        <time_frame>24 months</time_frame>
        <population>All available data has been reported and includes subjects on the drugs mentioned below. Not all subjects were on all the drugs.</population>
        <group_list>
          <group group_id="O1">
            <title>MitraClip System</title>
            <description>Percutaneous mitral valve repair using MitraClip System
MitraClip System: Percutaneous mitral valve repair using MitraClip System</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Patients with mitral regurgitation managed non-surgically based on standard hospital clinical practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Average Dosages of GDMT</title>
          <population>All available data has been reported and includes subjects on the drugs mentioned below. Not all subjects were on all the drugs.</population>
          <units>mg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="302"/>
                <count group_id="O2" value="312"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ACe Inhibitors</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="148"/>
                    <count group_id="O2" value="124"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.35" spread="13.36"/>
                    <measurement group_id="O2" value="12.32" spread="12.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ARBs</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="78"/>
                    <count group_id="O2" value="83"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.86" spread="9.10"/>
                    <measurement group_id="O2" value="11.67" spread="8.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Aldosterone Antagonists</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="173"/>
                    <count group_id="O2" value="165"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.36" spread="12.30"/>
                    <measurement group_id="O2" value="28.98" spread="32.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Beta Blockers</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="288"/>
                    <count group_id="O2" value="290"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.50" spread="25.15"/>
                    <measurement group_id="O2" value="27.66" spread="23.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vasodilators (Nitrate)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="24"/>
                    <count group_id="O2" value="39"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.81" spread="41.50"/>
                    <measurement group_id="O2" value="45.53" spread="33.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vasodilators (Hydralazine)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="60"/>
                    <count group_id="O2" value="76"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="135.20" spread="97.01"/>
                    <measurement group_id="O2" value="102.29" spread="85.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ARN Inhibitors</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="40"/>
                    <count group_id="O2" value="35"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.41" spread="7.34"/>
                    <measurement group_id="O2" value="8.52" spread="5.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Average Dosages of GDMT</title>
        <time_frame>3 years</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Average Dosages of GDMT</title>
        <time_frame>4 years</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Average Dosages of GDMT</title>
        <time_frame>5 years</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>The Number of Subjects With Changes in GDMT Dosage From Baseline</title>
        <time_frame>Between baseline and 30 days</time_frame>
        <population>Not all subjects were on all the drugs.</population>
        <group_list>
          <group group_id="O1">
            <title>MitraClip System</title>
            <description>Percutaneous mitral valve repair using MitraClip System
MitraClip System: Percutaneous mitral valve repair using MitraClip System</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Patients with mitral regurgitation managed non-surgically based on standard hospital clinical practice.</description>
          </group>
        </group_list>
        <measure>
          <title>The Number of Subjects With Changes in GDMT Dosage From Baseline</title>
          <population>Not all subjects were on all the drugs.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="302"/>
                <count group_id="O2" value="312"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ACE-Inhibitors</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="281"/>
                    <count group_id="O2" value="283"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44"/>
                    <measurement group_id="O2" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Angiotensin-Receptor Blocker (ARBs)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="282"/>
                    <count group_id="O2" value="282"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Aldosterone Antagonists</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="281"/>
                    <count group_id="O2" value="282"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O2" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Beta Blocker</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="281"/>
                    <count group_id="O2" value="283"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60"/>
                    <measurement group_id="O2" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vasodilators (Nitrate)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="281"/>
                    <count group_id="O2" value="280"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vasodilators (Hydralazine)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="281"/>
                    <count group_id="O2" value="282"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>The Number of Subjects With Changes in GDMT Dosage From Baseline to 6 Months</title>
        <time_frame>Between baseline and 6 months</time_frame>
        <population>Not all subjects were on all the drugs.</population>
        <group_list>
          <group group_id="O1">
            <title>MitraClip System</title>
            <description>Percutaneous mitral valve repair using MitraClip System
MitraClip System: Percutaneous mitral valve repair using MitraClip System</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Patients with mitral regurgitation managed non-surgically based on standard hospital clinical practice.</description>
          </group>
        </group_list>
        <measure>
          <title>The Number of Subjects With Changes in GDMT Dosage From Baseline to 6 Months</title>
          <population>Not all subjects were on all the drugs.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="302"/>
                <count group_id="O2" value="312"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ACE-Inhibitors</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="254"/>
                    <count group_id="O2" value="245"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53"/>
                    <measurement group_id="O2" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Angiotensin-Receptor Blockers (ARBs)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="252"/>
                    <count group_id="O2" value="244"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35"/>
                    <measurement group_id="O2" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Aldosterone Antagonists</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="253"/>
                    <count group_id="O2" value="245"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44"/>
                    <measurement group_id="O2" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Beta Blocker</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="254"/>
                    <count group_id="O2" value="245"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74"/>
                    <measurement group_id="O2" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vasodilators (Nitrate)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="252"/>
                    <count group_id="O2" value="245"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vasodilators (Hydralazine)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="251"/>
                    <count group_id="O2" value="245"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>The Number of Subjects With Changes in GDMT Dosage From Baseline and 12 Months</title>
        <time_frame>Between baseline and 12 months</time_frame>
        <population>Not all subjects were on all the drugs.</population>
        <group_list>
          <group group_id="O1">
            <title>MitraClip System</title>
            <description>Percutaneous mitral valve repair using MitraClip System
MitraClip System: Percutaneous mitral valve repair using MitraClip System</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Patients with mitral regurgitation managed non-surgically based on standard hospital clinical practice.</description>
          </group>
        </group_list>
        <measure>
          <title>The Number of Subjects With Changes in GDMT Dosage From Baseline and 12 Months</title>
          <population>Not all subjects were on all the drugs.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="302"/>
                <count group_id="O2" value="312"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ACE-Inhibitors</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="219"/>
                    <count group_id="O2" value="203"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61"/>
                    <measurement group_id="O2" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Angiotension-Receptor Blockers (ARBs)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="217"/>
                    <count group_id="O2" value="203"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Aldosterone Antagonists</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="220"/>
                    <count group_id="O2" value="202"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44"/>
                    <measurement group_id="O2" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Beta Blocker</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="221"/>
                    <count group_id="O2" value="203"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76"/>
                    <measurement group_id="O2" value="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vasodilators (Nitrate)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="220"/>
                    <count group_id="O2" value="203"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vasodilators (Hydralazine)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="220"/>
                    <count group_id="O2" value="203"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>The Number of Subjects With Changes in GDMT Dosage From Baseline and 24 Months</title>
        <time_frame>Between baseline and 24 months</time_frame>
        <population>Not all subjects were on all the drugs.</population>
        <group_list>
          <group group_id="O1">
            <title>MitraClip System</title>
            <description>Percutaneous mitral valve repair using MitraClip System
MitraClip System: Percutaneous mitral valve repair using MitraClip System</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Patients with mitral regurgitation managed non-surgically based on standard hospital clinical practice.</description>
          </group>
        </group_list>
        <measure>
          <title>The Number of Subjects With Changes in GDMT Dosage From Baseline and 24 Months</title>
          <population>Not all subjects were on all the drugs.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="302"/>
                <count group_id="O2" value="312"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ACE-Inhibitors</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="131"/>
                    <count group_id="O2" value="92"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36"/>
                    <measurement group_id="O2" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Angiotensin-Receptor Blockers (ARBs)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="131"/>
                    <count group_id="O2" value="92"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O2" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Aldosterone Antagonists</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="130"/>
                    <count group_id="O2" value="92"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Beta Blockers</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="131"/>
                    <count group_id="O2" value="92"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43"/>
                    <measurement group_id="O2" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vasodilators (Nitrate)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="131"/>
                    <count group_id="O2" value="91"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vasodilators (Hydralazine)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="131"/>
                    <count group_id="O2" value="92"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>The Number and Reasons for Any Changes in GDMT and GDMT Dosage From Baseline</title>
        <time_frame>Between baseline and 3 years</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>The Number and Reasons for Any Changes in GDMT and GDMT Dosage From Baseline</title>
        <time_frame>Between baseline and 4 years</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>The Number and Reasons for Any Changes in GDMT and GDMT Dosage From Baseline</title>
        <time_frame>Between baseline and 5 years</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>The Number of Subjects With Change in GDMT From Baseline That Result in a Greater Than 100% Increase or Greater Than 50% Decrease in Dose</title>
        <time_frame>Between baseline and 30 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>MitraClip System</title>
            <description>Percutaneous mitral valve repair using MitraClip System
MitraClip System: Percutaneous mitral valve repair using MitraClip System</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Patients with mitral regurgitation managed non-surgically based on standard hospital clinical practice.</description>
          </group>
        </group_list>
        <measure>
          <title>The Number of Subjects With Change in GDMT From Baseline That Result in a Greater Than 100% Increase or Greater Than 50% Decrease in Dose</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="302"/>
                <count group_id="O2" value="312"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ACE-Inhibitors (Decrease &gt; 50% or Stop)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACE-Inhibitors (Increase &gt; 100% or New Class)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ARB (Decrease &gt; 50% or Stop)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ARB (Increase &gt; 100% or New Class)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Aldosterone Antagonists (Decrease &gt; 50% or stop)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Aldosterone Antagonists (Increase&gt;100%orNewClass)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Beta Blockers (Decrease &gt; 50% or Stop)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Beta Blockers (Increase &gt;100% or New Class)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vasodilators (Nitrate) Decrease&gt;50% or Stop</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vasodilators (Nitrate) Increase &gt; 100% or NewClass</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vasodilators (Hydralazine) Decrease&gt;50% or Stop</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vasodilators(Hydralazine)Increase &gt;100% orNewClass</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ARN Inhibitors - Decrease&gt;50% or Stop</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ARN Inhibitors - Increase &gt; 100% or NewClass</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>The Number of Subjects With Any Changes in GDMT From Baseline That Result in a Greater Than 100% Increase or Greater Than 50% Decrease in Dose</title>
        <time_frame>Between baseline and 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>MitraClip System</title>
            <description>Percutaneous mitral valve repair using MitraClip System
MitraClip System: Percutaneous mitral valve repair using MitraClip System</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Patients with mitral regurgitation managed non-surgically based on standard hospital clinical practice.</description>
          </group>
        </group_list>
        <measure>
          <title>The Number of Subjects With Any Changes in GDMT From Baseline That Result in a Greater Than 100% Increase or Greater Than 50% Decrease in Dose</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="302"/>
                <count group_id="O2" value="312"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ACE-I (Decrease &gt; 50% or Stop)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACE-I (Increase &gt; 100% or New Class)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ARB (Decrease &gt; 50% or Stop)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ARB (Increase &gt; 100% or New Class)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Aldosterone Antagonists (Decrease &gt; 50% or Stop)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Aldosterone Antagonists (Increase &gt; 100% or NewCl)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Beta Blockers (Decrease &gt; 50% or Stop)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Beta Blockers (Increase &gt; 100% or New Class)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vasodilators (Nitrate) Decrease &gt; 50% or Stop</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vasodilators (Nitrate) Increase &gt; 100% or NewClass</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vasodilators (Hydralazine) Decrease &gt; 50% or Stop</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vasodilators(Hydralazine)Increase&gt;100% orNewClass</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ARN Inhibitors Decrease &gt; 50% or Stop</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ARN Inhibitors Increase &gt; 100% or New Class</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>The Number of Subjects With Any Changes in GDMT From Baseline That Result in a Greater Than 100% Increase or Greater Than 50% Decrease in Dose</title>
        <time_frame>Between baseline and 12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>MitraClip System</title>
            <description>Percutaneous mitral valve repair using MitraClip System
MitraClip System: Percutaneous mitral valve repair using MitraClip System</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Patients with mitral regurgitation managed non-surgically based on standard hospital clinical practice.</description>
          </group>
        </group_list>
        <measure>
          <title>The Number of Subjects With Any Changes in GDMT From Baseline That Result in a Greater Than 100% Increase or Greater Than 50% Decrease in Dose</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="302"/>
                <count group_id="O2" value="312"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ACE-Inhibitors Decrease &gt; 50% or Stop</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACE-Inhibitors Increase &gt; 100% or New Class</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ARBs Decrease &gt;50% or Stop</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ARBs Increase &gt; 100% or New Class</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Aldosterone Antagonists Decrease &gt; 50% or Stop</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Aldosterone Antagonists Increase&gt;100% or New Class</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Beta Blockers Decrease &gt; 50% or Stop</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Beta Blockers Increase &gt; 100% or New Class</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vasodilators(Nitrate) Decrease &gt; 50% or Stop</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vasodilators(Nitrate) Increase &gt; 100% or New Class</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vasodilators(Hydralazine) Decrease &gt; 50% or Stop</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vasodilators(Hydralazine) Increase&gt;100%orNewClass</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ARN Inhibitors Decrease &gt; 50% or Stop</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ARN inhibitors Increase &gt; 100% or New Class</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>The Number of Subjects With Any Changes in GDMT From Baseline That Result in a Greater Than 100% Increase or Greater Than 50% Decrease in Dose</title>
        <time_frame>Between baseline and 24 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>MitraClip System</title>
            <description>Percutaneous mitral valve repair using MitraClip System
MitraClip System: Percutaneous mitral valve repair using MitraClip System</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Patients with mitral regurgitation managed non-surgically based on standard hospital clinical practice.</description>
          </group>
        </group_list>
        <measure>
          <title>The Number of Subjects With Any Changes in GDMT From Baseline That Result in a Greater Than 100% Increase or Greater Than 50% Decrease in Dose</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="302"/>
                <count group_id="O2" value="312"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ACE-Inhibitors Decrease &gt; 50% or Stop</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACE Inhibitors Increase &gt; 100% or New Class</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ARBs Decrease &gt; 50% or Stop</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ARBs Increase &gt; 100% or New Class</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Aldosterone Antagonists Decrease &gt; 50% or Stop</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Aldosterone Antagonists Increase&gt;100% or New Class</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Beta Blockers Decrease &gt; 50% or Stop</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Beta Blockers Increase &gt; 100% or New Class</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O2" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vasodilators(Nitrate) Decrease &gt; 50% or Stop</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vasodilators(Nitrate) Increase &gt; 100% or New Class</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vasodilators(Hydralazine)Decrease &gt; 50% or Stop</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vasodilators(Hydralazine) Increase&gt;100%orNew Class</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ARN Inhibitors Decrease &gt; 50% or Stop</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ARN Inhibitors Increase &gt; 100% or New Class</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                    <measurement group_id="O2" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>The Number and Reasons for Any Changes in GDMT From Baseline That Result in a Greater Than 100% Increase or Greater Than 50% Decrease in Dose</title>
        <time_frame>Between baseline and 3 years</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>The Number and Reasons for Any Changes in GDMT From Baseline That Result in a Greater Than 100% Increase or Greater Than 50% Decrease in Dose</title>
        <time_frame>Between baseline and 4 years</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>The Number and Reasons for Any Changes in GDMT From Baseline That Result in a Greater Than 100% Increase or Greater Than 50% Decrease in Dose</title>
        <time_frame>Between baseline and 5 years</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Cardiopulmonary Exercise (CPX) Testing</title>
        <description>A substudy endpoint will utilize peak oxygen consumption oxygen uptake (VO2) as a parameter for cardiopulmonary exercise testing on a total of at least 50 and up to 100 subjects.
The CPX analysis variables are:
Peak VO2 (ml/kg/min) - CPX Sub-study endpoint, descriptive analysis only, not powered for statistical significance
Exercise duration (min)
Peak workload (watts)
Maximum heart rate during exercise (beats/min)
Peak VE (l/min)
Respiratory Exchange Ratio (RER, VCO2/VO2)
VE/VCO2 slope
Ventilatory Threshold (ml/kg/min)
Borg scale
Exercise termination reason
Type of exercise (treadmill vs cycling)</description>
        <time_frame>Baseline</time_frame>
        <population>A total of 14 subjects were enrolled in the CPA sub study. However CPX data was available for only 2 subjects in the device group and 1 subject in the control group.</population>
        <group_list>
          <group group_id="O1">
            <title>MitraClip System</title>
            <description>Percutaneous mitral valve repair using MitraClip System
MitraClip System: Percutaneous mitral valve repair using MitraClip System</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Patients with mitral regurgitation managed non-surgically based on standard hospital clinical practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Cardiopulmonary Exercise (CPX) Testing</title>
          <description>A substudy endpoint will utilize peak oxygen consumption oxygen uptake (VO2) as a parameter for cardiopulmonary exercise testing on a total of at least 50 and up to 100 subjects.
The CPX analysis variables are:
Peak VO2 (ml/kg/min) - CPX Sub-study endpoint, descriptive analysis only, not powered for statistical significance
Exercise duration (min)
Peak workload (watts)
Maximum heart rate during exercise (beats/min)
Peak VE (l/min)
Respiratory Exchange Ratio (RER, VCO2/VO2)
VE/VCO2 slope
Ventilatory Threshold (ml/kg/min)
Borg scale
Exercise termination reason
Type of exercise (treadmill vs cycling)</description>
          <population>A total of 14 subjects were enrolled in the CPA sub study. However CPX data was available for only 2 subjects in the device group and 1 subject in the control group.</population>
          <units>ml/kg/min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.85" spread="0.78"/>
                    <measurement group_id="O2" value="6.00" spread="NA">Data is available for only one subject. Hence Standard deviation is not applicable.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Cardiopulmonary Exercise (CPX) Testing</title>
        <description>A substudy endpoint will utilize peak oxygen consumption oxygen uptake (VO2) as a parameter for cardiopulmonary exercise testing on a total of at least 50 and up to 100 subjects.
The CPX analysis variables are:
Peak VO2 (ml/kg/min) - CPX Sub-study endpoint, descriptive analysis only, not powered for statistical significance
Exercise duration (min)
Peak workload (watts)
Maximum heart rate during exercise (beats/min)
Peak VE (l/min)
Respiratory Exchange Ratio (RER, VCO2/VO2)
VE/VCO2 slope
Ventilatory Threshold (ml/kg/min)
Borg scale
Exercise termination reason
Type of exercise (treadmill vs cycling)</description>
        <time_frame>12 months</time_frame>
        <population>A total of 14 subjects participated in the CPX sub-study. CPX test data was available in 2 subjects in the device group and 1 subject in the control group.</population>
        <group_list>
          <group group_id="O1">
            <title>MitraClip System</title>
            <description>Percutaneous mitral valve repair using MitraClip System
MitraClip System: Percutaneous mitral valve repair using MitraClip System</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Patients with mitral regurgitation managed non-surgically based on standard hospital clinical practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Cardiopulmonary Exercise (CPX) Testing</title>
          <description>A substudy endpoint will utilize peak oxygen consumption oxygen uptake (VO2) as a parameter for cardiopulmonary exercise testing on a total of at least 50 and up to 100 subjects.
The CPX analysis variables are:
Peak VO2 (ml/kg/min) - CPX Sub-study endpoint, descriptive analysis only, not powered for statistical significance
Exercise duration (min)
Peak workload (watts)
Maximum heart rate during exercise (beats/min)
Peak VE (l/min)
Respiratory Exchange Ratio (RER, VCO2/VO2)
VE/VCO2 slope
Ventilatory Threshold (ml/kg/min)
Borg scale
Exercise termination reason
Type of exercise (treadmill vs cycling)</description>
          <population>A total of 14 subjects participated in the CPX sub-study. CPX test data was available in 2 subjects in the device group and 1 subject in the control group.</population>
          <units>ml/kg/min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.50" spread="6.36"/>
                    <measurement group_id="O2" value="6.80" spread="NA">Data available for only 1 subject. Hence Standard deviation is not possible.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Cardiopulmonary Exercise (CPX) Testing: Mean Changes in Peak VO2</title>
        <description>Mean changes in peak VO2 (ml/kg/min) will be summarized at 12 months from baseline for the subset of patients who complete a CPX test at baseline and 12 months. A comparison of change from baseline between Device and Control groups will be presented.
The CPX analysis variables are:
Peak VO2 (ml/kg/min) - CPX Sub-study endpoint, descriptive analysis only, not powered for statistical significance
Exercise duration (min)
Peak workload (watts)
Maximum heart rate during exercise (beats/min)
Peak VE (l/min)
Respiratory Exchange Ratio (RER, VCO2/VO2)
VE/VCO2 slope
Ventilatory Threshold (ml/kg/min)
Borg scale
Exercise termination reason
Type of exercise (treadmill vs cycling)</description>
        <time_frame>Between baseline and 12 months</time_frame>
        <population>A total of 14 subjects participated in the CPX sub-study. CPX test data was available in 2 subjects in the device group and 1 subject in the control group.</population>
        <group_list>
          <group group_id="O1">
            <title>MitraClip System</title>
            <description>Percutaneous mitral valve repair using MitraClip System
MitraClip System: Percutaneous mitral valve repair using MitraClip System</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Patients with mitral regurgitation managed non-surgically based on standard hospital clinical practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Cardiopulmonary Exercise (CPX) Testing: Mean Changes in Peak VO2</title>
          <description>Mean changes in peak VO2 (ml/kg/min) will be summarized at 12 months from baseline for the subset of patients who complete a CPX test at baseline and 12 months. A comparison of change from baseline between Device and Control groups will be presented.
The CPX analysis variables are:
Peak VO2 (ml/kg/min) - CPX Sub-study endpoint, descriptive analysis only, not powered for statistical significance
Exercise duration (min)
Peak workload (watts)
Maximum heart rate during exercise (beats/min)
Peak VE (l/min)
Respiratory Exchange Ratio (RER, VCO2/VO2)
VE/VCO2 slope
Ventilatory Threshold (ml/kg/min)
Borg scale
Exercise termination reason
Type of exercise (treadmill vs cycling)</description>
          <population>A total of 14 subjects participated in the CPX sub-study. CPX test data was available in 2 subjects in the device group and 1 subject in the control group.</population>
          <units>ml/kg/min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.65" spread="5.59"/>
                    <measurement group_id="O2" value="0.80" spread="NA">Data is available for only 1 subject.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Health Economic Data</title>
        <time_frame>Through 5 years</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>24 Months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>MitraClip System</title>
          <description>Percutaneous mitral valve repair using MitraClip System
MitraClip System: Percutaneous mitral valve repair using MitraClip System</description>
        </group>
        <group group_id="E2">
          <title>Control Group</title>
          <description>Patients with mitral regurgitation managed non-surgically based on standard hospital clinical practice.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (15.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="80" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="121" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="243" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="264" subjects_at_risk="312"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="23" subjects_affected="20" subjects_at_risk="302"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Anaemia Macrocytic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Anaemia of Chronic Disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Coagulopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Haemorrhagic Anaemia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="302"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>Iron Deficiency Anaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>LEUKOCYTOSIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>MICROCYTIC ANAEMIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>PANCYTOPENIA</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>THROMBOCYTOPENIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="312"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>ACUTE CORONARY SYNDROME</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>ACUTE LEFT VENTRICULAR FAILURE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>ACUTE MYOCARDIAL INFARCTION</sub_title>
                <counts group_id="E1" events="11" subjects_affected="10" subjects_at_risk="302"/>
                <counts group_id="E2" events="16" subjects_affected="16" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>ANGINA PECTORIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>ANGINA UNSTABLE</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="302"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>ARRHYTHMIA</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="302"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>ARTERIOSCLEROSIS CORONARY ARTERY</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>ATRIAL FIBRILLATION</sub_title>
                <counts group_id="E1" events="28" subjects_affected="20" subjects_at_risk="302"/>
                <counts group_id="E2" events="24" subjects_affected="21" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>ATRIAL FLUTTER</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="302"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>ATRIAL SEPTAL DEFECT ACQUIRED</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>ATRIAL TACHYCARDIA</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>ATRIAL THROMBOSIS</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="302"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>ATRIOVENTRICULAR BLOCK COMPLETE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>BRADYCARDIA</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>CARDIAC ARREST</sub_title>
                <counts group_id="E1" events="13" subjects_affected="12" subjects_at_risk="302"/>
                <counts group_id="E2" events="20" subjects_affected="20" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>CARDIAC FAILURE</sub_title>
                <counts group_id="E1" events="32" subjects_affected="27" subjects_at_risk="302"/>
                <counts group_id="E2" events="102" subjects_affected="73" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>CARDIAC FAILURE ACUTE</sub_title>
                <counts group_id="E1" events="22" subjects_affected="20" subjects_at_risk="302"/>
                <counts group_id="E2" events="31" subjects_affected="24" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>CARDIAC FAILURE CHRONIC</sub_title>
                <counts group_id="E1" events="59" subjects_affected="39" subjects_at_risk="302"/>
                <counts group_id="E2" events="73" subjects_affected="59" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>CARDIAC FAILURE CONGESTIVE</sub_title>
                <counts group_id="E1" events="84" subjects_affected="59" subjects_at_risk="302"/>
                <counts group_id="E2" events="136" subjects_affected="83" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>CARDIAC TAMPONADE</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>CARDIO-RESPIRATORY ARREST</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="302"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>CARDIOGENIC SHOCK</sub_title>
                <counts group_id="E1" events="10" subjects_affected="9" subjects_at_risk="302"/>
                <counts group_id="E2" events="13" subjects_affected="13" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>CARDIOMYOPATHY</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="302"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>CARDIOPULMONARY FAILURE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>CARDIORENAL SYNDROME</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>CARDIOVASCULAR DECONDITIONING</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>CONGESTIVE CARDIOMYOPATHY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>CORONARY ARTERY DISEASE</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="302"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>CORONARY ARTERY OCCLUSION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>CORONARY ARTERY STENOSIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>INTRACARDIAC THROMBUS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>ISCHAEMIC CARDIOMYOPATHY</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="302"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>LEFT VENTRICULAR DYSFUNCTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>LEFT VENTRICULAR FAILURE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>MITRAL VALVE INCOMPETENCE</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="302"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>MITRAL VALVE STENOSIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>MYOCARDIAL INFARCTION</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="302"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>MYOCARDIAL ISCHAEMIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>PALPITATIONS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>PERICARDIAL EFFUSION</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="302"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>PERICARDIAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>SICK SINUS SYNDROME</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>SUPRAVENTRICULAR TACHYCARDIA</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>SYSTOLIC DYSFUNCTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>TACHYARRHYTHMIA</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>TACHYCARDIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>TORSADE DE POINTES</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>TRICUSPID VALVE INCOMPETENCE</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>VENTRICULAR ARRHYTHMIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>VENTRICULAR DYSSYNCHRONY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>VENTRICULAR EXTRASYSTOLES</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>VENTRICULAR FIBRILLATION</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="302"/>
                <counts group_id="E2" events="8" subjects_affected="7" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>VENTRICULAR TACHYCARDIA</sub_title>
                <counts group_id="E1" events="20" subjects_affected="13" subjects_at_risk="302"/>
                <counts group_id="E2" events="35" subjects_affected="23" subjects_at_risk="312"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>VERTIGO</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>CATARACT</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>CONJUNCTIVITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>DIPLOPIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>VISION BLURRED</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>ABDOMINAL PAIN</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="302"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>ABDOMINAL PAIN UPPER</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>ACQUIRED OESOPHAGEAL WEB</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>ASCITES</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="302"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>COLITIS</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>COLITIS ISCHAEMIC</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>COLITIS ULCERATIVE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>COLONIC PSEUDO-OBSTRUCTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>CONSTIPATION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>DIABETIC GASTROPARESIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>DIARRHOEA</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="302"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>DIVERTICULAR PERFORATION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>DIVERTICULUM INTESTINAL</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>DIVERTICULUM INTESTINAL HAEMORRHAGIC</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>DYSPHAGIA</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="302"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>ENTEROCUTANEOUS FISTULA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>ENTEROVESICAL FISTULA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>EROSIVE OESOPHAGITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>FLATULENCE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>GASTRITIS HAEMORRHAGIC</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>GASTROINTESTINAL ANGIODYSPLASIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>GASTROINTESTINAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="17" subjects_affected="14" subjects_at_risk="302"/>
                <counts group_id="E2" events="20" subjects_affected="19" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>HAEMATEMESIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>HAEMORRHOIDAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>HAEMORRHOIDS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>HIATUS HERNIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>IMPAIRED GASTRIC EMPTYING</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>INGUINAL HERNIA</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="302"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>INGUINAL HERNIA, OBSTRUCTIVE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>INTESTINAL ISCHAEMIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>INTESTINAL OBSTRUCTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>INTESTINAL PERFORATION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>JEJUNITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>LARGE INTESTINE PERFORATION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>LOWER GASTROINTESTINAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>MEGACOLON</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>MELAENA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>NAUSEA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>ODYNOPHAGIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>OESOPHAGEAL ULCER</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>PANCREATITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>PANCREATITIS ACUTE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>PROCTALGIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>PROCTITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>RECTAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>RECTAL PROLAPSE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>RECTAL ULCER</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>RECTAL ULCER HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>RETROPERITONEAL HAEMATOMA</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>RETROPERITONEAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>SMALL INTESTINAL OBSTRUCTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>UMBILICAL HERNIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>UPPER GASTROINTESTINAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>VOLVULUS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>VOMITING</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="312"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>ADVERSE DRUG REACTION</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="302"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>ASTHENIA</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="302"/>
                <counts group_id="E2" events="6" subjects_affected="4" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>CATHETER SITE HAEMATOMA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>CATHETER SITE HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>CHEST DISCOMFORT</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>CHEST PAIN</sub_title>
                <counts group_id="E1" events="12" subjects_affected="9" subjects_at_risk="302"/>
                <counts group_id="E2" events="15" subjects_affected="11" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>DEATH</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="302"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>DEVICE BATTERY ISSUE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>DEVICE DISLOCATION</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>DEVICE ELECTRICAL FINDING</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="302"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>DEVICE LEAD DAMAGE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>DEVICE LEAD ISSUE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>DEVICE MALFUNCTION</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>DRUG INTOLERANCE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>EXERCISE TOLERANCE DECREASED</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>FATIGUE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>GENERAL PHYSICAL HEALTH DETERIORATION</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>HERNIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>HERNIA OBSTRUCTIVE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>MEDICAL DEVICE COMPLICATION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>MULTI-ORGAN FAILURE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>NON-CARDIAC CHEST PAIN</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="302"/>
                <counts group_id="E2" events="9" subjects_affected="6" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>OEDEMA PERIPHERAL</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>PYREXIA</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="302"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>SUDDEN CARDIAC DEATH</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>VESSEL PUNCTURE SITE HAEMATOMA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>BILE DUCT STONE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>CHOLECYSTITIS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>CHOLECYSTITIS ACUTE</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>CHOLELITHIASIS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>HEPATIC CIRRHOSIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>HEPATIC MASS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>ISCHAEMIC HEPATITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>ANAPHYLACTIC REACTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>HEART TRANSPLANT REJECTION</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>IMMUNOSUPPRESSION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>TRANSPLANT REJECTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>ABDOMINAL ABSCESS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>ABSCESS LIMB</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>ACQUIRED IMMUNODEFICIENCY SYNDROME</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>BACTERAEMIA</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>BACTERIAL SEPSIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>BRONCHITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>BRONCHITIS VIRAL</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>BRONCHOPNEUMONIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>CELLULITIS</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="302"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>CLOSTRIDIAL INFECTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>CLOSTRIDIUM DIFFICILE COLITIS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>CYSTITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>DEVICE RELATED INFECTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="4" subjects_affected="2" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>DEVICE RELATED SEPSIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>DIVERTICULITIS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="302"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>EMPHYSEMATOUS CYSTITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>ENTEROCOCCAL BACTERAEMIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>ENTEROCOLITIS INFECTIOUS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>ESCHERICHIA BACTERAEMIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>ESCHERICHIA INFECTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>FUNGAEMIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>GANGRENE</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>GASTROENTERITIS VIRAL</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>HERPES ZOSTER</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>IMPLANT SITE INFECTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>INFECTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>INFLUENZA</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="302"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>INFUSION SITE CELLULITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>KLEBSIELLA BACTERAEMIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>LOBAR PNEUMONIA</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>LOWER RESPIRATORY TRACT INFECTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>OESOPHAGEAL INFECTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>OSTEOMYELITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>PARAINFLUENZAE VIRUS INFECTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>PERIRECTAL ABSCESS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>PERITONITIS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>PNEUMONIA</sub_title>
                <counts group_id="E1" events="25" subjects_affected="19" subjects_at_risk="302"/>
                <counts group_id="E2" events="26" subjects_affected="24" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>PNEUMONIA BACTERIAL</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>PNEUMONIA INFLUENZAL</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>PNEUMONIA NECROTISING</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>PNEUMONIA RESPIRATORY SYNCYTIAL VIRAL</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>PNEUMONIA STAPHYLOCOCCAL</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>POST VIRAL FATIGUE SYNDROME</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>PULMONARY SEPSIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>PYELONEPHRITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>RESPIRATORY TRACT INFECTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>SEPSIS</sub_title>
                <counts group_id="E1" events="16" subjects_affected="14" subjects_at_risk="302"/>
                <counts group_id="E2" events="12" subjects_affected="10" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>SEPSIS SYNDROME</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>SEPTIC SHOCK</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="302"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>SOFT TISSUE INFECTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>STAPHYLOCOCCAL BACTERAEMIA</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>STAPHYLOCOCCAL INFECTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>STREPTOCOCCAL BACTERAEMIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>SUBCUTANEOUS ABSCESS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>TRACHEOBRONCHITIS VIRAL</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>TUBERCULOSIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>URINARY TRACT INFECTION</sub_title>
                <counts group_id="E1" events="7" subjects_affected="4" subjects_at_risk="302"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>URINARY TRACT INFECTION BACTERIAL</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>URINARY TRACT INFECTION FUNGAL</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>UROSEPSIS</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="302"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="312"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>ANAEMIA POSTOPERATIVE</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>ANAESTHETIC COMPLICATION PULMONARY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>ARTERIOVENOUS FISTULA THROMBOSIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>ARTHROPOD BITE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>CARDIAC VALVE REPLACEMENT COMPLICATION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>CERVICAL VERTEBRAL FRACTURE</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>COMPLICATIONS OF TRANSPLANTED HEART</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>CONTUSION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>CRANIOCEREBRAL INJURY</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="302"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>FACE INJURY</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>FACIAL BONES FRACTURE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>FALL</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="302"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>FEMORAL NECK FRACTURE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>FEMUR FRACTURE</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="302"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>FRACTURE DISPLACEMENT</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>FRACTURED SACRUM</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>GASTROENTERITIS RADIATION</sub_title>
                <counts group_id="E1" events="7" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>HAEMATURIA TRAUMATIC</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>HEAD INJURY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>HIP FRACTURE</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="302"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>HUMERUS FRACTURE</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>IN-STENT CORONARY ARTERY RESTENOSIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>INJURY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>LACERATION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>PELVIC FRACTURE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>POCKET EROSION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>POST PROCEDURAL HAEMATOMA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>POST PROCEDURAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="302"/>
                <counts group_id="E2" events="5" subjects_affected="3" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>POSTOPERATIVE ILEUS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>PROCEDURAL COMPLICATION</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>PROCEDURAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>PROCEDURAL HYPOTENSION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>PROCEDURAL PAIN</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>PUBIS FRACTURE</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>RADIUS FRACTURE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>RENAL HAEMATOMA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>RIB FRACTURE</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="302"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>SPINAL COMPRESSION FRACTURE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>SPINAL FRACTURE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>SUBDURAL HAEMATOMA</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="302"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>TOXICITY TO VARIOUS AGENTS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>TRAUMATIC HAEMATOMA</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>TRAUMATIC INTRACRANIAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="302"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>UPPER LIMB FRACTURE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>VASCULAR ACCESS COMPLICATION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>VASCULAR PSEUDOANEURYSM</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>VENA CAVA INJURY</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>WOUND</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>ANTICOAGULATION DRUG LEVEL BELOW THERAPEUTIC</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>CARDIAC ENZYMES INCREASED</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>CARDIAC OUTPUT DECREASED</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>CATHETERISATION CARDIAC</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>COLONOSCOPY</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>DRUG LEVEL ABOVE THERAPEUTIC</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>EJECTION FRACTION DECREASED</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>ELECTROCARDIOGRAM AMBULATORY ABNORMAL</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>ELECTROCARDIOGRAM QRS COMPLEX PROLONGED</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>ELECTROCARDIOGRAM QT PROLONGED</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>ELECTROCARDIOGRAM ST SEGMENT ELEVATION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>ENTEROCOCCUS TEST POSITIVE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>HAEMOGLOBIN DECREASED</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>INFLUENZA A VIRUS TEST POSITIVE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>INTERNATIONAL NORMALISED RATIO DECREASED</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>INTERNATIONAL NORMALISED RATIO INCREASED</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>LABORATORY TEST ABNORMAL</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>LIVER FUNCTION TEST ABNORMAL</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>TRANSAMINASES INCREASED</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>TROPONIN INCREASED</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>URINE OUTPUT DECREASED</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>WHITE BLOOD CELL COUNT INCREASED</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>ACIDOSIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>DEHYDRATION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>DIABETES MELLITUS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>DIABETIC KETOACIDOSIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>ELECTROLYTE IMBALANCE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>FAILURE TO THRIVE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>FLUID OVERLOAD</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="302"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>GOUT</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>HYPERGLYCAEMIA</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="302"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>HYPERKALAEMIA</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="302"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>HYPOGLYCAEMIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>HYPOKALAEMIA</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="302"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>HYPONATRAEMIA</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>HYPOVOLAEMIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>IRON DEFICIENCY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>LACTIC ACIDOSIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>METABOLIC ACIDOSIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>METABOLIC ALKALOSIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>ARTHRALGIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>ARTHRITIS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>BACK PAIN</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>CERVICAL SPINAL STENOSIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>GOUTY ARTHRITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>INTERVERTEBRAL DISC DEGENERATION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>INTERVERTEBRAL DISC PROTRUSION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>LUMBAR SPINAL STENOSIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>MUSCLE HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>MUSCLE SPASMS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>MUSCULAR WEAKNESS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>MUSCULOSKELETAL CHEST PAIN</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>MUSCULOSKELETAL PAIN</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>NECK PAIN</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>OSTEOARTHRITIS</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>PAIN IN EXTREMITY</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>RHABDOMYOLYSIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>SPINAL COLUMN STENOSIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>VERTEBRAL FORAMINAL STENOSIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>ANGIOSARCOMA METASTATIC</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>B-CELL LYMPHOMA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>BASAL CELL CARCINOMA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>BONE SARCOMA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>BREAST CANCER</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>COLON CANCER</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>HEPATIC NEOPLASM MALIGNANT</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>LEUKAEMIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>LUNG ADENOCARCINOMA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>LUNG ADENOCARCINOMA METASTATIC</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>LUNG CANCER METASTATIC</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>LUNG CARCINOMA CELL TYPE UNSPECIFIED STAGE IV</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>LYMPHOMA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>MULTIPLE MYELOMA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>OESOPHAGEAL ADENOCARCINOMA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>OESOPHAGEAL CARCINOMA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>OVARIAN CANCER METASTATIC</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>PANCREATIC CARCINOMA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>PROSTATE CANCER</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>RENAL CANCER</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>SKIN CANCER</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>SQUAMOUS CELL CARCINOMA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>THYROID CANCER</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>TUMOUR HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>CAROTID ARTERY DISEASE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>CAROTID ARTERY STENOSIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>CARPAL TUNNEL SYNDROME</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>CEREBRAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>CEREBROVASCULAR ACCIDENT</sub_title>
                <counts group_id="E1" events="13" subjects_affected="12" subjects_at_risk="302"/>
                <counts group_id="E2" events="8" subjects_affected="7" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>CERVICOBRACHIAL SYNDROME</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>CONVULSION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>DEMENTIA ALZHEIMER'S TYPE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>DIZZINESS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="302"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>DIZZINESS POSTURAL</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>DYSARTHRIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>EMBOLIC STROKE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>ENCEPHALOPATHY</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>HAEMORRHAGE INTRACRANIAL</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>HEADACHE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>HEPATIC ENCEPHALOPATHY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>HYPOAESTHESIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>HYPOXIC-ISCHAEMIC ENCEPHALOPATHY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>INTRACRANIAL ANEURYSM</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>INTRACRANIAL HYPOTENSION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>ISCHAEMIC STROKE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>LOSS OF CONSCIOUSNESS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>METABOLIC ENCEPHALOPATHY</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>PARKINSON'S DISEASE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>PRESYNCOPE</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>SCIATICA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>SUBARACHNOID HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="302"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>SYNCOPE</sub_title>
                <counts group_id="E1" events="12" subjects_affected="10" subjects_at_risk="302"/>
                <counts group_id="E2" events="18" subjects_affected="17" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>TOXIC ENCEPHALOPATHY</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>TRANSIENT ISCHAEMIC ATTACK</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="302"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>VERTEBRAL ARTERY OCCLUSION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>CONFUSIONAL STATE</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="302"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>DELIRIUM</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>DISORIENTATION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>MENTAL STATUS CHANGES</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="302"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>PANIC ATTACK</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>AZOTAEMIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="5" subjects_affected="3" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>DYSURIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>HAEMATURIA</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>NEPHROLITHIASIS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>NEPHROPATHY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>RENAL FAILURE</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="302"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>RENAL FAILURE ACUTE</sub_title>
                <counts group_id="E1" events="32" subjects_affected="26" subjects_at_risk="302"/>
                <counts group_id="E2" events="44" subjects_affected="39" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>RENAL FAILURE CHRONIC</sub_title>
                <counts group_id="E1" events="10" subjects_affected="9" subjects_at_risk="302"/>
                <counts group_id="E2" events="16" subjects_affected="16" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>RENAL IMPAIRMENT</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>RENAL MASS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>URINARY RETENTION</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>BENIGN PROSTATIC HYPERPLASIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>VAGINAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>ACUTE PULMONARY OEDEMA</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="302"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>ACUTE RESPIRATORY DISTRESS SYNDROME</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>ACUTE RESPIRATORY FAILURE</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="302"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>ASTHMA</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>ATELECTASIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>BRONCHIAL SECRETION RETENTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>CHRONIC OBSTRUCTIVE PULMONARY DISORDER</sub_title>
                <counts group_id="E1" events="14" subjects_affected="9" subjects_at_risk="302"/>
                <counts group_id="E2" events="10" subjects_affected="7" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>COUGH</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>DYSPHONIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>DYSPNOEA</sub_title>
                <counts group_id="E1" events="22" subjects_affected="17" subjects_at_risk="302"/>
                <counts group_id="E2" events="13" subjects_affected="12" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>DYSPNOEA EXERTIONAL</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>EPISTAXIS</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>HAEMOPTYSIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>HAEMOTHORAX</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>HYPERCAPNIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>HYPOXIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>INCREASED UPPER AIRWAY SECRETION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>LARYNGEAL HAEMATOMA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>MEDIASTINAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>PLEURAL EFFUSION</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="302"/>
                <counts group_id="E2" events="15" subjects_affected="12" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>PNEUMONIA ASPIRATION</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="302"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>PNEUMONITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>PNEUMOTHORAX</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>PULMONARY CONGESTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>PULMONARY FIBROSIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>PULMONARY HYPERTENSION</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="302"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>PULMONARY OEDEMA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>RALES</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>RESPIRATORY DISTRESS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>RESPIRATORY FAILURE</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="302"/>
                <counts group_id="E2" events="16" subjects_affected="16" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>SLEEP APNOEA SYNDROME</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>ANGIOEDEMA</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>DIGITAL ULCER</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>RASH</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>SKIN DISCOLOURATION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>SKIN ULCER</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="312"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>AORTIC SURGERY</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>CARDIAC PACEMAKER BATTERY REPLACEMENT</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>CARDIAC PACEMAKER REPLACEMENT</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>CAROTID ENDARTERECTOMY</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>CHOLECYSTECTOMY</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>GASTRECTOMY</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>HEART TRANSPLANT</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>HIP ARTHROPLASTY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>IMPLANTABLE DEFIBRILLATOR INSERTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>IMPLANTABLE DEFIBRILLATOR REPLACEMENT</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>INGUINAL HERNIA REPAIR</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>MEDICAL DEVICE CHANGE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>MITRAL VALVE REPAIR</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>PERCUTANEOUS CORONARY INTERVENTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>SPINAL FUSION SURGERY</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>ANGIOPATHY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>AORTIC ANEURYSM</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="302"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>AORTIC STENOSIS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>ARTERIOSCLEROSIS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="302"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>DEEP VEIN THROMBOSIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>FEMORAL ARTERIAL STENOSIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>HAEMATOMA</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>HAEMODYNAMIC INSTABILITY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>HYPOTENSION</sub_title>
                <counts group_id="E1" events="18" subjects_affected="16" subjects_at_risk="302"/>
                <counts group_id="E2" events="13" subjects_affected="13" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>HYPOVOLAEMIC SHOCK</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>ILIAC ARTERY STENOSIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>INTERMITTENT CLAUDICATION</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>ORTHOSTATIC HYPOTENSION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>PERIPHERAL ARTERIAL OCCLUSIVE DISEASE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>PERIPHERAL ARTERY ANEURYSM</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>PERIPHERAL ISCHAEMIA</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="302"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>PERIPHERAL VASCULAR DISORDER</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>SHOCK</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>SHOCK HAEMORRHAGIC</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (15.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="222" subjects_at_risk="302"/>
                <counts group_id="E2" subjects_affected="219" subjects_at_risk="312"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>ANAEMIA</sub_title>
                <counts group_id="E1" events="16" subjects_affected="16" subjects_at_risk="302"/>
                <counts group_id="E2" events="19" subjects_affected="18" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>ANAEMIA FOLATE DEFICIENCY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>ANAEMIA MACROCYTIC</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>ANAEMIA OF CHRONIC DISEASE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>COAGULOPATHY</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>HAEMORRHAGIC ANAEMIA</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>IRON DEFICIENCY ANAEMIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>LEUKOCYTOSIS</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="302"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>LYMPHADENOPATHY MEDIASTINAL</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>MACROCYTOSIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>MICROCYTIC ANAEMIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>NEPHROGENIC ANAEMIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>NORMOCHROMIC NORMOCYTIC ANAEMIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>PANCYTOPENIA</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>SPLENIC INFARCTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>SPLENOMEGALY</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>THROMBOCYTOPENIA</sub_title>
                <counts group_id="E1" events="9" subjects_affected="7" subjects_at_risk="302"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="312"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>ACUTE MYOCARDIAL INFARCTION</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>ANGINA PECTORIS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="302"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>ANGINA UNSTABLE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>ARRHYTHMIA</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="302"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>ATRIAL FIBRILLATION</sub_title>
                <counts group_id="E1" events="25" subjects_affected="21" subjects_at_risk="302"/>
                <counts group_id="E2" events="15" subjects_affected="12" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>ATRIAL FLUTTER</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>ATRIAL SEPTAL DEFECT ACQUIRED</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>ATRIAL TACHYCARDIA</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>ATRIAL THROMBOSIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>BRADYCARDIA</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="302"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>CARDIAC ARREST</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>CARDIAC FAILURE</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="302"/>
                <counts group_id="E2" events="10" subjects_affected="9" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>CARDIAC FAILURE ACUTE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>CARDIAC FAILURE CHRONIC</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="302"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>CARDIAC FAILURE CONGESTIVE</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="302"/>
                <counts group_id="E2" events="22" subjects_affected="16" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>CARDIOGENIC SHOCK</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>CYANOSIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>INTRACARDIAC THROMBUS</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>ISCHAEMIC CARDIOMYOPATHY</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>LEFT VENTRICULAR DYSFUNCTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>MITRAL VALVE INCOMPETENCE</sub_title>
                <counts group_id="E1" events="9" subjects_affected="7" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>MITRAL VALVE STENOSIS</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>PALPITATIONS</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="302"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>PERICARDIAL EFFUSION</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>RIGHT VENTRICULAR FAILURE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>SICK SINUS SYNDROME</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>SINUS TACHYCARDIA</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>SUPRAVENTRICULAR TACHYCARDIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>TACHYCARDIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>TRICUSPID VALVE INCOMPETENCE</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>VENTRICULAR ARRHYTHMIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>VENTRICULAR FIBRILLATION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>VENTRICULAR TACHYCARDIA</sub_title>
                <counts group_id="E1" events="18" subjects_affected="16" subjects_at_risk="302"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="312"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>ATRIAL SEPTAL DEFECT</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>DEAFNESS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>DEAFNESS NEUROSENSORY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>DEAFNESS UNILATERAL</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>EAR DISORDER</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>EAR HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>VERTIGO</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>HYPERPARATHYROIDISM</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>HYPERTHYROIDISM</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>HYPOTHYROIDISM</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="302"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>THYROIDITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>BLEPHARITIS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>CATARACT</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="5" subjects_affected="3" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>CONJUNCTIVAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>DIPLOPIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>EYE HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>EYE PAIN</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>EYELID PTOSIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>RETINAL VASCULAR OCCLUSION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>VISION BLURRED</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>ABDOMINAL DISCOMFORT</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>ABDOMINAL DISTENSION</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>ABDOMINAL MASS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>ABDOMINAL PAIN</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="302"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>ABDOMINAL PAIN LOWER</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>ABDOMINAL PAIN UPPER</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="302"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>ASCITES</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="302"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>COLITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>CONSTIPATION</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="302"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>DENTAL CARIES</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>DIVERTICULUM INTESTINAL</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>DIVERTICULUM INTESTINAL HAEMORRHAGIC</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>DRY MOUTH</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>DUODENAL ULCER</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>DYSPHAGIA</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="302"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>FAECAL INCONTINENCE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>GASTRIC POLYPS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>GASTRIC ULCER</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>GASTRITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>GASTROINTESTINAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>GASTROOESOPHAGEAL REFLUX DISEASE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>GINGIVAL BLEEDING</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>HAEMATEMESIS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>HAEMATOCHEZIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>HAEMORRHOIDAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>HAEMORRHOIDS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>ILEUS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>IMPAIRED GASTRIC EMPTYING</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>INGUINAL HERNIA</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>INGUINAL HERNIA, OBSTRUCTIVE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>INTESTINAL MASS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>MELAENA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>MOUTH HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>NAUSEA</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="302"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>ODYNOPHAGIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>OESOPHAGEAL HYPOMOTILITY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>PAROTID GLAND INFLAMMATION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>POOR DENTAL CONDITION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>PROCTALGIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>RECTAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>SALIVARY GLAND DISORDER</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>TONGUE ULCERATION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>TOOTHACHE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>VOMITING</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="302"/>
                <counts group_id="E2" events="14" subjects_affected="13" subjects_at_risk="312"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>ADVERSE DRUG REACTION</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="302"/>
                <counts group_id="E2" events="11" subjects_affected="10" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>APPLICATION SITE PAIN</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>ASTHENIA</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="302"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>CATHETER SITE DISCHARGE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>CATHETER SITE HAEMATOMA</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>CATHETER SITE HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="15" subjects_affected="15" subjects_at_risk="302"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>CATHETER SITE INFLAMMATION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>CATHETER SITE PAIN</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>CHEST DISCOMFORT</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>CHEST PAIN</sub_title>
                <counts group_id="E1" events="13" subjects_affected="9" subjects_at_risk="302"/>
                <counts group_id="E2" events="15" subjects_affected="13" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>CYST</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>DEVICE BATTERY ISSUE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>DEVICE CAPTURING ISSUE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>DEVICE DISLOCATION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>DEVICE ELECTRICAL FINDING</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>DEVICE INFUSION ISSUE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>DEVICE ISSUE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>DEVICE LEAD DAMAGE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>DEVICE MALFUNCTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>DEVICE STIMULATION ISSUE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>EXERCISE TOLERANCE DECREASED</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>FATIGUE</sub_title>
                <counts group_id="E1" events="11" subjects_affected="8" subjects_at_risk="302"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>GENERALISED OEDEMA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>HYPOTHERMIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>INFUSION SITE HAEMATOMA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>INJECTION SITE HAEMATOMA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>INJECTION SITE HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>MALAISE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>MEDICAL DEVICE COMPLICATION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>MUCOSAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>NON-CARDIAC CHEST PAIN</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="302"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>OEDEMA</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="302"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>OEDEMA PERIPHERAL</sub_title>
                <counts group_id="E1" events="13" subjects_affected="12" subjects_at_risk="302"/>
                <counts group_id="E2" events="17" subjects_affected="12" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>PELVIC MASS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>PYREXIA</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="302"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>SWELLING</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>ULCER</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>VESSEL PUNCTURE SITE HAEMATOMA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>VESSEL PUNCTURE SITE HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>CHOLECYSTITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>CHOLELITHIASIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>HEPATIC CIRRHOSIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>HEPATIC CONGESTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>HEPATOMEGALY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>HYPERBILIRUBINAEMIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>LIVER DISORDER</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>DRUG HYPERSENSITIVITY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>SEASONAL ALLERGY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>ACUTE SINUSITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>ASYMPTOMATIC BACTERIURIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>BACTERAEMIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>BRONCHITIS</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="302"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>CANDIDIASIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>CATHETER SITE INFECTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>CELLULITIS</sub_title>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="302"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>CLOSTRIDIAL INFECTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>CLOSTRIDIUM DIFFICILE COLITIS</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="302"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>CYSTITIS KLEBSIELLA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>DEVICE RELATED INFECTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>DIVERTICULITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>EAR INFECTION</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>ENDOCARDITIS ENTEROCOCCAL</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>ENTEROCOCCAL BACTERAEMIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>ESCHERICHIA URINARY TRACT INFECTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>GASTROENTERITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>HERPES ZOSTER</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="302"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>INCISION SITE ABSCESS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>INFECTED BITES</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>INFLUENZA</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>INTERVERTEBRAL DISCITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>LOBAR PNEUMONIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>LOCALISED INFECTION</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>NASOPHARYNGITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>ONYCHOMYCOSIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>ORAL CANDIDIASIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>ORAL HERPES</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>OTITIS MEDIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>OTITIS MEDIA ACUTE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>PERITONITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>PHARYNGITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>PNEUMONIA</sub_title>
                <counts group_id="E1" events="11" subjects_affected="10" subjects_at_risk="302"/>
                <counts group_id="E2" events="13" subjects_affected="12" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>RESPIRATORY TRACT INFECTION VIRAL</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>RHINITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>RHINOVIRUS INFECTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>SEPSIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>SEPTIC SHOCK</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>SINUSITIS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="302"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>STAPHYLOCOCCAL BACTERAEMIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>STAPHYLOCOCCAL SEPSIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>TOOTH INFECTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>UPPER RESPIRATORY TRACT INFECTION</sub_title>
                <counts group_id="E1" events="9" subjects_affected="7" subjects_at_risk="302"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>URINARY TRACT INFECTION</sub_title>
                <counts group_id="E1" events="29" subjects_affected="20" subjects_at_risk="302"/>
                <counts group_id="E2" events="15" subjects_affected="15" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>URINARY TRACT INFECTION BACTERIAL</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>URINARY TRACT INFECTION ENTEROCOCCAL</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>UROSEPSIS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>VIRAEMIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>VIRAL INFECTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>VIRAL UPPER RESPIRATORY TRACT INFECTION</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>AGITATION POSTOPERATIVE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>ANAEMIA POSTOPERATIVE</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>ANIMAL BITE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>ANKLE FRACTURE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>CARDIAC PROCEDURE COMPLICATION</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>CATHETER SITE HAEMATOMA</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>CERVICAL VERTEBRAL FRACTURE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>CONTUSION</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="302"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>CRANIOCEREBRAL INJURY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>EAR ABRASION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>EAR INJURY</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>ENDOTRACHEAL INTUBATION COMPLICATION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>EXCORIATION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>FACE INJURY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>FALL</sub_title>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="302"/>
                <counts group_id="E2" events="23" subjects_affected="20" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>FEMUR FRACTURE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>FOOT FRACTURE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>FOREARM FRACTURE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>FROSTBITE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>HAEMATURIA TRAUMATIC</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>HAND FRACTURE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>HEAD INJURY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>HUMERUS FRACTURE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>IN-STENT CORONARY ARTERY RESTENOSIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>INJURY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>INTENTIONAL OVERDOSE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>INTERVERTEBRAL DISC INJURY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>JAW FRACTURE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>JOINT INJURY</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>LACERATION</sub_title>
                <counts group_id="E1" events="12" subjects_affected="11" subjects_at_risk="302"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>LIGAMENT SPRAIN</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>LIMB INJURY</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>LUMBAR VERTEBRAL FRACTURE</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>MULTIPLE FRACTURES</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>MUSCLE STRAIN</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>OPEN WOUND</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>PERIORBITAL HAEMATOMA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>POST PROCEDURAL DIARRHOEA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>POST PROCEDURAL HAEMATURIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>POST PROCEDURAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>POST PROCEDURAL HYPOTHYROIDISM</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>POST PROCEDURAL SWELLING</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>POST-TRAUMATIC PAIN</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>PROCEDURAL COMPLICATION</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>PROCEDURAL DIZZINESS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>PROCEDURAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>PROCEDURAL HEADACHE</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>PROCEDURAL HYPOTENSION</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>PROCEDURAL NAUSEA</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>RIB FRACTURE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>SKELETAL INJURY</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>SKIN WOUND</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>SUBCUTANEOUS HAEMATOMA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>THERMAL BURN</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>TOXICITY TO VARIOUS AGENTS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>TRAUMATIC HAEMATOMA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>TRAUMATIC HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>TRAUMATIC INTRACRANIAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>TRAUMATIC LUNG INJURY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>UPPER LIMB FRACTURE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>URETHRAL INJURY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>URINARY RETENTION POSTOPERATIVE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>VASCULAR GRAFT OCCLUSION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>WRIST FRACTURE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>ALANINE AMINOTRANSFERASE INCREASED</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>AMYLASE INCREASED</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>ANTIBIOTIC RESISTANT STAPHYLOCOCCUS TEST POSITIVE</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>ANTICOAGULATION DRUG LEVEL ABOVE THERAPEUTIC</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>ANTICOAGULATION DRUG LEVEL BELOW THERAPEUTIC</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>BLOOD ALKALINE PHOSPHATASE INCREASED</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>BLOOD CREATINE PHOSPHOKINASE INCREASED</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="302"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>BLOOD CREATINE MB PHOSPHOKINASE INCREASED</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="302"/>
                <counts group_id="E2" events="11" subjects_affected="8" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>BLOOD CREATININE INCREASED</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="302"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>BLOOD GLUCOSE INCREASED</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>BLOOD POTASSIUM DECREASED</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>BLOOD POTASSIUM INCREASED</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>BLOOD PRESSURE DECREASED</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>BLOOD THYROID STIMULATING HORMONE INCREASED</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>BLOOD UREA INCREASED</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>BRAIN NATRIURETIC PEPTIDE INCREASED</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="302"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>CARCINOEMBRYONIC ANTIGEN INCREASED</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>CARDIAC ENZYMES INCREASED</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>CARDIAC INDEX DECREASED</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>CARDIAC OUTPUT DECREASED</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>CLOSTRIDIUM TEST POSITIVE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>COMPUTERISED TOMOGRAM ABDOMEN ABNORMAL</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>DRUG LEVEL ABOVE THERAPEUTIC</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>EJECTION FRACTION DECREASED</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>ELECTROCARDIOGRAM ABNORMAL</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>ELECTROCARDIOGRAM CHANGE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>ELECTROCARDIOGRAM QT PROLONGED</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="302"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>FIBRIN D DIMER INCREASED</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>GAMMA-GLUTAMYLTRANSFERASE INCREASED</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>HAEMATOLOGY TEST ABNORMAL</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>HAEMOGLOBIN DECREASED</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>HEART RATE INCREASED</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>HELICOBACTER TEST POSITIVE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>HEPATIC ENZYME INCREASED</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>INTERNATIONAL NORMALISED RATIO INCREASED</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="302"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>LIPASE INCREASED</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>LIVER FUNCTION TEST ABNORMAL</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>N-TERMINAL PROHORMONE BRAIN NATRIURETIC PEPTIDE INCREASED</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>OCCULT BLOOD POSITIVE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>OXYGEN CONSUMPTION DECREASED</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>OXYGEN SATURATION DECREASED</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>PLATELET COUNT DECREASED</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>PROTHROMBIN TIME PROLONGED</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>TRANSAMINASES INCREASED</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>TROPONIN I INCREASED</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>TROPONIN INCREASED</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="302"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>ULTRASOUND ABDOMEN NORMAL</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>WEIGHT DECREASED</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>WEIGHT INCREASED</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="302"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>WHITE BLOOD CELL COUNT INCREASED</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="312"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>ACIDOSIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>CACHEXIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>DECREASED APPETITE</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>DEHYDRATION</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="302"/>
                <counts group_id="E2" events="8" subjects_affected="7" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>DYSLIPIDAEMIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>FAILURE TO THRIVE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>FLUID OVERLOAD</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="302"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>FLUID RETENTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="6" subjects_affected="4" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>GOUT</sub_title>
                <counts group_id="E1" events="13" subjects_affected="10" subjects_at_risk="302"/>
                <counts group_id="E2" events="15" subjects_affected="11" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>HYPERAMMONAEMIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>HYPERCALCAEMIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>HYPERGLYCAEMIA</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="302"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>HYPERKALAEMIA</sub_title>
                <counts group_id="E1" events="16" subjects_affected="15" subjects_at_risk="302"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>HYPERNATRAEMIA</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>HYPERPHOSPHATAEMIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>HYPERVOLAEMIA</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="302"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>HYPOCALCAEMIA</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>HYPOCHLORAEMIA</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>HYPOGLYCAEMIA</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="302"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>HYPOKALAEMIA</sub_title>
                <counts group_id="E1" events="13" subjects_affected="10" subjects_at_risk="302"/>
                <counts group_id="E2" events="10" subjects_affected="9" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>HYPOMAGNESAEMIA</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>HYPONATRAEMIA</sub_title>
                <counts group_id="E1" events="7" subjects_affected="5" subjects_at_risk="302"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>HYPOVOLAEMIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>LACTIC ACIDOSIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>LACTOSE INTOLERANCE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>MALNUTRITION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>METABOLIC ALKALOSIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>TYPE 2 DIABETES MELLITUS</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>VITAMIN D DEFICIENCY</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>ARTHRALGIA</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="302"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>ARTHRITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>BACK PAIN</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="302"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>BUNION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>BURSITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>FLANK PAIN</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>GOUTY ARTHRITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>JOINT EFFUSION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>LIMB DISCOMFORT</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>MOBILITY DECREASED</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>MUSCLE HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>MUSCLE SPASMS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>MUSCULAR WEAKNESS</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>MUSCULOSKELETAL CHEST PAIN</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>MUSCULOSKELETAL PAIN</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="302"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>MYALGIA</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>MYOSITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>NECK MASS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>NECK PAIN</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="302"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>OSTEOARTHRITIS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>PAIN IN EXTREMITY</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="302"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>RENAL OSTEODYSTROPHY</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>RHEUMATOID ARTHRITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>ROTATOR CUFF SYNDROME</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>TENDONITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>ADRENAL ADENOMA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>ANGIOSARCOMA RECURRENT</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>B-CELL LYMPHOMA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>BASAL CELL CARCINOMA</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>BOWEN'S DISEASE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>CANCER PAIN</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>LUNG NEOPLASM</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="302"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>MYELODYSPLASTIC SYNDROME</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>PARAPROTEINAEMIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>RENAL CELL CARCINOMA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>SEBORRHOEIC KERATOSIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>SKIN CANCER</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>SQUAMOUS CELL CARCINOMA</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>ALTERED STATE OF CONSCIOUSNESS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>AMNESIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>BALANCE DISORDER</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>CARPAL TUNNEL SYNDROME</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>COGNITIVE DISORDER</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>DEMENTIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>DEMENTIA ALZHEIMER'S TYPE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>DIABETIC NEUROPATHY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>DIZZINESS</sub_title>
                <counts group_id="E1" events="17" subjects_affected="15" subjects_at_risk="302"/>
                <counts group_id="E2" events="13" subjects_affected="11" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>DIZZINESS POSTURAL</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="302"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>DYSARTHRIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>ENCEPHALOPATHY</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="302"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>ESSENTIAL TREMOR</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>GUILLAIN-BARRE SYNDROME</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>HEADACHE</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="302"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>HYPOAESTHESIA</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="302"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>LACUNAR INFARCTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>LOSS OF CONSCIOUSNESS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>LUMBAR RADICULOPATHY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>METABOLIC ENCEPHALOPATHY</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>MIGRAINE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>MYOCLONUS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>PARAESTHESIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>PARKINSON'S DISEASE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>PARKINSONISM</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>PARTIAL SEIZURES</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>PHANTOM PAIN</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>PRESYNCOPE</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="302"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>RESTLESS LEGS SYNDROME</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>SCIATICA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>SOMNOLENCE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>SYNCOPE</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="302"/>
                <counts group_id="E2" events="9" subjects_affected="8" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>TRANSIENT ISCHAEMIC ATTACK</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>TREMOR</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>VASCULAR DEMENTIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>ANXIETY</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>CONFUSIONAL STATE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>DELIRIUM</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="302"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>DEPRESSION</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="302"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>HALLUCINATION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>INSOMNIA</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="302"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>MAJOR DEPRESSION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>MENTAL DISORDER</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>MENTAL STATUS CHANGES</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="302"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>PANIC ATTACK</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>STRESS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>BLADDER SPASM</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>CYSTITIS HAEMORRHAGIC</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>DYSURIA</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>HAEMATURIA</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="302"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>NEPHROLITHIASIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>NEPHROPATHY TOXIC</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>PYURIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>RENAL CYST</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>RENAL FAILURE</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="302"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>RENAL FAILURE ACUTE</sub_title>
                <counts group_id="E1" events="23" subjects_affected="21" subjects_at_risk="302"/>
                <counts group_id="E2" events="31" subjects_affected="21" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>RENAL FAILURE CHRONIC</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="302"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>RENAL IMPAIRMENT</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>RENAL INJURY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>RENAL MASS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>RENAL TUBULAR NECROSIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>URINARY RETENTION</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="302"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="312"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>ACQUIRED PHIMOSIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>BENIGN PROSTATIC HYPERPLASIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>BREAST INFLAMMATION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>BREAST MASS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>BREAST PAIN</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>BREAST TENDERNESS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>GYNAECOMASTIA</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>ACUTE RESPIRATORY FAILURE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>ASTHMA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>ATELECTASIS</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>CHRONIC OBSTRUCTIVE PULMONARY DISEASE</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="302"/>
                <counts group_id="E2" events="11" subjects_affected="4" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>COUGH</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="302"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>DYSPHONIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>DYSPNOEA</sub_title>
                <counts group_id="E1" events="19" subjects_affected="19" subjects_at_risk="302"/>
                <counts group_id="E2" events="29" subjects_affected="23" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>DYSPNOEA EXERTIONAL</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="302"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>DYSPNOEA PAROXYSMAL NOCTURNAL</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>EMPHYSEMA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>EPISTAXIS</sub_title>
                <counts group_id="E1" events="11" subjects_affected="10" subjects_at_risk="302"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>HAEMOPTYSIS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>HICCUPS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>HYPERCAPNIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>HYPOXIA</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="302"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>LUNG INFILTRATION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>NASAL CONGESTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>OROPHARYNGEAL PAIN</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="302"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>ORTHOPNOEA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>PAINFUL RESPIRATION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>PLEURAL EFFUSION</sub_title>
                <counts group_id="E1" events="18" subjects_affected="16" subjects_at_risk="302"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>PLEURITIC PAIN</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>PNEUMONIA ASPIRATION</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>PNEUMONITIS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>PNEUMOTHORAX</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>PRODUCTIVE COUGH</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="302"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>PULMONARY CONGESTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>PULMONARY FIBROSIS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>PULMONARY HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>PULMONARY HYPERTENSION</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="302"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>PULMONARY MASS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>PULMONARY OEDEMA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>RESPIRATORY FAILURE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>RHINITIS ALLERGIC</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>WHEEZING</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>ACTINIC KERATOSIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>ALOPECIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>ANGIOEDEMA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>CUTIS LAXA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>DECUBITUS ULCER</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="302"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>DERMATITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>DIABETIC FOOT</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>DRUG ERUPTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>ECCHYMOSIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>ECZEMA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>HYPERHIDROSIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>INCREASED TENDENCY TO BRUISE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>INGROWING NAIL</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>PETECHIAE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>PRURITUS ALLERGIC</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>RASH</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>RASH ERYTHEMATOUS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>SKIN HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>SKIN LESION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>SKIN ULCER</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>STASIS DERMATITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>URTICARIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>CARDIAC PACEMAKER BATTERY REPLACEMENT</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>CHOLECYSTECTOMY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>MEDICAL DEVICE BATTERY REPLACEMENT</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>RENAL STONE REMOVAL</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>ROUTINE HEALTH MAINTENANCE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>AORTIC ANEURYSM</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>AORTIC STENOSIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>ARTERIOVENOUS FISTULA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>DEEP VEIN THROMBOSIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>FEMORAL ARTERY OCCLUSION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>HAEMATOMA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>HYPERTENSION</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="302"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>HYPOTENSION</sub_title>
                <counts group_id="E1" events="34" subjects_affected="31" subjects_at_risk="302"/>
                <counts group_id="E2" events="27" subjects_affected="25" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>INTERMITTENT CLAUDICATION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>ORTHOSTATIC HYPERTENSION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>PERIPHERAL ISCHAEMIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>SUBCLAVIAN ARTERY OCCLUSION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="302"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="312"/>
              </event>
              <event>
                <sub_title>THROMBOPHLEBITIS SUPERFICIAL</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="302"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="312"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Sripad Bellary</name_or_title>
      <organization>Abbott</organization>
      <phone>4088458114</phone>
      <email>sripad.bellary@abbott.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

